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SUMMARY
Cytokines are glycoproteins produced by many different cell types which have wide 
ranging effects on the haemopoietic and immune systems and normal homeostatic 
mechanisms. The advent of recombinant DNA technology and the cloning of human 
cytokines has facilitated the production of recombinant cytokines in sufficient 
quantities to allow the characterisation of their biological properties and subsequent 
use as novel therapeutic agents in the treatment of viral and bacterial infections, cancer 
and cytopenias. However, the therapeutic use of heterologous cytokines in domestic 
animals has been of limited success, mainly due to the variable degree of conservation 
between species. Therefore, the isolation and characterisation of species specific 
cytokines is desirable in order to facilitate further studies of the role of cytokines in 
diseases of domestic animals. This thesis describes the approach used to isolate and 
clone the feline Thl type cytokines interleukin 12 (EL-12) and interleukin 18 (EL-18), 
express the recombinant IL-18 protein in a mammalian expression system and 
investigate the potential of both IL-12 and IL-18 to act as genetic adjuvants in FeLV 
DNA vaccination studies.
EL-12 is a recently discovered heterodimeric cytokine, which serves as a pivotal 
regulator of T and NK cell function, stimulating proliferation, cytolytic activity and 
cytokine induction. EL-18 is produced predominantly by activated macrophages, acts to 
strongly augment IFN-y production by spleen cells and enhances natural killer cell 
activity (NK). However, perhaps the most striking property of these cytokines is their 
marked ability to synergistically increase IFN-y production, a cytokine known to be 
integral to the development of a functional cellular immune response, in T cells 
previously exposed to antigen. cDNA clones encoding the p35 and p40 subunits of EL- 
12 and IL-18 were isolated using RT-PCR and their sequences determined. The p35 IL- 
12, p40 and IL-18 cDNAs encoded predicted full length proteins of 222, 329 and 192 
amino-acids, respectively. All three sequences possessed a high degree of homology 
with the respective cytokines of other species at both the nucleic acid and protein level. 
In order to evaluate the potential of IL-12, IL-18 and EFN-y DNA constructs to act as in 
vivo genetic adjuvants in FeLV DNA vaccination studies, these cytokines were cloned
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into the mammalian expression vector pCI-neo, and IL-18 protein and mRNA 
expression were demonstrated in an in vitro mammalian expression system using 
western and Northern blotting techniques.
To assess the potential of a DNA vaccine to protect against feline leukaemia virus 
(FeLV) infection, a significant pathogen of the domestic cat, a novel FeLV DNA 
vaccine was constructed, consisting of two separate plasmids, expressing FeLV 
gag/pol and FeLV env A genes. The constructs encoding feline interleukin 12 (IL-12), 
interleukin 18 (IL-18) and interferon gamma (IFN-y) were coinoculated with the 
vaccine to establish if protection could be enhanced. Twenty-nine SPF cats were 
included in the trial. Cats in group A were immunised intramuscularly with the FeLV 
DNA vaccine alone, cats in groups B, C and D were inoculated with the FeLV DNA 
vaccine and plasmids expressing IFN-y, IL-12 or IL-12 and IL-18, respectively, and the 
control cats, in group E, were immunised with empty pCI-neo plasmid. One hundred 
micrograms of each DNA construct was inoculated at 0, 2 and 4 weeks and 
intraperitoneal challenge with FeLV-A/Glasgow-1 viral isolate was performed at 7 
weeks. No detectable FeLV-specific humoral immune response was elicited following 
immunisation. Fifteen weeks after challenge, virus isolation (VI) revealed that 2 of the 
6 cats in group A, 2 of the 5 cats in group B, 4 of the 6 cats in group C, and 3 of the 6 
cats in group E, tested virus isolation positive, while all the cats in group D (vaccine, 
IL-12 and IL-18) tested virus isolation negative. These findings demonstrate that the 
combination of IL-12 and IL-18 may act as a potent vaccine adjuvant, markedly 
enhancing the efficacy of the novel FeLV DNA vaccine.
These studies provide the basis for further investigations of the potential of EL-12 and 
EL-18 in the treatment of feline disease, particularly as vaccine adjuvants against other 
feline pathogens, such as FEV, and the examination of their wider clinical potential in 
immunotherapy and cancer treatment. Ultimately these cytokines may form part of a 
new array of therapeutic agents to treat feline disease.
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1. CHAPTER ONE; GENERAL INTRODUCTION
17
1.1 FELINE LEUKAEMIA VIRUS
1.1.1 CLASSIFICATION AND ORIGINS OF FeLV
Feline leukaemia virus, (FeLV), is a naturally occurring retrovirus (Hayes et al. 1992), 
prevalent in the world domestic cat population. Retroviruses are single-stranded, 
diploid RNA viruses whose replication cycles involve reverse transcription into DNA 
that becomes stably integrated into host genomic DNA as proviruses. The retroviridae 
consist of three separate subfamilies Spumavirinae, Oncovirinae and Lentivirinae, as 
reviewed by Teich (Teich, 1984), (Teich, 1985). A member of the Oncovirinae 
subfamily, FeLV is also classed as a C-type retrovirus. The latter classification system 
is based on differences in morphology, visualised by electron microscopy (Bernhard, 
1958). Separate types of retroviridae are characterised according to differences in core 
structure and features of the surrounding membrane. FeLV is thought to have originally 
evolved from an ancestral rodent virus (Benveniste et al. 1975) and is remarkably 
similar in genetic structure and sequence to the leukaemogenic C-type retroviruses of 
the laboratory mouse (MuLV) (Neil et al. 1991).
1.1.2 DISCOVERY OF FeLV
FeLV was first reported to be an infectious disease, in 1964 by Jarrett et al (Jarrett et 
al. 1964). This group demonstrated that when a tumour homogenate from a field case 
of thymic lymphosarcoma was injected subcutaneously into four newborn kittens, all 
developed lymphosarcoma. Electron microscopy of the tissues of one kitten 
subsequently revealed virus-like particles in intracellular vesicles which closely 
resembled those of the viruses known to cause leukaemia in chickens and mice (Jarrett 
et al. 1964).
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FeLV was rapidly recognised as a significant pathogen of the domestic cat and as a 
model of contagiously transmitted retroviral disease in a natural, outbred mammalian 
population (Roy-Burman, 1995), (Neil et al. 1991). Thus FeLV has been of great 
importance in comparative medicine, influencing the studies which led to the isolation 
and characterisation of the human retroviruses, human T-cell leukaemia virus (HTLV- 
1) and human immunodeficiency virus (HIV-1) (Jarrett, 1991).
1.1.3 STRUCTURE OF FeLV
The genomic organisation of all retroviruses is broadly similar and has been reviewed 
by Coffin (Coffin, 1984), (Coffin, 1985). The RNA genome of FeLV consists of three 
genes, gag, pol and env, arranged from the 5’ to the 3’ end. Figure 1.1. illustrates the 
genetic organisation of FeLV. The gag gene (group-specific antigen gene) codes for the 
polyprotein precursors of the internal non-glycosylated core proteins, with molecular 
weights of 15,000 (pl5), 12,000 (pl2), 27,000 (p27), and 10,000 (plO) Daltons. These 
proteins are similar in all FeLV isolates. The env gene encodes the polyprotein 
precursor of the envelope proteins which is cleaved to yield a glycoprotein of 70,000 
Daltons (gp70) and an non-glycosylated protein of 15,000 Daltons (pi5(E)). Variations 
in the nucleotide sequences of the env genes determines the subgroup specificity of 
each individual isolate. The pol (polymerase) region codes for the protease, integrase 
and reverse transcriptase gene products.
The FeLV genome also consists of 5’ and 3’ U3, U5 and R regions. These are copied 
to form the proviral LTR. The LTRs contain sequence which is capable of initiating 
transcription, as well as the polyadenylation of viral RNA. The U3 region of the LTR is 
known to contain enhancer elements which promote viral transcription.
In a virus particle, the viral RNA and the reverse transcriptase are contained in a 
protective protein core, consisting of p27, p l2  and plO. Surrounding this core is the 
p l5  protein, which forms an inner protein coat. The viral envelope is the outermost 
structure. This is a phospholipid membrane into which the gp70 and pi5(E) proteins 
are inserted. The gp70 protein forms spikes, displayed on the outside surface of the
19
FeLV particle, and these are anchored into the membrane by the hydrophobic pi5(E) 
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Figure 1.1. FeLV genome structure
LTR, long terminal repeat; An, polyadenylation; cap, the capped nucleotide at the 5’ 
















Figure 1.2. FeLV particle and im portant antigens
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1.1.4 REPLICATION OF FeLV
A specific interaction of the viral surface glycoprotein with a host cellular receptor, 
initiates the infectious cycle of the virus (Rigby, 1989). Subsequent fusion between 
viral and cellular membranes allows entry of the virus into the host cell. The viral 
envelope is then shed, to allow the release of viral RNA into the cytoplasm. A single 
stranded DNA copy is synthesised from the RNA, by the viral reverse transcriptase 
(RT). This single stranded DNA, in turn, acts as a template for the formation of the 
double stranded DNA provirus. The provirus integrates into the host cell chromosome, 
facilitated by the virally encoded enzyme integrase, and in this way becomes part of the 
cellular genome.
Once integrated into the genome, the pro virus utilises the host cell’s machinery for 
transcription and processing of mRNA. Two separate mRNAs are transcribed from 
proviral DNA; the whole genome, gag-pol-env, from which the proteins gag and pol 
are translated; and env, which is transcribed independently. The constituents of the 
viral envelope travel to the cell surface and are inserted into the plasma membrane, to 
form a cup-like structure called the viral bud (Bolognesi et al. 1978). The gag 
polyprotein precursor is then transported to this site. One end of this polyprotein is 
connected to the viral RNA, while the other is linked to the viral envelope (Bolognesi 
et al. 1978).
This polyprotein precursor is then cleaved to release the individual core proteins, p i5, 
p i2, p27 and plO, which align to create the internal structure of the virus. The env 
precursor, meanwhile, is glycosylated and cleaved to yield gp70 and pi5(E) moieties 
(Bolognesi et al. 1978). The latter is further processed to produce pl2(E) (Neil et al. 
1980). When assembly and maturation are complete, new virus particles are released 
through the host cell membrane by budding, without damaging the cell. This results in 
a viral envelope consisting of host cell membrane and viral glycoproteins. This release 
of virus by infected cells, characteristic of the Retroviridae, occurs only during mitosis 
(Jarrett, 1994). This is an important feature of FeLV pathogenesis, since the main sites
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of viral replication are in actively dividing tissues, such as the bone marrow. A 
schematic overview of the life cycle of FeLV is illustrated in Figure 1.3.
There are multiple copies of endogenous FeLV-related sequences, known as enFeLV, 
in the genome of the domestic cat (Benveniste et al. 1975). Although even the full 
length enFeLV proviruses do not appear to encode infectious virus (Neil et al. 1991), 
they are believed to contribute to FeLV pathogenesis by recombining with exogenous 
FeLV A isolates to generate FeLV B variants (Neil et al. 1987), (Stewart et al. 1986). 
A truncated env protein, expressed by defective endogenous FeLVs may have a role in 
mediating resistance to infection with FeLV-B isolates (in the absence of FeLV-A 
isolates) by means of receptor blockade (McDougall et al. 1994). The subgroups of 
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Figure 1.3. Schematic representation of the life-cycle of FeLV
RT, reverse transcriptase enzyme.
1.1.5 FeLV SUBGROUPS
Exogenous FeLV isolates are classified into three distinct subgroups, A, B and C, on 
the basis of viral interference with superinfection (Sarma and Log, 1973). These 
subgroups most likely define envelope subtypes that use different cellular receptor 
molecules for viral entry (Rohn et al. 1997). The occurrence of the different subgroups 
in the field has been described in detail by Jarrett (Jarrett, 1980). FeLV-A viruses are 
ecotropic; that is, capable of infecting only feline cells. They are present in all field 
isolates (Jarrett and Russell, 1978), (Stewart et al. 1986), are readily transmissible and 
are highly conserved. This subgroup represents the dominant form of FeLV in nature.
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By contrast FeLV-B viruses are polytropic, infecting human cells in addition to feline 
cells and are estimated to occur in 30-60% of field isolates (Neil et al. 1991). This 
subgroup, and subgroup C, are always isolated together with FeLV-A viruses. Indeed, 
subgroup A viruses may facilitate transmission of B and C subgroup isolates as 
pseudotypes in vivo (Jarrett and Russell, 1978). The replication and transmission of B 
and C isolates is less efficient, and therefore their ability to establish persistent 
viraemia is significantly reduced. Concurrent infection with an FeLV-A subgroup 
isolate, however, may result in phenotypic mixing, whereby a FeLV-B or FeLV-C 
genome can be packaged in a FeLV-A envelope, thus allowing productive infection of 
cells not normally available to the FeLV-B and C subgroups (Jarrett et al. 1984), 
(Jarrett et al. 1973), (Rigby et al. 1992). FeLV-B isolates are thought to arise de novo, 
from recombination events between exogenous FeLV-A env sequences and 
endogenous FeLV (enFeLV) env elements (Stewart et al. 1986), (Tsatsanis et al. 
1994), as described in section 1.1.4.
The FeLV-B subgroup is generally associated with a higher rate of malignancies and 
immunosuppressive disorders, and can, in some cases, act to accelerate disease induced 
by weakly oncogenic FeLV-A isolates (Tzavaras et al. 1990). FeLV-B is 
overrepresented in viraemic cats with lymphosarcomas, relative to infected but 
otherwise healthy animals (Jarrett and Russell, 1978), (Jarrett et al. 1978). Moreover, 
although experimental infection with subgroup B viruses is inefficient, the occurrence 
of lymphoid tumours in animals inoculated with subgroup B virus alone has been 
documented (Jarrett et al. 1978). This demonstrates the existence of subgroup specific 
differences in viral pathogenicity and virulence.
FeLV-C subgroup isolates are polytropic and occur in only approximately 1% of 
infected cats. Viruses of this subgroup are always isolated with FeLV-A or a 
combination of FeLV-A and FeLV-B (Jarrett et al. 1978), again inferring that FeLV-A 
viruses are essential for the replication of subgroup C isolates in vivo. FeLV-C isolates 
are thought to arise de novo by mutation in the env gene of FeLV-A (Neil et al. 1991) 
and are not transmitted in nature. They are uniquely associated with the development 
of pure red cell aplasia, one of the most acute and aggressive degenerative retroviral 
diseases known (Onions et al. 1982), (Mackey et al. 1975).
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1.1.6 FeLV INFECTION
1.1.6.1 Source and Transmission of FeLV
Persistently viraemic cats are the main source of FeLV infection (Hardy et al. 1973). 
Virus is secreted continuously in the saliva of viraemic cats (Francis et al. 1977) and, 
therefore, is transmitted to susceptible animals during intimate social exchange. 
Although large amounts of infective virus are excreted in saliva, FeLV is extremely 
labile and virus survival in the environment, under conditions of desiccation, is less 
than two hours (Francis et al. 1977).
The generation of long distance aerosols or fomites in the environment are not 
important factors in the transmission of FeLV (Francis et al. 1977), and although the 
virus does replicate in the mucosal epithelium of the intestine and the urinary bladder, 
FeLV is poorly preserved in urine and faeces (Hoover et al. 1977). Similarly, although 
venereal transmission of the virus is possible, as virus has been detected in semen and 
vaginal fluids, the concurrent exposure to FeLV in saliva probably represents the 
greatest risk to the uninfected cat (Hoover and Mullins, 1991). Efficient transmission 
of FeLV, then, necessitates either direct transfer of virus in salivary or nasal secretions 
exchanged during intimate contact such as licking, or the prolonged use by infected 
and non-infected cats of common feed and water sources (Francis et al. 1977).
FeLV can also be transmitted congenitally, from an infected queen to her kittens. The 
virus may cross the placenta, infecting the developing embryos, and foetal resorption 
or abortion may occur (Cotter et al. 1975). Indeed, FeLV is the single most common 
infectious cause of infertility in queens (Jarrett, 1994). Less commonly, the pregnancy 
may be carried to term and congenitally infected kittens may be bom (Hoover and 
Mullins, 1991). These kittens are predisposed to neonatal mortality, and if they survive, 
they will generally succumb to an FeLV-related disease within two years. Interestingly, 
the transmission of FeLV from a latently infected non-viraemic queen to her kittens, 
via milk, has also been documented (Pacitti et al. 1986). This resulted in persistent
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FeLV infection of several litters, who were then able to transmit virus to other 
susceptible kittens by contact. Latent FeLV infection will be described in more detail 
in section I.2.2.3.
1.1.6.2 In vivo spread of FeLV
FeLV infection usually results from oronasal exposure to the virus. The virus enters 
and replicates in the tonsils and other regional lymphoid tissue, in the first two to four 
days following exposure (Loar, 1993). This initial phase results in the replication of 
virus within a small number of circulating monocytes and lymphocytes (Rojko et al. 
1979b). Dissemination of these virus-infected lymphocytes then occurs, and by 
fourteen days post-exposure, viral colonisation and replication is evident in the spleen, 
visceral lymph nodes, thymus and gut associated lymphoid tissue (Loar, 1993).
Crucially, in the next two weeks (14 to 28 days), the virus may spread to infect the 
bone marrow and intestinal epithelium. At this stage, viral antigen may be detected in 
increasing numbers of bone marrow cells, in particular the myelomonocytic precursors. 
As granulocytes mature, the quantity of antigen present increases and soon circulating 
neutrophils contain considerable amounts of cytoplasmic viral antigen. The release of 
free viral particles in the blood coincides with the appearance of these antigen- 
containing neutrophils and the growth of virus in the bone marrow (Hoover et al. 
1977).
Standard diagnostic tests can typically identify viraemia within 14 to 28 days after viral 
exposure. However, certain FeLV infected cats may require an incubation period of up 
to eight weeks before diagnostic tests produce a positive result. Finally, normally 
within days of the onset of viraemia (between 28 and 56 days post-exposure), the virus 
spreads to non-haemopoietic tissues. The virus replicates in and is excreted from 
various epithelial sites, particularly the salivary glands, bladder, oropharynx, pancreas 
and intestine (Loar, 1993), and in this way is transmitted to susceptible cats.
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1.1.6.3 Diseases associated with FeLV infection
1.1.6.3.1 Introduction
A large number of diseases are associated with FeLV infection. These have been 
described in detail by Jarrett (Jarrett, 1984) and are listed in Table 1.1. Broadly, these 
can be divided into two categories; firstly, malignant or neoplastic diseases and 
secondly, non-malignant or degenerative diseases. The diseases occur most commonly 
in young adult cats, between two and four years of age (Hosie et al. 1989), although 
there are some notable exceptions, such as alimentary lymphosarcoma, which occurs in 
older animals. Almost 80% of persistently infected cats die from FeLV-associated 




Lymphosarcoma thymic lymphosarcoma, multicentric lymphosarcoma, alimentary 
lymphosarcoma.
lymphoid leukaemia, myeloid leukaemia, erythroleukaemia.
Non-malignant haemopoietic diseases







Table 1.1. Diseases associated with FeLV infection
1.1.6.3.2 Malignant disease associated with FeLV
Malignant disease associated with FeLV include lymphosarcomas (thymic, 
multicentric and alimentary) and leukaemias (lymphoid, myeloid and 
erythroleukaemia). Lymphosarcoma is the most common feline malignant tumour and, 
in fact, represents approximately one third of all tumours (Jarrett, 1994). It is invariably 
fatal and, therefore, is a major cause of death in the adult cat population (Jarrett, 1994). 
However, FeLV is not isolated from all cats with lymphosarcoma (Hardy et al. 
1980).While 80% of cats with thymic lymphosarcoma and 60% of cats with 
multicentric or lymphatic lymphsarcoma are viraemic, only 30% of cats with 
alimentary lymphosarcoma are viraemic (Jarrett, 1994).
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There is some evidence to suggest, however, that FeLV is involved in the pathogenesis 
of these virus negative lymphosarcomas, perhaps by initiating the neoplastic process, 
before being attacked and removed by the immune system. In fact, an epidemiological 
association in multi-cat households (in which FeLV is enzootic) has been documented, 
between FeLV exposure and infection, and the occurrence of cases of virus-negative 
lymposarcomas, as well as virus positive tumours (Hardy et al. 1980). Lymphoid cells 
are involved in approximately 90% of feline haemopoietic tumours. Tumours of the 
non-lymphoid elements of the haemopoietic system, myeloid and erythroid cell 
leukaemias, meanwhile, are much less commonly diagnosed (Jarrett, 1994), but are 
thought to occur more frequently than is generally realised (Jarrett, 1994).
1.1.6.3.3 Non-malignant disease associated with FeLV
Non-malignant or degenerative haemopoietic diseases include anaemias, such as 
haemolytic anaemia, (which is rare in the cat), and erythroid hypoplasia, bone marrow 
aplasia and immunodeficiency (Jarrett, 1994). FeLV-associated anaemia may develop 
as a consequence of lymphoid or myeloid leukaemia, or it may arise due to a direct 
effect of the virus, as in erythroid hypoplasia. FeLV-associated immunodeficiency can 
occur in both kittens and adult cats. In adults, immunosuppression is the most common 
cause of death associated with FeLV. In young kittens the thymus may atrophy, leading 
to T lymphocyte depletion and a defective cell-mediated immune response (Anderson 
et al. 1971). The mechanism by which FeLV produces a state of immunodeficiency is 
still not fully understood. The strain of the virus may be an important causal factor, as 
some FeLV isolates have been documented to kill T lymphocytes in vitro (Hoover et 
al. 1987). Another hypothesis is that the viral protein, pl5(E), is directly cytotoxic to 
lymphocytes (Mathes et al. 1979). Regardless of the mechanism, viraemic 
immunocompromised cats are susceptible to infections with opportunistic, microbial 
agents, manifested clinically by respiratory tract and enteric infections, gingivitis, 
abscesses and septicaemia.
Less commonly, FeLV may be associated with non-malignant, non-haemopoetic 
disease, such as reproductive failure (mentioned in section 1.1.6.1), neurological
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syndromes and FeLV-related enteropathy, a chronic wasting/diarrhoeal syndrome. 
FeLV-related enteropathy is often associated with concurrent immunodeficiency 
syndromes or may be due to primary infection of the germinal (crypt) cells of the 
intestinal mucosa. Therefore, the origins of this condition are still to be fully 
understood (Hoover and Mullins, 1991).
1.1.7 OUTCOMES OF FeLV INFECTION
1.1.7.1 Factors which influence the outcome of FeLV infection
In the first weeks following viral exposure, interactions between the host’s immune 
system and the virus itself determine the eventual long-term outcome of infection; i.e., 
whether persistent productive infection is established, whether a latent infection 
develops or whether the virus is completely cleared (a self-limiting infection), and 
immunity is established (Hoover and Mullins, 1991). Rarely, an atypical infection 
develops, as explained in section 1.1.7.4., although these cases are likely to progress to 
either extinguished infection or persistent viraemia, over time (Rojko and Hardy, 



















Figure 1.4. Possible outcomes of FeLV infection in a multi-cat household
The above figure illustrates the four possible outcomes of FeLV infection, described in 
section 1.1.7: persistent viraemia, transient viraemia, atypical infection, and immunity, 
and the estimated percentages of cats in each category.
A number of factors are important in determining the eventual outcome of viral 
exposure (Sparkes, 1997). Probably the most important factor is the age at which the 
cat is first exposed to FeLV. Hoover et al. found that the susceptibility of cats to FeLV 
infection decreased with age (Hoover et al. 1976). When virus was inoculated 
experimentally, 100% of newborn kittens became persistently viraemic, as compared to 
only 15% of cats aged between four months and one year becoming persistently 
infected. The remaining cats in this group cleared the virus and became immune.
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Other significant factors which influence the outcome of FeLV infection are the dose 
of the virus received, the frequency of exposure to the virus and the strain and 
pathogenicity of the viral isolate. In nature FeLV infection is more prevalent in multi­
cat households or breeding colonies, where prolonged, close, social contact ensures 
that uninfected individuals are constantly exposed to high doses of virus from 
shedding, infected cats. In contrast, the cycle of viral transmission in free-ranging 
outdoor cats involves the excretion of small amounts of virus, for short periods, by 
transiently viraemic cats. There is widespread dissemination of virus throughout the cat 
population, and the majority of cats are therefore exposed. However, the dose of virus 
is small and, consequently, most cats recover. The nature of an individual cat’s 
immune response is also important. Cats which are immunosuppressed naturally, due 
to concurrent disease, or experimentally, due to the administration of high or prolonged 
doses of corticosteroids, have an increased risk of becoming persistently viraemic. In 
fact, natural age resistance to FeLV infection can be overcome by the administration of 
high doses of exogenous corticosteroids (Rojko et al. 1979a). It has also been 
suggested that the genotype of an individual animal is important in determining innate 
immunity and resistance to FeLV infection (Hoover et al. 1980).
1.1.7.2 Persistent infection
Bone marrow infection is generally established within two to six weeks of exposure to 
FeLV. If the immune response fails to contain viral replication at this crucial stage, 
there is the potential for large quantities of virus to be produced, which may 
overwhelm the immune system and establish persistent viraemia (Hoover and Mullins, 
1991). The persistently infected state is characterised by the presence of free infectious 
virus and viral antigen in the blood, and virus excretion (Hoover and Mullins, 1991). 
The in vivo spread of virus in a persistently infected cat is described in section 1.1.6.2.
Although persistently infected cats may remain asymptomatic for a period of months to 
years, the long term prognosis is very poor; most die within three years of infection, 
most commonly from non-neoplastic disease (Hardy, 1980). The majority of free- 
ranging, outdoor cats are exposed to the virus, but due to natural age resistance to 
FeLV infection, and the low virus doses transmitted, most healthy adults are able to
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resist persistent infection and develop naturally acquired protective immunity 
(Pedersen et al. 1977). In contrast, a significant proportion of adult cats that are 
immunocompromised, or are subjected to high doses of virus (such as breeding colony 
cats), (Hardy et al. 1973) and kittens, who are immunologically immature, become 
persistently infected (Hoover et al. 1976). Overall, persistent viraemia, (progressive 
infection), develops in approximately 30% of unvaccinated exposed cats in multi-cat 
households (Hardy et al. 1976).
1.1.7.3 Recovery from FeLV infection; immune cats
1.1.7.3.1 Introduction
Approximately 60% of cats exposed to FeLV develop a self-limiting infection and 
produce adequate cellular and humoral immune responses in the early stages of 
lymphoid tissue viral replication (Hoover and Mullins, 1991). Thus, viral replication 
and expression are effectively contained within four to eight weeks of FeLV infection, 
and immunity is established. In most cats, immunity is established before or during 
bone marrow infection, so a marrow-associated viraemia does not develop. In a 
fraction of cats, however, protective immunity does not develop until shortly after bone 
marrow-origin viraemia is established (Jarrett et al. 1982). In these cats (between 30 
and 40% of all recovered cats), transient viraemia and/or antigenaemia is observed for 
a short period, usually lasting only days to weeks, before the virus is cleared and the 
animal ostensibly recovers from FeLV infection (Hoover and Mullins, 1991). 
However, the development of transient viraemia, which usually remains undetected, 
may increase the likelihood that latent bone marrow infection will develop (Sparkes, 
1997), (section 1.1.7.5).
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1.1.7.3.2 Virus neutralising antibodies
Recovered, immune cats are those that have apparently eliminated all virus and virus 
infected cells from their bodies, and are immune to subsequent FeLV exposure. They 
consistently test negative for the presence of virus or viral p27 antigen in the blood, 
and usually develop a significant virus-neutralising (VN) antibody titre (Hoover and 
Mullins, 1991). Virus-neutralising antibodies inactivate virus and, by fixing 
complement, can destroy virus-expressing cells, in vitro (Grant et al. 1983). These 
antibodies are assumed to have a similar protective effect in vivo and are often detected 
in cats that have eliminated a transient viraemia (Jarrett et al. 1973); they are, in fact, 
often associated with recovery from FeLV infection. Moreover, small amounts of 
virus-neutralising antibodies have been shown to protect kittens from viraemia, when 
they were challenged with large doses of virus (Jarrett et al. 1977).
1.1.7.3.3 Anti-FOCMA antibodies
A  second type of antibody elicited in infected cats, are anti-FOCMA antibodies. These 
are raised against a cell membrane antigen, feline oncornavirus-associated cell 
membrane antigen, FOCMA, which is expressed on the cell surface of FeLV- 
transformed cells (Vedbrat et al. 1983). Originally, FOCMA was defined as an antigen 
present on the surface of the FL74 feline lymphosarcoma cell line, established by 
Theilen (Theilen et al. 1969), which reacted with sera from cats which had recovered 
from feline sarcoma virus infection (Essex et al. 1971), or exposure to FeLV (Riggs, 
1971).
However, the exact origin of FOCMA has not been completely established but is most 
likely to be through transcription of endogenous FeLV related sequences, (enFeLV), in 
FeLV infected cells (Rojko and Kociba, 1991). Anti-FOCMA antibodies in sera are 
very common, especially amongst free-ranging urban cats. Rogerson in 1975 
(Rogerson et al. 1975) found that 50% of urban cats had identifiable levels of these 
antibodies in their sera, whereas in a study by Russell and Jarrett in 1978 (Russell and 
Jarrett, 1978), only 4% of a similar population possessed a detectable titre of virus 
neutralising antibody. Thus, it appears that the presence of FOCMA antibodies in sera 
is a sensitive indicator of exposure to FeLV.
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Anti-FOCMA antibodies are not protective against persistent FeLV infection, as even 
persistently viraemic cats may often possess low antibody titres. However, the presence 
of these antibodies has been found to correlate with protection against the development 
of FeLV-related neoplasia (Rojko and Hardy, 1994), (Grant et al. 1980), as first 
suggested by Essex in 1971 (Essex et al. 1971). Low or non-existent antibody titres 
are frequently associated with the development of leukaemias or lymphomas, while 
high titres are often associated with protection from the development of neoplasia. 
Complement-mediated (antibody-dependent) lysis of the transformed cells is thought 
to be the mechanism by which anti-FOCMA antibodies achieve this protection (Grant 
et al. 1979).
Two of the five commercially available vaccines claim to incorporate FOCMA. 
However, if a vaccine protects against FeLV infection, it will also protect against the 
development of FeLV-related neoplasia, regardless of whether FOCMA is present in 
the preparation or not. There is no evidence to suggest that FOCMA affords any 
significant degree of protection from FeLV infection (Loar, 1993). Thus, the inclusion 
of FOCMA in a vaccine formulation is probably of no benefit.
1.1.7.3.4 Latency
A substantial proportion of ostensibly immune, non-viraemic/non-antigenaemic cats 
harbour a latent FeLV infection (Rojko et al. 1982). The latent state is discussed in 
more detail in section 1.1.7.5.
1.1.7.4 Atypical FeLV infection
Atypical infections develop in a small proportion of FeLV-infected cats, perhaps 
between five and ten percent (Hoover and Mullins, 1991). A sequestered source of 
FeLV p27 antigen or virus producing cells persist somewhere in the body (Jarrett et al. 
1991), but a partially protective immune response is thought to prevent replication and 
widespread viral dissemination. Viral p27 antigen produced by infected cells may 
reach the blood, but, presumably due to protective levels of circulating virus
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neutralising antibody, infective virus cannot. Therefore, these cats are frequently 
discordant (Hayes et al. 1992); they exhibit intermittent antigenaemia but are usually 
non-viraemic, over a prolonged period.
Atypical, localised FeLV infections have been described in the mammary gland of a 
lactating queen (Pacitti et al. 1986), in the spleen and intestinal crypt epithelia of a 
non-viraemic cat (Hayes et al. 1989) and in spleen, lymph nodes, bone marrow and 
small intestine of five non-viraemic animals, in a survey to determine the incidence of 
localised FeLV infection (Hayes et al. 1992). The full significance of these type of 
infections in the pathogenesis and epidemiology of FeLV is yet to be elucidated, 
although they are likely to progress to either extinguished infection or persistent 
viraemia, over time (Rojko and Hardy, 1994).
1.1.7.5 Latent FeLV infection
Latent infection of bone marrow occurs in a significant proportion (between 30 and 
60%) of ostensibly immune cats, following recent recovery from FeLV infection and 
viraemia (Pedersen et al. 1984). The marrow is thought to be one of the last reservoirs 
of FeLV, during recovery (Pedersen et al. 1984). Latent infection, is characterised by 
the presence of integrated provirus, within the genome of myelomonocytic precursor 
cells in the bone marrow (Rojko et al. 1982), and the generation of an immune 
response to the virus, identified by the presence of FeLV virus neutralising antibodies 
(Madewell and Jarrett, 1983). The phenomenon of viral persistence in the presence of 
an immune response is not unique to FeLV; it has been described in other retroviral 
diseases, such as enzootic bovine leukosis (Piper et al. 1979), equine infectious 
anaemia (Crawford et al. 1978), visna virus infection in sheep (Narayan et al. 1977) 
and human immunodeficiency virus (Maniatis et al. 1982).
Infectious virus released from latently infected cells is killed by the protective humoral 
immune response, maintaining the virus in its quiescent, integrated form and ensuring 
that virus does not reach the peripheral circulation. A study by Pacitti demonstrated 
that virus neutralising antibody prevented the spread of virus from latently infected 
cells in vitro (Pacitti et al. 1986). However, reactivation of productive infection and
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reversion to viraemia can occur, when host immunological control is breached. This 
can be attained by culturing bone marrow cells in vitro, or by immunosuppression in 
vivo; achieved experimentally by the administration of corticosteroids or naturally, due 
to concurrent illness, stress or changes in endogenous hormone levels (Rojko et al.
1982). Latent infection, however, is usually a temporary state {Pedersen, Meric, et al. 
1984 ID: 1566}, (Pacitti and Jarrett, 1985), and by six to eight months post-viraemia, 
most cats have completely eliminated the virus (Pedersen et al. 1984). However, a 
small proportion of animals may remain latently infected for longer periods (Pacitti and 
Jarrett, 1985) or even indefinitely (Hoover and Mullins, 1991).
The significance of the latent carrier state in the pathogenesis and epidemiology of 
FeLV infection is still to be completely defined, in terms of whether reversion to 
viraemia, productive infection and virus excretion can occur. Reactivation of latent 
FeLV infection in the post recovery period, due to substantial impairment of immune 
defences, has been observed in a small number of cats, (Rojko et al. 1982), (Hoover 
and Mullins, 1991). However, most animals mount an adequate immune response, 
produce significant amounts of virus neutralising antibody and eliminate virus 
following a latent infection. Therefore, reversion to the viraemic state is rare (Rojko 
and Hardy, 1994).
Several researchers have also considered whether the development of latency 
predisposes to the development of FeLV-related diseases, even in the absence of 
viraemia. Proviral integration into the host genome may result in insertional 
mutagenesis; that is, activation of oncogenes or suppression of tumour suppressor 
genes, which may eventually culminate in neoplasia. In a study by Rojko, FeLV was 
isolated from cultured bone marrow cells derived from two cats with FeLV negative 
lymphosarcoma (Rojko et al. 1982). Moreover, a study by Pedersen of 400 FeLV 
recovered cats documented a higher than expected incidence of virus negative 
neoplasia (of the type usually associated with active FeLV infection), although the 
number of latently infected cats was not stated (Pedersen et al. 1984). These findings 
suggest that cats with lymphosarcoma which test negative for virus may host latent 
viral infections which may predispose to the development of disease.
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A study by Jarrett, however, provided contrasting results; marrow cells collected and 
cultured from two cats with FeLV negative neoplasia, did not yield infectious virus 
(Madewell and Jarrett, 1983). More cases of FeLV-free lymphosarcomas and 
leukaemias must be investigated, and cats with latent infections examined, to further 
elucidate the role of latency in FeLV related disease. Interestingly, in vitro studies have 
identified a persistent neutrophil dysfunction, in the form of impaired cytotoxic 
function, in persistently and latently infected cats, (Lafrado et al. 1989). This may 
result in an immunosuppression, which renders the latently infected animal susceptible 
to the same opportunistic pathogens and disease syndromes associated with chronic 
persistent FeLV infection. The above may represent a mechanism by which latent 
FeLV infection establishes disease and, in wider terms, illustrates that persistent 
retroviraemia is not essential for the establishment of immunosuppression.
In terms of virus excretion, it appears that most latently infected cats do not shed 
virus, and therefore do not transmit virus to susceptible animals (Madewell and Jarrett,
1983). However, transmission of FeLV via the milk to the kittens of a latently infected 
nonviraemic queen has been demonstrated (Pacitti et al. 1986). This demonstrates that 
in a breeding colony, at least, latent FeLV infection may represent a potential source of 
infective virus.
1.1.8 CONTROL OF FeLV INFECTION
1.1.8.1 Test and removal schemes
Before the advent of efficacious vaccines, test and removal programmes were adopted 
in an attempt to limit and eradicate FeLV infection, especially in multi-cat households. 
Hardy described an effective control programme (Hardy et al. 1976) which basically 
involved testing all cats in the household for FeLV, identifying the cats that tested 
positive, then separating positive and negative animals. All cats were then retested 
after 12 weeks, and those which tested positive again were considered persistently 
viraemic, and were removed from the cohort (or isolated). Those which tested negative
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on second sampling were kept in isolation until they tested positive on two consecutive 
occasions and those that tested negative twice were considered truly non-viraemic. 
Frequent retesting, every six to twelve months was then recommended. This 
programme was indeed successful; in a study of multi-cat households, after removal of 
viraemic cats, only three out of 657 animals, (0.46%), became viraemic, compared to 
55 out of 284, (19.3%), which became persistently infected when viraemic cats were 
not removed (Hardy et al. 1976).
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1.2 FELINE LEUKAEMIA VIRUS VACCINES
1.2.1 EARLY HISTORY OF FeLV VACCINATION
Several observations led to the belief that the production of an effective vaccine against 
FeLV was possible. Firstly, many cats developed natural protective immunity to FeLV. 
Thus, recovered cats generated virus neutralising antibodies (Jarrett et al. 1973) and 
became resistant to re-infection with the virus. Secondly, maternally derived antibody 
was found to protect kittens from viral challenge (Jarrett et al. 1977), and thirdly, as 
the virus was transmitted through contact and not genetically (Hardy et al. 1973), the 
cycle of infection could potentially be broken.
Many different strategies for the development of FeLV vaccines have been employed, 
and advantages and disadvantages of these approaches are outlined in table 1.2. Jarrett 
reported the first attempt to produce a FeLV vaccine in 1974 (Jarrett et al. 1974), 
(Jarrett et al. 1975). Two cellularly derived vaccines were produced, which consisted 
of either live or paraformaldehyde-inactivated lymphoblastoid cells of the FL74 line, 
established by Theilen (Theilen et al. 1969). Both vaccines induced anti-FOCMA 
antibodies and it was found that the live cell vaccine protected cats against viral 
challenge. However, the cats vaccinated with the inactivated cell preparation were not 
challenged, so the efficacy of this vaccine, in terms of its ability to protect against 
infection, was never evaluated.
A major drawback to this work, however, was that the live FeLV-infected tumour cells 
used in the vaccine could generate infectious virus and therefore could potentially 
cause disease in some animals. The use of a live retroviral vaccine was also 
considered, at that time, to be a potential public health hazard. Consequently, attention 
was focused on the development of inactivated cell vaccines, using formalin, heat and 
ultraviolet light to kill live virus. Although these vaccines were able to elicit anti- 
FOCMA and occasionally virus neutralising antibodies, post-challenge protection from
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viraemia was uncommon. For example, in a study by Pedersen et al, an inactivated 
whole FL74 cell vaccine did not elicit a protective antibody response or confer 
protection against persistent infection, whereas a live vims vaccine was found to be 
highly efficacious in preventing the development of persistent infection (Pedersen et al. 
1979).
Moreover, when killed FeLV vims was added to inactivated cell preparations, in an 
attempt to improve vaccine efficacy, this actually appeared to increase the prevalence 
of FeLV associated disease in vaccinates (Olsen et al. 1977). Initially, this problem 
was attributed to the FeLV envelope protein pl5E , (Mathes et al. 1979), as this protein 
had reportedly caused immunosuppression in vivo and in vitro. Now, however, this is 
not a widely held belief. One study found that antibodies raised against p l5E  may play 
a role in FeLV neutralisation (Francis et al. 1977) while others have suggested that the 
presence of the pl5E  protein may actually improve vaccine efficacy, perhaps by 
enhancing the potency of cell-mediated immune responses (Hoover et al. 1991). In 
fact, data began to accumulate in the early 1980s, which suggested that inactivated 
whole vims vaccines could protect cats from persistent viraemia (Pedersen et al. 
1979), (Pedersen et al. 1986).
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Type of vaccine Advantages Disadvantages
Live attenuated virus vaccines.
Both cellular and humoral 
immunity generated. 
Provide good protection.
Not safe; may revert to 
virulence and cause 
disease in some animals
Inactivated whole virus 
vaccines.
All B and T cell epitopes 
presented.
Questionable safety. 
No CTL response. 
Expensive production. 
Adjuvants needed.
Viral subunit vaccines (from 
native virus, recombinant 
proteins, or peptides).




No CTL response, 
(exception: ISCOM)
Live viral vector vaccines. B and T cell responses.
Repeated boosters not 
possible? 
Limited antigenicity.
Table 1.2. Approaches for the development of FeLV vaccines; advantages and 
disadvantages
CTL, Cytotoxic T lymphocyte; ISCOM, immunostimulating complex vaccine
1.2.2 SUBUNIT PRODUCTS; THE FIRST COMMERCIAL FeLV VACCINE
In the late 1970s it was demonstrated that the manipulation of the tissue culture 
medium used to grow FL74 cells (FeLV infected tumour cells) allowed the generation 
and expression of large amounts of soluble FeLV antigens, including gp70 and 
FOCMA, without the production of large quantities of live infectious virus (Wolff et 
al. 1979). These viral antigens were later harvested, purified, and combined with an 
adjuvant, to produce a vaccine which Olsen and colleagues found to be protective 
against viral challenge (Lewis et al. 1981). A commercial vaccine based on this
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approach, originally manufactured by Norden Laboratories, (Lincoln, Nebraska, USA), 
became available in 1985. This vaccine, Leukocell, a subunit vaccine (Sharpee et al. 
1986), was the first commercial FeLV vaccine, and required the administration of three 
doses for initial immunisation. In 1988, modification of the original vaccine led to the 
licensing of its successor, Leukocell 2, which required the administration of only two 
immunisations in the initial vaccination course.
Several studies reported the efficacy of Leukocell and Leukocell 2 (Sharpee et al. 
1986), (Haffer et al. 1990), (Lafrado, 1994), (Pollock and Scarlett, 1990). Pollock 
conducted a long-term study with Leukocell, using natural exposure challenge in an 
infected multi-cat environment and found that the incidence of persistent viraemia, 
after challenge, was approximately three times greater among the non-vaccinates than 
among the vaccinates (Pollock and Scarlett, 1990). However, several recent studies 
have questioned the efficacy of Leukocell (Legendre et al. 1990), (Hoover et al.
1996), (Pedersen and Johnson, 1991).
A study conducted by Legendre, using natural exposure challenge, found that 64% of 
unvaccinated kittens and 70% of vaccinated kittens became infected after viral 
challenge, while 43% of unvaccinated and 39% of vaccinated kittens died (Legendre et 
al. 1990). These results indicated that the Leukocell vaccine provided no significant 
protection against infection with FeLV. Hoover, meanwhile, demonstrated a 
preventable fraction (PF) of only 12%, when testing the efficacy of Leukocell (Hoover 
et al. 1996). The PF is defined as the proportion of cats protected by vaccination in 
excess of that protected by natural innate resistance (Loar, 1993) so that the fact that 
often considerably less than 100% of control cats develop persistent viraemia is taken 
into account in the calculation. PF is calculated using the following formula.
PF (%) = % controls with persistent viraemia (PV) - % vaccinates with PV
% controls with PV
However, other factors are important in assessing vaccine efficacy. An evaluative 
study of Leukocell 2, conducted by Lafrado, illustrates this point (Lafrado, 1994).
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Twenty-six eight week old SPF kittens were vaccinated subcutaneously with 2 doses of 
the FeLV vaccine, and 26 age-matched specific pathogen-free cats were similarly 
vaccinated with a placebo vaccine containing the same adjuvant as the FeLV vaccine. 
Cats then were randomly assigned to 2 groups of 26 cats and each group was housed 
with 5 viraemic cats, previously inoculated with FeLV. All cats were tested biweekly 
for the next 26 weeks for evidence of FeLV antigenemia and the PF at the end of the 
trial was calculated as 100%. However this result reflected the development of 
persistent viraemia in only one of 26 control cats, and none of the 26 vaccinates. The 
fact that a very small percentage (4%) of the unvaccinated controls became persistently 
viraemic suggests that viral challenge was not vigorous enough. Therefore, taking into 
account the inadequacy of the challenge, it is impossible to evaluate the efficacy of 
Leukocell 2 from the results produced by this study. To date, the efficacy of these 
widely used vaccines, Leukocell and Leukocell 2, are still in question.
1.2.3 W H OLE VIRUS PRODUCTS
Although vaccination with attenuated but non-inactivated virus was found to be highly 
efficacious in protecting cats against FeLV challenge, the safety risks involved with the 
use of replicating live virus led many researchers to develop FeLV vaccines using 
distinct strains of inactivated virus, with or without adjuvants, (Hines et al. 1991), 
(Sebring et al. 1991), (York and York, 1991). These vaccines, Fevaxyn FeLV (Solvay- 
Dulphar/Fort Dodge), Fel-o-vax (Fort Dodge) and Leucat or VacSYN (Rhone 
Merieux/Synbiotics), respectively, were found to be highly efficacious by the 
researchers involved in their development. Chronologically, by the date of licensing, 
the vaccines became available in the US in the following years: Covenant 
(Haver/Diamond Scientific) in 1988, withdrawn in 1989, VacSYN (Rhone 
Merieux/Synbiotics) in 1989, Fel-o-Vax (Fort Dodge) in 1989 and Fevaxyn (Solvay- 
Dulphar/Fort Dodge) in 1991. Of these vaccines, only Fevaxyn FeLV is available in 
the United Kingdom.
However, the efficacy of several of the above vaccines and Leukocell has been 
questioned by many researchers (Osterhaus et al. 1989), (Pedersen and Johnson,
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1991), (Legendre et al. 1991), (Jarrett and Ganiere, 1996). Disadvantages associated 
with these vaccines were their inability to induce cytotoxic T lymphocyte (CTL) 
activity and their inherent lack of immunogenicity; powerful adjuvant systems were 
needed to induce an adequate immune response in vaccinates. In 1991, Legendre 
evaluated Fel-o-Vax, Leukocell 2 and VacSYN (Legendre et al. 1991) and found that 
although Fel-o-vax completely protected all vaccinates from viral challenge, a PF of 
only 34% was obtained with Leukocell 2 and a PF of 21% with VacSYN. A study by 
Pedersen, reported similar results (Pedersen and Johnson, 1991). A PF of only 17% 
was obtained after vaccination with Leukocell 2, and a PF of 39% after vaccination 
with VacSYN.
These results contrast dramatically with those of the developers of the vaccines (York 
and York, 1991), (Pollock and Haffer, 1991) and in-house studies performed by the 
vaccine manufacturers. However, due to differences in challenge methods, numbers of 
animals used, vaccine strains and doses, post-challenge monitoring protocols and the 
researchers’ definition of persistent viraemia, it is often extremely difficult to interpret 
and then to compare results to those obtained in other studies. Another problem is that 
the majority of FeLV vaccine trials have been performed or supported by vaccine 
manufacturers or distributors; fully independent trials are obviously preferable. 
However, experimental evidence does suggest that many conventional inactivated viral 
vaccines simply do not generate sufficient immunity to completely protect against the 
development of persistent (Jarrett and Ganiere, 1996) or transient viraemia, thus 
increasing the likelihood that latent bone marrow infection will develop (Sparkes,
1997).
Two inactivated whole viral vaccines, which were demonstrated to be highly 
efficacious in protecting cats against persistent viraemia by several investigators were 
Fel-O-Vax, (Fort Dodge), (Hoover et al. 1996), (Legendre et al. 1991) and Fevaxyn 
FeLV, (Solvay-Dulphar/Fort Dodge), (Pedersen, 1993), (Hines et al. 1991). Although 
Fel-O-Vax is extremely efficient in protecting against the development of persistent 
viraemia, one study demonstrated that almost one half of the non-viraemic, protected 
cats were transiently viraemic during the trial (Legendre et al. 1991) and almost half 
were latently infected, 23 weeks after viral exposure.
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Fevaxyn FeLV meanwhile, may be superior to Fel-O-Vax in terms of protecting 
against the development of transient viraemia and latent FeLV infection. However, in 
one trial using this vaccine (Hines et al. 1991), a significant number of cats were 
persistently viraemic at the end of the trial (12 out of 144 animals) or transiently 
viraemic during the trial (10 cats from the 132 protected cats). Also, five of the 
transiently viraemic cats were found to be latently infected at the termination of the 
experiment. Another study involving Fevaxyn FeLV, found that this vaccine 
completely protected all vaccinates (10/10), from latent infection (Pedersen, 1993). 
However, the strain of FeLV used for challenge, CT600, does not produce a high 
proportion of latent infections, compared with other strains, such as Rickard-FeLV 
(Pedersen et al. 1984). It is, therefore, difficult to judge how effective this particular 
vaccine is in preventing the development of latency. In summary, although Fevaxyn 
FeLV and Fel-O-Vax are efficacious inactivated whole virus vaccines, neither are able 
to completely prevent the development of transient or latent FeLV infection.
As well as the serious questions raised relating to the efficacy of the inactivated virus 
vaccines, there were concerns regarding the expense of their production and misgivings 
regarding the safety of administering the vaccines to cats (Loar, 1993) Firstly, there 
was the concern, albeit controversial, that the pl5E  protein present in whole virus and 
some subunit products, could exert an immunosuppressive effect (Mathes et al. 1979). 
Secondly, there was the fear that inoculation with an impure preparation, containing 
extraneous proteins to which cats had been sensitised to previously, perhaps through 
being vaccinated against other feline diseases, might increase the likelihood of 
initiating an allergic reaction (Kensil et al. 1991). A vaccine which contained serum 
proteins or feline cellular antigens could also potentially induce serum sickness or 
autoimmune disease. Lastly, and probably most importantly, there was the fear that 
residual, live virus could survive the inactivation process, contaminate the vaccine and 
replicate and establish FeLV infection in the vaccinate. All the aforementioned 
problems associated with inactivated whole virus vaccines led to attempts to produce 
novel vaccines using recombinant DNA technology.
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1.2.4 GENETICALLY ENGINEERED VACCINES
1.2.4.1 Introduction
Recombinant DNA technology allows for the consistent production of large quantities 
of pure, stable antigen of predictable quality. A major advantage that genetically 
engineered vaccines have over inactivated whole virus formulations is that specific, 
protective amino acid sequences may be selected for inclusion in the vaccine, while 
non-protective or potentially immunosuppressive sequences are deleted. Moreover, 
because live virus is not required for the production of the antigen, there is absolutely 
no chance that residual virus may survive the inactivation process. The manufacture of 
pure recombinant antigen also ensures that extraneous proteins and residual media 
components, which may initiate allergic reactions, or protease contaminants, which 
may destroy important antigenic proteins, are not present in the vaccine.
In the mid 1980s, much of FeLV vaccine research was focused on developing 
genetically engineered viral subunit protein vaccines. Among the various structural 
proteins of FeLV, the gp70 envelope glycoprotein was considered by many to be 
crucial to the development of protective immunity in cats (Salerno et al. 1978). 
Pedersen, aware of the growing interest in recombinant subunit FeLV vaccines, 
realised that the ability to protect against viral challenge and immunogenicity of native 
viral protein subunits had to be determined first. Therefore he produced a purified 
subunit FeLV vaccine, consisting only of viral gp70, which had been isolated from 
purified virions by affinity chromatography (Pedersen et al. 1986). This vaccine, 
however, proved to be ineffective and may actually have enhanced infection, as a 
greater proportion of vaccinated kittens became persistently viraemic after viral 
challenge compared to non-vaccinates (Pedersen et al. 1986).
1.2.4.2 Viral vector vaccines; vaccinia virus
Since then, several live viral vector systems, expressing one or more FeLV antigens in 
infected cells, have been considered as candidate vaccines (Willemse et al. 1996), 
(Wardley et al. 1992), (Tartaglia et al. 1993), (Gilbert et al. 1987). These vaccines
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were expected to elicit potent humoral and cellular immune responses, through the 
expression of endogenously processed antigen. However, a potential hazard associated 
with this type of vaccination is that booster immunisations may initiate an 
inappropriate immune response to the delivery vector which, in turn, may interfere 
with the immune response directed to the antigenic component of the vaccine (Ramsay 
et al. 1997). An attempt to use vaccinia virus to express the FeLV gp70 antigen 
protein was unsuccessful (Gilbert et al. 1987). Although cats raised a typical virus 
neutralising antibody response to the vaccinia virus vector, no antibodies elicited 
against FeLV gp70 were detected in any vaccinates. Moreover, a subsequent “booster” 
vaccination with killed FeLV demonstrated that immunologic priming had not been 
elicited by the recombinant vaccine. A personal communication from the above 
authors, cited in another paper, (Tartaglia et al. 1993), reported that this vaccine did 
not protect cats against viral challenge.
1.2.4.3 Viral vector vaccines; canarypox virus
In contrast, a canarypox vector, (ALVAC), vaccine, expressing both gag and env 
FeLV proteins, was successful (Tartaglia et al. 1993). This vaccine protected all of six 
cats against persistent viraemia, in the absence of detectable virus neutralising 
antibodies at the time of challenge. However, all protected cats developed virus 
neutralising antibody activity between nine and twelve weeks post-challenge. This 
suggests that protection was associated with the ability to raise a neutralising antibody 
response after challenge but does not rule out the possibility that other immune 
mechanisms such as the induction of cytotoxic lymphocyte activity, were also 
involved. This vaccine is in development for commercial use (Jarrett, 1996).
1.2.4.4 Viral vector vaccines; feline herpesvirus
Feline herpesvirus type 1 (FHV-1) had been considered a good candidate vector for 
expression of FeLV proteins, mainly because its primary sites of replication, the 
mucosae of the cat’s oral and nasal cavities, are also the primary targets of FeLV 
infection (Willemse et al. 1996). The first attempt to vaccinate with FHV-1, 
expressing only FeLV env protein, did not protect cats against viral challenge (Wardley
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et al. 1992). Meanwhile, attempts to vaccinate with herpesvirus expressing both FeLV 
gag and env proteins were also unsuccessful until a booster vaccination with 
baculovirus expressed FeLV gag and env proteins was administered (Wardley et al.
1992). A later attempt, using recombinant FHV-1 alone, expressing env, produced 
better results (Willemse et al. 1996). The construct used here differed from the 
previous study in that the insertion site and the promoter driving expression of the 
FeLV env gene were altered. The different insertion site, the thymidine kinase gene 
rather than the ORF2 locus, may have influenced local replication of the recombinant. 
Although this vaccine did afford some degree of protection against persistent infection 
in that 3/4 vaccinates were protected while 5/6 controls became persistently infected 
after challenge, all but one of the vaccinates was found to have latent FeLV infection in 
bone marrow (Willemse et al. 1996). Moreover, the small number of animals involved 
in this trial makes it difficult to accurately evaluate the efficacy of this vaccine.
1.2.4.5 Recombinant subunit vaccine; Leucogen
1.2.4.5.1 Introduction
Since the importance of the gp70 protein in protection from FeLV infection was 
identified, several attempts have been made to produce efficacious FeLV vaccines 
using this glycoprotein (Salerno et al. 1978), (Pedersen et al. 1986). These attempts 
were not successful, as described earlier in this section, either in terms of serological 
response or protection from viral challenge. However, one vaccine based on pure, 
recombinant FeLV gp70 antigen has proved to be efficacious and is now in widespread 
use (Kensil et al. 1991), (Marciani et al. 1991), (Clark et al. 1991).
1.2.4.5.2 Production o f Leucogen
A portion of the envelope gene of a FeLV subgroup-A clone, encoding the entire 
exterior envelope protein gp70 and the first 34 amino acids of the transmembrane 
protein pl5E , was cloned into a prokaryotic expression vector (Kensil et al. 1991). 
The recombinant antigen was then expressed by E. Coli and purified, by extracting
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from bacteria with urea and precipitating on to aluminium hydroxide. Finally, the 
antigenic protein component of this vaccine, the non-glycosylated form of gp70, 
termed p45 env, was used in conjunction with a novel purified saponin adjuvant,
QS-21 (Marciani et al. 1991). Thus, the use of recombinant DNA technology allowed 
the production of large quantities of purified recombinant protein which could then be 
combined with a highly effective adjuvant. This resulted in the production of the 
efficacious commercial vaccine, Leucogen (Virbac), which is perhaps the most widely 
used FeLV vaccine in the United Kingdom.
1.2.4.5.3 Antigenic component o f Leucogen
The question as to why Leucogen was able to elicit a protective immune response 
against FeLV challenge while other gp70 protein based vaccines did not (Salerno et al. 
1978), (Pedersen et al. 1986), (Gilbert et al. 1987) was explored. The development of 
an effective subunit vaccine must take both the antigenic and the adjuvant components 
into consideration. In terms of the antigenic component, a contributing factor to the 
lack of efficacy of previous subunit vaccines was thought to be the subgroup of the 
virus used for gp70 antigen isolation. A strong correlation between the generation of 
neutralising antibodies to FeLV A, but not subgroup B or C viruses, and protection 
against leukaemia, has been reported. Meanwhile, the production of many subunit 
vaccines have involved a mixture of viral subgroups, A, B and C, with subgroup B 
viruses as the immunodominant component. In contrast, the Leucogen vaccine contains 
only FeLV subgroup-A gp70 recombinant protein (Marciani et al. 1991).
Another interesting observation is that the gp70 protein does not need to be in its 
native form, in terms of glycosylation and conformation, to elicit a protective immune 
response to FeLV (Marciani et al. 1991). The recombinant gp70 protein used in the 
Leucogen vaccine was heavily denatured in production so that it was unable to fold 
towards a native conformation (Marciani et al. 1991). In contrast to the protective 
immune response elicited by this recombinant vaccine, immunisation with native FeLV 
gp70 showed an enhancement of FeLV infection (Pedersen et al. 1986).
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1.2.4.5.4 Adjuvant component o f Leucogen
An adjuvant may act as a potent immunostimulator and immunomodulator and/or as a 
carrier of the antigenic component of a vaccine. Addition of a potent adjuvant was 
considered crucial in overcoming the poor immunogenicity of the FeLV antigenic 
component of Leucogen (Marciani et al. 1991). The developers of the vaccine found 
that formulation of the same antigen with other commonly used adjuvants, as opposed 
to the novel saponin adjuvant present in Leucogen, generated a poor protective 
immune response in cats. The potency of the humoral immune response was found to 
be dependent on the adjuvant used (Marciani et al. 1991). Alum and oil emulsion 
adjuvants were found to induce a poor neutralising antibody response, in accordance 
with other reports (Salerno et al. 1978), (Pedersen et al. 1986). Therefore, the efficacy 
of the Leucogen recombinant subunit vaccine was probably due, in part, to the 
inclusion of a potent and effective adjuvant. Indeed, Pedersen suggested that the failure 
of their native viral subunit vaccines could be due to the adjuvant component 
(Pedersen et al. 1986).
1.2.4.5.5 Ejficay o f Leucogen
In terms of efficacy, preliminary trials involving Leucogen, demonstrated that 85% of 
vaccinates (seventeen out of twenty), resisted persistent FeLV infection, following 
stringent challenge exposure (Clark et al. 1991). This translates to a preventable 
fraction of 78.6% when taking into account the percentage of control cats persistently 
viraemic at the end of the trial. Similarly, Lehmann reported a preventable fraction of 
93.3% in a study involving FIV positive and negative cats in both control and 
vaccinated groups; only 1/8 cats was persistently viraemic on completion of the study 
(Lehmann et al. 1991). Interestingly, FIV status did not affect the protective immune 
response generated by the vaccine, although decreases in CD4+ lymphocyte 
populations have been observed in FIV infected cats as early as two months after 
infection. This result illustrates that in the early phase of FIV infection the immune 
system is not appreciably compromised and cats may be successfully vaccinated 
against FeLV (Lehmann et al. 1991).
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However, a recent independent study comparing the efficacy of Leucogen with two 
commercial FeLV inactivated virus vaccines demonstrated a level of protection 
significantly less than had been previously reported (Jarrett and Ganiere, 1996). 
Although superior to the two other vaccines, Leukocell 2 and Leucat, in protecting 
against FeLV-A challenge, 5/12 cats vaccinated with Leucogen were persistently 
viraemic at the termination of the study (Jarrett and Ganiere, 1996). This translated to a 
preventable fraction of only 52.4%. This study demonstrated, however, that although 
Leucogen was representative of only one FeLV subgroup, FeLV A, it could protect 
against challenge from all three subgroups, A, B and C.
Also of note regarding the efficacy of Leucogen, was the significant proportion of 
vaccinates which were transiently viraemic, post-challenge, in the trial conducted by 
Clark (Clark et al. 1991). Forty percent of cats (8/20) were transiently viraemic in the 
twelve weeks following viral challenge. The development of transient viraemia, which 
usually remains undetected in the field, has been reported to increase the probability 
that latent bone marrow infection will develop (Sparkes, 1997), (section 1.1.7.5). In 
conclusion, the Leucogen vaccine is not capable of providing complete protection 
against either transient (Clark et al. 1991) or, more importantly, persistent viraemia 
(Jarrett and Ganiere, 1996).
1.2.5 FeLV ISCOM  VACCINE
This type of FeLV vaccine was first described by Osterhaus in 1985 (Osterhaus et al. 
1985), and later in 1989 (Osterhaus et al. 1989) and 1991 (Osterhaus et al. 1991). 
The immunostimulating complex, ISCOM, was a novel structure for the antigenic 
presentation of membrane proteins from enveloped viruses (Morein et al. 1984). The 
matrix of the ISCOM was composed of the glycoside Quil A which in micelle form has 
regions accessible for hydrophobic interaction with the membrane proteins. In this way 
complexes of antigen were formed. The conformation of the FeLV envelope antigens, 
presented on the surface of the ISCOM matrix, appeared to greatly augment the host 
immune response, both cellular and humoral. Indeed, ISCOM preparations generated 
in this way were found to be highly immunogenic. They were able to elicit an antibody
53
response to even poorly antigenic membrane proteins (Osterhaus et al. 1985), without 
the attendant risks of immunisation with killed or live attenuated virus vaccines.
The construction of the FeLV ISCOM vaccine was reported initially by Osterhaus 
(Osterhaus et al. 1985). Virus was obtained from the cell culture supernatant of a 
persistently infected feline T cell lymphoma cell line, F422, or the FL74 tumour cell 
line. The virus was processed and the gp70/85 antigen-containing fraction was 
collected, pooled and complexed with matrix to generate ISCOMs. In the initial 
experiments, six kittens were vaccinated with the F422 derived preparation, and these 
and the six controls were challenged oronasally, with FeLV-A. Ten weeks after 
challenge none of the vaccinated cats was found to be persistently infected with FeLV, 
while three of the unvaccinated controls became persistently viraemic (Osterhaus et al. 
1985).
In a subsequent trial, involving 137 FeLV-negative household cats, the potential of the 
ISCOM preparation to induce anti-FeLV and virus neutralising, (VN), antibodies, was 
compared to that of Leukocell, a commercial inactivated FeLV vaccine, and a negative 
control group (Osterhaus et al. 1989). The cats were tested for seropositivity towards 
FeLV, before the trial began and were defined as seropositive or seronegative. In 
contrast to the animals in the two other groups, almost all cats vaccinated with the 
ISCOM preparation responded by seroconverting, or developing an increased antibody 
titre, two weeks after the last of three immunisations. It should be noted that viral 
challenge was not performed, so serological changes occurred in response to 
vaccination and not to challenge. Only 2 of 35 seronegative cats vaccinated with 
Leukocell developed a VN antibody titre, as opposed to 28 of 35 seronegative cats 
vaccinated with the ISCOM preparation. Similarly, only two of 12 seropositive cats 
vaccinated with Leukocell demonstrated a rise in VN antibody titre, in contrast to six 
of nine seropositive cats vaccinated with the ISCOM preparation. None of the cats in 
the negative control group developed a neutralising antibody response (Osterhaus et al. 
1989). This result is significant, as very few experimental or commercial FeLV 
vaccines are able to induce significant titres of virus neutralising antibodies, after 
vaccination (Jarrett, 1996).
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The authors reported, however, that the ISCOM preparations used in these studies were 
not highly purified, and they elicited antibodies to a variety of FeLV antigens other 
than gp70/85 (Osterhaus et al. 1985), (Osterhaus et al. 1989). Therefore, the 
protective effect of this vaccine may not have been solely due to gp70/85. This point 
was raised by Pedersen, when reporting the efficacy of a native gp70 protein subunit 
vaccine, which enhanced rather than protected against infection (Pedersen et al. 1986). 
In order to prove that the envelope proteins alone were responsible for the protective 
immunity generated by the ISCOM gp70/85 vaccines, ISCOM vaccines containing 
only highly purified gp70/85 antigen should be administered to cats.
ISCOM preparations have been shown to be highly effective in eliciting B-cell 
responses resulting in the generation of biologically active anti-viral antibodies, and T 
helper cell responses (Morein, 1988). Most viral subunit protein preparations are 
unable to elicit CD8+ MHC class I restricted CTL activity. In contrast to most other 
non-replicating immunogens, however, the ISCOM system is also capable of eliciting 
this type of cellular immune response. A single subcutaneous immunization with 
ISCOM preparations, containing either purified intact gpl60 envelope glycoprotein of 
the human immunodeficiency virus (HIV-1) or influenza haemagglutinin, has been 
shown to induce reproducible and long-lasting priming of HIV specific or influenza 
specific CD8+, MHC class I restricted CTL, in mice (Takahashi et al. 1990). ISCOM 
vaccines have also been reported to protect against infection with viruses belonging to 
virtually all membrane virus families (Morein, 1988). For the above reasons, ISCOM 
formulations have been developed as candidate vaccines against retroviral disease, 
such as FeLV, FIV and HIV (Osterhaus et al. 1985), (Tijhaar et al. 1997), (Sjolander 
et al. 1996).
1.2.6 COMMERCIALLY AVAILABLE FeLV VACCINES
At present there are five commercial FeLV vaccines marketed in Europe and the USA 
(Sparkes, 1997), although some are marketed by different companies, and under 
various labels, in different countries. These vaccines have been reviewed earlier in this
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section; none consistently provide 100% protection against persistent infection or 
generate sufficient mucosal immunity, to routinely prevent transient viraemia, after 
viral exposure (Sparkes, 1997). Table 1.3. provides details of the various vaccine 
preparations.
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mixed sub-unit from 
FeLV- 
infected tissue culture 
filtrate
Pfizer A, B & C Yes Yes
Table 1.3. FeLV vaccines commercially available within and outside the UK.
57
1.2.7 CONCLUSION
Many different types of FeLV vaccines have been constructed, with varying success. 
From the limited data available, regarding the commercial products, the whole virus 
vaccines, Fel-o-vax, (Fort Dodge) and Fevaxyn FeLV, (Solvay-Dulphar/Fort Dodge), 
appeared to demonstrate the most consistent protection against FeLV challenge. 
However, as reviewed in section 1.2.3. neither vaccine was able to completely prevent 
the development of transient or latent FeLV infection. Moreover inactivated virus 
vaccines have inherent disadvantages, regarding the quality and range of the immune 
response they induce, attendant risks, regarding safety, and production problems, 
regarding expense. Several of the experimental vaccines, such as the canarypox viral 
vector vaccine and the ISCOM preparations, proved to be efficacious in experimental 
trials; however, these vaccines are not without their shortcomings. The data reviewed 
here highlights the need to produce an FeLV vaccine capable of protecting against 
persistent and transient viraemia, and the consequent development of latent infection, 
and FeLV-related disease (Rojko and Hardy, 1994). For all these reasons, the 




Naked DNA vaccination presents a new approach in vaccine development. DNA 
vaccine constructs are created by the insertion of DNA encoding a desired antigen into 
an eukaryotic plasmid expression vector (Robinson and Torres, 1997). The purified 
plasmid DNA is inoculated directly into the host where it can transfect cells, following 
delivery by a number of different routes. The immunising protein is then expressed in 
transfected cells in vivo under the control of the plasmid expression vector promoter. 
Consequently, an immune response is elicited to the expressed antigen. As the host 
cells’ transcriptional machinery is utilised, the protein is expressed directly in the cells 
with the appropriate post-transcriptional modifications and tertiary structure to produce 
conformationally specific antigens. Also, through presentation via the endogenous 
pathway, cellular immune responses may be induced (Donnelly et al. 1997b). This 
unique approach to immunisation may allow the development of safe and efficacious 
prophylactic and therapeutic vaccines and may be useful as a research tool, for 
example, in the production of monoclonal antibodies (Tang et al. 1992). Indeed, 
numerous animal models for DNA vaccines against viral, bacterial and parasitic 
diseases have now been described (Donnelly et al. 1997b) and, more recently, human 
clinical trials have been undertaken (MacGregor et al. 1998).
1.3.2 EARLY HISTORY OF DNA VACCINATION
The earliest report of transfection of cells, in vivo, with injected purified DNA, was 
made almost thirty years ago (Ito, 1960). The potential of this discovery, however, was 
largely disregarded until relatively recently. The first evidence for direct in vivo gene 
transfer was reported by Wolff in 1990 (Wolff et al. 1990). This group demonstrated 
expression of a reporter gene in murine skeletal muscle and biological activity of the
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encoded enzymes for up to 60 days after inoculation. Meanwhile, the potential of this 
new technology to initiate immune responses was first described by Tang et al in 1992 
(Tang et al. 1992) who observed that mice inoculated by gene gun delivery, with 
plasmids expressing the gene for human growth hormone, developed specific primary 
antibody responses. Moreover, these responses could be boosted by subsequent 
immunisations. Further reports described the generation of antibodies raised against 
influenza virus haemagglutinin (HA) glycoprotein and HIV gpl20, in mice immunised 
by gene gun with the appropriate plasmids (Eisenbraun et al. 1993).
Meanwhile, Ulmer et al further developed the technique of delivering DNA 
immunogens intramuscularly (Ulmer et al. 1993). He reported that mice immunised 
with plasmids encoding the nucleoprotein (NP) gene of the A/PR/8/34 strain of 
influenza virus developed potent, specific CTL responses which were protective 
against a heterologous strain of influenza (Ulmer et al. 1993). These initial 
experiments marked the beginning of new and exciting developments in 
immunoprophylaxis. DNA vaccination was considered as a therapeutic tool, for the 
prevention and treatment of a wide range of conditions, including infectious disease, 
allergy, autoimmunity and cancer.
1.3.3 DNA VACCINE PLASMIDS
Plasmid DNA constructs used for vaccination are similar to those used for the delivery 
of reporter or therapeutic genes. These constructs have five main features in common 
(Davis, 1997). Firstly, they possess a bacterial origin of replication that facilitates 
amplification of large quantities of plasmid DNA for purification. Secondly, a 
prokaryotic selectable marker gene, such as an antibiotic resistance gene, is present. 
Thirdly, they contain eukaryotic transcription regulatory elements; these are usually 
strong viral promoter/enhancer sequences which direct high levels of gene expression 
in a wide host cell range. Importantly, they also possess DNA sequences which encode 
the antigenic protein or peptide of interest. Finally, these plasmids contain a 
polyadenylation sequence to ensure that the transcribed mRNA is appropriately 
terminated.
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Many vectors used for DNA vaccination also possess a signal sequence, to ensure that 
the expressed protein is secreted. However, this feature does not appear to be essential 
for the initiation of either cell mediated or humoral immunity (Michel et al. 1995), 
(Donnelly et al. 1996). Sequences which encode cytokines (Iwasaki et al. 1997), 
(Tsuji et al. 1997), (Kim et al. 1997), or B-7 costimulatory molecules (Iwasaki et al.
1997), which when adjacent to MHC molecules in the cell membrane lead to immune 
activation rather than the induction of tolerance, may also be included in DNA 
vaccines. The co-expression of these cytokines or costimulatory molecules may 
enhance and augment the immune response to the antigenic component of the vaccine. 
This will be described in more detail in section 1.4.3.2.
Another important feature of plasmid DNA is the presence of unmethylated CpG 
motifs, which have T-helper cell type 1 ( Thl) immunostimulatory activity (Pisetsky,
1996), (Klinman et al. 1996), (Sato et al. 1996). These CpG motifs are 6-base 
unmethylated DNA sequences which have in common a cytosine preceding a 
guanosine, flanked by two 5' purines and two 3' pyrimidines (Klinman et al. 1996). In 
their unmethylated form these DNA motifs have been demonstrated to be potent 
stimulators of several types of immune cell. Monocytes and macrophages are 
stimulated to produce a range of cytokines, including IL-12 and TN F-a (Halpem et al.
1996) and, in turn, these cytokines induce the lytic activity of natural killer (NK) cells 
and stimulate their secretion of IFN-y. CpG motifs may also rapidly activate murine B 
cells to secrete IL-6 and IgM, as well as to proliferate (Krieg et al. 1995), (Yi et al.
1996). These motifs are present at much lower frequencies in vertebrate DNA and are 
almost always methylated. Therefore, the immunostimulatory activity of bacterial 
DNA is likely to enhance the host immune response against invading pathogens. In 
DNA vaccine plasmids, this immunostimulatory activity, may act to mobilise the 
immune response against the DNA encoded antigen. Therefore, DNA vaccines possess 
endogenous adjuvant activity that is antigen independent and potently induces Thl type 
immune responses.
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1.3.4 ADVANTAGES AND DISADVANTAGES OF DNA VACCINATION
DNA vaccination possesses a number of potential advantages over current 
immunisation methods. This new technology combines many of the most attractive 
aspects of modem vaccination strategies, with few of the disadvantages. Primary 
advantages are the purity, physiochemical stability and simplicity of production (Davis,
1997) of plasmid DNA and the ability to formulate single dose vaccines containing 
many different antigens (from the same or different pathogens) rapidly, inexpensively, 
and on a large scale (Ramsay et al. 1997). In addition to the immense versatility of 
DNA vaccines, their low production costs and heat stability make them ideal 
prophylactic agents for use in the field in developing countries, where expensive 
refrigeration stores are not routinely available (Davis, 1997).
An ideal vaccine would be able to initiate both cellular and humoral immune responses 
(Davis, 1997). Antigen based vaccines containing the whole pathogen, such as 
inactivated vaccines, or a component of it, such as subunit vaccines, are able to elicit 
antibody production, but generally not CTL activity. They are processed solely as 
exogenous antigen, and are therefore limited to presentation by MHC class II 
molecules, with only a few exceptions (Jondal et al. 1996). Expression in the context 
of the cell’s MHC class I molecules, essential for the induction of MHC class I- 
restricted antigen-specific cytotoxic CD8+ T lymphocyte activity, does not occur. 
However, vaccines which are processed as endogenous antigen, such as live attenuated 
and live viral vector vaccines, while able to elicit both antibodies and CTL activity by 
the presentation of antigen in the context of MHC class I and II molecules, possess 
some potential disadvantages.
Live vaccine pathogens possess the potential to revert to a virulent form, of particular 
concern in immunosuppressed individuals, and live viral vector delivery systems may 
be associated with pre-existing vector immunity (Ramsay et al. 1997). Booster 
vaccinations may lead to the initiation of an inappropriate immune response to the 
delivery vector which may interfere with the immune response directed to the antigenic 
protein component of the vaccine. DNA vaccination, by contrast, utilises the host cells’ 
transcriptional machinery to endogenously produce antigen, mimicking aspects of live
62
attenuated vaccination and allowing MHC class I and class II antigen presentation and 
the induction of CTL activity and antibody production. However, the attendant risk of 
reversion to virulence and potential pathogenic replication is completely abrogated (Lu,
1998).
Moreover, CTL activity elicited by DNA vaccination may provide cross-strain 
protection against viral pathogens, such as influenza A virus, by recognition of 
epitopes from conserved internal viral proteins, associated with MHC class I molecules 
(Ulmer et al. 1993). Both CD4+ helper T cells and CD8+ CTL are efficiently elicited 
by DNA vaccines (Pardoll and Beckerleg, 1995) and their ability to induce specific and 
long-lived cellular and humoral immunity (Ulmer et al. 1993), (Wang et al. 1993), 
(Ulmer et al. 1996) has been frequently reported. Figure 1.5. and figure 1.6. illustrate 
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Figure 1.5. Pathway for DNA vaccine antigen processing and presentation by 
M HC class I molecules.
With relatively few exceptions, only vaccines which are processed as endogenous 
antigen, such as DNA vaccines, may be processed and presented by MHC class 1 
molecules, as described above.
ER, endoplasmic reticulum; CTL, cytotoxic lymphocytes; MHC, major 
histocompatability complex.
However, despite the huge potential advantages of DNA vaccination, some issues have 
been raised with regard to its safety. There is the theoretical possibility that integration 
of plasmid DNA into the host genome may occur, leading to insertional mutation, 
activation of oncogenes and, therefore, possible tumourigenesis (Ramsay et al. 1997). 
Similarly, there are concerns that DNA vaccination may lead to the development of
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autoimmune disease due to the induction of anti-DNA antibodies, or the breaking of 
tolerance to self proteins due to prolonged expression of antigen (Ramsay et al. 1997). 
Of lesser importance is the concern that expressed antigens, for example, from non- 
viral intracellular pathogens, may not be correctly glycosylated leading to the 
generation in the host of antibodies of the incorrect specificity (Ramsay et al. 1997).
Synthesis of antigen in cell or internalisation of 
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Figure 1.6. Pathway for DNA vaccine antigen processing and presentation by 
MHC class II molecules.
Vaccines which are processed as endogenous antigen, such as DNA vaccines, are able 
to elicit both antibodies and CTL activity, by the presentation of antigen in the context 
of both MHC class I and II molecules.
T helper cells, T helper lymphocytes; MHC, major histocompatability complex.
65
As DNA vaccination is such a recently developed technology, emerging in the last six 
years, it is too early to unequivocally define it as a completely safe method of 
immunisation. However, to date, no experimental evidence for chromosomal 
integration of injected DNA has been produced (Nichols et al. 1995), (Wolff et al.
1992). Similarly, although bacterial DNA is immunogenic, no consequent pathology or 
exacerbation of autoimmune conditions has been observed following vaccination 
(Ramsay et al. 1997). Several human clinical trials are now in progress and in a recent 
study investigating a DNA-based vaccine for the treatment of HIV-1 infection 
(MacGregor et al. 1998), it was found that patients did not develop anti-DNA 
antibodies or raised muscle enzyme levels indicative of immune-mediated muscle 
damage. In fact, no laboratory test abnormalities or local or systemic adverse reactions 
were observed, at any time, during the course of the trial.
1.3.5 DNA VACCINE DELIVERY
Direct delivery of plasmid DNA is preferred for the introduction of antigen-encoding 
DNA sequences, and this may be carried out by a number of different routes. Among 
the most popular delivery methods, are intramuscular (i.m.) and intradermal (i.d.) 
injections of DNA, and the use of a “gene gun” to bombard skin with DNA coated gold 
particles (Davis, 1997), (Robinson and Torres, 1997).
Intramuscular inoculation of pure plasmid DNA, encoding a wide range of antigens, 
has been used in a diverse range of species, from fish (Anderson et al. 1996), to cats 
(Hosie et al. 1998), to chimpanzees (Davis et al. 1996), with generally good results. 
Following i.m. inoculation, most antigen expression initially occurs in skeletal muscle 
(Wolff et al. 1990). This route, however, may be less effective in larger animals, due 
to lower muscle cell transfection efficiencies, arising as a result of cellular architectural 
differences between species (Davis, 1997). The amount of DNA needed to elicit an 
immune response, injected either intramuscularly or intradermally, appears to be fairly 
independent of the size of the immunised animal; similar doses of DNA, within a log 
of each other, have been used to immunise mice, calves and monkeys. Doses of 
between lpg  and 100(ig of DNA have been used to inject mice, while between lOpg
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and lm g of DNA have been used to inject monkeys and calves (Robinson and Torres,
1997).
Intradermal inoculation of DNA vaccines can also induce potent cellular and humoral 
immune responses against the encoded protein (Raz et al. 1994), (van Drunen et al.
1998) although only a small number of cells are transfected (Raz et al. 1994). The 
efficacy of the immune response is likely to be related to the direct transfection of 
professional APCs in the skin, such as Langerhans’ cells (Condon et al. 1996), as 
inoculation of plasmid DNA into the subcutaneous space, where such cells are absent, 
fails to generate effective immunity.
Another method employed for plasmid DNA delivery is the gene gun. This method 
involves the introduction of DNA coated gold particles into the epidermis. A particle 
accelerator or compressed helium is employed to fire the gold particles at high 
velocities into the epidermis (Haynes et al. 1996). This method of delivery is 
particularly efficient as very small amounts of DNA are able to elicit very potent 
immune responses (Fynan et al. 1993), (Pertmer et al. 1995). Gene gun inoculations 
in mice have used between lOng and lOjLig of plasmid DNA, between one hundred and 
one thousand times less than the amount of DNA required for an intramuscular or 
intradermal immunisation (Robinson and Torres, 1997). The reason for this enhanced 
efficiency is probably because the gene gun facilitates the direct and accurate 
penetration of many DNA coated gold particles into APCs such as Langerhans’ cells 
(Fynan et al. 1993), thus allowing efficient antigen presentation and subsequent 
recognition in the draining lymph nodes.
Other, less invasive methods of plasmid DNA delivery are currently being developed. 
Administration of DNA to mucosal surfaces as DNA drops (Fynan et al. 1993), in 
liposomes (McCluskie et al. 1998), or in microspheres (Jones et al. 1997) has shown 
variable success. Schubbert demonstrated that it may be possible to deliver DNA 
vaccines orally, by administering microencapsulated DNA, targeted to the Peyers 
patches (Schubbert et al. 1994). Attenuated Shigella bacteria have been considered as 
a delivery vehicle for vaccine DNA to mucosal surfaces (Sizemore et al. 1997). These 
bacteria infect the colonic mucosa and due to an engineered mutation, burst open once
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inside cells, releasing DNA expression plasmids. Intranasal DNA vaccination against 
measles virus with a highly attenuated Shigella flexneri vector has proved to be both 
safe and efficacious, eliciting cellular and humoral immunity (Fennelly et al. 1999). 
These mucosal methods of DNA delivery, via the respiratory and intestinal surfaces, 
hold great hope for the development of vaccines which selectively protect these main 
pathogen entry sites by inducing specific mucosal immunity.
1.3.6 IMMUNE RESPONSES RAISED BY DNA VACCINATION
1.3.6.1 Antibody responses raised by DNA vaccination
As DNA vaccination effectively mimics natural infection, it is able to raise both strong 
humoral and cellular immune responses. Most successful DNA vaccination trials have 
demonstrated the generation of a significant antibody response against the encoded 
immunogen (Shiver et al. 1996), (Raz et al. 1994), (Xiang et al. 1994). Many factors 
have been reported to affect the efficacy and nature of the DNA-elicited antibody 
response, such as the route of DNA delivery (Pertmer et al. 1996), the DNA 
expression vector and the form of the DNA encoded antigen, whether the antigen is 
secreted, intracellular, or membrane associated. However, it appears that the most 
important factor influencing DNA-induced antibody responses is the expressed antigen 
itself. Some antigens, such as the influenza haemagglutinin antigen, are able to elicit 
potent and long-lived antibody responses in mice (Robinson et al. 1997) whereas 
others, such as HIV or SIV envelope antigen, raise only a transient, low-level antibody 
titre in mice (Lu et al. 1996). The difference in antibody responses may, in fact, reflect 
basic differences in the physical structure of antigens, and how they interact with the 
immune system (Robinson and Torres, 1997)
1.3.6.2 T-helper cell responses raised by DNA vaccination
T helper cells function by providing help, in the form of cytokines, to B cells and 
cytotoxic T cells. At least two different types of Th cells are thought to exist in humans 
and mice, Thl and Th2, which support two different types of immune response. The
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Thl response, characterised by IFN-y synthesis and IL-2 production, controls cellular 
immunity, while the Th2 response, characterised by IL-4 production, is associated with 
humoral immune responses. Thl cells stimulate the development of cytotoxic T cells, 
activate phagocytic cells and assist B cells to make IgG2a antibody, a complement 
binding IgG subclass, which acts to opsonise invading microbes (Feltquate, 1998). Th2 
cells, meanwhile, activate non-phagocytic defences, such as mast cells, and assist B 
cells to produce IgE and IgGl antibody, a non-complement binding subclass of IgG 
(Feltquate, 1998). The dominance of either a Thl or Th2 response is governed, in part, 
by the nature of the antigen. There is, however, an argument to suggest that Thl and 
Th2 are not distinct cell subtypes, but instead reflect different cytokine expression 
patterns.
In general, Thl responses are more efficient in controlling bacterial and chronic viral 
infections, whereas Th2 responses are more effective in controlling parasitic or 
mucosal infections. It appears that certain types of pathology are associated with a 
particular T helper cell response. Aberrant Thl responses may result in the 
development of autoimmune disease, while aberrant Th2 responses may support the 
development of allergic conditions. Thus, it appears that the predominance of either a 
Thl or Th2 immune response may greatly influence the outcome of a particular disease 
process. Therefore, the ability to skew the immune response towards one or other of 
the T helper cell responses would be very valuable. The advent of DNA vaccination 
technology has facilitated this.
DNA vaccination with the same vaccine plasmid is able to raise responses biased 
towards either type 1 or type 2 T cell help, depending on the method of vaccine 
delivery employed; either saline inoculations of DNA, or gene gun delivery (Pertmer et 
al. 1996). To date, most reports have demonstrated that saline DNA inoculations by 
the intradermal or intramuscular routes stimulate predominantly Thl immune 
responses, whereas gene gun inoculations stimulate Th2 responses (Feltquate et al.
1997). The type of response initiated by saline DNA inoculations may also be modified 
by changing the form of the DNA encoded antigen, from cell associated to secreted 
(Robinson and Torres, 1997) or by the coinoculation of cytokine or other 
immunostimulant plasmid DNA constructs (Chow et al. 1998).
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Thus, DNA vaccination technology has given us the ability to engineer the immune 
response raised to vaccine antigens and to manipulate the errant immune responses 
responsible for the development of autoimmune and allergic conditions. Table 1.4. 
outlines the type of immune response elicited by different delivery methods and 
different forms of DNA encoded antigen. The mechanisms that support the different 
types of T cell help generated by DNA vaccination remain incompletely understood. 
Following DNA inoculation, it appears that different migration patterns of antigen 
presenting cells, the site of antigen presentation, and the nature of the antigen 
presenting cells, themselves, may influence whether a Thl or Th2 response develops 
(Robinson and Torres, 1997).
Form of DNA encoded antigen
Method of Delivery Intracellular Plasma membrane Secreted
Gene gun delivery Th2 Th2 Th2
Intramuscular saline 
inoculation
Thl Thl Mixed, 
Thl and Th2
Table 1.4. Type of immune response elicited by different delivery methods and 
different forms of DNA encoded antigen.
1.3.6.3 Cytotoxic T cell responses raised by DNA vaccination
In contrast to many other types of vaccine, DNA vaccines are extremely efficient in 
eliciting cytotoxic T cell, CTL, activity. This is probably due to the fact that vaccine 
immunogens are presented by MHC class I molecules, a prerequisite for the activation 
of CD8+ cytotoxic T lymphocytes. There are many reports of potent and persistent 
cytotoxic T cell activity following DNA inoculation (Davis et al. 1997), (Raz et al. 
1994), (Lu et al. 1996) which is possibly a result of vaccine expression vectors
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expressing high levels of antigenic protein, and thus achieving high levels of MHC 
class I display.
1.3.7 DNA VACCINATION; MECHANISMS OF IMMUNISATION
1.3.7.1 Cellular transfection and antigen expression after DNA vaccination
Depending on the route and method of DNA vaccination, a wide range of cells may be 
transfected. Between 1-3% of myocytes within a muscle bundle have been transfected 
and have shown prolonged antigen expression, following a single intramuscular DNA 
inoculation (Wolff et al. 1992). However, it is now known that a significant proportion 
of antigen expressing myocytes may be cleared from muscle tissue within weeks, by 
antigen-specific cytotoxic T cells (Davis et al. 1997) so these cells do not act as the 
main reservoir of antigen expression. Following gene gun and intradermal DNA 
vaccination, keratinocytes are the predominant cell type to be transfected (Raz et al. 
1994). Antigen expression within these cells peaks at 24 hours post-transfection and is 
essentially absent after five to ten days due to natural epidermal sloughing. Several 
other types of epithelial cell have been transfected following saline DNA inoculations. 
These cells are only a tiny fraction of the total transfected cell population, after 
intramuscular or intradermal DNA vaccination. After intravenous saline DNA 
inoculation, the vascular endothelial cells are the predominant cell type to be 
transfected (Zhu et al. 1993).
Importantly, it appears that professional APCs such as tissue macrophages and 
dendritic cells are transfected during most methods of DNA vaccination. Macrophages 
resident in inoculated tissues as well as those in lymph nodes and spleen have been 
reported to contain plasmid DNA (Chattergoon et al. 1998). APCs in these specialised 
lymphoid tissues are thought to acquire plasmid DNA by either or both of the 
following ways. Plasmid DNA has been identified in draining lymph nodes only 20 
minutes after DNA inoculation. This result suggests that DNA can leave the injection 
site in blood or lymph, travel to local lymph nodes and subsequently transfect 
macrophages and dendritic cells resident in the node (Kuklin et al. 1997).
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Alternatively, APCs resident in the target site may be directly transfected and 
subsequently migrate to the draining node. In support of this hypothesis, labelled 
Langerhans’ cells have been found in draining lymph nodes, 24 hours after gene gun 
inoculation of DNA into fluorescein coated skin (Condon et al. 1996).
1.3.7.2 Antigen presentation after DNA vaccination
Optimal antigen presentation is mediated by APCs which are central to the production 
of most immune responses by taking up, processing and presenting antigen to T cells in 
the context of MHC class I and II molecules, with the costimulatory signals necessary 
for T cell activation. Antigen is presented in the context of the APC’s MHC class I 
and/or class II molecules, depending on whether the antigen is synthesised 
endogenously, MHC class I and II presentation, or acquired exogenously, MHC class II 
presentation alone. MHC class I antigen presentation stimulates the cellular T cell 
response and activates CD8+ cytotoxic T lymphocytes, (CTLs). These CTLs, once 
activated, are able to directly lyse infected target cells. MHC class II molecules, 
meanwhile, present antigen to CD4+ T helper cells, which are divided into two subsets, 
Thl and Th2, depending on the pattern of cytokines they produce. Thl cells control 
cellular immunity and provide cytotoxic T cell help, while Th2 cells help B cells to 
proliferate and differentiate and are associated with humoral immune responses.
After DNA vaccination, DNA antigens expressed intracellularly are presented by both 
MHC classes, eliciting humoral and cellular immune responses. However, the question 
arises as to which cells actually serve as APCs following this method of inoculation. 
Experimental evidence suggests that non-professional APCs, such as muscle cells, do 
not act as antigen presenting cells following DNA vaccination (Corr et al. 1996). 
Studies involving bone marrow chimaeric mice have shown conclusively that bone 
marrow derived professional APCs function as antigen presenting cells following both 
gene gun and saline DNA inoculations (Iwasaki et al. 1997). Two theories have been 
proposed to explain how professional APCs acquire antigen for presentation following 
DNA vaccination (Pardoll and Beckerleg, 1995).
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In the first model, directly transfected APCs are considered to be the cells responsible 
for eliciting the immune response. These cells can process and present antigen through 
MHC class I and II pathways. Antigen production by non-professional APCs, such as 
keratinocytes and muscle cells, would play only a minor role in the developing 
immunity. In support of this theory, it has been demonstrated that a DNA vaccine 
plasmid, containing an APC-specific promoter, was capable of eliciting an immune 
response (Xiang et al. 1997). Transfection and antigen expression by non-APCs was 
obviously not essential to the development of this response. Another group 
demonstrated that the transfer of transfected, antigen expressing APCs into mice was 
sufficient to raise a detectable immune response (Casares et al. 1997). Moreover, a 
study using timed muscle ablations, demonstrated that antigen production by muscle 
cells, non-APCs, was not essential for generating immunity (Torres et al. 1997). 
Removal of muscle tissue minutes after DNA inoculation resulted in the development 
of an immune response, equal in potency and longevity to that of non-ablated control 
mice, indicating that sufficient DNA may leave the injection site, in blood or lymph, to 
transfect APCs located elsewhere, such as in the spleen or lymph nodes.
In the second model, the majority of the transfected cells which are non-APCs such as 
muscle cells and keratinocytes, are thought to act as factories (Feltquate, 1998) 
producing antigen which is subsequently transferred to professional APCs. The APCs 
then process and present antigen to the immune system in the usual way. Directly 
transfected APCs would represent only a small proportion of the total population of 
APCs involved in the generation of immunity. Most evidence supporting this model 
illustrates that antigen production by non-APCs is necessary to maximise and enhance 
the developing immune response. In contrast to the results obtained in the muscle 
ablation studies, when skin was removed soon after gene gun inoculation, the immune 
response was completely abrogated (Torres et al. 1997). The longer skin was left in 
place following DNA inoculation, the greater the magnitude of the immune response 
raised. Thus, following gene gun inoculation, it appears that production of antigen by 
keratinocytes, the proposed “factory” cells, is essential for the generation of immunity.
Considering all the relevant experimental data, it appears that generation of the optimal 
immune response relies on a combination of both models. Although direct transfection
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of professional APCs may be adequate to produce an immune response, APC 
distribution may be sparse at some injection sites and, therefore, it seems probable that 
the most potent, effective immunity would be elicited by a combination of both models 
(Feltquate, 1998). In fact a recent study using a transactivating plasmid system and 
bone marrow chimaeras has shown that both mechanisms appear to be involved (Corr 
et al. 1999), although the bulk of the immune response is dependent on the expression 
of antigen by non-lymphoid cells and the subsequent transfer to APCs. Figure 1.7. 
provides a schematic overview of the two models. Different delivery methods or routes 
of DNA vaccination may tip the balance in favour of one pathway, as compared with 
the other. Gene gun inoculation of skin appears to elicit immunity either by direct 
transfection of epidermal Langerhans’ cells, of which there is a substantial number in 
the skin, or by direct transfection of keratinocytes, and subsequent transferal of 
expressed antigen to professional APCs, such as Langerhans’ cells (Feltquate, 1998), 













Figure 1.7. Schematic overview illustrating models of antigen acquisition by 
APCs, following DNA vaccination.
Ag, antigen; APC, antigen presenting cell.
Two theories have been proposed, to explain how APCs acquire antigen for 
presentation, following DNA vaccination. In the first model, directly transfected APCs 
are considered to be the cells responsible for eliciting the immune response, while in 
the second model, the majority of transfected cells, non-APCs such as muscle cells and 
keratinocytes, are thought to act as antigen producing “factories”. This antigen is 
subsequently transferred to professional APCs, which then process and present antigen 
to the immune system, in the usual fashion.
Intramuscular inoculation with plasmid DNA may raise an immune response in one or 
all of the following ways. Mentioned earlier in this section, following intramuscular 
inoculation, DNA and possibly some transfected blood cells, may rapidly leave the 
muscle in blood or lymph and transfect professional APCs located in lymphoid tissues, 
such as lymph nodes or spleen (Robinson and Torres, 1997). Alternatively, 
professional APCs resident in muscle tissue may be directly transfected. However, due
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to the paucity of professional APCs in this tissue, it is unlikely that these cells are 
central to the generation of immune responses (Giese, 1998).
Muscle cells themselves may be the primary target cells for transfection following 
DNA vaccination. Although muscle cells are directly transfected and can express 
antigen (Giese, 1998), they lack the appropriate co-stimulation signals expressed by 
professional APCs necessary for T cell activation. Instead, it has been proposed that 
muscle cells express antigen and then deliver it, by means of secretion or apoptotic cell 
death, to professional APCs (Giese, 1998). These APCs are recruited to the inoculation 
site following local tissue damage by the injection needle. Several groups have now 
demonstrated that exogenous protein molecules are able to prime MHC class I 
restricted CTL responses (Martinez-Kinader et al. 1995). APCs may take up cell 
debris by phagocytosis, and this exogenous scavenger pathway may process these 
exogenous antigens for presentation by MHC class I molecules, to antigen specific 
CD8+ cytotoxic T lymphocytes (Giese, 1998). Thus, this cross-priming mechanism can 
circumvent the classical MHC class I processing pathway, via indirect antigen 
presentation.
1.3.7.3 Site of antigen presentation following DNA vaccination
Classically, antigen presentation and immune activation occur in the lymph nodes and 
spleen, where a favourable organ architecture and rich cellular help enhance the 
process. Following gene gun inoculation, assays for DNA-expressing cells, using green 
fluorescent protein, and post-boost localisation of antibody secreting cells, have 
identified the inguinal lymph nodes, which drain the abdominal skin, as an important 
site for antigen presentation (Condon et al. 1996). In contrast, subsequent to 
intramuscular immunisations with plasmid DNA, studies involving post-boost 
localisation of antibody secreting cells, have identified the spleen, and not the draining 
lymph nodes, to be the primary site of antigen presentation (Robinson and Torres,
1997). Therefore, following gene gun inoculation of skin, directly transfected or 
antigen loaded epidermal Langerhans cells appear to migrate to the draining lymph 
nodes to present antigen. Following intramuscular DNA vaccination a significant 
proportion of DNA appears to leave the muscle, in blood or lymphatic fluid, and
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travels to the spleen. Once there, the DNA may transfect resident APCs (Winegar et al.
1996) which then present antigen and initiate an immune response.
1.3.7 .4 Longevity of immunity raised by DNA vaccines
The mechanism behind the longevity of immunity raised by DNA vaccines remains 
incompletely understood. Historically, after intramuscular inoculation, antigen 
expression has been demonstrated in transfected muscle cells for up to 19 months 
following DNA injection (Wolff et al. 1992). In contrast, after intradermal inoculation, 
transfected skin cells have been documented to support antigen expression for only five 
to ten days, coinciding with the normal sloughing of the epidermis (Eisenbraun et al.
1993). Interestingly, both methods of DNA inoculation have the ability to elicit long- 
lasting humoral immune responses (Raz et al. 1994) and (Davis et al. 1997).
It was demonstrated that a strong humoral response against hepatitis B virus surface 
antigen (HBsAg) persisted for up to 74 weeks, following a single intramuscular 
administration of DNA (Davis et al. 1997). Although the longevity of the response 
was thought to be due to sustained expression of antigen in muscle cells, this group 
documented the destruction of a portion of antigen expressing muscle fibres. This was 
probably due to their presentation of antigenic peptides on MHC class I molecules, and 
occurred between ten and twenty days after gene delivery (Davis et al. 1997). This 
result suggests that long-term humoral immunity does not require long-term DNA 
expression in muscle, and may be due instead to antigen expression and storage in the 
germinal centres on follicular dendritic cells (Davis, 1997).
Meanwhile, Raz reported that a single intradermal inoculation of free plasmid DNA, 
encoding the influenza nucleoprotein gene, induced anti-nucleoprotein-specific 
antibody (and CTLs) that persisted for at least 68-70 weeks after vaccination (Raz et al.
1994). This suggests that short-term expression of antigen in epidermal skin cells is 
sufficient to raise long-term humoral immunity. Alternatively, long-term antigen 
expression may occur in the dermis, or transfected resident and/or circulating immune 
cells such as Langerhans’ cells or specialised circulating epidermotropic T 
lymphocytes, present in the target tissue at the time of gene delivery. This long-term
77
antigen expression may maintain the humoral immune response (Robinson et al.
1996). The maintenance of long-term CTL activity, meanwhile, appears to be 
independent of the maintenance of long-term antibody levels. A recent simian 
immunodeficiency virus DNA vaccine trial in macaques, demonstrated that while 
antibody responses fell with time, cytotoxic T-cell responses persisted. (Lu et al.
1996). Several trials have documented the ability of DNA inoculation to elicit long- 
lasting CTL activity (Raz et al. 1994), (Lu et al. 1996).
1.3.8 APPLICATIONS OF DNA VACCINATION
Since the inception of DNA vaccination technology, there have been a large number of 
successful experimental trials. Using this method of immunisation for prophylactic 
vaccination against infectious disease, immune responses to more than twenty viral 
antigens have been demonstrated, including those of influenza A viruses (Ulmer et al. 
1993), (Fynan et al. 1993), hepatitis B virus (Davis et al. 1993) and rabies virus, 
(Xiang et al. 1994), as well as many bacterial and parasitic antigens (Donnelly et al. 
1997b), (Ertl and Xiang, 1996). In most cases potent cellular and humoral immune 
responses have been initiated, and frequently protection against live pathogenic 
challenge.
It has also been reported that DNA vaccines can effectively immunise neonates (Wang 
et al. 1997) in situations where conventional vaccines have failed to elicit immunity, 
leading to immune activation rather than the induction of tolerance. This may be due to 
sustained antigen expression, more efficient antigen presentation and processing, or the 
presence of the CpG immunostimulatory motifs in the plasmid backbone. Several 
human phase I clinical trials are now in progress, or nearing completion, testing the 
safety and immunogenicity of DNA vaccination against HIV, influenza, hepatitis B and 
malaria. A recently published study, regarding the first human trial of a DNA-based 
vaccine for the treatment of HIV-1 infection, demonstrated the safety and potential 
immunogenicity of an DNA vaccine, encoding HIV-1 env and rev genes (MacGregor 
et al. 1998). These findings have encouraged further studies and, indeed, DNA
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vaccination technology currently possesses a central role in the development of 
therapeutic strategies against retroviral disease, which is discussed in a later section.
DNA vaccines may also be useful in the treatment of individuals with chronic viral 
infections, such as hepatitis B. In many cases, failure to mount an adequate immune 
response in the early stages of viral infection results in incomplete clearance of the 
virus, and development of the chronic carrier state. DNA vaccination, with an encoded 
viral antigen, elicits potent, effective and specific CD8+ CTL activity, due to 
endogenous synthesis of antigen and subsequent MHC class I presentation. These 
antigen specific immune responses may then be able to break the state of 
immunological tolerance the immune system has developed towards the chronic viral 
infection. A study of a transgenic mouse model of the hepatits B chronic carrier state 
demonstrated that DNA vaccination could break immunological tolerance, resulting in 
the complete clearance of circulating hepatitis B surface antigen and the long-term 
control of transgene expression in hepatocytes (Mancini et al. 1996).
DNA vaccination has also been considered as a useful tool in the immunotherapy for 
cancer. Idiotypic determinants of the immunoglobulin expressed on the surface of B- 
cell lymphomas are tumor-specific antigens which can be targeted by immunotherapy. 
A recent report demonstrated that immunization with DNA constructs encoding the 
idiotype (Id) of a murine B-cell lymphoma induced specific anti-ld antibody responses 
and protected mice against subsequent tumor challenge (Syrengelas et al. 1996). Use 
of DNA encoding an Id and GM-CSF cytokine (granulocyte-macrophage colony- 
stimulating factor) fusion protein improved vaccine efficacy. These results indicate that 
DNA vaccination may be an efficacious means of eliciting immune responses against a 
weak, previously unrecognised tumor antigen, enhanced by simultaneous cytokine 
DNA co-expression. Rakhmilevich reported that gene gun delivery of plasmid DNA 
encoding murine interleukin 12, to the epidermis overlying implanted intradermal 
tumours, resulted in regression of both the established primary and the metastatic 
tumours (Rakhmilevich et al. 1996).
DNA vaccination may also be useful in the treatment of allergic conditions. Raz 
demonstrated that DNA immunization with a plasmid encoding beta-galactosidase,
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induced a Thl response that dominated an ongoing protein-induced Th2 response and 
inhibited specific IgE antibody production (Raz et al. 1996). This suggests that 
immunization with plasmid DNA encoding allergens may provide a novel type of 
immunotherapy for allergic diseases. DNA vaccination technology has also been 
applied to the therapy of autoimmune disease. Prevention of autoimmune 
encephalomyelitis in mice by vaccination with DNA encoding a variable region gene 
of the T cell receptor, has been reported (Waisman et al. 1996). Analysis of T cells in 
vaccinated mice demonstrated a reduction in the Thl cytokines interleukin-2 (IL-2) and 
interferon-gamma (IFN-y). In parallel, there was an elevation in the production of IL-4, 
a Th2 cytokine associated with suppression of disease. The potential of DNA 
immunization to reverse the autoimmune response from Thl to Th2, may make this 
approach attractive for treatment of Thl-mediated diseases like multiple sclerosis, 
juvenile diabetes and rheumatoid arthritis. DNA vaccination has also proved to be an 
effective research tool, for the generation of polyclonal (Sundaram et al. 1996) and 
monoclonal (Barry et al. 1994) antibodies. The simplicity of DNA vaccination, and the 
potent humoral immune responses it induces, make this technique ideal for antibody 
production, and circumvents the need to produce pure recombinant protein for 
immunisation, a costly and time consuming affair.
1.3.9 ENHANCEMENT OF DNA VACCINATION EFFICACY BY 
COINOCULATION OF DNA ENCODING CYTOKINE GENES
Several studies in vivo in mice and cats have shown that the magnitude and nature of 
an immune response elicited by a DNA vaccine can be engineered by the coinoculation 
of DNA encoding cytokine genes, (Chow et al. 1998), (Chow et al. 1998), (Kim et al.
1997), (Tsuji et al. 1997), (Hosie et al. 1998). The next section introduces the 
cytokines, considers the immunoregulatory and immunomodulatory functions of these 
proteins and discusses their potential to act as adjuvants in DNA vaccination studies.
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1.4 DNA PLASMIDS ENCODING CYTOKINE GENES; 
POTENTIAL ADJUVANTS IN DNA VACCINATION STUDIES
1.4.1 THE CYTOKINES; AN OVERVIEW
The cytokines are a large family of glycoproteins that may be produced by virtually 
every nucleated cell type in the body. They exert pleiotropic regulatory effects on many 
cell types involved in both host defence and normal and abnormal homeostatic 
mechanisms (Cohen and Cohen, 1996). Cytokines affect cells in a complex network of 
both positive and negative interactions by enhancing or suppressing cellular 
proliferation, differentiation, activation or motility (Cohen and Cohen, 1996). An 
understanding of the actions of a single cytokine is therefore not possible without 
consideration of these interactions. The rapidly expanding field of cytokine research 
has arisen from the former independent disciplines involving the study of lymphokines, 
interferons, haemopoietic growth factors and the more classical growth factors.
Originally, each cytokine was named according to the response it was first shown to 
produce in a biological assay (Campos et al. 1991). For example, the term interferon 
(IFN), was coined by Isaacs and Lindemann in 1957 to refer to a molecule which 
interfered with viral replication (Isaacs and Lindemann, 1957) and the term tumour 
necrosis factor (TNF) was given to a protein which was capable of inducing the 
necrosis of certain tumours (Carswell et al. 1975). Subsequently, cytokines were 
grouped according to the cell type in which they were produced. For example, the 
terms monokine and lymphokine identified cytokine proteins which were produced by 
monocytes and lymphocytes, respectively. However, it later became apparent that 
single cytokines had multiple biological actions (pleiotropy) and that in many cases a 
range of different cell types was capable of producing the same cytokine protein.
Cytokines are involved in orchestrating the immune response and may serve as 
chemical messengers between leukocytes. Therefore, the term interleukin was 
introduced in 1979 to reflect this basic property of cytokines and to help remove some
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of the confusing nomenclature (Mizel and Farrar, 1979). Many well characterised 
cytokines are now referred to as interleukins, although others, such as colony 
stimulating factors (CSF) and interferons, have not been included in this system even 
though they are involved as mediators during immune responses. Therefore, the term 
“cytokine” is used to define a group of proteins which include lymphokines, 
monokines, interleukins, interferons, growth and colony stimulatory factors, and a 
variety of other proteins (Campos et al. 1991). Consequently, due to their diverse 
nature, it is difficult to formulate a precise definition as to what constitutes a cytokine. 
Vilcek and Le (1994) proposed a definition of cytokines as "regulatory proteins 
secreted by white blood cells and a variety of other cells in the body; the pleiotropic 
actions of the cytokines include numerous effects on cells of the immune system and 
modulation of inflammatory responses" (Vilcek and Le, 1994). Table 1.5. describes 
some of the most important properties of cytokines.
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• Most cytokines are secreted but some are also found associated with cell 
membranes.
• Cytokines are polypeptides, which may be glycosylated. The monomeric 
molecular mass of the mature cytokines ranges from 15 to 30kDa. Only one 
known cytokine, IL-12, is a heterodimer.
• The production of cytokines is not generally constitutive but is induced by 
altering the level of transcription or translation.
• Production of cytokines is generally transient and actions are mediated at close 
range, in either an autocrine or paracrine fashion.
• Cytokine actions are mediated via binding to high affinity cell-surface 
receptors.
• Actions are due largely to modulations in gene expression in target cells leading 
to alterations in cell proliferation, differentiation or function.
• Whilst their actions are often diverse, they generally include effects upon 
haemopoietic cells.
Table 1.5. The characteristic features of cytokines
1.4.2 IMMUNOREGULATORY CYTOKINES; TH1 AND TH2 TYPES
The cytokines which will be considered in depth here are the Thl enhancing, 
immunoregulatory cytokines IL-12 and IL-18. Simplistically, T lymphocytes may be 
classified into functional groups: T helper cells, T suppressor cells, and cytotoxic T 
cells. Functionally distinct subsets of helper T cells, distinguishable by their different 
patterns of cytokine production, are found in both mice and humans (Abbas et al.
1997). These functionally polar subsets of T helper cells are the principal regulators of 
the immune system (Hnilica and Angarano, 1997). The T helper 1 (Thl), phenotype is 
characterised primarily by the production of DFN-y and tumour necrosis factor (3 
(TNFp) and the Th2 phenotype by the production of IL-4, IL-5 and IL-13 (Lichtman 
and Abbas, 1997). A schematic representation of the cytokines involved in Thl and 
Th2 type immune responses is provided in figure 1.8. As a direct result of the 
cytokines they produce, Thl cells promote macrophage activation and stimulate
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production of antibodies that bind the Fey receptor and fix complement. Th 1 responses 
are important for protective, cell-mediated immune responses against intracellular 
microbes, such as mycobacteria and viruses, but these responses may also lead to tissue 
injury, typified by the delayed-type hypersensitivity reaction (Lichtman and Abbas,
1997).
In contrast, the cytokines produced by Th2 cells promote IgE production and 
eosinophil rich inflammatory infiltrates, which together lead to the killing of parasites. 
Th2 type cytokines also act to downregulate Thl dependent, cell-mediated immune 
responses. Th2 type immune responses, therefore, can protect against parasitic 
infections, and can limit the harmful effects of Thl type responses, but may also 
promote the development of immediate hypersensitivity (allergic), reactions. 
Simplistically, then, Thl type cytokines stimulate innate and cell-mediated immunity, 
while Th2 type cytokines stimulate humoral immunity (Hnilica and Angarano, 1997). 
When stimulated, each T helper subset inhibits the development of the alternative 












Figure 1.8. The cytokines involved in T h l and Th2 type immune responses 
IFN-y, interferon gamma; TNF, tumour necrosis factor.
Different lines of evidence have shown that the early decision towards a Thl or Th2 
type immune response is mainly dependent on the balance between levels of IL-12 
(which favours a Thl response) and IL-4 (which favours a Th2 response (Trinchieri,
1993). IL-12 plays an essential role in the generation of Thl cells (Trinchieri, 1994) 
and consequently the development of effective cell-mediated immune responses. Not 
only does IL-12 stimulate the development of naive T lymphocytes into Thl cells (type 
1 helper T lymphocytes) (Manetti et al. 1993), this cytokine also facilitates antigen- 
induced activation of already differentiated Thl cells, resulting in the proliferation and 
secretion of IFN-y (Murphy et al. 1994). Although IL-18 is not able to induce the 
development of Thl cells itself, this cytokine is essential for the effective induction 
and activation of Thl cells by IL-12 (Okamura et al. 1998). In fact, IL-12 and IL-18 
synergise to dramatically enhance levels of IFN-y production (Micallef et al. 1996). 





immune response. In chapter 3 the biological function of both these cytokines is 
discussed in greater depth.
1.4.3 CYTOKINES AS ADJUVANTS IN DNA VACCINATION
1.4.3.1 Introduction
The ability to induce protective immunity against a pathogen by vaccination depends 
upon the expansion of a memory T lymphocyte population which, upon subsequent 
activation, will be capable of responding rapidly, leading to the elimination of the 
pathogen. Vaccine development has been revolutionised by the advent of techniques 
such as peptide chemistry and recombinant DNA technology. However, the new 
generation of vaccines possess a major disadvantage. Due to their small molecular 
structures, recombinant proteins, synthetic peptides and DNA vaccines are often less 
immunogenic than the killed or attenuated whole organisms contained in many 
traditional, successful vaccines. This has lead, in turn, to interest in the development of 
novel, safe and effective adjuvants, to make the new vaccines more effective.
An adjuvant acts to enhance the efficacy of a particular vaccine by serving as a depot 
for the antigen and promoting the immune response raised to the vaccine immunogen. 
Many classes of adjuvants have been investigated, including ISCOMs 
(immunostimulatory complexes), liposomes and cytokines. Since Raz et al. reported 
that inoculation of cytokine genes into muscle resulted in the characteristic biological 
actions of these cytokines in vivo and could enhance the immune response raised to a 
protein antigen (Raz et al. 1993) it has been reported that in many cases the 
coinoculation of plasmids encoding cytokine genes could significantly enhance the 
immune response raised to DNA vaccine antigens (Cohen et al. 1998).
While, in most cases, cytokine adjuvanticity is not as powerful as that shown by the 
best experimental adjuvants, such as saponin or Freund’s adjuvant, it rivals that of 
many of the adjuvants currently allowed for human use. Moreover, the use of particular 
cytokines as adjuvants has the major advantage that it may allow the engineering of in
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vivo immune responses, favouring either the development of cellular or humoral 
immunity, or both (Kim et al. 1998). The first studies using cytokine genes as 
adjuvants in DNA vaccination studies, involved using plasmids encoding the cytokine 
IL-2 (Smith, 1988). Chow demonstrated that inoculation of a vector encoding hepatitis 
B surface antigen (HbsAg) and IL-2 on the same plasmid induced significant increases 
in antibody responses, T cell proliferation and enhanced T cell production of IL-2 and 
IFN-y, compared to inoculation of the HbsAg expressing plasmid alone (Chow et al.
1997). These results suggested that coinoculation with plasmids expressing the IL-2 
gene could augment the cellular and humoral immune responses elicited to a plasmid- 
encoded antigen and enhance Thl type cytokine production.
Subsequently many different cytokine genes have been reported to have a significant 
effect on the immune response raised to a plasmid encoded antigen. Plasmids encoding 
three different types of cytokine have been studied: proinflammatory cytokines, such as 
IL-1 (Kim et al. 1998) and GM-CSF (Iwasaki et al. 1997), Thl inducing cytokines, 
such as IL-12 (Kim et al. 1997) and IL-18 (Kim et al. 1998), and Th2 inducing 
cytokines, such as EL-4, IL-5 and IL-10 (Kim et al. 1998). In general, pro- 
inflammatory cytokines, such as IL-1, have enhanced the cellular and humoral immune 
responses raised to DNA vaccines (Kim et al. 1998), Thl inducing cytokines, such as 
EL-12, have potently enhanced the cellular immune response (Kim et al. 1997) and 
Th2 inducing cytokines, such as IL-4, have augmented the humoral and downregulated 
the cellular immune response (Kim et al. 1998).
While these studies demonstrate the ability of cytokine genes to enhance the immune 
response raised to DNA vaccine antigens, these effects have mainly been examined in 
rodent models. Future research must investigate the effect of cytokines on DNA 
vaccination in target animals of different species to assess the long-term effects of 
cytokine gene expression, particularly from an efficacy and safety perspective. The use 
of cytokines as genetic adjuvants in humans is currently considered unsuitable due to 
concerns that persistent cytokine expression may lead to unwanted local and/or 
systemic immunological or haematopoietic side effects (Pasquini et al. 1997). The use 
of DNA plasmids containing suicide genes or inducible promoters may prove to be a 
safer approach for the use of cytokines as adjuvants in DNA vaccination studies in
87
humans (Pasquini et al. 1997). Thus, the information gained from studying the 
adjuvant effect of cytokines in experimental animal models, such as the feline model 
described in the course of this thesis, may prove extremely valuable when developing 
and planning future human DNA vaccination trials.
1.4.3.2 T h l cytokines as adjuvants in DNA vaccination
As detailed above, both Thl and Th2 inducing cytokines have proved to be effective 
adjuvants in DNA vaccination studies. This section will consider the use of Thl 
inducing cytokines as immunological adjuvants in DNA vaccination studies.
The adjuvant effect of DNA plasmids expressing IL-12 is clear. In fact, it has been 
hypothesised that the adjuvanticity of commonly used and effective bacterial adjuvants, 
such as complete Freund’s adjuvant, relates, in part, to the ability of bacterial 
molecules to stimulate DL-12 production (Scott and Trinchieri, 1997). The main 
biological actions of IL-12 are the potentiation of Thl type cytokine production, 
particularly IFN-y, in T lymphocytes and NK cells, as a growth factor for activated T 
and NK cells, and in the generation of CTLs (cytotoxic T lymphocytes) and the 
activation of cytotoxicity in both CD 8 + and NK cells (Gherardi et al. 1999). 
Additionally, IL-12 has a central role in the generation of Thl cells and the optimal 
differentiation of CTLs (Trinchieri, 1994).
Therefore, the use of plasmids delivering cytokines capable of triggering a Thl 
response, such as IL-12 and IFN-y, in conjunction with plasmid encoded vaccine 
antigens, may help to induce a potent and stable cell-mediated immune response 
against the vaccine immunogens. Consequently, protection from challenge may also be 
enhanced. In fact, IL-12 expressing plasmids have been shown to increase the cellular 
immune response raised to plasmid encoded vaccine antigens in several different 
experimental models. This may be especially relevant in the development of a DNA 
vaccine against HIV-1. Several studies have emphasised the importance of CTL 
activity and cell-mediated immunity in combating HIV-1 infection and controlling the 
development of AIDS (Rowland-Jones et al. 1997).
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A study involving the coinoculation of mice with a plasmid-encoding the HIV-1 
envelope gene and a plasmid encoding the IL-12 gene clearly demonstrated that HIV-1- 
specific cell-mediated immunity was enhanced by inoculation of the IL-12 expressing 
plasmid (Tsuji et al. 1997). Similarly, Kim reported that the codelivery of IL-12 
expression cassettes with DNA vaccine formulations for HIV-1 Ag, in mice, resulted 
in a shift in the specific immune responses induced. A decreased production of specific 
antibodies, increased T cell proliferation and a dramatic increase in virus-specific CTL 
responses were demonstrated, following combined HIV-1 antigen (env or gag/pol), and 
IL-12 inoculation (Kim et al. 1997). This work illustrates the power of DNA delivery 
in vivo for the production of new and effective vaccines and as an analytical tool for 
the molecular dissection of the mechanisms of immune function. Interestingly, Iwasaki 
has reported that coinoculation with an IL-12 encoding DNA plasmid could convert a 
weak plasmid DNA immunogen, a non-immunogenic mutant of influenza 
nucleoprotein (NP), into one capable of inducing a strong CTL response (Iwasaki et al.
1997).
Chow reported that mice immunised with a hepatitis B virus (HBV) DNA vaccine and 
the IL-12 or IFN-y gene exhibited a significant enhancement of Thl cells, as well as a 
marked inhibition of Th2 cells (Chow et al. 1998). The CTL activity induced by HBV 
DNA vaccination was most significantly enhanced by codelivery of the IL-12 or IFN-y 
gene, whereas codelivery of the IL-4 gene, a Th2 inducing cytokine, suppressed the 
activity. Sin investigated the use of an IL-12 expressing plasmid as an adjuvant for a 
herpes simplex virus-2 (HSV-2) DNA vaccine, in a mouse challenge model (Sin et al. 
1999). He reported that IL-12 coinjection with a plasmid encoding HSV-2 gD protein 
increased Thl type cytokine secretion (IL-2 and IFN-y), inducing significantly better 
protection from lethal HSV-2 challenge, compared with HSV-2 gD DNA vaccination 
alone, in both outbred and inbred mice. Thus, in this experimental model, IL-12, as a 
DNA vaccine adjuvant, potentiated an antigen specific Thl type immune response, 
which resulted in reduced morbidity and mortality in the HSV-2 challenged mice.
In a similar murine DNA vaccination study, Sin investigated whether the Thl or the 
Th2 type immune response, in general, was more important in protecting against HSV-
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encoding Thl-type (IL-2, IL- 12, IL-15, and IL-18) and Th2-type (IL-4 and IL-10) 
cytokines were studied in an effort to drive the immune response induced by 
vaccination towards the cellular or the humoral arm. (This is one of the very few 
published studies to utilise a plasmid encoding IL-18 as a DNA vaccination adjuvant. 
EL-18 is a recently discovered cytokine (Okamura et al. 1995) and its central role in the 
development of Thl cells and the enhancement of cell mediated immunity has only 
recently been elucidated). Coinoculation with any of the Thl type cytokine genes 
enhanced the survival rate and also reduced the frequency and severity of herpetic 
lesions following intravaginal HSV challenge, while coinjection with Th2 cytokine 
genes increased the rate of mortality and morbidity of the challenged mice. Of the Thl- 
type cytokine genes tested, IL-12 was a particularly potent adjuvant although EL-18 was 
also effective, in this HSV-2 murine challenge model. In contrast to these results, a 
recent paper reporting the efficacy of IL-18 as an adjuvant in an HEV-1 DNA 
vaccination trial noted that the immunomodulatory chararcteristics of IL-18 were 
similar to a Th2 type cytokine, rather than a Thl type cytokine (Kim et al. 1998). The 
EL-18 expressing DNA plasmid induced dramatic increases in antibody production 
with only modest increases in CTL activity. The results of this study illustrate the 
important cautionary point that a particular cytokine may mediate different 
immunomodulatory effects in different systems and experimental models.
Plasmids expressing IFN-y have been utilised as adjuvants in several DNA vaccination 
trials. A DNA plasmid encoding feline EFN-y acted as an adjuvant when coinoculated 
with a FEV DNA vaccine consisting of a defective mutant provirus of FFV 
(FEVDeltaRT) (Hosie et al. 1998). In this trial, immunisation with FEV DNA and IFN- 
y gave the highest proportion of protected cats following challenge. As discussed 
above, Chow also reported the effective adjuvanticity of IFN-y in mice inoculated with 
a hepatitis B virus DNA vaccine which exhibited a significant enhancement of Thl 
cells, a marked inhibition of Th2 cells and a significant enhancement of CTL activity 
compared to mice inoculated with the HBV DNA vaccine alone (Chow et al. 1998).
By contrast, dramatically different results were obtained when a plasmid encoding 
mouse EFN-y was coinoculated with a plasmid vector expressing the rabies virus 
glycoprotein (Xiang et al. 1997). Xiang found that the effect of EFN-y was dependent
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glycoprotein (Xiang et al. 1997). Xiang found that the effect of IFN-y was dependent 
on the promoter driving expression of the viral antigen. The immune responses to 
antigen-expressing plasmids carrying a viral promoter such as the SV40 early promoter 
or the major histocompatibility (MHC) class I promoter were reduced in the presence 
of IFN-y, while the B and T helper cell responses to a plasmid expressing the antigen 
under the control of the MHC class II promoter were not affected. This result reiterates 
the important point that a particular cytokine may mediate different 
immunomodulatory effects in different systems and different experimental models.
In conclusion, several in vivo studies in mice and cats have shown that the amplitude 
and direction of an immune response elicited by a DNA vaccine can be engineered by 
the coinoculation of plasmid DNA constructs expressing cytokine genes (Chow et al.
1998), (Kim et al. 1997), (Tsuji et al. 1997), (Hosie et al. 1998). Codelivery of 
plasmids expressing IL-12, IL-18 and IFN-y with vaccine antigens has been shown to 
enhance the development of Thl cell populations, the production of Thl cytokines, and 
the generation of antigen-specific CTL responses, essential in the development of a 
functional cellular immune response (Chow et al. 1998), (Sin et al. 1999), (Kim et al. 
1997). As discussed later, cell-mediated immunity may be extremely important in the 
generation of an effective immune response against FeLV (Charreyre and Pedersen, 
1991), (Tompkins and Tompkins, 1985). Therefore, the coadministration of these Thl 
type cytokine genes, IL-12, IL-18 and IFN-y, with FeLV vaccine antigens may steer the 
immune response towards the cellular arm, enhancing the efficacy of the FeLV DNA 
vaccine, which is described within this thesis.
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1.5 SUMMARY
Feline leukaemia virus, identified by Jarrett in 1964, (Jarrett et al. 1964), is a 
significant pathogen of the domestic cat and represents a model of contagiously 
transmitted retroviral disease, in a natural outbred mammalian population (Neil et al. 
1991). At present, none of the experimental or commercially available FeLV vaccines 
consistently provide 1 0 0 % protection against the development of transient or persistent 
viraemia or latent bone marrow infection following exposure to virus (Sparkes, 1997).
Naked DNA vaccination, a recently described technology, presents a new and exciting 
approach in vaccine development. DNA vaccine constructs are created by the insertion 
of DNA encoding a desired antigen into an eukaryotic plasmid expression vector 
(Robinson and Torres, 1997). The purified plasmid DNA is inoculated directly into the 
host, and, as the host cells’ transcriptional machinery is utilised, the protein is 
expressed directly in these cells with the appropriate post-transcriptional modifications 
and tertiary structure to induce potent humoral and cellular immune responses 
(Donnelly et al. 1997b). This approach to immunisation may allow the development of 
safe and efficacious prophylactic and therapeutic vaccines (Tang et al. 1992). Indeed, 
numerous animal models for DNA vaccines against viral, bacterial and parasitic 
diseases have now been described (Donnelly et al. 1997b) and, more recently, human 
clinical trials have been undertaken (MacGregor et al. 1998). Therefore, DNA vaccine 
technology may prove to be a useful approach in the development of a novel and 
efficacious FeLV DNA vaccine.
Cytokines are naturally occurring glycoproteins, which are involved in the 
orchestration of the immune response, regulation of haemopoeisis and in tissue repair 
and differentiation mechanisms. Cytokines possess a wide therapeutic potential and 
may act as potent vaccine adjuvants, modulating the amplitude and direction of an 
immune response elicited by a DNA vaccine (Kim et al. 1998). Interleukin-12, 
interleukin-18 and IFN-y, Thl type cytokines, may enhance the development of Thl 
cell populations and the development of cellular immune responses, when coinoculated 
with DNA vaccines (Chow et al. 1998), (Sin et al. 1999). As cell-mediated immunity
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may be extremely important in the generation of an effective immune response against 
FeLV (Charreyre and Pedersen, 1991), the coinoculation of these cytokine adjuvants 
may enhance the efficacy of the novel FeLV DNA vaccine.
1.6 AIMS OF THE PROJECT
Many trials examining the adjuvant effect of cytokine genes in DNA vaccination 
models are currently in progress. The aims of this project were to clone, sequence and 
express cDNAs encoding feline IL-12 and IL-18 cytokine genes with the ultimate goal 
of investigating their potential as adjuvants in feline leukaemia virus DNA vaccination 
studies. The primary aims of the FeLV DNA vaccination trial were to determine if the 
FeLV DNA vaccine alone could provide protection against viral challenge, and 
secondly, to establish if plasmids encoding feline Thl type cytokines, IL-12, IL-18 and 
IFN-y, could act as adjuvants when coinoculated with the vaccine. This work formed 
part of a larger project within the Department of Veterinary Pathology which aimed to 
isolate a number of feline haemopoietic and immunomodulatory cytokines. The 
availability of a number of feline cytokines may facilitate the development of new 
methods for use in the prophylaxis and therapy of various feline diseases and assist in 
the understanding of the pathogenesis of diseases of the cat.
The objectives of the project were:
•  To amplify, by the polymerase chain reaction, cDNA encoding feline IL-12 and DL- 
18, from mRNA derived from feline alveolar macrophages.
•  To sub-clone the individual PCR products into a plasmid vector and sequence the 
recombinant DNA.
•  To express the feline IL-18 cDNA as a glycosylated protein, using a mammalian 
expression vector system and to demonstrate this expression using Northern and 
western blotting techniques.
•  To investigate the potential of these feline Thl type cytokines, IL-12, IL-18 and 
IFN-y, to act as genetic adjuvants in FeLV DNA vaccination studies.
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The following chapters will describe the experimental techniques used to achieve these 
objectives and the results that were obtained.
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2. CHAPTER TWO; MATERIALS AND METHODS
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2.1 MATERIALS
Materials in regular use, such as equipment, general reagents and solutions are detailed 
in this section.
2.1.1 CELL CULTURE MATERIALS
2.1.1.1 Cell lines
ON 10 cells were grown and maintained for use in the FeLV virus isolation technique, 
kindly performed by Mr Mathew Golder and Mr Mike MacDonald, in the Feline Virus 
Unit, University of Glasgow.
FEA cells were kindly supplied by M. Golder, as above.
293 cells were grown and maintained for use in transfection experiments by Dr Derek 
Bain (Department of Veterinary Pathology, University of Glasgow).
293T cells were kindly supplied by Christine McGillivray (Molecular Medicine 
Laboratory, Department of Veterinary Pathology, University of Glasgow).
2.1.1.2 Plasticware
Tissue culture flasks, 96 well plates etc. were supplied by Costar (Cambridge, MA). 
Cryotubes and 35mm petri dishes were supplied by Nunc (DK 400, Roskilde, 
Denmark). Falcon conical centrifuge tubes (15 and 50ml) were supplied by Becton 
Dickinson UK Ltd. (Oxford, UK).
All the plasticware used by the Feline Virus Unit staff in the virus isolation, bone 
marrow and cell culture techniques, was supplied by Gibco BRL Life Technologies.
2.1.1.3 Solutions, media and supplements
All solutions and media for cell culture were supplied by Gibco BRL Life 
Technologies, unless otherwise stated.
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2.1.1.3.1 Media
All media were supplied as sterile solutions and stored at +4°C.
Alpha Minimal Essential Medium




Foetal Calf Serum: (FCS), TCS Biologicals Ltd., (Buckingham, UK): virus screened, 
mycoplasma screened. FCS was heat inactivated at 56 °C for 30 minutes, then stored in 
50ml aliquots at -20 °C until use.
L-glutamine: supplied 200mM (100X) stock solution. This was stored in five millilitre 
aliquots at -20 °C and routinely added to culture media prior to use. 
Penicillin/streptomycin: supplied as a 100X stock solution of 10,000 units penicillin 
and 10,000 units streptomycin per millilitre. Stored in five millilitre aliquots at 
-20 °C.
Trvpsin-EDTA: supplied as 10X liquid, stored at -20 °C. This was diluted 1:10 in 
sterile PBS prior to use and stored at +4 °C.
Preservative free heparin (Sigma)
Hydrocortisone succinate (Sigma).
Sodium pyruvate: supplied as a lOOmM stock solution
Polvbrene: supplied by Abbott laboratories, a registered trademark for hexadimethrine . 
MEM Non Essential Amino Acids (NEAA): supplied as 100 x solution containing L- 
alanine (890 mg/L), L-asparagine (1320 mg/L), L-aspartic acid (1330 mg/L), L- 
glutamic acid (1470 mg/L), glycine (750 mg/L), L-proline (1150 mg/L) and L-serine 
(1050 mg/L). Stored at+4°C.
L-arginine: Supplied as lyophilised powder; reconstituted in 10 ml of culture medium 
to make solution of 20 mg/ml and stored at +4°C.
L-asparagine: Supplied as lyophilised powder; reconstituted in 10 ml of culture 
medium to make solution of 5 mg/ml and stored at +4°C.
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Ciprofloxacin: Anti-mycoplasma antibiotic added to tissue culture medium as
necessary to a final concentration of lOmg/ml (Miles, Bayer Diagnostics).
G418: Selection media for 293T cells added to tissue culture medium at a 
concentration of 400pg/ml.
2.1.2 RADIOCHEMICALS
ra-3 5 Sl-dATP (specific activity of > 37 TBq/mmol at reference date), for DNA 
sequencing was supplied by Amersham Life Science (Bucks, UK). [a-3 5 S]-dATP was 
stored in 2 pi aliquots, in screw-top eppendorf tubes, at -70°C, until use. 
a( P) dCTP specific activity 3000Ci/mmol, for labelling probes, was supplied by 
Amersham Life Science.
2.1.3 GENERAL CHEMICALS
Chemicals used were of analytical or ultrapure quality and were supplied by Sigma 
Chemical Company (Dorset, England), Fisons Scientific Equipment (Loughborough, 
UK), Boehringer Mannheim, Pharmacia Biotech (Herts, UK), GibcoBRL or BDH Ltd. 
(Poole, England), unless stated otherwise.
2.1.4 COMPLETE KITS
First-Strand cDNA synthesis kit and OuickPrep mRNA purification kit supplied by 
Pharmacia Biotech (Herts, UK).
Original TA Cloning Kit supplied by Invitrogen (NV Leek, The Netherlands).
Perkin Elmer GeneAmp PCR Core Reagents kit supplied in the UK by Applied 
Biosystems Ltd.
Perfectprep Plasmid DNA Preparation kit (Flowgen, UK).
OIAGEN Plasmid Purification Maxi kit supplied by Qiagen (UK).
OIAamp Blood Kit (Qiagen, UK).
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OIAquick Gel Extraction kit (Qiagen, UK).
High Prime DNA labelling kit (Boehringer Mannheim): Premixed solution for random 
primed DNA labelling using (a3 2 P) dCTP and random oligonucleotides as primers 
(Boehringer Mannheim).
ThermoSequenase Fluorescent Labelled Primer Cycle Sequencing Kit with 7-deaza- 
dGTP (Amersham Life Science).
Sequenase Version 2.0 DNA Sequencing Kit (USB, Cleveland, Ohio) distributed in the 
UK by Amersham Life Science.
ProFection Mammalian Transfection System (Promega, UK).
2.1.5 BACTERIAL STRAINS
E.coli IN V aF : One Shot Competent cells, (Invitrogen). F' endAl recAl h sdR ll(rL, 
mk+) supEAA thi-\ gyrA96 relA l <|)80/acZAM15 A(lacZYA-arg¥)Ul69 deoR+ X'.
E.coli D H 5a: MAX Efficiency D H 5a Competent Cells, Life Technologies, 
(GibcoBRL). F' (J)80/acZAM 15 A(lacZYA-arg¥)\Jl69 deoR recAl endAl h sd R llir^', 
mk+) sup¥44 X'thi- 1 gyrA96 relA l.
Epicurian Coli XL2-Blue MRF’ ultracompetent cells (Stratagene): A(racrA)183 
A(mcrCB-hsdSM R-mrr)ll3 endAl supE44 thi-l recAl gyrA96 relA l lac [¥’ proAB 
lacPZAM15 TnlO (Tetr) Amy Camr]a
All of the above strains have the /acZAM15 marker, enabling blue-white screening by 
a-complementation of (3-galactosidase encoded by vector DNA (e.g. pCR™ II). The 
genotypes endAl and h sd R ll  give improved quality of miniprep DNA; recAl denotes 
recombination negative, recommended for stable replication of high copy number 
plasmids
2.1.6 DNA
Plasmid, molecular weight marker and oligonucleotide DNAs were stored at -20°C.
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2.1.6.1 Plasmid Vectors
pCR2.1 (Invitrogen): lacZ+, a m p , kan , T7 promoter and priming site, M13 forward 
and reverse primer annealing sites. Plasmid designed for direct cloning of PCR 
products with 3’ deoxyadenonosine residues (A - overhangs), generated by the non­
template dependent activity of Taq polymerase. The vector is supplied as linearised 
DNA with single 3’ deoxythymidine (T) residues allowing for efficient ligation of 
target sequence to vector.
pCRU: As above but also has SP6  promoter and priming sites (Invitrogen). 
pUC18/19 (Invitrogen): pBR322 based cloning vector. lacZ+, ampT, multiple cloning 
site and M l3 forward and reverse primer annealing sites. Plasmid supplied with TA 
cloning kit for use as positive control for verifying the transformation efficiency of 
competent bacteria; concentration of 0 . 1  jig/ml.
pCI-neo (Promega): The pCI-neo Mammalian Expression Vector carries the human 
cytomegalovirus (CMV) immediate-early enhancer/promoter region to promote 
constitutive expression of cloned DNA inserts in mammalian cells (Promega, 1998). 
The pCI-neo vector contains the neomycin phosphotransferase gene, a selectable 
marker for mammalian cells, and can be used for transient expression or for stable 
expression by selecting transfected cells with the antibiotic G-418. The pCI-neo 
plasmid contains the T7 and T3 promoter and priming sites, a chimeric intron and the 
SV40 late polyadenylation signal.
2.1.6.2 M olecular Size Standards
(j)X174 RF DNA/Hae m  fragments (size range 72-1,353 bp) and X DNA/HindlH 
fragments (size range 125-23,130 bp) were supplied by Gibco BRL.
2.1.6.3 Oligonucleotide Primers
Oligonucleotides: Unlabelled and IRD-41 fluorescent labelled oligonucleotides, for use 
in PCR amplification reactions and cycle sequencing, were synthesised by MWG 
Biotech. Primers were reverse phase purified and supplied as lyophilised DNA.
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Primers were reconstituted in d t^O , quantified by spectrophotometry and unlabelled 
oligonucleotides were resuspended to 1 mg/ml, while IRD-41 labelled oligonucleotides 
were resuspended to lpm ol/p l Aliquoted primers were stored at -20°C and IRD-41 
labelled oligos were also protected from light.
ft actin primers (Clontech): for use in PCR amplification reactions were supplied by 
Cambridge Bioscience. Primers were supplied at 20 |iM  concentration.
2.1.7 ENZYMES
All enzymes were stored at -20°C, being removed immediately before use.
Restriction enzymes and their associated reaction buffers were supplied by Gibco BRL. 
T4 DNA Ligase was provided by Gibco BRL or Invitrogen (as part of the TA Cloning 
Kit).
Tag DNA polymerase was provided by Perkin Elmer, as part of the GeneAmp PCR 
Core Reagents kit.
Pfu DNA polymerase was provided by Stratagene Ltd, Cambridge, UK.
Murine Moloney Virus Reverse Transcriptase Enzyme was supplied by Pharmacia 
Biotech (as part of the First-Strand cDNA synthesis kit).
RNAse A was supplied by Sigma.
2.1.8 PROTEIN SDS-PAGE STANDARDS
Kaleidoscope Prestained SDS-PAGE standards (7.5 - 216 KDa) were supplied by 




2.1.9.1 M ajor Equipment
Benchtop centrifuges: Omnifuge 2.0 RS and Megafuge 1.0 (Heraeus Sepatech - 
Germany).
Microcentrifuge: Biofuge 13 (Heraeus Sepatech).
Incubators for tissue culture: supplied by Heraeus Sepatech and Leec Ltd. 
(Nottingham, UK).
Water baths: supplied by Grant Instruments (Cambridge) Ltd.(England). 
Spectrophotometer: Model DU640, Beckman.
Vacuum dessicator: Hetovac, Heto Laboratory Equipment, Denmark.
Manual Sequencing Apparatus: Flowgen.
Automatic Sequencing Apparatus: Li-Cor model 4000 DNA sequencer (MWG- 
Biotech).
Automated Processor: Kodak X-omat processor, model ME-3, Eastman Kodak Co., 
New York, USA.
Gel dryer: Model 583 gel dryer, Biorad, Hercules, CA.
Pippetteman (P20, P200, P1000): supplied by Gilson Medical Electronics (Villiers-le- 
Bel, France).
Automatic Sarpette: supplied by Sarstedt.
Ultraviolet Transilluminator: supplied by UV Products Inc. (San Gabriel, CA). 
Autoradiography (Film) cassettes: with intensifying screens (Cronex), supplied by 
Dupont.
MWG 2000i gel documentation system (MWG-Biotech).
2.1.9.2 Consumables
Bottle top filters (0.22|Lim pore size) were supplied by Sigma; for sterilisation of tissue 
culture media.
Screw top 1.5 ml eppendorf tubes, 0.5 ml and 1.5 ml flip top tubes were supplied by 
Treff AG (Degersheim, Switzerland).
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Pipette tips were supplied by Sarstedt.
Syringes (two, five, 10, 20 and 50 ml) were supplied by Becton Dickinson.
Flat ended gel loading tips were supplied by Sorenson Bioscience Ltd.
Filter tip pipette tips (30 |il and 200 pi) were supplied by Rainin Instrument Co. 
(Woburn, MA); for use in setting up PCR reactions.
Acrodisc syringe filters (0.22 and 0.4 pm) were supplied by Gelman Sciences (Ann 
Abor, MI); used for filter sterilising of small volumes of solutions.
Petri dishes, bijoux and universals were supplied by Greiner (Stonehouse, Glos., UK). 
Disposable, sterile scalpels were supplied by Swann-Morton (Sheffield, England).
2.1.10 EXPERIMENTAL ANIMALS
Specific pathogen free (SPF) cats were obtained from a commercial breeding unit, 
housed at Glasgow University and fed a commercial diet. All procedures were carried 
out in accordance with Home Office regulations.
2.1.11 BUFFERS, SOLUTIONS AND GROWTH MEDIA
2.1.11.1 Water
Tissue culture grade distilled water was supplied by Gibco BRL. Ultrapure water (for 
procedures involving recombinant DNA, PCR etc.) was provided by a Millipore Q50 
water purification system (Millipore (UK) Ltd., Watford, UK). A Millipore RO10 
system was used to supply water for preparation of general solutions and media.
2.1.11.2 Antibiotics
Ampicillin (Penbritin™ - Beecham Research (Herts, England)): Solution of 100 mg/ml 
prepared by addition of 5 ml of dH2 0  to vial of ampicillin; filter sterilised and stored in 
aliquots at -20°C until use.
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2.1.11.3 Buffers and solutions
Ammonium persulphate: 10% (w/v) stock solution in ddH2 0 , freshly made.
10 x TBE Buffer: Tris base 216 g, boric acid 110 g, EDTA 16.9 g. pH 8 .2/8.3, made 
up to 2 L.
50 x TEA Buffer Solution: Tris base 484.5g, NaOAc 272.15 g, NaCl 116.8 g,
Na2EDTA 74.45 g. pH adjusted to 8.15 with glacial acetic acid and made up to 2 L 
volume.
Lvsis Buffer: 25 mM Tris HC1 pH 8.0, 10 mM EDTA, 50 mM Glucose.
1% SDS/ 0.2M NaOH: Made up immediately prior to use by combining equal
volumes of 2% SDS and 0.4M NaOH.
KoAc solution: 60 ml 5M Potassium acetate, 11.5 ml acetic acid, 28.5 ml dH 2 0 .
1M Tris HC1: 12Ig Tris base, 800ml dH 2 0 . Adjusted to desired pH with concentrated 
HC1 and made up to 1L.
TE Buffer: 10 mM Tris-HCl (pH 8.0), 1 mM EDTA.
1 xPBS: 140 mM NaCl, 2.7 mM KC1, 10 mM Na2 H P0 4  , 1.8 mM KH 2 P 0 4  (pH 7.3). 
10 x DNA Gel Loading Buffer: 20% w/v Ficoll 400, 0.1 M Na2EDTA, pH 8 , 1.0% 
w/v sodium dodecyl sulphate, 0.25% bromophenol blue, 0.25% xylene cyanol. Stored 
at room temperature and used at a 1 : 1 0  dilution.
RNA gel Loading Buffer: 50% formamide, 2.2M formaldehyde, IX MOPS, in ddH2 0 . 
Made fresh.
Ethidium bromide: made to a working solution of 3mg/ml with dH20  in a fume 
cupboard. Stored away from light.
10 x SDS-PAGE Electrode (Running) Buffer: tris base 60 g, glycine 288 g, SDS 
20 g. Made up to 2 L by addition of dH 2 0 .
5x Protein Sample Loading Buffer: SDS Reducing Buffer: 62.5 mM Tris-HCl, pH 6 .8 , 
20% glycerol, 2% SDS, 5% (3-mercaptoethanol. dH20  3.0 ml, 0.5M Tris-HCl, pH 6 . 8  
1.0 ml, glycerol, 1.6 ml, 10% SDS 1.6 ml, (3-mercaptoethanol 0.4 ml, 0.5% (w/v) 
bromophenol blue (in dH2 0 ) 0.4 ml; stored at 4°C. Sample diluted at least 1:4 with 
buffer and heated at 100°C for 5 minutes prior to loading gel.
10 x Tris Buffered Saline (TBS): Tris base 24.2 g, NaCl 80.0 g, HC1 38.0 ml. pH 7.6. 
dH2Q to 1L.
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10 x Semi Dry Transfer Buffer: Tris base (48mM) 58 g, glycine (39mM) 29 g, SDS 
(0.01%) 1 g. CIH2 O to 1L. Working stock was prepared prior to use by the addition of 
100 ml 10 x stock to 200 ml methanol and 700 ml dH2 0 .
NT buffer: lOmM Tris, 1.2lg/litre, 0.15M NaCl, 8.7g/litre, pH to 8.0 with HC1.
ACK lvsis buffer: 8.29 g NH4 C1 (0.15 M), 1 g KHC3 (1.0 mM), 37.2 mg Na2EDTA 
(0.1 mM). Dissolved in 800 ml dH2 0 , pH adjusted to 7.2 - 7.4 with 1 M HC1, then 
dH2 0  added to one litre.
X-gal solution (5-bromo-4-chloro-3-indolvl-b-galactoside): prepared as 40 mg/ml
stock in dimethylformamide; stored at -20°C in the dark.
X-Gal assay solution: 5mM Potassium Ferrocyanide, 5mM Potassium Ferricyanide, 
2mM MgCh, 1 mg/ml X-Gal, made up in 0.1M PBS pH 7.4. (X-Gal was dissolved at 
40mg/ml in DMSO fresh, when required).
Polyacrylamide solution: Acrylamide/Bis acrylamide stock solution. 30% (w/v)
acrylamide, 1.579% (w/v) bis acrylamide, ratio 19:1. Severn Biotech Ltd., stored in the 
dark at 4 °C.
Polyacrylamide (4%) solution with urea for automated sequencing: 4.8ml Sequagel 
XR ultra pure concentrate (National Diagnostics), 25.2g urea, 7.2ml 10X TBE in a 
total volume of 60ml with ddH2 0 . The solution was filtered through a 0.4 Jim syringe 
filter. 400|il of 10% ammonium persulphate and 40pl of TEMED was added for each 
sequencing gel using the 6 6 cm Li-Cor gel apparatus.
Sequencing gel solution (6 %: for manual sequencing): prepared with 21 g ultrapure 
urea, five millilitres 10 x TBE buffer, six millilitres Long Ranger Gel solution (AT 
Biochem, Malvern, PA) and dH 2 0  to 50 ml. This was filtered through a 0.4 p,m 
syringe filter, and stored at +4°C for no longer than one week.
Pre-hybridisation buffer for Northern blots: 50% deionised formamide, 4 X Denhardt’s 
solution, 4 X SSC, 1.6 X Gene Screen, 0.1% SDS, 8 % Dextran Sulphate and 30mg/ml 
heat denatured, sheared salmon sperm DNA.
RNA ladders: 0.24-9.5kb RNA ladder, stored at -70°C. 3-5mg/lane (GibcoBRL). 
RNase A : Prepared as a lOmg/ml stock in lOmM Tris-HCl pH7.5 and 15mM NaCl. 
Boiled for 15 minutes and cooled slowly. Stored at 20°C.
SSC (20X): 3M NaCl, 0.3M Sodium Citrate in dH20  and adjusted to pH7.0. Stored 
at room temperature.
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Denhardt’s solution (50X): 1% bovine Serum Albumin (BSA), 1% Ficol, 1% polyvinyl 
pyrollidone in ddH 2 0 . Aliquoted and stored at -20°C.
Gene screen (20X: 0.5M NaH2 P 0 4, 0.5M Na2HP0 4, pH6.5. Stored at room 
temperature.
Hvbond N/N+: Nylon membrane for the transfer of nucleic acids (Amersham Life 
Science).
MOPS buffer (IPX ): 200mM MOPS pH7.0, 50mM potassium acetate, lOmM EDTA. 
Stored at 4°C in the dark.
Nick column: Sephadex G-50, Pharmacia Biotech, stored at room temperature.
The ProFection® Mammalian Transfection System. Calcium Phosphate System, 
(Promega). Store at -20°C
2X HBS (HEPES-Buffered Saline): for use with the above kit. 50mM HEPES, 
pH 7.1, 280mM NaCl, 1.5mM Na2H P 04. The final pH should be 7.1.
Materials and solutions for anti-gp70 antibody ELISA 
Monoclonal antibody: 3-17 (EVL BV, The Netherlands).
FeLV: FeLV-A/F422, purified by sucrose density gradient centrifugation. Resuspended 
in TBS and stored in lOOjil volumes at -80°C, until use.
Coating buffer: 1.59g Na2 CO3 , 2.93g NaHC0 3 , to 1 litre of water and pH 9.0.
Tris buffered saline (TBS): 0.1M NaCl, 0.01M Tris HC1, pH 7.4.
TBT Wash buffer: 1 x TBS and 0.1% Tween
Blocking buffer: Non-fat milk proteins (Marvel) 2% w/v in TBS.
Virus disruption buffer: 1% w/v Empigen in TBS.
Goat serum: Scottish Antibody Production Unit, Law Hospital, Carluke.
Conjugate: Goat anti-cat IgG-alkaline phosphatase (Sera-Lab), diluted in wash buffer. 
Substrate: Phosphate substrate (KPL).
Stop solution: 0.4M NaOH.
Plates: Immulon 2.
2.1.11.4 Bacteriological Media
Media was sterilised by autoclaving at 121 °C for 15 minutes, unless stated otherwise.
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LB Medium : 20 g tryptone, 20 g NaCl, 10 g Yeast Extract, to 2 L with dH2 0 , pH 
adjusted to 7.0 with NaOH.
SOC Medium: 2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KC1, 10 mM 
MgCl2, 10 mM MgS0 4 , 20 mM glucose.
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2.2 METHODS
Methods used throughout the thesis are described in this chapter, whilst techniques 
specific to one area are described in later chapters. Many of the methods described are 
based on standard techniques, which are detailed in several laboratory manuals 
(Maniatis et al. 1982), (Ausubel et al. 1994).
2.2.1 GROWTH AND MANIPULATION OF MAMMALIAN CELLS
2.2.1.1 Basic Techniques
All procedures involving manipulation of mammalian cells were carried out using 
standard aseptic procedures. Where possible all procedures were performed in a 
laminar flow hood.
2.2.1.1.1 Cryopreservation o f cells
In order to preserve stocks of cell lines for long term use, cells were stored over liquid 
nitrogen. Cells to be frozen were grown to mid-log phase (as described below) and 
removed into a sterile 50 ml centrifuge tube (using trypsin-EDTA where necessary). 
The cells were centrifuged at 400 x g for five minutes, the supernatant discarded and 
the cells resuspended in freezing medium (appropriate culture medium supplemented 
with FCS to 20% and 10% DMSO) to a concentration of approximately 2 x 106 
cells/ml. The cell suspension was transferred in one millilitre aliquots, to labelled 
cryovials and brought to -70°C in a controlled rate cell freezer (Kryo 10 - Planer 
Products Ltd., Sunbury on Thames, UK). The vials were then transferred to a liquid 
nitrogen freezer. Cell stocks were revived by rapid thawing in a 37°C water bath and 
subsequently cultured using standard techniques (described below).
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2.2.1.1.2 Cell counting
Cells were counted using a haemocytometer (Weber Scientific International), as 
follows. Cell were diluted in PBS to give an approximate concentration of 5 x 105 to 1 
x 106 cells/ml. The cell suspension was introduced to the haemocytometer chamber 
and cells counted under an inverted microscope with 4 x or 10 x objective; cells lying 
on the top and right hand perimeter of each large (one millimetre) square were 
included, those on the bottom or left hand were excluded. Cell concentration (cells/ml) 
was calculated by multiplying the mean number of cells per large square by 1 0 4  and 
correcting for the dilution factor. Where an estimate of live cell numbers was required 
0.4% trypan blue (Gibco BRL) was added to the cell suspension (1:1) and allowed to 
incubate for five minutes at room temperature prior to counting; dead cells take up the 
stain and therefore appear blue.
2.2.1.2 FEA cell line
The FEA cell line is a fibroblast cell line derived from whole feline embryos (Jarrett et 
al. 1973). The cells grow as an adherent monolayer in culture. Cells were cultured in 
20- 30 ml Dulbecco’s MEM containing 10% foetal calf serum (FCS), 10 mM HEPES, 
2 mM L-glutamine, 100 IU/ml penicillin and 100 Jig/ml streptomycin in 75 cm2 tissue 
cultures flasks at 37°C, 5% CO2 . Cultures were split, typically 1:3 to 1:4, every three to 
four days, when sub-confluent. The medium was decanted from the cell monolayer, the 
cells washed with trypsin-EDTA and then incubated at 37°C with approximately one 
millilitre of fresh trypsin-EDTA for three to five minutes. The detached cells were then 
washed in fresh medium and pelleted by centrifugation at 400 x g for five minutes, 
prior to resuspending in fresh medium and seeding new tissue culture flasks.
2.2.1.3 QN10 cell line
The QN10 cell line is derived from a clone of AH927 feline fibroblasts into which had 
been introduced the provirus of the Moloney murine sarcoma virus (Jarrett and 
Ganiere, 1996). The cells grow as an adherent monolayer in culture. Stock cultures of 
cells were cultured in 20 - 30 ml growth media, consisting of Dulbecco’s MEM 
containing 25mM HEPES buffer, 10% Foetal calf serum, 1% lOOmM sodium,
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pyruvate, 1% 200mM L-Glutamine, and 400 IU/ml penicillin/streptomycin, in 75 cm2  
tissue cultures flasks at 37°C, 5% CO2 . Cultures were split, typically 1:5 every three to 
four days, when sub-confluent and were trypsinised and seeded into new flasks as 
described above.
2.2.1.4 293 cell line
The 293 cell line is a permanent line of primary human embryonal kidney transformed 
by sheared human adenovirus type 5 (Ad 5) DNA (Graham et al. 1977). The cells are 
highly permissive for adenovirus DNA, and contain and express the transforming 
genes of Ad 5. Stock cultures of cells were cultured in 20 - 30 ml growth media, 
consisting of Dulbecco’s MEM, 10% heat-inactivated foetal calf serum, 1% lOOmM 
sodium pyruvate, 1% 200mM L-Glutamine, 400IU/ml penicillin/streptomycin and IX 
MEM Non Essential Amino Acids (NEAA) in 75 cm 2 tissue cultures flasks at 37°C, 
with 5% CO2 . The cells grow as an adherent monolayer in culture. Cultures were split, 
typically 1:3 when sub-confluent and were trypsinised and seeded into new flasks as 
described above.
2.2.1.5 293T cell line
The 293T cell line, a highly transformed human renal epithelial cell line, is derived 
from the 293 cell line and expresses the SV40 large T antigen (DuBridge et al. 1987). 
The cells grow as an adherent monolayer in culture. Stock cultures of cells were 
cultured in 20 - 30 ml growth media, consisting of Dulbecco’s MEM, 10% Foetal calf 
serum, 1% lOOmM sodium pyruvate, 1% 200mM L-Glutamine, 400IU/ml 
penicillin/streptomycin, IX MEM Non Essential Amino Acids (NEAA) and 400p,g/ml 
G418 in 75 cm2 tissue cultures flasks at 37°C, with 5% CO2 . Cultures were split, 
typically 1 : 1 0  every three to four days when sub-confluent and were trypsinised and 
seeded into new flasks as described above.
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2.2.1.6 Feline alveolar macrophage culture
Specific pathogen free (SPF) domestic cats were bled out under deep anaesthesia, then 
euthanased via intracardiac injection of pentobarbitone. The lungs with the trachea and 
larynx intact were then removed. In a laminar flow tissue culture hood the larynx and 
proximal trachea were removed under sterile conditions. A sterile funnel was inserted 
into the trachea and medium, Dulbecco’s MEM, (with sodium pyruvate), 10% FCS, 
20mM Hepes buffer, 2mM glutamine and lOOIU/ml penicillin/streptomycin, was 
poured in until the lungs were inflated to approximately normal inspiratory volume. 
The medium was then poured off into a sterile beaker and the cells spun down in 
falcon tubes at 1700rpm for 5-10 minutes. The cell pellet was washed in 20ml of 
medium and resuspended in approximately 150X the volume of medium, before being 
transferred to tissue culture flasks (approximately 20ml per 75cm2 ). The flasks were 
then gased with 5% CO2 and incubated at 37°C. The medium was replaced after four 
hours to remove any contaminating red blood cells, as the macrophages were adherent 
after this time. The macrophage cultures were then stimulated the following morning 
with 10(ig/ml LPS and after four hours the cells were harvested for mRNA isolation.
2.2.2 RECOMBINANT DNA TECHNIQUES
2.2.2.1 Storage and growth of bacteria
Plasmids were maintained in E.coli strains DH5a or INVaF'. To enable storage of 
these E.coli host strains and of transformants obtained during this work, glycerol 
stocks were prepared. The desired bacterial culture was streaked onto a 1.5% agar 
plate (1.5% agar in LB medium); in cases where the bacterial stock contained a 
plasmid conferring ampicillin resistance (all vector strains used in this project) the 
medium was supplemented with 50 - 100 Jig/ml ampicillin. The plate was incubated 
overnight at 37°C and the following day single colonies were picked using a pipette 
tip, into 10 ml LB medium (supplemented as appropriate with 50 - 100 p,g/ml 
ampicillin) in a sterile universal. The cultures were incubated at 37°C overnight in an 
orbital incubator. Confirmation that the overnight culture was derived from bacteria 
containing the desired recombinant plasmid was achieved by DNA extraction and
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restriction digest (section 2.2.2A). Glycerol stocks were prepared by the addition of 
200 pi of 80% glycerol to one millilitre of culture; stocks were stored at -70°C. 
Bacterial stocks were revived for subsequent work by using a sterile platinum wire to 
scratch the surface of the stock, following which it was streaked onto an agar plate as 
outlined above.
2.2.2.2 Extraction and purification of plasmid DNA
Plasmid DNA was isolated using a modification of the alkali lysis technique described 
by Bimboim and Doly (Bimboim and Doly, 1979).
2.2.2.2.1 Large Scale Plasmid Preparations.
Large quantities of high quality plasmid DNA, for sequencing purposes or 
transfections, were purified from 500ml of an exponentially growing overnight culture 
of recombinant bacteria using the QIAGEN Plasmid Purification Maxi kit. A 10 ml 
overnight culture of the desired transformant was grown and used to seed a 500 ml 
culture which was then grown overnight at 37°C, with shaking. The remainder of the 
protocol was performed according to the manufacturer’s instructions. DNA was stored 
at -20° C.
2.2.22.2 Small-Scale Preparations.
One and a half millilitres of an overnight culture of the desired transformant was 
removed to an eppendorf and spun at 13,000 rpm in a microcentrifuge for two minutes. 
The supernatant was discarded and the tubes inverted for two minutes to ensure that 
the pellet was media free. The pellet was resuspended in 150 pi of lysis buffer 
containing approximately 0.5 mg of lysozyme. Lysis was effected by addition of 300 
pi of 1% SDS/0.2 M NaOH to the resuspended cells. Following gentle mixing the 
tubes were left on ice for five minutes. Protein, bacterial chromosomal DNA and 
cellular debris were precipitated by addition of 225 pi of 3M KoAc and following 
gentle mixing the tubes were left on ice for five minutes. After centrifugation at
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13,000rpm for five minutes the supernatant was removed into a clean eppendorf. The 
plasmid DNA was recovered by addition of 630 pi of 100% ethanol followed by 
centrifugation at 13,000 rpm for 10 minutes. The pellet was washed with one millilitre 
of 70% ethanol and again centrifuged (13,000 rpm, two minutes). The ethanol was 
removed and the pellet dried in a vacuum desiccator for one minute. The DNA was 
then resuspended in 20 - 40 pi dH 2 0 .
2.22.2.3 Preparation o f DNA fo r  cycle sequencing
Small scale purification of sequencing grade plasmid DNA was purified from 1.5 - 3ml 
of an overnight culture using the PERFECTprep Plasmid DNA purification Kit 
(Flowgen), according to the manufacturer’s instructions. 500ng of DNA was used per 
cycle sequencing reaction. DNA was stored at -20°C.
2.2.2.3 Determination of nucleic acid concentration
2.2.2.3.1 Determination by spectrophotometry
The nucleic acid sample was diluted 1:100 by addition of 4 pi of nucleic acid to 396 pi 
of dH2 0 . The optical density was measured at 260 nm and 280 nm, in comparison to a 
blank of dH2 0 . An OD reading of 1.0 at 260 nm corresponds to an approximate 
nucleic acid concentration of 50 pg/ml for double stranded DNA, 40 pg/ml for RNA, 
or 33 pg/ml for single stranded oligonucleotides. The ratio of the OD readings at 260 
nm and 280 nm (OD2 6 o/OD2 go) was used to estimate the purity of the nucleic acid. 
Pure preparations of DNA and RNA have an OD2 6o/OD2go of 1.8 and 2.0, respectively; 
a lower value suggests possible protein or phenol contamination.
2.2.2.32 Estimation o f double stranded DNA concentration via gel electrophoresis
In cases where there was insufficient sample to permit quantification via 
spectrophotometry or where it was desired to verify the purity of DNA fragments of a 
certain size, the concentration of dsDNA was determined by running the sample on a
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polyacrylamide or agarose gel (see section 22.2.5) and comparing the intensity of the 
fluorescence of the unknown DNA to that of a known quantity of the appropriate size 
marker (c()X174 RF DNA/Hae HI fragments or X DNA/Hindm fragments), following 
staining with ethidium bromide and visualisation by UV transillumination.
2.2.2.4 Restriction endonuclease digestion
Typically, 1 - 2 |ig of DNA was digested in a 20 fil reaction mix containing the 
appropriate buffer, 5 mM spermidine and 5 - 1 0  units of the desired restriction enzyme. 
The reactions were incubated at 37°C for a minimum of one hour. Where the isolation 
of restriction fragments was required, larger quantities of DNA, generally 5 - 1 0  fig, 
were digested, with the reaction volume and components being increased 
proportionally. When digesting plasmid DNA prepared by the small scale procedure, 
likely to contain significant RNA contamination, this was followed by the addition of 
10 fig of RNAse A with a further 15 minute incubation at 37°C.
2.2.2.5 Electrophoresis of DNA
2.2.2.5.1 Agarose gel electrophoresis
DNA fragments of 1.0-10 kb were separated and identified by agarose gel 
electrophoresis using a submarine agarose gel kit (Mini the Gel Cicle - Hoefer 
Scientific Instruments, San Francisco, CA). Typically, 0.5 - 0.75 g agarose was added 
to 50 ml of TAE buffer, melted in a microwave and mixed to produce a 1 - 1.5% gel. 
Once the gel mix had cooled to 55°C, the gel was poured into a 100 x 65 mm gel 
support in its casting tray and an appropriate gel comb (eight or twelve well) inserted. 
The gel was allowed to solidify before transferring to an electrophoresis tank; the gel 
was immersed in TEA buffer and the comb carefully removed. DNA samples were 
prepared by the addition of an appropriate volume of 1 0  x gel loading buffer. 
Molecular size standard DNA was prepared similarly and the samples loaded into the 
wells using a micropipette. Gels were run at 40 - 50 volts for 60 - 120 minutes, then 
removed from the gel apparatus and stained in buffer solution containing 0.5 pg/ml
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ethidium bromide for 30 minutes. Following destaining for 30 minutes in dt^O , gels 
were visualised on a UV transilluminator and photographed using black and white 
Polaroid film (Type 667 - Polaroid UK Ltd., St Albans, Herts, UK).
22.2.5.2 Polyacrylamide gel electrophoresis
In order to separate, visualise and determine the size of DNA fragments under 
approximately 1.2 kb (including PCR products and products of restriction digests), 
non-denaturing polyacrylamide gel electrophoresis was employed. Glass plates of 16 
cm x 16 cm size were assembled with a 0.75 mm spacer in a casting stand (Atto). Five 
to six percent gels were prepared with five to six millilitres of 30%:0.8% 
acrylamide/bisacrylamide solution (Scotlab, Strathclyde, Scotland), three millilitres of 
10 x TBE buffer and dH20 added to 30 ml total volume. Following the addition of 25 
pi of TEMED and 250 pi 10% APS, the gel solution was poured between the 
assembled gel plates and a comb (12 or 20 well) inserted. After polymerisation, the gel 
plates were removed from the casting apparatus, the spacer removed and the plates 
transferred to the gel electrophoresis apparatus. The apparatus was filled with 1 x TBE 
buffer, the gel comb removed and the wells flushed with buffer. Samples were 
prepared as described in 2.2.2.5.1 and loaded onto the gel using 0.4 mm flat ended gel 
loading tips; (J)X174 RF DNA/Hae HI fragments were used as a molecular size 
standard. Gels were electrophoresed at 220 V for 45 - 90 minutes then removed and 
stained in buffer solution containing 0.5 pg/ml ethidium bromide for 15 minutes. 
Following destaining for 30 minutes in dH20, gels were visualised on a UV 
transilluminator and photographed using black and white Polaroid film.
2.2.2.6 Purification of restriction enzyme fragments
Where purification of DNA fragments was required for construction of recombinant 
plasmids, DNA was purified from agarose gels using the QIAquick Gel Extraction kit 
(Qiagen). Following electrophoresis, DNA fragments of interest were excised from 
agarose gels using a clean scalpel, and the remainder of the procedure was performed 
according to the manufacturers instructions.
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2.2.2.7 Ligation of vector and target DNA
Fragments of DNA generated by restriction digestion were ligated into approximately 
50ng of vector using T4 DNA ligase (GibcoBRL) according to the manufacturers 
instructions. Vector and insert DNA were mixed at a molar ratio of 1:1 to 1:5 (typically 
using 50 - 100 ng vector DNA), with an appropriate volume of ligation buffer and 4 
units DNA ligase, in a volume of 10 - 20 p i  Vector DNA was linearised using an 
appropriate restriction enzyme. To prevent re-circularisation of the vector DNA, both 
5 '-phosphate groups were hydrolysed with 0.5 units of calf intestinal alkaline 
phosphatase (CLAP, Promega) at 37°C for 30 min. If one or both ends of a DNA 
fragment generated by a restriction enzyme digest needed to be converted into blunt 
ends for cloning, the 5' or 3V protruding ends were ‘filled-in’ or removed using T4 
DNA polymerase (GibcoBRL) which has a 5 '-3 ' polymerase activity as well as a 5 '-3 ' 
exonuclease activity. Ligation of DNA fragments generated by PCR were carried out 
according to the manufacturer’s instructions with the Original TA Cloning Kit ( 
Invitrogen). Reactions were allowed to proceed overnight at 14°C and stored thereafter 
at -20°C if not used immediately. A control ligation, omitting insert DNA was 
generally set up in parallel to the above, in order to check for ‘background’ when 
performing subsequent bacterial transformations.
2.2.2.8 Transformation of bacteria with plasmid DNA
In addition to the transformation with recombinant plasmid, the bacteria were also 
transformed with a control plasmid (as a positive control) and a ligation reaction from 
which the insert DNA had been omitted (as a negative control).
Transformation o fD H 5 a  cells: Cells were thawed on wet ice, gently mixed and 20 |il 
of cells aliquoted to a chilled microcentrifuge tube for each transformation required. 
Unused cells were refrozen in 20 |il aliquots in a dry ice/ethanol bath for five minutes 
before returning them to the -70 °C freezer. One microlitre of ligation reaction or 
control plasmid (pUC18) was added to the cells (1 - 10 ng DNA), moving the pipette 
through the cells while dispensing in order to facilitate mixing. Cells were left on ice 
for 30 minutes then heat shocked in a 42°C water bath for 40 seconds. After heat
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shocking the cells were placed on ice for 2 minutes, 80 \i\ of SOC medium was added 
and the tubes were incubated at 37°C for 1 hour with shaking at 225 rpm. Cells were 
plated onto LB plates (containing 50 |ig/ml ampicillin; 25 jllI of X-Gal stock solution 
was spread on the plate one hour prior to use if blue-white colour selection was used) 
and incubated at 37°C overnight.
Transformation o f INVocF' cells: The transformation procedure for these cells was 
essentially as described for D H 5a cells with minor modifications: one vial of cells (50 
jil) was used for each transformation; 2 jil of 0.5 M 2-ME was added to the cells prior 
to incubation on ice; cells were heat shocked for 30 seconds; 450 |il of SOC medium 
was added to the cells; typically 100 |il of cells was spread on each LB agar plate.
Transformation o f Epicurian Coli XL2-Blue M RF’ ultracompetent cells: The 
transformation procedure for these cells was essentially as described for DH5a cells 
with minor modifications. lOOjxl of cells per transformation were aliquoted into 
prechilled 15 ml Falcon polypropylene tubes. 1.7 |il of 0.5 M 2-ME was added to the 
cells prior to a ten minute incubation on ice. After adding the DNA to the cells the 
tubes were incubated for a further 30 minutes on ice. The cells were heat shocked for 
30 seconds and 900 pi of SOC medium was added to the cells; typically 100 fil of cells 
was spread on each LB agar plate.
2.2.2.9 Screening of transformants for desired recombinant plasmids
All plasmid strains used in this project conferred ampicillin resistance upon host 




The pCRD and pCR2.1 plasmids contain genes encoding the lacZa  fragment of (3- 
galactosidase and the lac promoter and therefore are capable of complementation with 
the cp fragment encoded by the E.coli host strains D H 5a and IN V aF’, giving active P- 
galactosidase. The incorporation of X-gal into LB agar plates allows the selection of 
transformants based on blue-white screening. Disruption of lacZa  expression occurs 
with the cloning of fragments into the multiple cloning site of this vector, hence 
recombinants with plasmid containing insert DNA appear white whilst non­
recombinants, expressing a functional p-galactosidase, appear blue.
22.2.9.2 Restriction analysis o f small-scale plasmid preparations
Plasmid DNA, isolated as described in 2.2.2.2.2., was subjected to restriction digest 
with the appropriate enzyme(s), and the resulting products of digestion were run on a 
polyacryamide or agarose gel. Bacteria with plasmids containing inserts of the desired 
size were stored as glycerol stocks as detailed in section 2.2.2.1.
2.2.3 PREPARATION OF NUCLEIC ACIDS
2.2.3.1 Preparation of mRNA
For procedures involving RNA preparation and subsequent manipulation, care was 
taken to avoid degradation by ribonucleases. All plastic ware used was either new or 
was treated by soaking overnight in DEPC treated water, followed by autoclaving 
twice at 121 °C for 15 minutes. All solutions were prepared using DEPC treated water. 
Gloves were worn and changed frequently.
The preparation of high quality mRNA was facilitated by the use of the QuickPrep 
mRNA Purification kit (Pharmacia). Tissue is disrupted in guanidinium isothiocyanate 
to ensure rapid inactivation of endogenous RNAse activity and dissociation of cell
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components from the mRNA (based on the method of Chirgwin et al (Chirgwin et al. 
1979)). After adjustment of the buffer concentration and pelleting of cellular debris and 
insoluble proteins by centrifugation, polyadenylated mRNA is extracted by binding to 
oligo(dT) cellulose columns (Aviv and Leder, 1972). Finally, following washes to 
remove DNA, protein and non-poly A+ RNA, the mRNA is eluted from the column.
The manufacturer’s instructions were followed, briefly, as follows. Cultured cells 
(< 5 x 10 7 cells) were pelleted by centrifugation at 400 x g for five minutes. The cells 
were resuspended in 1.5 ml extraction buffer (aqueous solution containing 
guanidinium thiocyanate and N-lauroyl sarcosine) and homogenised by passing 
through a 21 G needle attached to a syringe. To the sample was added three millilitres 
of elution buffer (10 mM Tris-HCl (pH 7.5), 1 mM EDTA); after brief homogenisation 
the sample was transferred to a sterile polypropylene centrifuge tube and centrifuged at 
10,000 rpm in a Beckman JA-20 rotor for 10 minutes. An oligo(dT)-cellulose spun 
column was prepared by centrifugation (all centrifuge steps involving the spin column 
were at 350 x g for two minutes) with both top and bottom closures removed; the 
supernatant was then applied to the column and mixed gently for 15 minutes. The 
column was centrifuged with both closures on and the supernatant discarded. The 
column was then washed (followed each time by centrifugation) three times with high- 
salt buffer (10 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.5 M NaCl) and twice with low- 
salt buffer (10 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.1 M NaCl). The mRNA was 
then eluted with three sequential washes of 0.25 ml elution buffer warmed to 65°C. 
The mRNA was precipitated overnight at -70°C following the addition of 10 pi 
glycogen solution (5 -10 mg/ml glycogen in DEPC treated water), 75 pi 2.5 M KoAc 
solution and 1.5 ml of 95% ethanol. The mRNA was then pelleted by centrifugation at 
13 K for 15 minutes, the ethanol removed, and the mRNA dried for one minute in a 
vacuum desiccator. The mRNA was then resuspended in 20 - 40 pi DEPC treated 
water and its concentration determined by spectrophotometry (section 2.2.2.3.1).
2.2.3.2 First-strand cDNA synthesis
In order to maximise the likelihood of obtaining full-length cDNA copies of mRNA, a 
commercial cDNA synthesis kit was employed (First-strand cDNA synthesis kit -
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Pharmacia Biotech). The kit contained all components required for first strand cDNA 
synthesis, including a pre-assembled reaction mix containing Moloney Murine 
Leukaemia Virus (M-MuLV) reverse transcriptase (Roth et al. 1985), RNAguard (an 
RNAse inhibitor), RNAse/DNAse free BSA, and dNTPs in an aqueous buffer. An 
oligo-dT primer (Not I-d(T)i8 primer) supplied with the kit was used to prime cDNA 
synthesis; the sequence is as follows:
5’-d[AAC TGG AAG AAT TCG CGG CCG CAG GAA T i8]-3’
Typically, 200 ng mRNA was placed in a microcentrifuge tube and brought to 20 jil 
with RNAse free water. The RNA was denatured at 65°C for 10 minutes then chilled 
on ice. To the RNA was added 11 (il bulk first strand reaction mix, 1 |il of 200 mM 
DTT and 1 jllI (0.2 |ig) Not I-d(T)is primer. The reaction mix was incubated for one 
hour at 37°C, then kept on ice (or stored at -70°C) prior to amplification by the 
polymerase chain reaction.
2.2.4 AMPLIFICATION OF DNA BY THE POLYMERASE CHAIN 
REACTION
The polymerase chain reaction (PCR) is a powerful technique for amplification of 
specific DNA sequences from a complex mixture of DNA. The procedure was 
developed by Mullis and co-workers in the mid 1980s (Mullis et al. 1986), (Mullis and 
Faloona, 1987) enabling large amounts of a single copy gene to be generated from 
genomic (Saiki et al. 1985), (Saiki et al. 1986) or viral DNA (Kwok et al. 1987). The 
initial method used the Klenow fragment of DNA polymerase I, which had to be 
replenished during each cycle as it is readily denatured by the amplification conditions 
used. The substitution of thermostable Taq polymerse, isolated from Thermus 
aquaticus, circumvented this problem and allowed the automation of thermal cycling 
(Saiki etal. 1988).
PCR enables the amplification of unknown DNA sequence by the simultaneous 
extension of a pair of primers, flanking the unknown sequence, each complimentary to 
opposite strands of the DNA. The uses of PCR are many and it has superseded more 
conventional molecular biological methods in many areas, including sequencing (Innis
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et al. 1988), cloning (Scharf, 1990) and detection and analysis of RNA (Veres et al.
1987). An extensive overview of PCR, its applications and detailed protocols are given 
in Innis et a l  (Innis et al. 1990). An overview of the procedure is given below, with 
more detail in the appropriate chapters.
2.2.4.1 Primer design
Primer design was aided by some basic guidelines as suggested by Innis and Gelfland 
(Innis and Gelfand, 1990). Primers were generally 1 8 - 2 8  nucleotides in length, with a 
G + C composition of 50 - 60% where possible. For a given primer pair, the annealing 
temperatures (Tm), were balanced and complementary regions between and within 
primers were avoided; design of primers in this respect was aided by the Oligo primer 
analysis software program (Version 4.1 - Medprobe AS, Oslo, Norway).
2.2.4.2 Preparation of PCR reactions
As PCR is such a sensitive procedure it is essential to take stringent precautions to 
avoid PCR contamination from tube to tube or carry over of PCR products (Saiki et al.
1988). PCR reactions were set up in a designated area, at a site distant from the main 
laboratory area, where the PCR products were handled. A set of micropipettes were 
kept for the sole purpose of setting up PCR reactions. Filter tip pipette tips were used 
to decrease the risk of carry over of reaction components from one tube to the next. A 
bulk reaction mix was used in order to minimise the number of pipetting steps. 
Reaction components (including primers) were aliquoted prior to use and aliquots 
stored at -20°C.
2.2.4.3 Reaction conditions
The use of high quality reagents is essential to the success of PCR; to facilitate this the 
Perkin Elmer Gene Amp Kit, containing all necessary reagents, was used. The 
manufacturer’s instructions were followed. Typically a reaction mix was set up in 50 
pi volume in 0.5 ml tubes containing 1.25 mM each dNTP, 1 x PCR buffer (10 mM
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Tris-HCl, pH 8.3, 50 mM KC1, 1.5 mM MgCl2, 0.01% gelatin), 2.5 units Taq DNA 
polymerase, 0.2 - 2.0 pM each primer and an appropriate volume of DNA or cDNA 
template. The reaction was then overlaid with mineral oil. Thermal cycling was carried 
out in a DNA thermal cycler (Perkin Elmer), with a typical cycle consisting of an initial 
denaturation of 94°C for five minutes, followed by 30 - 35 cycles of: denaturation at 
94°C, for one minute; annealing at 45 - 60°C for one minute; extension at 72°C for one 
minute; with a final extension step of 72°C for five minutes. Reaction products were 
visualised by polyacrylamide gel electrophoresis as detailed in 2.2.2.5.2, generally 
using five-ten microlitres of reaction product per well.
2.2.5 DNA SEQUENCE ANALYSIS
2.2.5.1 M anual sequencing by the chain termination method
2.2.5.7.7 Sequencing reactions
Manual sequencing employed the Sequenase version 2.0 DNA sequencing kit, which is 
based on the chain termination method originally described by Sanger et al. (Sanger et 
al. 1977). This method of sequencing was performed in an attempt to resolve the 
compressions in DNA sequences encountered when using automated sequencing 
methods. The latter method was employed for all other sequencing procedures 
undertaken in the project. The kit uses Sequenase 2.0 DNA polymerase, a modified 
version of the original Sequenase enzyme, described by Tabor and Richardson (Tabor 
and Richardson, 1987). The enzyme lacks 3’ - 5’ exonuclease activity, present in the 
wild type enzyme, and shows higher speed and processivity. The manufacturer’s 
instructions were followed; the procedure is described briefly below, divided into four 
stages.
Denaturation o f dsDNA template: Double-stranded plasmid DNA, prepared as 
described in 2.2.2.2.2, (approximately six to ten micrograms contained in 36 pi dH20 ) 
was denatured by the addition of four microlitres of 2 M NaOH followed by incubation
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at 37°C for 15 minutes. Eight microlitres of 5 M ammonium acetate was added to 
neutralise the mixture, and the DNA precipitated with 2 - 2.5 volumes ethanol at -70°C 
for 30 minutes. The DNA was pelleted by centrifugation at 13,000 rpm for 15 minutes, 
the supernatant discarded and the pellet washed in 500 pi 70% ethanol. After a brief 
centrifugation at 13,000 rpm, the pellet was dried in a vacuum desiccator, then 
dissolved in 14 pi dH20 , providing sufficient DNA for two sequencing reactions.
Annealing step: Plasmid DNA, contained in seven microlitres of dH20 , was mixed 
with two microlitres of reaction buffer (200 mM Tris-HCl (pH 7.5), 100 mM MgCl2, 
250 mM NaCl) and one microlitre (0.5 - 2.0 pmol) of primer in a microcentrifuge tube. 
The mixture was brought to 65°C for two minutes, then removed to a beaker of water 
at 65°C and allowed to cool slowly to 35°C, at which point the reaction was considered 
complete and the tube placed on ice.
Labelling step: The primer annealed to the DNA template was extended using limiting 
concentrations of a mix of dNTPs, including radioactively labelled dATP. This step 
results in the generation of a mix of labelled DNA chains, varying from several to 
hundreds of nucleotides in length. To the above template-primer mix was added one 
microlitre 0.1 M DTT, 0.5 pi of [ot-35S]-dATP and two microlitres of labelling mix 
(7.5 pM dGTP, 7.5 pM dCTP, 7.5 pM dTTP) diluted five-fold with dH20 . Finally 
Sequenase enzyme was diluted 1:8 with ice cold enzyme dilution buffer (10 mM Tris- 
HCl (pH 7.5), 5 mM DTT, 0.5 mg/ml BSA), two microlitres was added to the labelling 
mix, and the reaction was incubated for five minutes at room temperature.
Chain-termination step: DNA synthesis was continued using a mix of dNTPs and a 
dideoxynucleoside triphosphate; this results in the termination of DNA synthesis with a 
known ddNTP. Two and a half microlitres of each termination mix (80 pM each 
dNTP, 50 mM NaCl plus 8 pM appropriate ddNTP) was aliquoted into labelled screw- 
top microcentrifuge tubes and pre-warmed to 37°C for one minute. Three and a half 
microlitres of the above labelling reaction was then added to each tube, mixed by 
gentle pipetting, and incubated at 37°C for 15 minutes. The reactions were terminated 
by the addition of four microlitres of stop solution (95% formamide, 20 mM EDTA,
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0.05% bromophenol blue, 0.05% xylene cyanol FF). Reactions were stored at -20°C 
for up to one week prior to gel electrophoresis.
2.2.5.1.2 Gel electrophoresis
The completed sequencing reactions were run on six percent denaturing 
polyacrylamide gels, incorporating Long Ranger polyacrylamide gel solution (AT 
Biochem, Malvern, USA). Long Ranger gel mix contains modified acrylamide 
monomers and a modified crosslinker that results in a gel that produces longer readable 
sequence, is stronger and more elastic than conventional gels, and does not require 
fixing or removal of urea prior to drying. Glass sequencing plates (50 x 22 cm) were 
cleaned with 1% SDS, rinsed thoroughly then cleaned with ethanol. Repelcote (BDH) 
was applied to the surface of one plate to ensure that the gel would not stick to the 
glass plate. The sequencing plates were assembled with 0.2 mm spacers and plastic 
adhesive tape. To 50 ml of sequencing gel mix was added 25 pi of TEMED and 250 pi 
of 10% APS. The gel was poured using a 50 ml syringe, and a 24 well sharkstooth 
comb was inserted in an inverted position and clamped in place using ‘bulldog’ clips. 
The gel was then allowed to polymerise in a near-horizontal position for at least one 
hour at room temperature. The tape at the bottom of the gel plates was removed, the 
plates mounted into the sequencing apparatus and the upper and lower gel tanks filled 
with 1 x TBE. The comb was removed, the surface of the gel rinsed with buffer and the 
comb reinserted in the correct orientation. The gel was pre-electrophoresed for 15 
minutes at 35 Watts. The DNA samples were denatured by heating to 75°C for two to 
five minutes immediately prior to loading two to three microlitres of sample per well. 
Aliquots of each reaction were run at 35 Watts for approximately two hours and four 
hours; this generally allowed 350 - 500 bp to be read from each sequencing reaction.
Following electrophoresis, the plates were removed from the sequencing apparatus, 
allowed to cool briefly then separated. The gel was transferred to Whatman 3 MM 
filter paper (Whatman International Ltd., Maidstone, England), covered with Saran 
wrap (Dow Chemical Co.) and dried, gel side uppermost, under vacuum in a gel drier 
for 30 - 60 minutes at 80°C. The plastic wrap was then removed and the top of the gel 
trimmed to fit an autoradiography cassette. A sheet of autoradiography film (Biomax
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HR single sided emulsion film or X-omat AR double sided emulsion film (both 35 x 
43 cm) - IBI Limited, A Kodak Company, Cambridge, England) was placed in contact 
with the gel and exposed overnight, at room temperature, prior to developing in an 
automated processor. The sequence was read manually over a light box, and the data 
stored on a UNIX computer system. DNA sequence was analysed using the GCG 
package (Wisconsin Package Version 9.1, Genetics Computer Group (GCG), Madison, 
Wisconsin), using notably ‘SeqEd’, ‘Bestfit’, ‘Lineup’ and ‘Pileup’ programs and 
database searches were carried out by FastA searches in GCG.
2.2.5.2 Automated sequencing
The Licor model 4000 automated sequencer was employed for almost all sequencing 
procedures undertaken in this project. The sequencer utilises an infrared detection 
system, whereby DNA fragments are detected following labelling with IRD41 labelled 
primers, as they run through the denaturing polyacrylamide gel. Cycle sequencing 
reactions were carried out using IRD41-labelled primers (MWG-Biotech) and the 
ThermoSequenase Fluorescent Labelled Primer Cycle Sequencing Kit with 7-deaza- 
dGTP (Amersham Life Science). Cycle sequencing is based on the chain termination 
method of Sanger (Sanger et al. 1977), but uses a thermostable DNA polymerase to 
give multiple rounds of high temperature DNA synthesis. This variation on the original 
method of chain termination sequencing was first described by Innis et al. (Innis et al.
1988). The method allows direct sequencing of dsDNA without alkali denaturation, 
requires less template and is generally more efficient at sequencing templates that are 
G/C rich or have high secondary structure.
Briefly, 500ng of plasmid DNA, lpmol of IRD-41 labelled primer (MWG-Biotech) 
and 2 jllI of reaction mix which contained 45mM each of dGTP, dATP, dTTP and 
dCTP, reaction buffer and thermostable DNA polymerase, were mixed in a 0.5ml 
reaction tube. The reaction was made up to 8|il with d d ^ O , overlaid with 20|il of 
mineral oil, denatured for 5 min at 95°C then passed through 25 cycles of 95°C for 30 
seconds, 48-60°C for 30 seconds and 72°C for 30 seconds. The mineral oil was then 
removed by running each sample down a parafilm gradient and collecting the aqueous 
phase at the bottom of the slope. 4 jlx1 of formamide loading buffer supplied with the kit
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was then added to each reaction tube. The gel mix was prepared before use with 4.8ml 
Sequagel XR ultra pure concentrate (National Diagnostics), 25.2g urea, 7.2ml 10X 
TBE in a total volume of 60ml with ddH^O. To the gel mix was added 400jll1 10% 
APS. Three millilitres of the gel mix was removed to a bijou and 32 pi 10% APS and 
four microlitres of TEMED added; a pasteur pipette was then used to inject the mix 
between the bottom of the glass plates to form a plug. After the plug had polymerised, 
36pl TEMED was added to the remaining gel solution, mixed and the gel poured.
A comb was inserted and clamped in place using two ‘bulldog’ clips; the gel was then 
inclined at approximately 30° from horizontal, and allowed to polymerise for a 
minimum of 90 minutes. The gel was then transferred to the electrophoresis apparatus, 
both buffer tanks filled with 1 x TBE, the comb removed and the wells flushed. The 
gel was pre-electrophoresed for 30 - 45 minutes, during which time the scanning 
microscope was focused and the gain controls adjusted. Sequencing reactions were 
denatured at 95°C for three minutes prior to loading; generally 0.8 - 1.5 pi was loaded 
per well. Data recording was performed on a Li-Cor model 4000 DNA sequencer 
(MWG-Biotech). Typically 800-1000bp of sequence was generated from one run. 
DNA sequence was analysed as described above, using the GCG package, and database 
searches were carried out by FastA searches in GCG.
2.2.6 ANALYSIS O F RECOM BINANT PROTEINS
2.2.6.1 SDS - polyacrylamide gel electrophoresis of proteins
The separation and analysis of proteins was facilitated by one dimensional denaturing 
discontinuous gel electrophoresis, as originally described by Laemmli (Laemmli, 
1970). Proteins are denatured by boiling in the presence of SDS and (3- 
mercaptoethanol. The sample is then loaded onto a discontinuous gel consisting of a 
stacking buffer which concentrates the loaded protein sample into a narrow band and a 
separating gel which separates proteins on the basis of molecular size, with smaller 
proteins migrating faster towards the anode.
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Minigels (8.0 x 7.3 cm) were formed and run using the Mini-PROTEAN II 
electrophoresis system (Biorad, Herts, UK) as recommended by the manufacturer. 
Glass plates were assembled with 0.75 mm spacers in a casting stand. The separating 
gel was poured to a depth of approximately 5 cm; consisting of 4 ml 30%:0.8% w/v 
acrylamide/bisacrylamide (giving a 12% gel), 3.35 ml dH20, 2.5 ml 1.5 M Tris-HCl 
(pH 8.8), 50 pi 20% SDS, 100 pi 10% APS and 10 pi TEMED. This was overlaid with 
tris-saturated butanol and allowed to polymerise. The butanol was then poured off, the 
surface of the separating gel rinsed with dH20 and the stacking gel poured. The 
stacking gel consisted of 650 pi 30%:0.8% w/v acrylamide/bisacrylamide, 3.0 ml 
dH20 , 1.25 ml 0.5M Tris-HCl (pH 6.8), 25 pi 20% SDS, 25 pi 10% APS and 7 pi 
TEMED. A 10 well comb was inserted and the gel allowed to polymerise. The gel was 
then transferred to the electrophoresis tank, both buffer tanks filled with running 
buffer, the comb removed and the wells flushed. Protein samples (typically 5 - 30 pg 
of protein in 5 - 25 pi) were prepared by addition of an appropriate volume of 5 x 
protein sample loading buffer, followed by heating to 100°C for five minutes. Samples 
were then loaded onto the gel using 0.2 mm flat ended gel loading tips. A protein 
molecular weight standard (5 -10 pi) was loaded in one or both outer wells to allow 
estimation of the size of sample proteins. Gels were electrophoresed at MOV for 60 - 
80 minutes until the bromophenol blue dye reached the bottom of the separating gel. 
The gel was then removed from the glass plates, the stacking gel discarded, and the 
protein bands detected by immunodetection (section 2.2.6.2).
2.2.6.2 Detection of proteins by immunoblotting
The detection of proteins by immunoblotting (western blotting) is a rapid and sensitive 
technique that exploits the inherent specificity of antigen recognition by antibodies 
(Towbin et al. 1979). Proteins were transferred to PVDF membrane by electroblotting, 
following electrophoretic separation and detected using ECL reagents (Amersham Life 
Science). This detection system is based on the emission of light following the 
oxidation of luminol by horse radish peroxidase (HRP labelled antibodies), in the 
presence of chemical enhancers such as phenols (enhanced chemiluminescence), 
(Durrant, 1990) and is particularly sensitive (Gillespie and Hudspeth, 1991). The light
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emitted can be detected by a short exposure to blue-light sensitive film (Hyperfilm 
ECL, Amersham).
Following SDS-PAGE, as described in section 2.2.6.1, the gel was removed from the 
glass plates and rinsed in TBS. Hybond-ECL membrane was prewetted in 100% 
methanol for 15 seconds, with distilled water for 2 minutes and then allowed to 
equilibrate with transfer buffer for 10 minutes prior to blotting. Proteins were 
transferred to the membrane using a semi-dry electroblotting system (Transblot SD - 
Biorad Laboratories, Hercules, CA) The gel and membrane were sandwiched in close 
apposition between two sheets of extra thick filter paper (Biorad), pre-soaked in 
transfer buffer, and transferred at 10 V for 45 minutes.
The membrane was then rinsed in TBS and non-specific binding sites blocked by 
immersing the membrane for 30 minutes in 10% low fat dried milk (Marvel - Premier 
Beverages, Stafford, UK) and TBS-T (0.1% Tween in tris buffered saline) solution at 
room temperature on an orbital shaker. The membrane was rinsed briefly with TBS-T, 
washed once for 15 minutes then twice for five minutes, with shaking at room 
temperature. The membrane was then incubated with the primary antibody, at a pre­
determined dilution in 5% low fat dried milk, TBS-T, for two hours at room 
temperature, with shaking. The membrane was then washed as detailed above prior to 
incubating with the secondary antibody (HRP labelled), appropriately diluted in 5% 
low fat dried milk, TBS-T, for one hour, at room temperature, with shaking.
The membrane was washed (as above) before detection by the ECL method, which was 
carried out in a darkroom. An equal volume of detection reagent A was mixed with 
reagent B (typically 0.5 ml each). Excess buffer was drained from the membrane and 
the detection solution was pipetted onto the surface of the membrane carrying the 
protein. After incubation for one minute at room temperature, excess reagent was 
drained from the membrane which was then wrapped in plastic film. The membrane 
was placed, protein side up, in a film cassette and a sheet of autoradiography film 
(Hyperfilm-ECL) placed on top, in the dark. The cassette was closed and the film 
exposed for 15 - 30 seconds, before developing in an automated processor. A second
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sheet of film was then exposed, generally for 2 - 2 0  minutes, the time being estimated 
from the appearance of the first autoradiograph.
2.2.7 TRANSIENT TRANSFECTION OF MAMMALIAN CELLS
2.2.7.1 Calcium phosphate mediated transfection
Calcium phosphate mediated transfection involves mixing DNA directly with CaC^ 
and a phosphate buffer to form a fine precipitate which is dispersed over the cultured 
cells (Graham and Eb, 1973). This technique for DNA transfer was extended by Wigler 
et al. when they demonstrated that the thymidine kinase gene could be transfected and 
stably expressed in mouse cells (Wigler et al. 1977). The ProFection® Mammalian 
Transfection System, designed for high efficiency transfer of DNA into mammalian 
cells, was used for the transient transfection of genes into 293T cells.
The 293T cells were split 1 in 5 the day before the transfection experiment, so the cells 
were 30-40% confluent on the day of transfection. G-418 was omitted from the 
medium, at this stage. Three hours prior to transfection medium was removed from the 
cells and replaced with fresh culture medium. All system components were thawed and 
then warmed to room temperature, mixing each component thoroughly by vortexing. 
DNA to be transfected was resuspended in TE buffer at a final concentration of 0.5- 
1.0p,g/|il and DNA purity was checked by determining the ratio of absorbance at 
260nm (A2 6 0 ) to 280nm (A2 8 0 X using a spectrophotometer. For each transfection, the 
DNA and 2X HBS solutions were prepared in two separate sterile tubes. 6p,g of DNA 
and the appropriate volume of sterile, deionised water to a volume of 300|il, were 
added to the first tube and mixed well, before adding 37|il of the 2M CaCb and mixing 
again. Meanwhile, 300|il of 2X HBS solution was added to the second tube. Working 
in a sterile tissue culture hood, the tube containing the 2X HBS solution was vortexed 
gently while the DNA solution was slowly added dropwise to the 2X HBS. This 
transfection solution was vortexed again, immediately prior to the addition of the 
solution, dropwise, to the plates of cells. The plates were swirled to distribute the 
precipitate evenly over the cells and then were returned to a 37°C CO2 incubator. 18
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hours after transfection the culture media was changed and the cells were finally 
harvested 48 hours after transfection.
The cell supernatants were removed from the flasks, placed into 15ml Falcon tubes 
and spun at 1000 rpm for 5 minutes to remove cell debris. The resulting supernatants 
were pipetted into fresh tubes and stored at -20°C. The cell monolayers were washed 
briefly with 5ml of IX PBS and 250|il of IX protein sample reducing buffer was added 
to the cell lysates which were to be subjected to western blot analysis. The IX protein 
sample reducing buffer was swirled over all the cells and then scraped off with a cell 
scraper into 1.5 ml screw top eppendorfs. The lysates were then bolied for ten minutes, 
spun for 5 minutes at 13000rpm in a microcentrifuge, and finally the cell lysate 
supernatants were aliquoted into fresh eppendorfs and stored at -20°C for future 
western blot analysis. Cell lysates to be subject to Northern blot analysis were washed 
briefly in IX PBS as above, then 1.5ml extraction buffer from the Quickprep mRNA 
purification kit was added. The cells were scraped off using a cell scraper and the 
resultant suspension was pipetted into sterile 15ml Falcon tubes. These were 
homogenised with a 21’ gauge needle, before 3ml of elution buffer from the kit was 
added. Finally, homogenisation with the needle and syringe was performed again, 
before proceeding with the manufacturer’s protocol, as detailed in section 2.2.3.1 .
2 .2 .12  p-galactosidase assay to assess transfection efficiency
To monitor transfection efficiency, a control transfection was performed alongside all 
the test transfections, using a plasmid expressing P-galactosidase. Cells expressing this 
enzyme could then be visualised in situ by staining with X-Gal substrate. Cells were 
transfected, as described above, with the pSV-P-galactosidase Control Vector 
(Promega) and the p-galactosidase assay was performed 48 hours after transfection, 
when the test transfection cells were harvested. All tissue culture medium was 
aspirated from the cells and they were rinsed quickly with warm 0.1M PBS pH 7.4. 
The cells were then fixed for 15 minutes with 4% w/v paraformaldehyde 0.1M PBS 
0.12M sucrose pH 7.4. The fix was subsequently removed and the cells subjected to 
three five minute washes with warm 0.1M PBS pH 7.4. The cells were then 
permeabilised for five minutes with 0.1% v/v Triton/PBS. After aspiration of the
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Triton solution, the cells were washed three times, as above, before the X-Gal assay 
solution was applied to just cover the cells. The flask of cells was then incubated at 
37°C overnight, checking the reaction process after three hours. Finally, the assay 
solution was aspirated and the cells washed as described previously. The cells were 
then examined under a microscope with the 4 x or 10 x objective and the number of 
blue cells (transfected cells) in the dried monolayer counted and compared to the 
number of unstained cells (non-transfected cells). Transfection efficiency for a 
particular set of transfections was thus determined.
2.2.8 RNA HYBRIDISATION ANALYSIS
2.2.8.1 Northern blot transfer of RNA
l-5|ig of polyA+ mRNA was lyophilised (VR-1 Hetovac, Heto) then resuspended in 
20pl of RNA loading buffer and denatured for 15 min at 65°C. Subsequently, 3-5p,l of 
RNA running dye was added and the samples electrophoresed for 3 hours at 100V in 
200ml of a 1% agarose gel containing 1 X MOPS and 2.2M formaldehyde in IX 
MOPS buffer that was continually recirculated. 5p,g of RNA ladders (GibcoBRL), 
which were treated in the same way as the RNA samples, were used as molecular 
weight markers. Following electrophoresis, the marker lanes were removed using a 
clean scalpel and stained in 3pg/ml ethidium bromide for 30 min, then destained 
overnight and photographed. The rest of the gel was washed twice in d d ^ O  for 20 
min to remove formaldehyde, then equilibrated in 10 X SSC and transferred overnight 
onto Hybond-N in 10 X SSC. The membrane was removed and rinsed briefly in 2 X 
SSC and the RNA crosslinked to the membrane (Spectrolinker XL-1500 UV 
Crosslinker, Spectronics Corporation). All northern blots were probed with a rat 
GAPDH probe to control for RNA loading and integrity. The GAPDH probe is a 
750bp EcoKl fragment purified from the plasmid pGAPDH.
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2.2.8.2 Preparation of radiolabelled DNA probes
PCR generated or restriction fragment DNA probes were gel-purified, using the 
QIAquick Gel Extraction kit (Qiagen), and radioactively labelled using a ‘random 
prime’ DNA labelling kit (High Prime, Boehringer Mannheim), and a (32P) dCTP, 
specific activity 3000Ci/mmol (Amersham). Generally, 20-50ng of heat denatured 
DNA was radiolabelled using 50pCi (1.85Mbq) of a (32P) dCTP and 4|il of High Prime 
in a final volume of 20jil, following the manufacturer’s instructions. Unincorporated 
nucleotides were removed by gel-filtration through Sephadex-G50 beads (Nick 
Columns, Pharmacia) and labelled fragments were eluted in 400|il of TE buffer and the 
activity of 2|il was determined. Typically, incorporations of 108 - 109 cpm/|ig were 
achieved.
2.2.8.3 Hybridisation of labelled probes to membrane bound nucleic acids
Standard high stringency conditions for the hybridisation of specific radiolabelled 
probes on nucleic acids immobilised on nylon membranes were as follows. Membranes 
which had been pre-wetted in 2 X SSC and rolled into Hybaid hybridisation bottles 
were pre-hybridised in 10-20ml of the northern blot pre-hybridisation buffer (section 
2.1.11.3.) at 42°C for at least 2 hours in a Hybaid oven with continual rotation. Freshly 
boiled DNA probe was added to the pre-hybridisation solution: 106 cpm/ml was used 
for Northerns. Filters were hybridised overnight as above. After rinsing briefly with 2 
X SSC, the membrane was washed for 20 min with three changes of 0.1X SSC, 0.5% 
SDS at 60°C, unless otherwise stated. Membranes were then sealed in polythene and 
exposed to X-ray film (Kodak). Following hybridisation, filters were stripped of probe 
by continuous shaking in boiling dHiO containing 0.1%SDS until the solution had 
cooled to room temperature.
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3. CHAPTER THREE; CLONING, SEQUENCING AND 





The application of recombinant human cytokine proteins in the treatment of feline 
disease has been of limited success, mainly due to the poor degree of conservation 
between the human and feline proteins, resulting in poor therapeutic efficacy and the 
generation of neutralising antibodies in treated cats (Dunham, 1999). To facilitate the 
production of feline specific cytokines, as therapeutic agents and to aid studies into the 
role of cytokines in feline disease, the isolation and cloning of feline cytokines has 
been undertaken by many different research groups, (reviewed by Dunham 1999). 
Determination of the unique feline nucleotide sequence allows techniques such as 
quantitative RT-PCR, Northern assays or in situ hybridisation to be performed. The 
cytokine protein may also be expressed in an appropriate expression system and 
antibodies generated, to evaluate both the in vitro and in vivo effects of the cytokine. 
Ultimately many cytokines are likely to form a new array of therapeutic agents to treat 
feline disease. As discussed in the introduction, the isolation of the feline Thl type 
cytokines IL-12 and IL-18, cytokines integral to the development of cell-mediated 
immunity, was undertaken to investigate their potential to act as genetic adjuvants in 




Interleukin 12 (IL-12), a recently discovered heterodimeric cytokine, is a pivotal 
regulator of T and NK cell function (Gubler et al. 1991), stimulating proliferation, 
cytolytic activity and cytokine induction. IL-12 was identified by two independent 
research groups at the Wistar Institute (Kobayashi et al. 1989) and Hoffmann-La 
Roche (Stem et al. 1990), who named it natural killer cell stimulatory factor (NKSF) 
or cytotoxic lymphocyte maturation factor (CLMF), respectively. Subsequent cloning 
of the cDNAs encoding these proteins revealed that NKSF and CLMF were the same 
molecule (Gubler et al. 1991), now generally known as IL-12. Although IL-12 shares 
many of its activities with other interleukins, such as IL-2, IL-12 has, more recently, 
been found to play a critical and unique role in promoting Thl type cytokine responses 
(Manetti et al. 1993), leading to the enhancement of the cell-mediated immune 
response. Based on these immuno-enhancing activities, the therapeutic potential of IL- 
12 in the treatment of infectious disease (Khan et al. 1994) and cancer (Brunda et al.
1993) has been evaluated in animal models, and protective effects have been observed.
While experimental work to isolate the feline IL-12 gene was ongoing, two 
independent research groups cloned and sequenced the feline IL-12 cDNA (Schijns et 
al. 1997), (Fehr et al. 1997). However, efforts to elucidate the full length sequences of 
both subunits of the cytokine, p35 and p40, continued, as differences between the 
published p40 nucleic acid sequences and the p40 nucleic acid sequence obtained 
during the course of this project were discovered. As data regarding the molecular 
biology and biological activity of feline IL-12 were extremely limited at the time of 
writing, the current data regarding human and murine IL-12 are reviewed below.
3.1.2.2 Structure and molecular biology
IL-12 is a disulphide-linked heterodimeric cytokine comprised of 40kDa (p40) and 
35kDa (p35) chains (Kobayashi et al. 1989). The mature human p40 subunit is 306 
amino acids long and contains ten cysteine residues and four potential N-linked
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glycosylation sites, while the mature p35 chain is 197 amino acids long with seven 
cysteine residues and three potential N-linked glycosylation sites (Gubler et al. 1991). 
Murine IL-12 possesses a similar structure to human IL-12, with the p40 and p35 
chains sharing 70% and 60% of the amino acid sequence identity, respectively 
(Schoenhaut et al. 1992). Meanwhile, Fehr et al. demonstrated that feline interleukin- 
12 (IL-12) possessed similar structure and mediated similar biological activities to the 
human and murine molecules (Fehr et al. 1997). Schijns et a l  determined that the 
feline IL-12 p35 cDNA contained an open reading frame encoding a 222 amino acid 
protein, while the p40 cDNA contained an open reading frame encoding a 329 amino 
acid protein (Schijns et al. 1997). Comparison of the predicted amino acid sequence 
revealed that the feline EL-12 p35 protein shared 90.5%, 81.5%, 85.1% and 55.4% 
identity with the dog, bovine, human and murine IL-12 p35 chain, respectively, while 
the predicted feline IL-12 p40 protein shared 92.1%, 84.8%, 84.2% and 68.1% identity 
with the dog, bovine, human and murine IL-12 p40 chain, respectively (Schijns et al.
1997).
The primary amino acid sequence of the IL-12 p35 chain indicates an a-helix-rich 
structure, similar to most cytokines (Trinchieri, 1994). Interestingly, the gene for feline 
IL-12 p35 was cloned in 1994, and it was found that this molecule shared many 
conserved leucine-zipper motifs with human and murine p35 (Bush et al. 1994). The 
genes for human p40 (chromosome 5, 5q31-q33) and p35 (chromosome 3, 3 p l2- 
3ql3.20) are found on separate chromosomes (Sieburth et al. 1992). There is no 
sequence homology between the p35 and p40 subunits, but the p35 subunit is distantly 
related to the cytokines EL-6, granulocyte colony stimulating factor (G-CSF) and 
chicken myelomonocytic growth factor (Hendrzak and Brunda, 1995). Meanwhile, p40 
possesses sequence homology with the extracellular domain of the IL-6 receptor and 
the ciliary neurotropic factor receptor. It has therefore been suggested that IL-12 is 
structurally analogous to a secreted disulphide linked complex of a cytokine with a 
cytokine receptor (Gately and Brunda, 1995).
Coexpression of both subunits of IL-12 is required to generate the bioactive 
heterodimer (Wolf et al. 1991). Cells transfected with only one subunit gene did not 
secrete active IL-12 (Gubler et al. 1991) and structural analysis of IL-12 using site-
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specific chemical modification revealed that intact disulphide bonds were essential for 
bioactivity (Podlaski et al. 1992). However, mixing recombinant monomeric p40 with 
monomeric p35 did result in IL-12 biological activity, but at concentrations from 2-5 
orders of magnitude higher than those at which the covalently linked heterodimer IL-12 
was active. (Trinchieri, 1994). It has been observed that mouse IL-12 p40-containing 
culture supernatants could specifically inhibit the biological activity of the mouse IL- 
12 heterodimer in several in vitro assays (Mattner et al. 1993). Similarly, a disulphide 
linked homodimer of human IL-12 p40 has been shown to act as a specific antagonist 
of IL-12 (Ling et al. 1995). Lymphoid cells that have been induced to secrete IL-12 
heterodimer are known to produce p40 in substantial excess of the heterodimer 
(Podlaski et al. 1992), so perhaps p40 homodimers may act as physiological regulators 
of IL-12 activity in vivo.
3.1.2.3 Interleukin 12 receptor and signalling by interleukin 12
IL-12 receptors (IL-12Rs) have been detected on activated human T cells and on 
resting or activated Natural Killer (NK) cells, while no EL-12Rs have been found on 
resting T cells, resting or activated B cells or monocytes (Desai et al. 1992). The IL- 
12R can be upregulated by mitogens or alloantigen stimulation of T cells and on NK 
cells activated by IL-2 or IL-12 (Naume et al. 1993). Ligand binding studies have 
identified three classes of IL-12R with apparent affinities of 5 to 20pM (high affinity), 
50 to 200pM (medium affinity) and 2 to 6nM (low affinity) (Chua et al. 1994). The 
structure of the IL-12 receptor is not yet completely understood. The cDNAs for two 
subunits of the IL-12R have been cloned from human and mouse T cells and have been 
designated EL-12R(3l (Chua et al. 1994), and IL-12(32 (Presky et al. 1996) Both of 
these subunits belong to the gpl30 subgroup of the cytokine receptor superfamily. 
They are type I transmembrane glycoproteins, with molecular sizes of about lOOkDa 
(IL-12Rp 1) and 130kDa (IL-12p2). On the cell surface, each of the two recombinant 
IL-12R subunits occur as dimers/oligomers and the formation of these higher order 
structures was found to be ligand independent (Gately et al. 1998). When expressed in 
recombinant form on COS cells, each human subunit binds labelled IL-12 with only 
low affinity. Coexpression of both the IL-12Rpl and IL-12p2 subunits is required for 
the generation of human high affinity IL-12 binding sites (Presky et al. 1996). A
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proposed model for IL-12 signalling indicates that IL-12R|3l interacts with Janus- 
family kinase 2 (JAK2) and EL-12(32 interacts with TYK2 and with signal transducers 
and activators of transcription 3 (STAT3) and STAT4. IL-12 activates JAK2 and 
TYK2 and induces tyrosine and serine phosphorylation of STAT3 and STAT4 (Lamont 
and Adorini, 1996).
3.1.2.4 Production of IL-12
The requirement for expression of two different genes to produce the biologically 
active IL-12 heterodimer renders the genetic control of the production of this cytokine 
particularly complex. EBV transformed cell lines, stimulated PBMCs and neutrophils 
produce the free p40 chain in a 10-50 fold excess over the biologically active p70 
heterodimer (DAndrea et al. 1992). Furthermore, although the stimulation of PBMCs 
with bacterial products upregulated the production of p35 and p40 mRNA transcripts, 
the induction of the p40 gene was much more marked. The abundance of p40 
transcriptions was up to 200 fold higher than that of the p35 transcripts, explaining the 
excess production of the p40 protein (Cassatella et al. 1995). As discussed in section 
3.1.2.2., perhaps the excess p40 protein forms homodimers, which may act as 
physiological regulators of IL-12 activity in vivo.
Bioactive IL-12 is produced mainly by dendritic cells (DCs), macrophages and 
neutrophils (DAndrea et al. 1992). Keratinocytes and Langerhans cells are also 
capable of low levels of IL-12 production, but normal B cells produce very little, if 
any, of this cytokine. Production of IL-12 by DCs and macrophages can be induced by 
interaction with activated T cells, which provide costimulatory signals via molecules 
such as the CD40 ligand (Shu et al. 1995). These signals appear to be essential, as 
their inhibition can abrogate IL-12 production. In phagocytic cells, IL-12 production is 
induced by many stimuli, but particularly by bacteria, bacterial products and 
intracellular parasites (Vieira et al. 1994). Cytokines such as EFN-y and GM-CSF may 
also upregulate the ability of phagocytic cells to produce EL-12 (Trinchieri and Gerosa,
1996).
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3.1.2.5 Biological activities of interleukin 12
The major target cells for IL-12 are NK and T cells, on which IL-12 mediates three 
major effects: firstly, the induction of cytokine production, secondly, a proliferative 
effect on activated T and NK cells, and finally, the enhancement of cytotoxic functions 
(Kobayashi et al. 1989). Among the cytokines induced by IL-12, IFN-y clearly 
predominates, due to the potency of IL-12 in inducing IFN-y gene transcription in 
resting and activated T and NK cells, and in its ability to synergise with other IFN-y 
inducers, such as IL-2, antigen stimulation, mitogens and the recently described 
cytokine, IL-18 (Yoshimoto et al. 1998). Indeed, the ability to induce the production of 
large amounts of IFN-y is one of the most important properties of IL-12 and this 
cytokine mediates many of its biological activities through IFN-y. However, other 
cytokines, such as TNF-a, GM-CSF and IL-2 are also induced by IL-12. In terms of its 
proliferative effects, IL-12 activity can be easily detected on preactivated T or NK cell 
blasts, possibly due to the upregulation of the IL-12 receptor on these cells. IL-12 has 
also been shown to act as a cofactor mediating proliferation of T cells in conjunction 
with other mitogens (Kobayashi et al. 1989), and is often required for the optimal 
proliferation of T cell clones. The enhancing effect of IL-12 on cell-mediated 
cytotoxicity can be demonstrated by a short-term enhancement of NK cell-mediated 
cytotoxicity and by its ability to enhance the generation of lymphokine-activated killer 
cells and cytotoxic T lymphocytes (Kobayashi et al. 1989), (Stem et al. 1990). 
Finally, IL-12 is also known to have a direct enhancing effect on colony formation by 
early pluripotent and committed haemopoietic progenitor cells induced by other 
colony-stimulatory factors (Jacobsen et al. 1993).
The most distinctive and perhaps the most important of EL-12’s activities is its ability 
to regulate the balance between Thl and Th2 cells, described in section 1.4.2. Studies 
in both human (Manetti et al. 1993) and murine systems (Heinzel et al. 1993) have 
shown that IL-12 promotes Thl responses, resulting in the production of IL-2 and IFN- 
y, the promotion of cell mediated immunity, macrophage activation and the production 
of opsonising immunoglogulin IgG2a. However, IL-12 inhibits the generation of Th2 
cells, which predominantly produce IL-4, IL-5, IL-10, and promote humoral immunity 
and the production of IgGl, IgE and IgA isotypes. In addition to promoting the
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commitment of naive Th cells to the Thl pathway, IL-12 has also been shown to serve 
as an important costimulus for the activation of fully differentiated Th 1 cells (Murphy 
et al. 1994). It is likely that the Thl/Th2 dichotomy is mainly regulated by the balance, 
early during an immune response, between levels of IL-12, favouring Thl responses, 
and IL-4, favouring Th2 responses.
3.1.2.6 Therapeutic potential of interleukin 12
Numerous studies have demonstrated that endogenous IL-12 and IFN-y are required to 
induce a protective Thl type immune response to many intracellular pathogens in 
murine models, such as Leishmania major (Sypek et al. 1993), Toxoplasma gondii 
(Gazzinelli et al. 1993), Mycobacterium tuberculosis (Cooper et al. 1995), 
Histoplasma capsulatum (Zhou et al. 1997) and Candida albicans (Romani et al.
1994). Similarly, exogenous IL-12 has been shown to be an effective therapeutic, as 
well as vaccine, adjuvant in many of these murine models of disease (McDyer et al.
1998). EL -12 has been most extensively studied in the infectious disease model of 
murine leishmaniasis (Heinzel et al. 1993), (Sypek et al. 1993), the progression of 
which is associated with the development of IL-4 producing Th2 cells, and the 
resolution associated with the presence of IFN-y producing Thl cells. Experimental 
studies suggest that EL -12 effectively cured murine leishmaniasis by promoting a 
protective Thl-type cytokine response, leading to IFN-y-induced macrophage 
activation, while inhibiting the development of a deleterious Th2-type response. In this 
disease model, IL-12 has also been demonstrated to be an effective vaccine adjuvant, 
when administered with soluble leishmania antigen; protection again correlated with 
the development of Leishmania-specific Thl cells (Afonso et al. 1994). IL-12 is also 
effective against some infectious diseases via a T cell independent mechanism, 
involving the production of IFNy by NK cells, as is the case in infection with the 
intracellular parasite Toxoplasma gondii (Gazzinelli et al. 1993).
IL-12 has proven to be effective in therapy against viral infections, such as type 2 
herpes simplex virus (HSV-2), murine cytomegalovirus (Gately and Mulqueen, 1996) 
and a model of retrovirus-induced murine acquired immunodeficiency syndrome 
(MAIDS) (Gazzinelli et al. 1994). IL-12 has also been widely tested as a vaccine
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adjuvant, enhancing the immune responses raised in mice against pathogens as diverse 
as hepatitis B virus, HSV-2 and HIV, as reviewed in section 1.4.3.2, and has been 
considered as an immunotherapeutic agent in the treatment and/or prevention of atopic 
and allergic disorders (McDyer et al. 1998).
Due to its multiple immunoregulatory functions, including activation of NK cells, 
CTLs and Thl cells, IL-12 has also been utilised as an antitumour agent. In fact, the 
antimetastatic and antitumour activities of IL-12 have been demonstrated in a number 
of murine models. Both the inhibition of established experimental pulmonary or 
hepatic metastases and a reduction in spontaneous metastases have been achieved by 
treating with murine IL-12 (Brunda et al. 1996). Systemic treatment of mice bearing 
subcutaneous tumours with IL-12 results in tumour growth inhibition, prolonged 
survival and, in some models, tumour regression. Experiments have demonstrated that 
both T cells and IFN-y induction are required for the optimal antitumour effects of IL- 
12. Interestingly, a recent paper describing the cloning and expression of canine IL-12 
reported that this cytokine possessed strong cytotoxic activity against an established 
canine mammary tumour cell line (Okano et al. 1997). The encouraging results in 
animal models have prompted the use of EL-12 as an anti-tumour agent in human 
oncology and Phase I and II clinical trials in patients suffering from renal cell 
carcinomas and breast carcinomas are ongoing (Lamont and Adorini, 1996). However, 
although IL-12 is an effective therapeutic agent in many different disease models, it has 
been implicated in the induction of pathology associated with Thl cell mediated 
autoimmune diseases, such as experimental allergic encephalomyelitis (EAE) and 
insulin-dependent diabetes mellitus (EDDM) (Trembleau et al. 1995). Figure 3.1. 
























Figure 3.1. A schematic presentation of the role of IL-12 in the development of 
Thl effector cells in infectious and autoimmune disease.
Key: Ag, antigen; IFN gamma, interferon gamma; APC, antigen presenting cell; Th, 





Interleukin 18 (IL-18), originally designated as interferon gamma inducing factor 
(IGIF), has been recently cloned by Okamura and colleagues. (Okamura et al. 1995). 
This novel pro-inflammatory cytokine is produced predominantly by activated 
macrophages, such as Kupffer cells, and acts to augment IFN-y production in spleen 
cells (Okamura et al. 1995), enhance their natural killer cell activity (NK), enhance the 
expression and function of Fas ligand on T cells and NK cells (Dao et al. 1996), and 
activate nuclear factor-KB, (NF-kB) in murine T helper type 1 cells (Matsumoto et al.
1997). Most activities are due to a receptor complex that recruits the IL-1 receptor- 
activating kinase (IRAK), leading to translocation of NF-kB. This property and others 
described later, such as the fact that one of the EL-18 receptor chains is the IL-1 
receptor-related protein, (IL-lRrp) (Torigoe et al. 1997) support the hypothesis that 
IL-18 is related to the IL-1 family (Dinarello et al. 1998). In conclusion, the ability of 
IL-18 to induce tumour necrosis factor a  (TNF-a), IL-1 p and both CXC and CC 
chemokines (Puren et al. 1998), together with the properties already described, suggest 
that this cytokine is an important contributor in the generation of local and systemic 
inflammatory responses, participating in both innate and acquired immunity. Again, as 
data regarding the molecular biology and biological activity of feline IL-18 were 
unavailable at the time of writing, the current data regarding human and murine IL-18 
are reviewed below.
3.1.3.2 Structure and molecular biology of IL-18
IL-18, a 24kDa single peptide chain, is enzymatically cleaved from the inactive 
precursor form, to a mature active protein, with a molecular weight of 18kDa (Bazan et 
al. 1996). Cloned murine and human IL-18 cDNA encode the novel proteins 
consisting of 192 and 193 amino acids, respectively (Okamura et al. 1995), (Ushio et 
al. 1996) and possess an unusual leader sequence 35 amino acids in length. The human
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EL-18 gene has recently been mapped to Ilq22.2-q22.3, closely linked to the DRD2 
locus and distinct from the currently identified human IDDM loci, and the mouse and 
human genes map to syntenic chromosomal locations (Nolan et al. 1998). IL-18 is 
related to the IL-1 family in terms of structure (Dinarello, 1999). IL-18 and IL-1 (3 share 
significant primary amino acid sequences, are similarly folded as all-beta pleated sheet 
molecules, and Bazan demonstrated that IL-18 shared a 12P sheet structure in common 
with that of the IL-1 family (Bazan et al. 1996). However from sequence alignments of 
IL -la , IL -lp, IL-IRa and EL-18 it became apparent that IL-18 did not share substantial 
identity with the regions of IL-1 (3 which interacted with the IL-1 receptor (IL-1R) 
(Dinarello, 1994). Moreover, a 1000 fold excess of IL-1 (3 was unable to effect the 
biological activity of IL-18, indicating that IL-18 acted through a receptor distinct from 
the IL-1 receptor (Udagawa et al. 1997).
At the amino acid level, murine and rat IL-18 share 64% identity with the human 
molecule, porcine and human IL-18 share 76% identity (Gillespie and Horwood,
1998), and the canine IL-18 sequence was found to be 74% and 62% homologous to 
the human and mouse amino acid sequences, respectively (Argyle et al. 1999), (Okano 
et al. 1999). Each of these homologues of IL-18 share features of the IL-1 signature­
like sequence, although IL-18 differs from IL-1 at three key amino acids within this 
signature motif (Gillespie and Horwood, 1998). Due to these differences, IL-18 
appears to exhibit its own signature motif which is modified but distinct from that of 
EL-1 (Gillespie and Horwood, 1998). In conclusion, although IL-18 does possess a 
significant relationship with the IL-1 family, the fact that the former cytokine exhibits 
different biological activities to IL-1 and utilises a different cellular receptor signifies 
that IL-18 should be considered as an independent cytokine and not simply as a 
member of the IL-1 family (Gillespie and Horwood, 1998).
3.1.3.3 Expression and activation of IL-18.
Although only limited tissue distributions for IL-18 have been performed, IL-18 
mRNA appears to be widely, but not universally expressed. mRNA has been detected 
in the pancreas, kidney, skeletal muscle, liver, lung, bone and skin, indicating 
constitutive expression in these tissues (Gillespie and Horwood, 1998). The cell types
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expressing IL-18 in many of these tissue compartments have yet to be identified, 
although activated macrophages appear to be the predominant source. The human IL- 
18 precursor protein, termed pro-IL-18, is 193 amino acids long and lacks a 
conventional signal sequence. The N-terminus of the mature protein occurs after Asp 
(Asp35 in the murine sequence) and it has been demonstrated that interleukin 1(3 
converting enzyme (ICE, or caspase-1), an aspartic acid-specific protease, cleaves the
' X f t  i cIL-18 molecule C-terminal to Asp (human) or Asp (mouse) (Gu et al. 1997), to 
facilitate the removal of the pro sequence and liberate biologically active, mature EL- 
18. In fact the presence of bioactive ICE is an absolute requirement in the generation of 
active IL-18; when wild type pro-IL-18 was coexpressed in cells with an inactive form 
of ICE, no EL -18 bioactivity was detected in the culture supernatants (Gu et al. 1997). 
The activation of IL-18 by ICE raises further parallels to EL -1(3, which is also activated 
by ICE.
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Pro-IL-18 mRNA
IL-18
Figure 3.2. Regulation and processing of IL-18
LPS and cold stress are known to regulate IL-18mRNA levels in different cells. 
Increased gene expression leads to synthesis of inactive pro-IL-18 which is cleaved by 
ICE in the cytoplasm and is secreted from cells as mature IL-18.
Pro-IL-18, full length inactive IL-18 precursor; ICE, Interleukin-1 (3 converting 
enzyme; LPS, lipopolysaccharide.
3.1.3.4 IL-18 receptor
The IL-18 receptor has recently been identified (Torigoe et al. 1997), although it was 
originally characterised as an IL-1-receptor-related protein (IL-Rrp) (Pamet et al.
1996). Torigoe et a l reported that IL-lRrp is the functional component of the IL-18 
receptor. However, the K<j for EL-18 binding to EL-lRrp transfected into COS cells was 
45nM, an unusually low affinity for a cytokine with a biological activity in the 
picomolar range. Nakanishi has recently reported that there are both high (0.4nM) and 
low (40nM) affinity binding sites for IL-18 in murine primary T cells (Nakanishi et al.
1997). Therefore, the IL-1 Rrp component could account for the low affinity IL-18
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binding sites, and an unidentified second receptor component could account for the 
high affinity binding sites (Dinarello et al. 1998). It is likely that the IL-18 receptor 
complex is comprised of a high affinity ligand binding IL-18Ra chain, with the second 
chain being the IL-lRrp component. Recently, an IL-18 binding protein has been 
purified from urine, and this is thought to be the soluble (extracellular) form of the IL- 
18Ra-chain (Novick et al. 1999).
3.1.3.5 Biological activities of IL-18
IL-18 is presently considered as a costimulatory factor that induces IFN-y production 
from T cells, B cells and NK cells (Okamura et al. 1998). This cytokine was originally 
described as a factor that enhanced EFN-y production from anti-CD3-stimulated Thl 
cells, particularly in the presence of IL-12 (Okamura et al. 1995). Naive T cells 
respond meagrely to IL-18 or IL-12 alone, on anti-CD3 coated plates, although IL-18 
appears to induce IFN-y more potently than does IL-12 (Okamura et al. 1995). 
However, the combination of both these cytokines induced these T cells to proliferate 
and to produce IFN-y in a synergistic manner (Okamura et al. 1995) and, subsequently, 
it was discovered that the presence of the anti-CD3 stimulation was not required in this 
process. Recently, investigations into the mechanism of this synergism have revealed 
that IL-12 upregulates the expression of the IL-18 receptor on cells producing IFN-y 
(Ahn et al. 1997), rendering these T cells more responsive to IL-18. Interestingly, 
under certain conditions IL-18 is able to trigger the production of IFN-y independently 
of IL-12 and augment IFN-y production and proliferation of Thl clones, even in the 
presence of saturating amounts of IL-12, demonstrating that IL-18 and IL-12 are 
functionally distinct with respect to receptor binding and signal transduction pathways 
(Kohno et al. 1997). Furthermore, IL-18 also enhances the production of GM-CSF and 
IL-2 by T cells (Ushio et al. 1996).
IL-18, like IL-12, acts as a costimulatory factor on Thl cells, but not on Th2 cells 
(Kohno et al. 1997). Kohno and colleagues have revealed that IL-18 itself cannot 
induce Thl differentiation, but instead serves as a strong costimulatory factor (Kohno 
et al. 1997). Robinson et al corroborate this fact and claim that IL-18 is unable to
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independently drive Thl cell development, and merely potentiates IL-12 induced Thl 
development (Robinson et al. 1997). This group and others have also suggested that T 
cell subsets differ in their expression of the receptors for IL-1 family molecules: IL- 
18R being expressed on Thl cells (Xu et al. 1998) and IL-1R (type 1R) on Th2 cells. 
This may help to explain the differential responsiveness of Thl and Th2 cells to IL-18 
and IL-1, both of which activate the common transcription factor NF-kB.
IL-18 also mediates important effects on B cells. In combination with IL-12, IL-18 
induces anti-CD40-activated highly purified murine B cells to produce IFN-y, which 
inhibits IL-4-dependent IgE and IgGl production and enhances IgG2a production 
without inhibiting the B-cell proliferative response (Yoshimoto et al. 1997). Turning 
to NK cells, this cell type appears to be the primary target for IL-12 and IL-18 when 
infection or other stresses occur. IL-18 increases the cytotoxic activity of spleen cells 
against YAC cells (Okamura et al. 1998). This effect was not inhibitable by treatment 
with antibodies against IL-2, a potent NK cell stimulatory factor, indicating that IL-18 
directly, or at least not via IL-2, upregulates the cytotoxicity of lymphocytes. As IL-18 
had no such effect on the spleen cells derived from NK cell-depleted mice, EL-18 
facilitates the cytotoxicity of NK cells. Furthermore, IL-18 acts on NK cells 
independently of IL-12 and activates the perforin/granzyme system (Okamura et al.
1998). Additionally, IL-18 enhances the action of a second killing apparatus of NK 
cells, Fas ligand (FasL). IL-18 acts directly and independently of IFN-y on NK cells to 
induce the expression of FasL and to augment their cytotoxicity against Fas-transfected 
cells (Tsutsui et al. 1996). Finally, as discussed above, in an in vitro system, it has 
been demonstrated that IL-12 and IL-18 induce anti-CD40-activated B cells to produce 
IFN-y, which inhibits IL-4-dependent IgE and IgGl production and enhances IgG2a 
production. This result indicates that B cells can act as regulatory cells in the immune 
response and, as IgE responses are an important factor in the pathogenesis of allergic 
conditions, IL-12/IL-18 treatment may present an unique approach in the therapy of 
these debilitating conditions (Yoshimoto et al. 1997).
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3.1.3.6 Therapeutic potential of IL-18
As IL-18 is a multifactorial cytokine, having a major effect on both innate and acquired 
immunity, its use in therapy has been considered by several researchers (Qureshi et al. 
1999), (Kremer et al. 1999), (Tanaka-Kataoka et al. 1999), (Osaki et al. 1999), (Tan 
et al. 1998). To date, IL-18 has been evaluated as an effective anti-tumour agent 
(Osaki et al. 1998), (Tan et al. 1998), (Micallef et al. 1997), (Fukumoto et al. 1997), 
(Coughlin et al. 1998), (Osaki et al. 1999) an anti-microbial agent (Qureshi et al.
1999), (Kremer et al. 1999), (Tanaka-Kataoka et al. 1999), and as a vaccine adjuvant 
(Kim et al. 1998), (Sin et al. 1999). Strategies to prevent the activity of IL-18 in 
inflammatory disorders, such as rheumatoid arthritis, have also been devised (Dinarello 
et al. 1998). Many of these therapeutic strategies have investigated the effects of IL-18 
in combination with IL-12. Direct injection of an adenoviral vector expressing the 
mature form of murine IL-18 into an established MCA205 murine fibrosarcoma 
completely eradicated tumours in all animals and induced protective systemic 
immunity (Osaki et al. 1999). Interestingly, coadministration of systemic IL-12 
provided synergistic anti-tumour effects in this model. Another study investigated the 
mechanism of the anti-tumour effects of murine IL-18 on the growth of several mouse 
tumour cell lines in vivo (Osaki et al. 1998). Mice receiving EL-18 before or after 
challenge with mouse melanoma or sarcoma cell lines were found to have significantly 
suppressed tumour growth. IL-18 appeared to mediate these effects through the action 
of NK and CD4+ T cells and independently of EL-12 and EFN-y. Recent experiments 
with canine IL-18 have demonstrated that the growth of canine tumours transplanted 
into SCID mice may be inhibited by the inoculation of recombinant canine EL-18 
(Okano et al. 1999).
Recently, a study to investigate the in vivo antiviral effects of IL-18 in a mouse model 
of vaccinia virus infection has been conducted (Tanaka-Kataoka et al. 1999). 
Intraperitoneal inoculation of IL-18 at 0, 2 and 4 days after infection with vaccinia 
virus, was found to significantly suppress pock formation on the tails of BALB/c mice, 
perhaps through the action of NK and CTL cells. Another study has examined the 
effect of injecting the cDNA of full length pro-EL-18, (cloned into a plasmid containing 
the CMV promoter), into the skin of mice (Kremer et al. 1999). When mice were
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subsequently infected with Mycobacterium bovis bacillus Calmette-Guerin (BCG), 
they produced lower levels of anti-BCG antibody than control animals, but higher 
amounts o f antigen-specific EFN-y after in vitro restimulation. Therefore, it appeared 
that IL-18 increased the Thl type response, indicating that this cytokine may be useful 
in the development of new immunoprotective strategies against infection by 
intracellular parasites, such as mycobacteria. IL-18 has also proved to be an effective 
therapeutic agent against Cryptococcus neoformans, (in combination with IL-12), 
(Zhang et al. 1997), (Qureshi et al. 1999), and Yersinia enterocolitica infection 
(Bohn et al. 1998). The use of IL-18 as an adjuvant in DNA vaccination studies has 
been discussed in section 1.4.3.2.
3.1.4 CLONING OF NOVEL CYTOKINES
The earliest of human cytokines to be described and studied in detail were the 
interferons; in particular interferon-a. Studies were initially limited by the availability 
of sufficient quantities of pure preparations of interferon-a, which had to be purified 
from the supernatants of human leukocyte cultures. However, for most cytokines such 
large scale production was impossible, until the advent of recombinant DNA 
technology. The ability to clone and manipulate genes of interest has enabled the 
production of many cytokines in sufficient quantities to allow the characterisation of 
their biological activities and subsequent use in clinical therapy. Traditionally, the 
isolation of novel genetic sequences using recombinant DNA technology relied upon 
the generation of genomic or cDNA libraries, followed by screening using one of a 
number of techniques. The isolation of a given genetic sequence is particularly difficult 
when the gene exists only rarely, as a single copy gene in a complex genome, or as a 
rare mRNA species in an mRNA population. Where an mRNA of interest is strongly 
inducible it may represent a much higher proportion of the total mRNA population and 
isolation may be possible using techniques such as subtractive hybridisation. While, 
rare mRNAs can be obtained by screening cDNA libraries, ideally the library should 
utilise mRNA that contains the mRNA sequence of interest at a high level, to simplify 
the screening procedure and to maximise the chance of obtaining a full length clone.
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Advancements in protein sequencing techniques have allowed the determination of N- 
terminal amino acid sequence from increasingly smaller quantities of protein. The 
availability of such amino acid sequence data permits the design of degenerate 
oligonucleotide probes which may then be used to screen a cDNA library. With the 
advent of the polymerase chain reaction (Mullis et al. 1986), peptide sequence data 
could be used to design degenerate primers for PCR amplification of specific 
oligonucleotides, with complete homology to the desired gene. These oligonucleotides 
may then be utilised as hybridisation probes to screen cDNA libraries. If a cDNA of 
interest has already been cloned and sequenced in a limited number of species, it is 
possible to use a probe derived from known sequence data to screen a cDNA library of 
another species under reduced stringency conditions. This technique has been widely 
used, for example in the isolation of canine IL-18 (Okano et al. 1999). Furthermore, 
use of the polymerase chain reaction may enable the direct amplification of cDNA 
clones from mRNA using the reverse transcriptase - polymerase chain reaction (RT- 
PCR). This technique avoids the frequently difficult and laborious process of cDNA 
library generation and screening and significantly reduces the quantity of mRNA that is 
needed to successfully clone a gene of interest. This approach has recently been used 
in this department to isolate a number of cytokine cDNAs (Curran et al. 1994), 
(Argyle et al. 1995), (Dunham et al. 1995).
3.1.5 THE CLONING OF FELINE IL-12 AND IL-18
The technique of RT-PCR was chosen to clone feline IL-12 and IL-18, for several 
reasons. Firstly, both IL-12 and IL-18 show high sequence homology between species 
and, consequently, the use of PCR primers, designed from conserved regions flanking 
the protein coding sequence, was considered to have a good chance of success. 
Secondly, the RT-PCR technique offered a simpler and potentially faster approach than 
techniques involving the generation and screening of cDNA libraries. Thirdly, as one 
of the ultimate aims of this project was to express the feline cytokines as proteins, 
using a mammalian expression vector system, it was necessary to obtain only the 
protein coding sequence (i.e. DNA sequence data from introns or non-coding 5’ and 3’
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flanking mRNA was not required). An important consideration when attempting the 
isolation of any gene is the choice of a suitable cell line or tissue. Feline alveolar 
macrophages stimulated with LPS were used as a substrate for the isolation of feline 
IL-12 and IL-18 by RT-PCR. This choice was based on the knowledge that activated 
macrophages are a potential source of both these cytokines (Okamura et al. 1998). 
This chapter describes the cloning and sequencing of both IL-12 and EL-18 using an 
RT-PCR based technique. An overview of the experimental procedure employed is 




Amplification of feline IL-12 and IL-18 using PCR
Cloning of cDNA into PCRII/PCR2.1
Sequencing of recombinant plasmids
LPS-stimulated feline alveolar 
macrophage cultures
Figure 3.3. Overview of the experimental procedure used to clone cDNAs for 
feline IL-12 and IL-18
PCR, polymerase chain reaction; cDNA, complementary DNA; mRNA, messenger 
RNA; LPS, lipopolysaccharide.
3.1.6 GENE EXPRESSION SYSTEMS
Heterologous protein expression systems are frequently used to produce proteins for 
biological uses. They have the advantages of ease of manipulation and frequently 
enable the production of protein in higher levels than would be achieved by direct 
isolation of the native protein. Recombinant proteins have been successfully expressed 
in a wide variety of different systems which include bacterial, yeast, fungal, insect, 
plant and mammalian cells. In order to evaluate the potential of IL-12 and IL-18 DNA
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constructs to act as in vivo genetic adjuvants in FeLV DNA vaccination studies, these 
cytokines were cloned into the mammalian expression vector pCI-neo, and IL-18 
protein and mRNA expression was evaluated in an in vitro mammalian expression 
system. Ideally, in vitro expression of the IL-12 gene would also have been studied at 
this time. However, the limited time scale of this project precluded this evaluation.
The expression of proteins from higher eukaryotes in an in vitro mammalian system 
has certain inherent advantages. Proteins are usually expressed in the correct cellular 
compartment and appropriately modified. Authentic modifications reduce the 
likelihood of the expressed protein proving immunogenic or having altered biological 
activity or pharmacokinetics. However, mammalian expression systems tend to be 
more technically demanding and expensive to use. Transient expression systems are 
commonly used to produce small amounts of proteins to evaluate the functional 
activity of a novel cDNA, as is the case with feline IL-18. 293T cells are often used for 
such short term expression. The 293T cell line, a highly transformed human renal 
epithelial cell line (Marazzi et al. 1998), has been transformed with SV40 virus 
carrying a defective origin of replication. The cells do not, therefore, produce whole 
virus, but do produce large quantities of the viral protein, SV40 large tumour (T) 
antigen. This protein directs the amplification of vectors containing the SV40 origin of 
replication to high levels (10,000 - 100,000 copies per cell) 48 - 72 hours following 
transfection. Plasmids containing a cDNA or genomic DNA insert can therefore direct 
the synthesis of large amounts of protein in a short time, under the control of an 
appropriate promoter. The mammalian expression vector pCI-neo, into which feline 
IL-18 was cloned, contains the SV40 origin of replication, and thus optimises the 
amount of IL-18 protein expressed from transfected cells. However, a major 
disadvantage of this system is that transfected cells generally die after a number of 
days, because the protein production machinery of the transformed cell is effectively 
'hijacked'. Therefore, the large scale production of proteins in mammalian systems 
requires the establishment of stably transfected cell lines and gene amplification.
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3.1.7 EXPRESSION OF FELINE IL-18
The reasons for choosing a mammalian system to express feline IL-18 are discussed in 
section 3.1.6. This chapter describes the expression of three forms of feline IL-18; pro- 
EL-18 + pCI-neo (inactive, full-length precursor), mature IL-18 + pCI-neo (active form) 
and PsecI IL-18, (mature IL-18 cloned into a vector derived from pCI-neo, containing a 
synthetic immunoglobulin secretory component to facilitate the secretion of the active 
cytokine). PCR and restriction enzyme digests were employed in the synthesis of these 
constructs. To assess in vitro expression of IL-18 before in vivo administration to cats, 
293T cells were transfected with the three feline IL-18 DNA constructs and, 
subsequently, cell lysates and supernatants were harvested and mRNA isolated from 
the transfected cells. Expression of the feline IL-18 mRNA and protein was then 
confirmed using Northern and western blotting techniques, respectively.
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3.2 MATERIALS AND METHODS
3.2.1 ISOLATION OF mRNA FROM FELINE ALVEOLAR MACROPHAGES
Messenger RNA (mRNA) was isolated from LPS stimulated feline alveolar 
macrophages using the Quickprep mRNA isolation kit (Pharmacia) as described in 
section 2.2.3.1. Feline alveolar macrophages were cultured as described in section
2.2.1.6. Cells were harvested from a 162 cm2 tissue culture flask by applying 1.5 ml 
extraction buffer directly to the cell monolayer, after removal of culture medium. Upon 
completion of mRNA extraction the yield and purity of the RNA was measured by 
spectrophotometry. The harvested mRNA was then used as a template for cDNA 
synthesis.
3.2.2 SYNTHESIS OF cDNA
Complementary DNA (cDNA) was synthesised from feline alveolar macrophage 
mRNA using a First-strand cDNA synthesis kit (Pharmacia) as described in section
2.23.2. The completed first strand reaction was heated to 90°C for five minutes then 
chilled on ice immediately prior to use as a PCR template; this was performed to 
denature the RNA-cDNA duplex.
3.2.3 PCR AMPLIFICATION OF FELINE IL-12 p35 AND p40 SUBUNITS
The amplification of both subunits of feline IL-12 will be described in this section, but 
each subunit will be considered separately.
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3.2.3.1 Design of primers
In order to amplify the p35 and p40 subunits of feline EL-12 it was necessary to design 
oligonucleotide primers which flanked the protein coding sequence of both subunits. 
For the p40 subunit, primers were chosen which flanked the 5’ and 3’ ends of the 
protein coding sequence of the canine IL-12 p40 cDNA (Buttner et al. 1998), 
(GenBank accession number U49100, Buttner), as the canine and feline sequences 
were thought to be highly conserved.
5’ primer: 5’-GCAAGATGCATCCTCAG-3’
3 ’ primer: 5 ’ -CATCCTGGGGGTGGAACC-3 ’
These primers were expected to amplify a p40 IL-12 cDNA of approximately 1010 
nucleotides in size, containing the complete protein coding sequence.
The design of primers for the amplification of the p35 subunit was more complicated, 
as the use of primers based on the known sequences of canine, human, murine and 
even feline p35 cDNAs, which flanked the entire protein coding sequence, did not 
amplify the full length p35 cDNA. (The feline p35 EL-12 sequence, accession number 
Y07761, became available in the later stages of this project (Schijns et al. 1997)). 
Therefore, the full length gene sequence of the p35 subunit of feline IL-12 was 
amplified by PCR in two overlapping fragments, using a nested PCR strategy. Primers
were designed using the canine and human (earlier stages of the project) and feline
(later stages of the project) p35 subunit sequences. cDNAs were aligned using the 
‘Lineup’ and ‘Pileup’ programs (UWGCG software) and primers were chosen from 
conserved areas of the protein coding sequence.
To amplify the 3’ end of the p35 gene nested PCR was performed using the primers 
5 ’ primer: 5 ’ -CAGTGCCGGCTCAGCATGTG-3 ’
3 ’ primer: 5 ’ -GACCTCMGCWTTYTAGGAAC-3 ’
A 5jxl aliquot of this completed PCR reaction was then used in second round 
amplification using the primers
5 ’ primer: 5 ’ -C A AG A ATG AGAGTTGCCT-3 ’
3 ’ primer: 5 ’ -GCTTTTT AGG AAGC ATTC AG AT AGC-3 ’
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These primers were expected to amplify a 3’ fragment of p35 IL-12 cDNA of 
approximately 390 nucleotides in size, containing the partial p35 subunit protein 
coding sequence.
To amplify the 5’ end of the p35 gene nested PCR was performed using the primers 
5’ primer: 5’-CAGTGCCGGCTCAGCATGTG-3’
3’ primer: 5’-GAAGTATGCAGAGCTTGA-3’,
A 5pl aliquot of this completed PCR reaction was then used in second round 
amplification using the primers
5’ primer: 5’-GCATGTGCCCGCCGCGTG-3’
3’ primer: 5’-CCAGTTCTTTCAGGGAG-3’
These primers were expected to amplify a 5’ fragment of p35 IL-12 cDNA of 
approximately 550 nucleotides in size, containing the partial p35 subunit protein 
coding sequence.
3.2.3.2 Positive and negative controls
In order to assess the efficiency of the PCR process a number of controls were set up 
each time PCR amplification of the feline IL-12 p35, IL-12 p40 or IL-18 cDNA was 
attempted.
3.2.3.2.1 Positive controls 
P-actin primers:
P-actin is a gene that is constitutively expressed at high levels in many cell and tissue 
types, making it a suitable choice for a positive control. The gene is highly conserved 
between species, making it possible to amplify feline p-actin using primers designed 
for the amplification of human p-actin (Clontech Laboratories Inc., Palo Alto, CA). 
The following primers were provided at a concentration of 20 p,M.
5 ’ primer: 5 ’ - ATCTGGC ACC AC ACCTTCT AC A ATG AGCTGCG-3 ’
3 ’ primer: 5 ’ -CGTCATACTCCTGCTTGCTGATCCACATCTGC-3 ’




A further positive control is included with the GeneAmp PCR reagent kit; whole 
bacteriophage lambda is used as a template for PCR amplification using the primer 
pair:
Primer 1: 5 ’ -GATG AGTTCGTGTCCGT AC AACTGG-3 ’
Primer 2: 5 ’ -GGTT ATCGA AATC AGCC AC AGCGCC-3 ’
These primers amplify a 500 bp fragment (nucleotides 7131 to 7630) of the lambda 
target DNA.
These “internal controls” ensured that should any PCR failures occur, then the cause of 
failure could be localised. For example, if both positive controls failed to amplify 
efficiently this would suggest a problem involving the bulk reaction mix (e.g. Taq 
polymerase, dNTPs or PCR buffer) or the PCR cycler, while failure of the P-actin 
positive control alone (with alveolar macrophage cDNA template) would suggest either 
that the starting mRNA was of poor quality or had been inefficiently reverse 
transcribed to cDNA (e.g. due to inefficient denaturation of the mRNA template or 
failure of the reverse transcriptase enzyme). Finally, if both positive controls worked 
efficiently but there was no or poor amplification of cDNA using the IL-12 p3 5 or IL- 
12 p40 primers this would suggest that the reaction conditions were inappropriate (e.g. 
annealing temperature too high/low or PCR primer concentration too low), that IL-12 
p35 or p40 was expressed at low levels in the starting mRNA or that the PCR primers 
did not anneal efficiently to the cDNAs of interest, due to mismatches.
3.2.32.2 Negative controls
Each time a series of PCR reactions was set up a negative control was also included. A 
reaction mix was set up containing all PCR components (primers, dNTPs, PCR buffer 
and Taq polymerase) except template. This control was performed to check that there 
was no contamination of the PCR reactions with extraneous template that might serve 
as a template for PCR amplification.
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3.2.3.3 Reaction conditions
Reactions were performed in a 50 fil volume in 0.5 ml tubes. A master reaction mix 
was prepared by combining five microlitres 10 x PCR buffer, 4pl of 25mM MgCl2 
solution and five microlitres of deoxynucleotide (dNTP) mix (1.25 mM each dNTP). 
The use of such a master mix minimises losses and inaccuracies associated with 
pipetting and ensures consistency from tube to tube. 14|il of this mix was then pipetted 
into each reaction tube, which contained 20pmoles of each primer and 5 jll1 DNA 
template, and the volume was made up to 45 pi by the addition of dH20. The reaction 
mix was then overlaid with mineral oil and the tubes were transferred to the thermal 
cycler. After a 5 minute denaturation incubation at 94°C, the tubes were removed and 
2.5U (0.5pl) of Taq polymerase in 4.5 pi dH20 was added to each tube. The tubes were 
then returned to the thermal cycler and cycled as described below.
To isolate the full length gene sequence of the p40 subunit of feline IL-12, the thermal 
cycler was programmed to give 30 cycles of denaturation (94°C for 1 minute), 
annealing (55°C for 1 minute) and extension (72°C for 2 minutes), followed by a 7 
minute extension step at 72°C and finally by a 4°C ‘soak’. PCR reaction products were 
visualised by polyacrylamide gel electrophoresis as detailed in 2.2.2.5.2, using five 
microlitres of reaction product per well. A series of optimisation experiments was 
carried out investigating the effect of annealing temperature on the amplification of 
feline IL-12 p40.
The full length gene sequence of the p35 subunit of feline IL-12 was amplified by PCR 
in two overlapping fragments. To amplify the 3’ end of p35 the thermal cycler was 
programmed to give 30 cycles of denaturation (94°C for 1 minute), annealing (55°C for
1.5 minutes) and extension (72°C for 1 minute), followed by a 7 minute extension step 
at 72°C. A 5pl aliquot of this completed PCR reaction was then used in second round 
amplification, using cycling conditions as for first round amplification, except 35 
cycles were performed and annealing was conducted at 60°C. PCR reaction products 
were visualised by polyacrylamide gel electrophoresis as detailed in 2.2.2.5.2, using 
five microlitres of reaction product per well. To amplify the 5’ end of p35 the thermal 
cycler was programmed to give 30 cycles of denaturation (94°C for 1 minute),
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annealing (60°C for 1.5 minutes) and extension (72°C for 1 minute), followed by a 7 
minute extension step at 72°C. A 5jxl aliquot of this completed PCR reaction was then 
used in second round amplification, using cycling conditions as for first round 
amplification. Five microlitres of completed reaction products were then visualised by 
polyacrylamide gel electrophoresis, as described previously.
3.2.4 PCR AMPLIFICATION OF FELINE IL-18
3.2.4.1 Primer design
In order to amplify the full length feline IL-18 cDNA it was necessary to design 
oligonucleotide primers which flanked the protein coding sequence. 5’ and 3’ primers 
were designed which were based on the human, murine and especially the canine IL-18 
cDNA sequences, (recently cloned in the department of Veterinary Pathology, 
University of Glasgow, by David Argyle and Christine McGillivray), (Argyle et al.
1999), as the canine and feline sequences were thought to be highly conserved. 
Initially, the complete coding sequence was obtained in two overlapping fragments.
To amplify the 5’ end of the IL-18 gene PCR was performed using the primers 
5 ’ primer: 5 ’ -GC AGG A AT A AAGATGGCTGC-3 ’
3’ primer: 5 ’ -GCGTTTTG A AC AGTGA AC AT -3’
These primers were expected to amplify a 5’ fragment of feline IL-18 cDNA of 
approximately 580bp nucleotides in size.
To amplify the 3’ end of the IL-18 gene PCR was performed using the primers 
5’ primer: 5 ’ -G AC A AT ACGCTTT ACTTT AT -3’
3 ’ primer: 5 ’ -GGC ATG A A ATTTT A AT AGCT A -3 ’
These primers were expected to amplify a 3’ fragment of feline IL-18 cDNA of 
approximately 540bp nucleotides in size.
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Sequencing of these two overlapping fragments allowed for the design of two feline 




These primers were expected to amplify the full length feline IL-18 cDNA, 
approximately 595bp nucleotides in size, containing the complete protein coding 
sequence.
3.2.4.2 Reaction conditions
PCR reactions were set up and denatured for 5 minutes before thermal cycling, as 
described for feline IL-12, in section 3.2.3.3. To amplify the 5’ end of IL-18 the 
thermal cycler was programmed to give 30 cycles of denaturation (94°C for 40 
seconds), annealing (45°C for 55 seconds) and extension (72°C for 2 minutes), 
followed by a 7 minute extension step at 72°C. PCR reaction products were visualised 
by polyacrylamide gel electrophoresis as detailed in section 2.2.2.5.2, using five 
microlitres of reaction product per well. To amplify the 3’ end of IL-18 the thermal 
cycler was programmed as above. However, a secondary PCR reaction, using the same 
cycling conditions and primers as for primary PCR, was required to amplify this 
fragment. PCR reaction products were visualised as previously described. Finally, PCR 
was performed with the feline specific primers,
5 ’ -GC AGG A AT AA AG ATGGCTGC-3 ’ and 5 ’ -GCT AATTCTTGTTTTG A AC AG-3 ’ 
which amplified the entire coding sequence of feline IL-18 in one fragment. The 
following cycling conditions were employed; 30 cycles of denaturation (94°C for 45 
seconds), annealing (58°C for 60 seconds) and extension (72°C for 2 minutes), 
followed by a final 7 minute extension step at 72°C and the 595bp fragment obtained 
was visualised using polyacrylamide gel electrophoresis.
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3.2.5 CLONING OF FELINE IL-12 AND IL-18 PCR PRODUCTS
Products of PCR reactions using the p35 IL-12, p40 IL-12 and IL-18 primer pairs were 
cloned into the pCRII or pCR2.1 vectors. One microlitre of PCR product was added to 
50 ng (two microlitres) vector, one microlitre 10 x ligation buffer, five microlitres 
dH20  and four units (one microlitre) T4 DNA ligase. The ligation reactions were 
incubated overnight at 14°C. The ligated vectors were then cloned into INVocF E.coli 
cells as detailed in section 2.2.2.8. Colonies were selected on LB agar plates containing 
50 (ig/ml ampicillin. White colonies were picked and small scale DNA preparations 
made. Miniprep DNA was subjected to restriction endonuclease digestion for one hour 
at 37°C, using appropriate restriction enzymes to cut the cloned PCR products out of 
the pCRH or pCR2.1 vectors. Subsequently, products of digestion were run on 5% 
polyacrylamide gels and inserts of the desired size could be seen. Finally, bacterial 
glycerol stocks were made from the isolates that contained inserts of the appropriate 
size.
3.2.6 SEQUENCING OF FELINE IL-12 AND IL-18
DNA for cycle sequencing was prepared by the procedure detailed in section 2.2.2.23. 
Cycle sequencing reactions were carried out using the ThermoSequenase Fluorescent 
Labelled Primer Cycle Sequencing Kit with 7-deaza-dGTP, as outlined in section
2.2.5.2. Cycling conditions were as described in section 2.2.5.2, with annealing for all 
reactions being performed at 55°C, except for those to cycle sequence the IL-12 p40 
subunit, in which annealing was performed at 60°C. Sequencing reactions employed 
M l3 universal IRD41 labelled primers with the following sequence:
M13 forward (-29) Primer: 5 ’ -CACGACGTTGTAAAACGAC-3 ’
M l 3 reverse Primer: 5 ’ -GG AT A AC AATTTC AC AC AGG-3 ’
The reaction products were run on a Licor Model 4000 automated sequencer as 
described in section 2.2.5.2. The sequence data was collected and read automatically 
and any sequence ambiguities were checked by visual inspection of the gel image. For 
each cDNA, p40 IL-12, p35 IL-12 (both fragments), 3’ and 5’ fragments of IL-18 and 
full length IL-18, automated sequencing was carried out on at least six separate clones,
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taken from three different PCR reactions. This was performed in order to check for the 
misincorporation of nucleotides, which may occur occasionally during DNA synthesis 
by Taq DNA polymerase. Using this sequence data, consensus sequences were 
obtained, as described in section 3.2.7., for all the cDNAs, with the exception of p40 
IL-12, as described below. The consensus sequence of the feline p35 IL-12 subunit was 
obtained by aligning the cloned sequences of the overlapping 5’ and 3’ fragments and 
analysing the data using the GCG package.
Automated sequence analysis of the IL-12 p40 subunit clones yielded incomplete 
sequence data. The central portion of the p40 cDNA was found to be very GC rich, and 
it appeared that these GC rich areas were annealing with adjacent nucleotides, forming 
loops of internal secondary structure. Therefore, the thermostable DNA polymerase 
was unable to read through these compressions on both forward and reverse strands of 
the cDNA. Manual sequencing analysis was required to resolve these compressions. 
DNA for manual sequencing was prepared by the procedure detailed in 2.2.2.22. The 
DNA was sequenced using a Sequenase version 2.0 sequencing kit as outlined in 
section 2.2.5.1.1. After the acquisition of initial sequence data from the automated 
sequencer it was possible to design internal primers which spanned the compressed 
areas, allowing the complete sequence of both strands of the insert DNA to be 
accurately determined. Manual sequencing reactions used primers with the following 
sequence:
5 ’ Primer 5 ’ -GCTGACGGCAATCAGTACCG-3 ’
3 ’ Primer 5 ’ -AGTTTTCGTACTTGAGCTTG-3 ’
Primers were chosen to be stable at their 5’ ends but less stable at their 3’ ends to 
reduce false priming. Primers were 20 nucleotides in length and were chosen to anneal 
30 - 60 bp upstream (5’) to the sequence of interest. Completed sequencing reactions 
were run on six percent denaturing polyacrylamide gels and the gels were dried and 
exposed to autoradiography film as described in section 2.2.5.1.2. Finally, the 
sequences were read manually over a light box, and the data stored on a UNIX
computer system and analysed as described below. This manual sequencing method
did indeed resolve the areas of compression and a consensus sequence for the IL-12 
p40 subunit was subsequently obtained.
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3.2.7 SEQUENCE DATA ANALYSIS
Sequence data was stored and managed on a UNIX computer system using GCG 
software (University of Wisconsin). ‘Raw’ sequence data was handled and edited using 
the ‘SeqEd’ program. Consensus sequences were obtained using the ‘Lineup’, ‘Pileup’, 
‘Pretty’ and ‘Ugly’, commands. The sequences of IL-12 p35, IL-12 p40 and IL-18 from 
other species were downloaded from the EMBL database using the ‘Fetch’ command. 
Sequence (nucleotide and amino acid) comparisons, to identify degrees of conservation 
between feline and other species, were performed using ‘BestFit’ which aligns 
sequences using the algorithm of Smith and Waterman. The amino acid sequences of 
feline IL-12 p35, IL-12 p40 and IL-18 were predicted using ‘Translate’.
3.2.8 CREATION OF IL-12 EXPRESSION CONSTRUCTS
To create the IL-12 expression constructs the p35 and p40 subunits of feline IL-12 
were cloned into the mammalian expression vector pCI-neo (Promega), as two separate 
plasmids. The IL-12 p40 cDNA was subcloned from the pCR2.1 vector into the pCI- 
neo vector as an EcoRl fragment. The p35 IL-12 expression construct was created by 
digesting the pCR2.1 (5’IL-12 p35) plasmid with Xhol and Rjal, and digesting the 
pCR2.1 (3’IL-12 p35) plasmid with Rsal and Notl. The digested 5’ and 3’ ends were 
subsequently gel purified and ligated into the pCI-neo vector, previously digested with 
Xho I and Not I. ENVocF' E.coli bacteria were then transformed with the ligation 
reactions, colonies were picked and small scale DNA preparations were performed. 
The presence of inserts of the correct size was verified by subjecting a quantity of the 
DNA to restriction enzyme digestion with appropriate enzymes, followed by 
polyacrylamide gel electrophoresis. Subsequently, clones of the correct size were 
sequenced, as described previously, to ascertain that the nucleotide sequence was 
identical to that previously described. These plasmids were employed as the EL-12 
adjuvant constructs in the FeLV DNA vaccination trial, described in chapter four. Due 
to time constraints the in vitro expression of these IL-12 constructs was not evaluated.
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3.2.9 CREATION OF IL-18 EXPRESSION CONSTRUCTS
Three feline IL-18 expression constructs were created: pro-EL-18, the inactive, full- 
length precursor, was cloned into pCI-neo; mature IL-18, the biologically active form 
of IL-18, was cloned into pCI-neo, and mature IL-18 was cloned into a vector derived 
from pCI-neo, PsecI, which contained a synthetic immunoglobulin secretory 
component to facilitate the secretion of the active cytokine. The PsecI plasmid was 
constructed by Dr Lesley Nicolson. As explained in section 3.1.3.3. the presence of 
bioactive ICE is an absolute requirement in the generation of active IL-18 (Gu et al.
1997). Therefore, the PsecI (IL-18) construct was created to allow secretion of the 
active from of IL-18 from cells which did not express ICE.
The full length pro-IL-18 cDNA was subcloned from the pCR2.1 plasmid into the pCI- 
neo expression vector (Promega) as an EcoRl fragment, to create pCI-neo (pro-IL-18). 
To produce the mature IL-18 and pCI-neo construct, PCR was first performed to 
amplify the mature, biologically active form of IL-18, using lOOng of the pCR-2.1 
(pro-IL-18) construct as a template. Primers were used at 1.0 |iM concentration in a 
100 jixl volume reaction mix and were designed such that EcoRl and Notl restriction 
enzyme sites were created at the 5’ and 3’ ends, respectively, of the amplified mature 
IL-18 gene.
5 ’ primer 5 ’ -GTG ATG A AGA ATTCG A A AC AATGIACTTTGGC-3 ’
EcoRl start of mature IL -18
3 ’ primer 5 ’ -GTAGCGGCCGCCAGTGTGCTGGAAATCGGCTTGCTAA-3 ’.
Notl stop
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PCR amplification, using similar reaction conditions to those described in section 
3.2.3.3., was achieved by 30 cycles of denaturation (94°C for 1 minute), annealing 
(65°C for 1 minute) and extension (72°C for 1 minute), followed by a 10 minute 
extension step at 72°C. The 520bp PCR product was then gel purified using the 
QIAquick Gel Extraction Kit (Qiagen), digested with EcoRl and Notl, and subcloned 
into the pCI-neo expression vector as an EcoRl-Notl fragment, to create pCI-neo 
(mature-IL-18). To produce the PsecI (IL-18) construct, employed as an adjuvant in 
the FeLV DNA vaccination trial, PCR to amplify the mature, biologically active form 
of IL-18 from the pCR-2.1 (pro-IL-18) template was performed, as described above. 
Primers were used at 1.0 pM concentration in a 100 pi volume reaction mix and were 
designed such that EcoRN  and Notl restriction enzyme sites were created at the 5’ and 
3’ ends, respectively, of the amplified mature IL-18 gene.
5’ primer 5 ’ -GGCCGATATCTACTTTGGCAAGCTTGAA-3 ’
EcoRN  start of mature IL -18
3’primer 5 ’ -GT AGCGGCCGCC AGTGTGCTGG AAATCGGCTTGCT A A-3 ’.
Notl stop
The resulting PCR product was then gel purified using the QIAquick Gel Extraction 
Kit (Qiagen), digested with EcoRN  and Notl, and subcloned into the expression vector 
PSecI, as an EcoRN-Notl fragment. All three IL-18 expression constructs were 
subsequently cloned and sequenced, as described in section 3.2.8.
3.2.10 IN  VITRO  EXPRESSION OF FELIN E IL-18
To evaluate in vitro mRNA and protein expression of the IL-18 constructs described 
above, calcium phosphate mediated transfection of DNA into 293T cells was first 
performed using the ProFection® Mammalian Transfection System, as detailed in 
section 2.2.7. For each set of transfections 11 flasks were needed; 2 flasks for pCI-neo 
(pro-IL-18) DNA, 2 flasks for pCI-neo (mature-IL-18) DNA, 2 flasks for PsecI (EL- 
18) DNA, 2 flasks for pCI-neo DNA alone (no insert), 2 negative control flasks
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for each of the sets of IL-18 transfection flasks (cells only, no DNA) and a control 
transfection, performed alongside all test transfections, to assess transfection 
efficiency, (described in section 2.2.1.2.). Two separate flasks of 293T cells were 
transfected with 6fig of each construct, as mRNA was to be isolated from one flask 
of cells, and the cell lysates and supernatants harvested from the other flask, to assess 
IL-18 mRNA and protein expression, respectively, using Northern and western blot 
analysis. Cell lysates to be subject to Northern blot analysis were prepared as 
described in section 2.2.7.1., before proceeding with the isolation of mRNA, using 
the Quickprep mRNA purification kit (section 2.2.3.1.). Freshly isolated mRNA was 
stored at -70°C until required. Cell lysates to be subject to western blot analysis were 
resuspended in 250jll1 of IX protein sample reducing buffer, scraped into 1.5 ml 
screw top eppendorfs, boiled for ten minutes, spun for 5 minutes at 13000rpm in a 
microcentrifuge, and finally the supernatants were aliquoted into fresh eppendorfs 
and stored at -20°C until required.
3.2.10.1 Identification of IL-18 mRNA by Northern Blot analysis
In order to ascertain whether the IL-18 constructs had expressed IL-18 mRNA in 
vitro, mRNA synthesised from the transfected 293T cells was run on a 1% agarose 
gel containing 1 X MOPS and 2.2M formaldehyde. 3|ig of polyA+ mRNA from each 
sample was lyophilised (VR-1 Hetovac, Heto) then resuspended in 20jll1 of RNA 
loading buffer and denatured for 15 min at 65°C. Subsequently, 5jll1 of RNA running 
dye was added and the samples were electrophoresed for 3 hours at 100V. The gel 
was then washed and the RNA was transferred overnight onto Hybond-N in 10 X 
SSC and crosslinked to the membrane, as described in section 2.2.8.1. A feline IL-18 
specific DNA probe was generated by PCR, using 50ng of pCR2.1(Pro-EL-18) as a 
template and the primers;
5’ primer: 5’-GCAGGAATA A AG ATGGCTGC-3’
3 ’ primer: 5 ’ -GCT A ATTCTTGTTTTG A AC AG-3 ’
The following cycling conditions were employed; 30 cycles of denaturation (94°C for 
45 seconds), annealing (58°C for 60 seconds) and extension (72°C for 2 minutes).
168
The PCR product was subsequently gel-purified, using the QIAquick Gel Extraction 
kit (Qiagen), and radioactively labelled using a ‘random prime’ DNA labelling kit 
(High Prime, Boehringer Mannheim), as described in section 2.2.8.2. Standard 
methodologies for the hybridisation of labelled probes to membrane bound nucleic 
acids were used, as described in section 2.2.8.3. and hybridisation was carried out for 
12 hours. High stringency washes were performed using 0.1% SSC and 0.5% SDS at 
60°C and exposure to autoradiography films was performed at -70°C for three days. 
Subsequently, filters were stripped of the IL-18 probe and re-probed with a rat 
GAPDH probe to control for RNA loading and integrity. The GAPDH probe is a 
750bp EcoRl fragment purified from the plasmid pGAPDH and was kindly supplied 
by Anne Terry, Molecular Oncology Laboratory, Department of Veterinary 
Pathology, University of Glasgow. Hybridisation and high stringency washes were 
performed as described for the IL-18 probe and exposure to autoradiography films 
was performed overnight at -70°C.
3.2.10.2 Identification of IL-18 protein by western blot analysis
In order to ascertain whether the IL-18 constructs had expressed IL-18 protein in 
vitro, transfected 293T cell lysates, resuspended in IX protein sample reducing 
buffer, were run on SDS-polyacrylamide gels, as described in section 2.2.6.1. 10pJ of 
each sample and lOjil of Kaleidoscope Prestained SDS-PAGE standards (Biorad) 
were run on each gel. Subsequently, proteins were transferred from the gels to PVDF 
membrane by electroblotting, and immunodetection was performed as outlined in 
section 2.2.6.2., using ECL reagents (Amersham Life Science). The primary antibody 
used was a rabbit anti-equine IL-18 polyclonal antibody (kindly provided by Dr 
Lesley Nicolson and colleagues, Department of Veterinary Pathology, University of 
Glasgow), used at a 1:1000 dilution and the secondary antibody employed was an 
HRP conjugated goat anti-rabbit IgG monoclonal antibody (Sigma), used at a dilution 
of 1:5000. Following incubation with ECL reagents for one minute, the membranes 
were exposed to autoradiography film (Hyperfilm-ECL) for 30 seconds, one minute, 
five minutes and ten minutes, developing each film in an automated processor.
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3.3 RESULTS
3.3.1 RT-PCR AMPLIFICATION OF FELINE IL-12 AND IL-18 cDNA
The synthesis of mRNA gave yields of between six and ten micrograms per 162cm2 
flask and the purity of this mRNA, determined by the OD2 6 0 /OD2 8 0  reading, was 
generally very good; (OD2 6 0/OD 2 8 0  = 2.0). Figure 3.4 shows a polyacrylamide gel 
with the PCR products from the reactions used to amplify the p35 and p40 subunits 
of feline IL-12 and the appropriate controls. The product amplified using the p35 3’ 
fragment primers (390bp, lane 2) is extremely strong, while the product amplified 
using the p35 5’ fragment primers (550bp, lane 5) is very faint. Indeed, many PCR 
reactions, using different cycling conditions and reaction conditions, (such as varying 
MgCL and primer concentrations) were performed before even this faint product was 
obtained (data not shown). Lanes 3 and 7 contain PCR reactions performed in an 
attempt to optimise the p35 5’ fragment PCR; both these PCR reactions failed to 
generate a product of the correct size. The product amplified using the p40 IL-12 
primers (lane 4) is very intense and is approximately 920bp in size, somewhat 
smaller than the predicted size of lOlObp. The lambda and P-actin positive control 
primers both generated products of the expected sizes (lane 1 500bp and lane 6 
838bp, respectively), although the lambda PCR product was quite faint. Finally, no 
products were seen with the negative control (no DNA template, lane 9). (j)X174 RF 
DNA/Hae HI fragments (size range 72-1,353 bp) were run in lane 8, to allow the 
approximate determination of the sizes of the PCR products.
Meanwhile figure 3.5. shows a polyacrylamide gel with the PCR products from the 
reactions used to amplify feline IL-18 and the appropriate controls. Lanes 1 and 6 
contain (()X174 RF DNA/Hae El fragments (size range 72-1,353 bp), to allow the 
approximate determination of the sizes of the PCR products. The product amplified 
using the full length feline IL-18 primers (lane 3) is extremely strong, and is 
approximately 590bp, in good agreement with the predicted size of 595bp. The P- 
actin positive control primers generated a product of the expected size (lane 5
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838bp), and no products were seen with the negative control (no DNA template, lane 
2).
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Figure 3.4. 5% polyacrylamide gel showing the reaction products of a typical 
PCR reaction used to amplify feline p35 and p40 IL-12 cDNAs and the control 
reactions carried out concurrently. Lane 8: molecular size markers (<j)X 174 RF 
DNA/Hae III fragments); Lane 2: p35 3’ fragment primers - feline alveolar 
macrophage cDNA template; Lane 5: p35 5’ fragment primers - feline alveolar 
macrophage cDNA template; Lane 4: p40 EL-12 primers - feline alveolar macrophage 
cDNA template; Lane 6: P-actin primers - feline alveolar macrophage cDNA 
template; Lane 1: lambda primers - lambda DNA template; Lane 9: negative control 
(no added template). Lanes 3 and 7 contain PCR reactions performed in an attempt to 
optimise the p35 5’ fragment PCR; both these PCR reactions failed to generate a 
product of the correct size (550bp).
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Lane no 1 2 3 4 5 6
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Figure 3.5. 5% polyacrylamide gel showing the reaction products of a typical 
PCR reaction used to amplify feline IL-18 cDNA and the control reactions 
carried  out concurrently. Lane 1 and 6: molecular size markers (0X174 RF 
DNA/Hae III fragments; lane 6 also contains X DNAJHind III fragment markers); 
Lane 3: full length feline IL-18 primers - feline alveolar macrophage cDNA template; 
Lane 5: (3-actin primers - feline alveolar macrophage cDNA template; Lane 2: 
negative control (no added template).
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3.3.2 NUCLEOTIDE SEQUENCE OF FELINE IL-12 AND IL-18
For each cDNA, p40 IL-12, p35 IL-12 (both fragments), 3’ and 5’ fragments of IL-18 
and full length IL-18, automated sequencing was performed on at least six separate 
clones, taken from three different PCR reactions. Additionally, manual sequencing 
analysis was required to resolve the compressions present in the p40 subunit of felinq 
IL-12. Using this sequence data, consensus sequences were obtained, as described in 
section 3.2.7.; the consensus sequence of the feline p35 IL-12 subunit was obtained 
by aligning the cloned sequences of the overlapping 5’ and 3’ fragments and 
analysing the data using the GCG package. The consensus feline p35 IL-12, p40 IL- 
12 and IL-18 nucleotide sequences and deduced amino acid sequences are illustrated 
in figures 3.6, 3.7 and 3.8, respectively. The PCR primer sequences are underlined in 
each consensus sequence.
From the start to the stop codon the feline p35 IL-12 cDNA was 669bp in length and 
contained an open reading frame encoding a 2 2 2  amino acid predicted protein (figure
3.6.). Comparison of the full-length feline p35 IL-12 cDNA to published sequences 
in other species shows homology of 92.8% to canine, 89.7% to human and 70.8% to 
murine p35 IL-12 cDNAs. From the start to the stop codon the feline p40 IL-12 
cDNA was 990bp in length and contained an open reading frame encoding a 329 
amino acid predicted protein (figure 3.7.). Comparison of the full-length feline p40 
IL-12 cDNA to published sequences in other species shows homology of 93.3% to 
canine, 87.8% to human and 76.4% to murine p40 IL-12 cDNAs.
From the start to the stop codon the feline IL-18 cDNA was 579bp in length and 
contained an open reading frame encoding a 192 amino acid predicted protein (figure 
3.8.). The 192 amino acid protein was predicted to be the full length inactive 
precursor form of IL-18, pro-IL-18, cleaved by interleukin 1(3 converting enzyme, 
(ICE), or caspase-1, to yield the mature, active protein, 157 amino acids in length. 
The cleavage site was determined by comparing the feline IL-18 amino acid sequence 
with the human and murine sequences, illustrated in figure 3.11. Interleukin lp  
converting enzyme (ICE, or caspase-1), an aspartic acid-specific protease, cleaves the
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EL -18 molecule C-terminal to Asp3 6  (human) or Asp35 (mouse), to facilitate the 
removal of the pro sequence and liberate biologically active, mature IL-18. Therefore 
the cleavage site of interleukin lp  converting enzyme in the predicted feline IL-18 
amino acid sequence was determined to be C-terminal to Asp35, yielding an active 
protein, 157 amino acids long. In figure 3.8. the nucleotides of the inactive precursor 
sequence are depicted in bold type. Comparison of the full-length feline LL-18 cDNA 
to published sequences in other species shows homology of 90% to canine, 8 6 % to 
human and 74% to murine IL-18 cDNAs. The nucleotide sequence of feline IL-18 
has been submitted to the Nucleotide Sequence Database, EMBL, Outstation EBI, 
Cambridge, England, and has been referenced under the accession number Y13923.
3.3.3 PREDICTED POLYPEPTIDE SEQUENCE OF FELINE IL-12 AND IL- 
18
3.3.3.1 Homology and predicted features of feline p35 IL-12 protein
The predicted amino acid sequence of feline p35 IL-12 is shown in alignment with 
those of other species in Figure 3.9. The 222 amino acid derived protein shows 
identity of 90.5% to canine, 85.1% to human and 55.4% to murine homologues. 
Feline p35 IL-12 has five predicted N-glycosylation sites (NXT or NXS), at Asn, 
(asparagine), 42, 96, 110, 183 and 220. Proteins secreted via the endoplasmic 
reticulum are often glycosylated, that is modified by the addition of oligosaccharides, 
and the addition of these moieties generally occurs via asparagine (AMinked 
glycosylation) or may occur via serine, threonine or hydroxylysine residues (O-linked 
glycosylation). Feline p35 IL-12 also possesses eight cysteine residues, all of which 
are conserved in the canine, human and murine p35 IL-12 amino acid sequences, 
shown in figure 3.9. Cysteine residues are able to form intramolecular and 
intermolecular disulphide bonds, the formation of which determine the tertiary and 
quaternary structure of the particular protein.
175
3.3.3.2 Homology and predicted features of feline p40 IL-12 protein
The predicted amino acid sequence of feline p40 IL-12 is shown in alignment with 
those of other species in Figure 3.10. The 329 amino acid derived protein shows 
identity of 92.1% to canine, 84.2% to human and 68.1% to murine homologues. 
Feline p40 IL-12 has two predicted A-glycosylation sites (NXT or NXS), at Asn 135 
and 223, and nine cysteine residues, all of which are conserved in the canine, human 
and murine p40 IL-12 amino acid sequences, shown in figure 3.10.
3.3.3.3 Homology and predicted features of feline IL-18 protein
The predicted amino acid sequence of feline IL-18 is shown in alignment with those 
of other species in Figure 3.11. The 192 amino acid derived full length protein shows 
identity of 89% to canine, 82% to human and 71% to murine homologues. The first 
35 amino acids, shown in bold type in figure 3.11., indicate those belonging to the 
inactive precursor portion of feline IL-18, cleaved by interleukin lp  converting 
enzyme to yield the mature, active protein. The predicted amino acid sequence 
contains no hydrophobic signal peptide-like sites and no N-glycosylation sites. Four 
cysteine residues, three of which are conserved in the canine, human and murine IL- 
18 amino acid sequences, are found in the feline IL-18 predicted amino acid 
sequence, illustrated in figure 3.11. The IL-1 signature-like sequence, F-x(12)-F-x-S- 
x(6 )-F-L, is also present in the feline predicted amino acid sequence, between amino 
acids 137 and 160, again highlighting the significant relationship between IL-18 and 
the IL-1 family.
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5 '  FRAGMENT 5 '  P R IM E R
1 ATG TGC CCG CCG CGT GGC CTC CTC CTT GTA ACC 
1 M C P P R G L L L V T
61 CAC CTC AGT TTG GCC AGG AAC CTC CCC ACA CCC 
21 H L S L A R N L  P T  P
1 2 1  CTC AAC CAC TCC CAA ACC CTG CTG CGA GCC ATC 
4 1 L N H S Q T L L R A I
1 8 1  ACT CTA GAA TTT TAC TCC TGC ACT TCC GAA GAG 
6 1 T L E F Y S C T S E E
2 4 1  AAA ACC AGC ACA GTG GAG GCC TGC TTA CCA CTG 
8 1 K T S T V E A C L P L
3 01 GCT TCC AGA GAG ATC TCT CTG ATA ACT AAT GGG 
10 1  A S R E I S L I T N G
3 61 TTT ATG ACG ACC CTG TGC CTT AGC AGT ATC TAT 
1 2 1  F M T T L C L S S I Y
4 2 1  TTC AAG GCT ATG AAT GCA AAG CTG TTA ATG GAT 
14 1  F K A M N A K L L M D
4 8 1  AAC ATG CTG ACA GCT ATT GAT GAG CTG TTA CAG 
161  N M L T A I D E L L Q  
5 '  FRAGMENT 3 '  PR IM E R  
5 4 1  CCA CAG AAC TCC TCC CTG GAA GAA CCA GAT TTT 
1 81  P Q N S S L E E P D F
6 01 CTT CTT CAT GCT TTC AGA ATT CGT GCA GTG ACC 
2 01  L L H A F R I R A V T
6 6 1  GCT TCC TAA 669 
2 2 1  A S * 222
ATC CTG GTC CTG TTA AAC CAC CTG GAC 60 
I L V L L N H L D 2 0
ACA CCA AGC CCA GGA ATG TTC CAG TGC 120  
T P S P G M F Q C 4 0
AGC AAC ACG CTT CAG AAG GCC AGA CAA 180 
S N T L Q K A R Q 6 0
ATT GAT CAT GAA GAT ATC ACA AAA GAT 240  
I D H E D I T K D 8 0  
3 '  FRAGMENT 5 '  PR IM E R
GAA TTA ACC ATG AAT GAG AGT TGC CTG 300  
E L T M N E S C L  100
AGT TGC CTG GCC TCC AGA AAG ACC TCT 3 60 
S C L A S R K T S  120
GAG GAC TTG AAG ATG TAC CAG GTG GAG 420  
E D L K M Y Q V E  140
CCT AAA AGG CAG ATC TTT CTG GAT CAA 480  
P K R Q I F L D Q  160
GCC CTG AAT GTC AAC AGT GTG ACT GTG 540 
A L N V N S V T V  180
TAT AAA ACT AAA ATC AAG CTC TGC ATA 600 
Y K T K I K L C  I  200 
3 '  FRAGMENT 3 '  PR IM E R
ATC AAT AGA ATG ATG AGC TAT CTG AAT 6 60 
I N R M M S Y L N  220
Figure 3.6. Nucleotide sequence and deduced amino-acid sequence of feline p35 IL- 
12 cDNA. Primers used in the PCR to amplify the 5’ and 3’ fragments are underlined.
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1 ATG CAT CCT CAG CAG CTG GTC ATC GCC TGG TTT TCC CTG GTT TTG CTG GCA CCT CCC CTC 60 
1 M H P Q Q L V I A W F S L V L L A P P L 2 0
61 ATG GCC ATA TGG GAA CTG GAG AAA AAC GTT TAT GTT GTA GAG TTG GAC TGG CAC CCT GAT 120
21 M A I  W E  L E K N V Y V V E  L D W H  P D 4 0
12 1  GCC CCC GGA GAA ATG GTG GTC CTC ACC TGC AAT ACT CCT GAA GAA GAT GAC ATC ACC TGG 180
4 1 A P G E M V V L T C N T P E E D D I T W 6 0
18 1  ACC TCT GAC CAG AGC AGT GAA GTC CTA GGC TCT GGT AAA ACT CTG ACC ATC CAA GTC AAA 240  
6 1 T S D Q S S E V L G S G K T L T I Q V K 8 0
2 4 1  GAA TTT GCA GAT GCT GGC CAG TAT ACC TGT CAT AAA GGA GGC GAG GTT CTG AGC CAT TCG 30 0  
81 E F A D A G Q Y T C H K G G E V L S H S  100
3 0 1  TTC CTC CTG ATA CAC AAA AAG GAA GAT GGA ATT TGG TCC ACT GAT ATC TTA AGG GAA CAG 3 60 
1 0 1  F L L I H K K E D G I W S T D I L R E Q  120
3 61 AAA GAA TCC AAA AAT AAG ATC TTT CTA AAA TGT GAG GCA AAG AAT TAT TCT GGA CGT TTC 420  
1 2 1  K E S K N K I F L K C E A K N Y S G R F  140
4 2 1  ACC TGC TGG TGG CTG ACG GCA ATC AGT ACC GAT TTG AAA TTC ACT GTC AAA AGC AGC AGA 48 0  
1 4 1  T C W W L T A I S T D L K F T V K S S R  160
4 81 GGC TCC TCT GAC CCC CAA GGG GTG ACT TGT GGA GCA GCG ACA CTC TCA GCA GAG AAG GTC 540 
16 1  G S S D P Q G V T C G A A T L S A E K V  180
5 4 1  AGA GTG GAC AAC AGG GAT TAT AAG AAG TAC ACA GTG GAG TGT CAG GAG GGC AGT GCC TGC 600 
18 1  R V D N R D Y K K Y T V E C Q E G S A C  200
60 1  CCG GCT GCC GAG GAG AGC CTA CCC ATT GAA GTC GTG GTG GAC GCT ATT CAC AAG CTC AAG 660 
2 0 1  P A A E E S L P I E V V V D A I H K L K  220
66 1  TAC GAA AAC TAC ACC AGC AGC TTC TTC ATC AGG GAC ATC ATC AAA CCG GAC CCA CCC AAG 72 0 
2 21  Y E N Y T S S F F I R D I  I K P D P P K  240
7 2 1  AAC CTG CAA CTG AAG CCA TTA AAA AAT TCT CGG CAT GTG GAA GTG AGC TGG GAA TAC CCT 780  
2 4 1  N L Q L K P L K N S R H V E V S W E Y P  260
7 8 1  GAC ACC TGG AGC ACC CCA CAT TCC TAC TTC TCC TTA ACA TTT GGC GTA CAG GTC CAG GGC 840 
2 6 1  D T W S T P H S Y F S L T F G V Q V Q G  280
84 1  AAG AAC AAC AGA GAA AAG AAA GAC AGA CTC TCC GTG GAC AAG ACC TCA GCC AAG GTC GTG 900 
2 8 1  K N N R E K K D R L S V D K T S A K V V  300
9 0 1  TGC CAC AAG GAT GCC AAG ATC CGC GTG CAA GCC AGA GAC CGC TAC TAT AGC TCA TCC TGG 960 
3 0 1  C H K D A K I R V Q A R D R Y Y S S S W  320
96 1  AGC AAC TGG GCA TCC GTG TCC TGC AGT TAG 99 0  
3 2 1  S N W A S V S C S *  32 9
Figure 3.7. Nucleotide sequence and deduced amino-acid sequence of feline p40 IL- 
12 cDNA. 5’ Primer used in the PCR to amplify the p40 subunit is underlined; 3’ primer 
is outwith the 3’ coding sequence.
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1 ATG GCT GCT ATA CCA GTA GAT GAT TGC ATC AAC TTT GTG GGA ATG AAA TTT ATT GAC AAT 60
1 H A A  I  P V D D C  I  N F V G M K F  I  D N 2 0
61 ACA CTT TAC TTT GTA GCT GAC AGT GAT GAA AAC CTG GAA ACA GAT-ItAC TTT GGC AAG CTT 120
2 1  T L Y F V A
1 2 1  GAA CAT AAA CTC TCA ATC 
4 1  E H K L S I
1 8 1  GAT CAA CCT GTG TTT GAG
61 D Q P V F E
2 41  GAA TTT ATC ATA TAT ATG
81 E F I  I  Y M
3 01 GTG AAT TAT AAG ACC ATG
1 0 1  V N Y K T M
3 61 ATG AGT CCT CCT GAG AGT
1 2 1  M S P P E S
4 2 1  GTT CCA GGA CAT GAT GAT
1 4 1  V P G H D D
4 81 GCT TGT GAA AAA GAG AAA
1 6 1  A C E K E K
5 41  GAT AAG TCC ATA ATG TTC
1 81  D K S I  M F
D S D E N L E T
TTA CGA AAC TTG AAC GAC CAA GTT 
L R N L N D Q V
GAT ATG CCT GAT TCT GAC TGT ACA 
D M P D S D C T
TAT AAA GAT AGC CTC ACT AGA GGT 
Y K D S L T R G
TCT ACT CTC TCC TGT GAG AAC AAA 
S T L S C E N K
ATC AAT GAT GAA GGA AAT GAC ATC 
I N D E G N D I
AAG ATA CAA TTT GAG TCT TCA TTG 
K I Q F E S S L
GAT CTT TTC AAA CTC ATT TTG AAA 
D L F K L I L K
ACT GTT CAA AAC AAG AAT TAG 579  
T V Q N K N * 192
D Y F G K L 40
CTC TTC ATT AAC CAG GGA 180
L F I  N Q G 60
GAT AAT GCA CCC CGG ACT 240
D N A P R T 80
CTG GCA GTA ACC ATC TCT 3 00
L A V T I  S 100
ATT ATT TCC TTT AAG GAA 360
I  I  S F K E 120
ATA TTC TTT CAG AGA AGT 420
I  F F Q R S 140
TAC AAG GGG TAC TTT CTA 480
Y K G Y F L 160
AAA AAG GAT GAA AAT GGG 540
K K D E N G 180
Figure 3.8. Nucleotide sequence and deduced amino-acid sequence of full length 
feline IL-18 cDNA. The nucleotides of the inactive precursor sequence are depicted in 
bold type and I  indicates the interleukin lp  converting enzyme, (ICE), or caspase-1, 
cleavage site. Primers used in the PCR to amplify full length IL-18 are underlined.
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•  •  NXS
1 MCPPRGLLLV TILVLLNHLD HLSLARNLPT PTPSPGMFQC LNHSQTLLRA 50
1 ---------------  S-— TW— S---AS----- 1 ----- N----50
1  A-S AT  V A— D P- -H N 47
1 — QS-Y--FL AT-A-...-N------- VI-V SG-A....R- -SQ-RN— KT 43
•  •  NXS •
51 ISNTLQKARQ TLEFYSCTSE EIDHEDITKD KTSTVEACLP LELTMNESCL 100
51 V--------- — DYIP -------------   100
48 V— M ----------  P----------------------   K -97
44 TDDMVKT--E K-KH A- D R- Q LKT  HK 93
N XS* •
101 ASREISLITN GSCLASRKTS FMTTLCLSSI YEDLKMYQVE FKAMNAKLLM 150
1 0 1 ---------- ------- G - A -  V------ ----------M - ------------ 150
98 N -T-F ---------------MA------------------- --T---------- 147
94 -T--T-ST-R PPQ L-M--- G - -  T- -Q-I--A-QN 143
NXS •
151 DPKRQIFLDQ NMLTAIDELL QALNVNSVTV PQNSSLEEPD FYKTKIKLCI 2 00
1 5 1 --------------------   F--- --K---  200
1 4 8 ------------ AV----M ----F —  E—  --K--------------------- 197
144 HNHQ— I —  K G— V  M -S— H-GE-L R-KPPVG-A- P-RV-M 193
N XS
2 01 LLHAFRIRAV TINRMMSYLN AS 222 FELINE
2 0 1 ---------- — D------- S- 222 CANINE
1 9 8 ---------- — D-VT---- —  219 HUMAN
1 9 4  S T - V -  V-G--S SA 215 MURINE
Figure 3.9. Alignment of the amino-acid sequences of feline, canine, human and 
murine p35 interleukin 12 polypeptides. Identical amino-acids are indicated by 
dashes (-) and dots indicate gaps introduced to maintain optimal sequence alignment. 
Cysteine residues are depicted by • and potential N-glycosylation sites by NXS.
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1 MHPQQLVIAW FSLVLLAPPL MAIWELEKNV YWELDWHPD
•
APGEMWLTC 50
1 -------- S- ------- SS- -T------ D- ---------- ---------- 50
1 -CH-----S- ----F— S— V-----K-D- ------- Y— ---------- 50
1 -C— K-T-S- -AI-- VS-- --M-----D- ----V— T— ----T-N--- 50
51 NTPEEDDITW TSDQSSEVLG SGKTLTIQVK
•
EFADAGQYTC HKGGEVLSHS 100
51 H--------- --A------- ---------- __G------- ----K---R- 100
51 D-----G--- _ L -------- ---------- --G------- ---------- 100
51 D--------- ----RHG-I- T__
•  NXS •
100
101 FLLIHKKEDG IWSTDILREQ KESKNKIFLK CEAKNYSGRF TCWWLTAIST 150
101 L--------- ------- K-- 150
101 L— L------ ------- KD_ __p---T--R ---------- ------T ------- 150
101 H— L----N- ----E-- . . .
•
-NF------T ------- p --S--VQRNM 
•  •
147
151 DLKFTVKSSR GSSDPQGVTC GAATLSAEKV RVDNRDYKKY TVECQEGSAC 200
151 ------ s ------------ -F------------------ --V-----------R- ---------- ---------- 200
151 —  T-S----- ---------- -------- R- -G— KE-.E- S -----D--- 199
148 ----NI---S S-P-SRA--- -M-S------
NXT
TL-Q---E - - S-S-- DVT- 197
201 PAAEESLPIE VWDAIHKLK YENYTSSFFI RDIIKPDPPK NLQLKPLKNS 250
201 -S-------- ---------------------T 250
200 -M-- V---- 249
198 - T ---T---- LALE-RQQN- ----ST---- ---------- ---M------ 247
2 5 1 RHVEV SWEY P DTWSTPHSYF SLTFGVQVQG KNNREK.......................... KDRLSV 2 9 2
2 5 1 ------ C — A — ----------------- ----------------------C - 2 9 2
2 5 0 _Q------------------ ----------------------- -------- c ------------ - S K ---------------- ------------------- VFT 2 9 1
2 4 8 • Q ------------------ _ S - - K - F - R I - R -K E K M -E T E E  G C N Q -G A F L - 2 9 6
2 9 3
•
D K T SA K W C H KDAKIRVQAR DRYYSSSW SN
•
WASVSCS 3 2 9  F E L I N E
2 9 3 --------------- D ----------------  3 2 9  C A N IN E
2 9 2 -------- T _ x _ R - N - S - S - R - Q --------------- E ------- p__ 3 2 8  HUMAN
2 9 7 E ------ T E - Q -  . -G G N V C------ Q -------- N - - C - K
r
- - C - P - R V R S  3 3  5 MURINE
Figure 3.10. Alignment of the amino-acid sequences of feline, canine, human and 
murine p40 interleukin 12 polypeptides. Identical amino-acids are indicated by 
dashes (-) and dots indicate gaps introduced to maintain optimal sequence alignment. 
Conserved cysteine residues are depicted by • and potential N-glycosylation sites by 
NXS or NXT.
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1 MAA. IPV DD C IN FV G M K FID NTLYFVADSD ENLETDYFGK LEHKLSILRN 49
1 -----NLIE-N- —  L-K---VN ---------K-E— -G--S--------- _ _ p ------- z __ 50
1 ---E.-E-N- -S--E----N ------------- EN- -D--S--------- --P-------1-- 49
1 -----EPVE-N- -------A --------- --------- i_ed- -------S---------- --S-----VI-- 50
1 ----MSE-S- V--KE-M--- -----IPEEN GD--S-NF-R -HCTTAVI— 49
50 LNDQVLFINQ GDQPVFEDMP DSDCTDNAPR TEFIIYMYKD SLTRGLAVTI 99
5  1 ------- v-E -N---------- H -I---------- 100
5 0 ---------- -H-A-----------  S--Q -V---------- 99
5 1  D_ -NR-L T  R------ -I S -QP--M 100
50 I------ VDK .R------- T -I-QSASE-Q -RL-------- -EV------ L 98
100 SVNYKTMSTL SCENKIISFK EMSPPESIND EGNDIIFFQR SVPGHDDKIQ 149
101 --K------- --K--T Q K D -------------  150
100 --QC-K  -K--TL  D N - D - ------------ 149
101 --KCEKI ---------- --N--DN-K- TKS  N-M- 150
99 --KDSK  -K------ E — D N-D- IQS-L K -V .N-ME 147
150 FESSLYKGYF LACEKEKDLF KLILKKKDEN GDKSIMFTVQ NKN 192 FELINE
151 -------- H- ---K--N--- -----D---- ---------- --S 193 CANINE
150 ---------- ---K--N--- -----E---C ---------- ---- 192 PORCINE
151 ----S-E--- ------R--- ----------E— L — R------- -ED 193 HUMAN
148 ------ E-H- ---Q--D-A- ---------- ----V---LT -LHQS 192 MURINE
Figure 3.11. Alignment of the amino-acid sequences of feline, canine, porcine, 
human and murine interleukin 18 polypeptides. Identical amino-acids are indicated 
by dashes (-) and dots indicate gaps introduced to maintain optimal sequence alignment. 
Conserved cysteine residues are depicted by • and the IL-1 signature-like sequence F- 
x(12)-F-x-S-x(6)-F-L is underlined. The amino acids shown in bold type indicate those 
belonging to the inactive precursor portion of full length feline IL-18. The predicted 
amino acid sequence contained no hydrophobic signal peptide-like sites and no N- 
glycosylation sites.
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3.3.4 IDENTIFICATION OF IN VITRO EXPRESSION OF FELINE IL-18
Feline IL-18 mRNA and protein expression were evaluated by performing Northern 
and western blot analysis, respectively, on 293T cell lysates. These 293T cells had 
been previously transfected with the IL-18 expression constructs. Six micrograms of 
each of the plasmids were co-transfected into 293T cells and transfection efficiency 
was monitored using a (3-galactosidase construct control and was found to be in the 
order of 50%.
3.3.4.1 Identification of IL-18 mRNA expression by Northern Blot 
analysis
Northern blot analysis, using a feline IL-18 specific probe to assess in vitro mRNA 
expression of the constructs pCI-neo (pro-IL-18), pCI-neo (mature-IL-18) and PsecI 
(E L -18), revealed the presence of specific bands at approximately, 1050bp, 950bp and 
lOOObp, respectively, illustrated in figure 3.12. This was in good agreement with the 
expected sizes of pCI-neo derived pro-IL-18 mRNA transcripts, 1040bp; pCI-neo 
derived mature EL -18 mRNA transcripts, 930bp; and PsecI derived mature EL -18 
mRNA transcripts, 980bp. Moreover, the IL-18 specific probe did not hybridise with 
mRNA made from the control transfection reactions; 293T cells transfected with 
pCI-neo only, and non-transfected 293T cells (no DNA). Therefore, it appeared that 
the feline EL-18 probe employed in this hybridisation technique specifically detected 
feline IL-18 mRNA and, therefore, that all three forms of feline IL-18 mRNA were 
expressed in vitro in transfected mammalian cells. Additionally, to control for RNA 
loading and integrity, filters were stripped of the IL-18 probe and re-probed with a rat 
GAPDH probe. This probe, a 750bp EcoRI fragment purified from the plasmid 
pGAPDH, hybridises to a 1.3kb GAPDH mRNA transcript, expressed at high levels 
in all cell types. Hybridisation with this probe revealed the presence of specific bands 
at 1.3kb, of approximately the same intensity, in each of the five lanes of mRNA; 
pCI-neo (pro-IL-18), pCI-neo (mature-IL-18), PsecI (E L -18), pCI-neo alone and non- 
transfected 293T cell mRNA, illustrated in figure 3.13. This indicated that all the
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mRNAs were of good quality and integrity, and that similar amounts of mRNA had 
been loaded into each well of the 1% agarose, MOPS and formaldehyde gel.
Figure 3.12. An autoradiograph of a northern  blot, after hybridisation with a 
feline IL-18 specific probe to assess in vitro mRNA expression of the constructs 
pCI-neo (pro-IL-18), lane 1; pCI-neo (mature-IL-18), lane 2; PsecI (IL-18), lane 
3; pCI-neo only, lane 4 and non-transfected 293T cells, lane 6 . The presence of 
specific bands at approximately, 1050bp, 950bp and lOOObp, in lanes 1, 2 and 3 
respectively, was in good agreement with the expected sizes of the pCI-neo derived 
pro-IL-18 mRNA transcripts, 1040bp; pCI-neo derived mature EL-18 mRNA 
transcripts, 930bp; and PsecI derived mature IL-18 mRNA transcripts, 980bp. Lanes 
4 and 6 are blank, indicating that the IL-18 specific probe did not hybridise with 
mRNA made from the negative control transfection reactions; 293T cells transfected 
with pCI-neo only, and non-transfected 293T cells (no DNA).
N.B. Due to the scale of this diagram only one RNA size marker (1050bp) is in the 
visible field.
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Lane no 1 2 3 4 5 6
Figure 3.13. An autoradiograph of the northern  blot illustrated in figure 3.12, 
after stripping and reprobing with a ra t GAPDH probe, in order to assess in 
vitro expression of the GAPDH mRNA transcrip t. The GAPDH probe hybridised 
to a 1.3kb GAPDH mRNA transcript, expressed at high levels in all cell types. 
Hybridisation with this probe revealed the presence of specific bands at 1.3kb, of 
approximately the same intensity, in each of the five lanes of mRNA; pCI-neo (pro- 
IL-18), lane 1; pCI-neo (mature-IL-18), lane 2; PsecI (IL-18), lane 3; pCI-neo alone, 
lane 4 and non-transfected 293T cell mRNA, lane 6. This indicated that all the 
mRNAs were of good quality and integrity, and that similar amounts of mRNA had 
been loaded onto the gel.
N.B. Due to the scale of this diagram only one RNA size marker (1300bp) is in the 
visible field.
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3.3.4.2 Identification of IL-18 protein expression by western blot analysis
Western blot analysis and immunodetection, using a rabbit anti-equine IL-18 
polyclonal antibody to assess in vitro protein expression of the pCI-neo (pro-IL-18), 
pCI-neo (mature-IL-18) and PsecI (IL-18) constructs, demonstrated the presence of a 
single 24kDa species, the predicted size of the feline pro-IL-18 protein, (illustrated in 
figure 3.14). However, specific signals were only observed in the lanes which 
contained the cell lysates from the 293T cells transfected with the feline pCI-neo 
(pro-IL-18) construct (lane 3), and the two positive controls, lp,g of recombinant 
equine mature and pro-IL-18 proteins, (lanes 7 and 8 , respectively). The feline and 
equine pro-IL-18 proteins were estimated to be approximately 24kDa, while the 
equine mature IL-18 protein was estimated to be approximately 18kDa. No signal 
was observed in the lanes containing the cell lysates from the 293T cells transfected 
with pCI-neo only (lane 2) and cell lysates from non-transfected cells, (lane 6 ). 
Moreover, no signal was observed in the lanes containing the cell lysates from the 
293T cells transfected with the feline pCI-neo (mature-IL-18) and PsecI (IL-18) 
constructs (lanes 4 and 5, respectively). Therefore, it appeared that either the rabbit 
anti-equine IL-18 polyclonal antibody did not recognise the mature form of the feline 
IL-18 protein (18kDa), or that the pCI-neo (mature-IL-18) and PsecI (IL-18) 
constructs did not express IL-18 protein in mammalian cells in vitro. However, the 
signal in the lane containing the cell lysates from 293T cells transfected with the 
feline pCI-neo (pro-IL-18) construct was strong and specific, indicating that feline 
pro-IL-18 protein was expressed in mammalian cells in vitro. Taken together, these 
experiments confirmed that feline IL-18 mRNA and protein were expressed in vitro 
in transfected mammalian cells.
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Figure 3.14. An autoradiograph of a western blot after immunodetection using a 
rabbit anti-equine IL-18 polyclonal antibody, to assess in vitro protein expression of 
the pCI-neo (pro-IL-18), pCI-neo (mature-IL-18) and PsecI (IL-18) constructs; lanes 
3, 4 and 5, respectively. A single 24kDa species, the predicted size of the feline pro- 
IL-18 protein, was identified in lane 3, while no signals were detected in the lanes 
containing the cell lysates from 293T cells transfected with pCI-neo only, (lane 2), 
feline pCI-neo (mature-IL-18), (lane 4), PsecI (IL-18), (lane 5), or cell lysates from 
non-transfected cells (lane 6). However, specific signals of 18kDa and 24kDa were 
detected in the lanes which contained recombinant equine mature and pro-IL-18 
proteins, (lanes 7 and 8, respectively), the predicted sizes of the equine IL-18 
proteins. Two different exposures of the blot are illustrated; 30 seconds, where the 
positive control signals were detected, (lanes 7 and 8), but the pro-IL-18 transfection 
signal was not, (lane 3), and two minutes, where the 24kDa species was detected in 
lane 3, but the positive control signals were much too intense. Kaleidoscope 
Prestained SDS-PAGE standards, to allow the approximate estimation of protein 




3.4.1 AMPLIFICATION OF FELINE IL-12 AND IL-18 BY PCR
The polymerase chain reaction provides an attractive method of isolating novel 
genes, in cases where there is limited information regarding nucleotide sequence. Its 
utilisation in this project enabled the isolation of three feline Thl type cytokine 
genes, p35 IL-12, p40 IL-12 and IL-18, without having to generate and screen a 
cDNA library, a time consuming and technically more difficult process. However, the 
use of PCR is not without potential disadvantages. The most significant of these 
disadvantages is the total failure to amplify the desired cDNA. This may occur 
despite attempts to optimise the PCR by varying conditions, including primer 
annealing temperature, primer concentration, number of PCR cycles and reaction 
conditions, such as Mg2+ concentration. A number of potential causes of PCR failure 
can be considered. Firstly, the mRNA of interest may simply not be present, or may 
be degraded, in the starting material. The correct choice of starting cells or tissue, 
additional mitogen stimulation and timing of mRNA harvest are absolutely essential 
in order to achieve optimal levels of mRNA expression of the gene of interest. 
Alternatively, there may be a failure of reverse transcription, in synthesising full 
length cDNA from mRNA, either due to the reaction conditions or because of 
secondary structure present in the mRNA. Treatment of mRNA with methylmercury 
hydroxide may help to remove secondary structure, in certain circumstances.
Another important consideration when attempting the isolation of cDNAs where the 
exact sequence is unknown, is the design of the oligonucleotide primers, for use in 
the PCR amplification. If there are mismatches between the primer and cDNA 
sequences, the primers may not anneal efficiently to the cDNA. In such 
circumstances, the design of alternative primers or the use of degenerate primers may 
prove successful. Another potential outcome of non-specific primer binding may be 
the generation of multiple PCR products, seen as multiple bands or smears on
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polyacrylamide gels, or poor yield of specific product. The use of 'hot-starf protocols 
(e.g. using anti Taq antibody or wax beads) may improve the yield of a specific 
product by reducing the extension of primers bound non-specifically.
The full length feline p35 IL-12 cDNA sequence could not be amplified with any 
combination of primers or reaction conditions and, indeed, the full length sequence 
was only obtained when primers were designed to generate two overlapping 
fragments of the cDNA. In contrast, the p40 IL-12 cDNA was amplified by PCR with 
comparative ease. As discussed in section 3.1.2.4., stimulated PBMCs expressed p40 
mRNA at a much higher level than p35 mRNA; the abundance of p40 transcriptions 
was up to 200 fold higher than that of the p35 transcripts (Cassatella et al. 1995). 
Therefore, the low levels of p35 mRNA compared to p40 mRNA, may help to 
explain the difficulties encountered in amplifying the former cytokine by PCR.
Furthermore, if isolation by RT-PCR is successful, another inherent disadvantage 
which must be examined is the misincorporation of nucleotides during DNA 
synthesis by Taq DNA polymerase. The most common error is that of single base 
substitutions, which generally occur at a low frequency (around one base substitution 
per 106 nucleotides). This error rate, however, may be increased when higher than 
optimal nucleotide and magnesium concentrations are employed, and may approach 
one per thousand nucleotides in unfavourable conditions. The nucleotide differences 
seen between different clones of p35 EL-12, p40 IL-12 and IL-18, were attributed to 
such errors. The sequencing of a number of cDNA clones, from different RT-PCR 
reactions enabled a consensus sequence to be determined with a relatively high 
degree of confidence. It has been suggested that sequencing of between three to six 
clones will generally suffice in the determination of a consensus sequence at a given 
allele (Ennis et al. 1996). The use of thermostable DNA polymerases which possess 
proof reading activity (e.g. Pfu polymerase or Vent polymerase) may result in an 
increase in fidelity over that seen with Taq polymerase. Therefore, the use of these 
alternative enzymes should be considered in future projects.
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3.4.2 FEATURES OF THE PREDICTED FELINE p35 IL-12, p40 IL-12 AND 
IL-18 PROTEINS
Feline p35 IL-12, p40 IL-12 and IL-18 proteins share a high degree of homology with 
the respective cytokines from other mammalian species; between 70 and 90% at the 
nucleotide level and between 55 and 90% at the amino acid level. Canine cDNA and 
amino acid sequences display the greatest degree of conservation with the feline 
sequences, and murine the least. This evolutionary conservation suggests a similar 
biological role for these Thl type cytokines in the cat to that described for other 
species, such as mice and humans.
3.4.2.1 Feline p35 IL-12 protein
The p35 subunit of feline IL-12 is predicted to be a 222 amino acid derived protein, 
possessing identities of 90.5%, 85.15 and 55.4% to the canine, human and murine 
homologues, respectively. The predicted feline p35 amino acid sequence is the same 
size as the canine homologue, three amino acids longer than the human homologue 
and seven amino acids longer than the murine homologue. Feline p35 IL-12 has five 
predicted N-glycosylation sites (NXT or NXS), at Asn, (asparagine), 42, 96, 110, 183 
and 220, and eight cysteine residues, the latter of which are conserved in the canine, 
human and murine p35 IL-12 amino acid sequences. These cysteine residues may be 
important in determining the tertiary and quaternary structure of the p35 protein and 
IL-12 heterodimer.
The human p35 protein possesses a hydrophobic signal-like sequence, 22 amino 
acids in length, yielding a mature protein composed of 197 amino acids (Podlaski et 
al. 1992). A signal peptide acts to direct ribosomal protein synthesis to the 
endoplasmic reticulum; the signal sequence is then removed on the luminal side of 
the endoplasmic reticulum. Signal sequences typically have an N-terminal basic 
region, a hydrophobic core and a polar C-terminal region followed by a proteolytic 
cleavage site (von Heijne, 1983). Interestingly the predicted feline p35 IL-12 protein 
may possess a similar signal sequence to the human homologue; 18 of the first 25
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amino acids in the feline sequence are hydrophobic in nature ( the amino acids 16, 17 
and 18 in the feline sequence are deleted in the human sequence).
3.4.2.2 Feline p40 IL-12 protein
The feline p40 IL-12 subunit is predicted to be a 329 amino acid derived protein, 
possessing identities of 92.1%, 84.2% and 68.1% to the canine, human and murine 
homologues, respectively. The predicted feline p40 amino acid sequence is the same 
size as the canine homologue, one amino acid longer than the human homologue, and 
six amino acids shorter than the murine homologue. The feline p40 IL-12 protein has 
two predicted A-glycosylation sites (NXT or NXS), at Asn 135 and 223, and nine 
cysteine residues, all of which are conserved in the canine, human and murine p40 
IL-12 amino acid sequences. Similar to the p35 subunit protein, these cysteine 
residues may be important in determining the tertiary and quaternary structure of the 
p40 protein and the IL-12 heterodimer. The human p40 protein possesses a 
hydrophobic signal-like sequence, 22 amino acids in length, yielding a mature protein 
composed of 306 amino acids (Trinchieri, 1994). Interestingly, the predicted feline 
p40 IL-12 protein may possess a similar signal sequence to the human homologue; 18 
of the first 22 amino acids in the feline p40 sequence are hydrophobic in nature and 
the feline p40 signal-like sequence also possesses an N-terminal basic region, (the 
second residue is histidine, a basic amino acid).
While experimental work to isolate the feline IL-12 gene was ongoing, two 
independent research groups cloned and sequenced the feline p35 and p40 IL-12 
cDNAs (Schijns et al. 1997), (Fehr et al. 1997). Both p40 nucleotide sequences 
were submitted to the Nucleotide Sequence Database, EMBL, and were referenced 
under the accession numbers Y07762 (Schijns) and U83184 (Fehr). Interestingly, 
differences between these published sequences and the feline p40 nucleic acid 
sequence obtained during the course of this project were discovered.
Three individual base pair changes were discovered when comparing the p40 cDNA 
sequence illustrated in this thesis (figure 3.7.) with the published p40 cDNA 
sequence Y07762; at positions 16, 31 and 500. The nucleotide change at position 16
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was from a C to a T (Y07762). However, this nucleotide change did not initiate an 
amino acid change; the amino acid at position 6 was leucine in both polypeptide 
sequences. The nucleotide change at position 31 was from a T to a C (Y07762) and 
this nucleotide change did initiate an amino acid change at position 11; from 
phenylalanine, a neutral, very hydrophobic amino acid, to leucine, also a neutral, 
hydrophobic amino acid (Y07762). Therefore, although an amino acid change was 
evident at position 11, both amino acids possessed similar properties and this 
substitution was predicted to have little effect on the structure or function of the p40 
protein. Moreover, the amino acid at position 11 in the canine, human and murine 
p40 amino acid sequences was also found to be phenylalanine.
The nucleotide change at position 500 was from a G to an A (Y07762) and this 
nucleotide change did initiate an amino acid change at position 167; from glycine, a 
neutral, hydrophobic amino acid, to glutamic acid, an acidic, hydrophilic amino acid 
(Y07762). These two amino acids obviously possessed very different properties. 
Significantly, the amino acid at position 167 in the canine and human p40 amino acid 
sequences was also found to be glycine, conserved with the author’s p40 sequence. 
Interestingly, this area of the p40 nucleotide sequence was very GC rich and 
additional manual sequencing was required to resolve compressed loops of secondary 
structure; automated sequence analysis alone was not effective. Although the amino 
acid substitution at position 167 may reflect allelic variation between different gene 
pools of cats, the evidence above may imply that Schijns and colleagues did not 
effectively sequence through the compressed areas of the p40 cDNA and therefore 
did not obtain the correct feline p40 IL-12 cDNA sequence.
Four individual base pair changes were discovered when comparing the p40 cDNA 
sequence illustrated in this thesis with the published p40 cDNA sequence U83184; at 
positions 150, 151, 153 and 156. Significantly, the author’s p40 cDNA sequence and 
the sequence U83184 were conserved at positions 16, 31 and 500. The nucleotide 
change at position 150 was from a C to a T (U83184). However, this nucleotide 
change did not initiate an amino acid change; the amino acid at position 50 was 
cysteine in both the published (U83184) and the author’s p40 polypeptide sequences. 
The nucleotide changes at position 151 and 153 were from an A to a G (U83184) and
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a T to a C (U83184), respectively. These nucleotide changes did initiate an amino 
acid change at position 51; from asparagine, a neutral, hydrophilic amino acid, to 
aspartic acid, an acidic hydrophilic amino acid (U83184). Therefore, although an 
amino acid change was evident at position 51, both amino acids possessed similar 
properties and this substitution was predicted to have little effect on the structure or 
function of the p40 protein. Interestingly, the amino acid at position 51 in the canine 
p40 amino acid sequence was found to be histidine, a basic hydrophilic amino acid; 
while the amino acid at position 51 in the human and murine p40 amino acid 
sequence was found to be aspartic acid, conserved with the published p40 amino acid 
sequence U83184.
Finally, the nucleotide change at position 156 was from a T to a G (U83184). 
However, this nucleotide change did not initiate an amino acid change; the amino 
acid at position 52 was threonine in both the published (U83184) and the author’s 
p40 polypeptide sequences. It is likely that the majority of these amino acid 
substitutions reflect allelic variation between different gene pools of cats. It should be 
noted that two of the observed base pair changes between the author’s p40 sequence 
and the published p40 sequence Y07762 are found in the hydrophobic signal-like 
sequence. The signal-like sequence is probably only necessary for the transport of the 
protein out of cells; it is cleaved from the mature form of the p40 protein and is 
therefore not important in terms of the structure or biological activity of the active 
protein. Therefore, there is perhaps less evolutionary pressure for the signal-like 
amino acid sequence to remain conserved.
3.4.2.3 Feline IL-18 protein
The full length feline IL-18 species is predicted to be a 192 amino acid protein, 
possessing identities of 89% to canine, 82% to human and 71% to murine 
homologues. The predicted feline IL-18 amino acid sequence is one amino acid 
shorter than the canine and human homologues and the same size as the porcine and 
murine homologues. Four cysteine residues, three of which are conserved in the 
canine, human and murine IL-18 amino acid sequences, are found in the feline IL-18 
predicted amino acid sequence. Interestingly, the size of the recombinant human EL-
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18 protein did not change after treatment with the reducing agent DTT (Ushio et al.
1996). This suggested that no disulphide bonds existed in the protein structure, 
although the human IL-18 protein contains four cysteine residues. Similar to the 
human and murine sequences (Ushio et al. 1996), the feline IL-18 protein has no 
predicted A-glycosylation sites. This is in contrast to the canine IL-18 predicted 
amino acid sequence, which contains three predicted N-glycosylation sites (Argyle et 
al. 1999), (Okano et al. 1999). Significantly, the IL-1 signature-like sequence, F- 
x(12)-F-x-S-x(6)-F-L, identified in the human, murine and canine IL-18 amino acid 
sequences (Ushio et al. 1996), (Argyle et al. 1999), (Okano et al. 1999), is also 
present in the feline IL-18 predicted amino acid sequence, between amino acids 137 
and 160. Again, this highlights the significant relationship between IL-18 and the IL- 
1 family.
The predicted feline IL-18 amino acid sequence contains no hydrophobic signal 
peptide-like sites, similar to the human, murine and canine IL-18 amino acid 
sequences (Ushio et al. 1996), (Argyle et al. 1999), (Okano et al. 1999). As 
discussed in the introduction, Gu et al have demonstrated that the activation of 
human E L -18 occurs via the cleavage of the inactive leader sequence by the enzyme 
interleukin 1(3 converting enzyme (ICE, or caspase-1) (Gu et al. 1997). The N- 
terminus of the human mature protein occurs after Asp36 (Asp35 in the murine 
sequence) and it has been demonstrated that ICE, an aspartic acid-specific protease, 
cleaves the human EL-18 precursor molecule C-terminal to Asp36 (human) or Asp35 
(mouse). This facilitates the removal of the inactive pro sequence and liberates the 
biologically active, mature EL -18 protein. The similarity between the feline and the 
human and murine full length IL-18 amino acid sequences, regarding the lack of a 
conventional hydrophobic signal sequence, suggests that the cellular handling of full 
length feline E L -18 may occur in a similar fashion to the human and murine 
homologues. The first 35 amino acids, shown in bold type in figure 3.11., indicate 
those predicted to belong to the inactive precursor portion of feline E L -18. ICE may 
cleave the feline IL-18 precursor molecule C-terminal to Asp to facilitate the 
removal of the inactive pro sequence and liberate the biologically active, mature 
feline IL-18 protein, 157 amino acids in length.
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3.4.3 IN VITRO EXPRESSION OF FELINE IL-18
All three forms of feline DL-18 mRNA, expressed from the pCI-neo (pro-IL-18), pCI- 
neo (mature-IL-18) and PsecI (IL-18) constructs, were expressed in vitro in 
transfected mammalian cells, as detected by Northern blot analysis. However, 
western blot analysis, performing immunodetection with a rabbit anti-equine IL-18 
polyclonal antibody, demonstrated protein expression from only one of the 
constructs, pCI-neo (pro-IL-18). It is likely that the failure to demonstrate protein 
expression from the constructs pCI-neo (mature-IL-18) and PsecI (IL-18) was 
associated with lack of antibody specificity (using an anti-equine antibody to detect a 
feline protein), rather than a complete failure of these constructs to express mature 
IL-18 protein. Perhaps the anti-equine IL-18 antibody predominantly recognised 
epitopes present in the full length, pro-IL-18 protein, which were absent in the mature 
feline IL-18 protein. To facilitate more specific and sensitive detection of feline 
mature and pro-IL-18 proteins, future work should concentrate on the generation of 
polyclonal and monoclonal anti-feline IL-18 antibodies, to be used in feline specific 
assays.
A biological assay for human IL-18 has been developed, using the human 
myelomonocytic cell line, KG-1, which produces IFN-yin response to human IL-18 
(Konishi et al. 1997). However, attempts to utilise feline IL-18 in the human KG-1/ 
IFN-y assay have proved unsuccessful. Obviously the development of a feline- 
specific bioassay for this molecule would be extremely useful, especially when 
determining which constructs would be the most effective for in vivo usage. 
Evaluation of which constructs expressed biologically active feline IL-18 most 
potently in vitro could quickly and easily be determined. Future studies should 
attempt to create a specific bioassay for feline IL-18.
Furthermore, future studies should evaluate the in vitro expression of the feline IL-12 
expression constructs described in this chapter, using Northern and western blotting 
techniques and a suitable bioassay. A recent paper describing the cloning and
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expression of canine IL-12 cDNA described a lymphocyte proliferation assay, used 
the evaluate the biological activity of EL-12 in this species (Okano et al. 1997). The 
supernatants of COS-1 cells co-transfected with the vectors expressing each subunit 
of canine IL-12, was demonstrated to stimulate the proliferation of canine 
lymphocytes activated with PHA. Perhaps a similar lymphocyte proliferation assay 
would be suitable to evaluate the biological activity of feline IL-12.
3.4.4 CONCLUSION
The isolation of feline IL-12 and IL-18 sequences provides pivotal information which 
will enable investigation into the role of these feline Thl type cytokines in immune- 
regulation and immunotherapy. This information will also allow the expression of 
feline IL-12 and IL-18 in vitro using a number of potential techniques. Ultimately 
these cytokines may form part of a new array of therapeutic agents to treat feline 
disease. IL-12 and IL-18 DNA constructs and recombinant proteins may be utilised in 
cancer treatment, immunotherapy and as vaccine adjuvants against retroviral 
pathogens such as FeLV, as discussed in chapter four, and FIV.
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4. CHAPTER FOUR; FeLV DNA VACCINATION TRIAL
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4.1 INTRODUCTION
4.1.1 DNA VACCINATION AGAINST RETROVIRUSES
The principles of DNA vaccination are described in detail in Chapter 1. The success 
of DNA vaccination technology has led many researchers to investigate the potential 
of this approach in providing protection against retroviral pathogens, such as FIV, 
SIV and, most importantly, HIV (Hosie et al. 1998), (Cuisinier et al. 1997), (Letvin 
et al. 1997), (Boyer et al. 1997), (MacGregor et al. 1998). A recent report regarding 
the first human trial of a DNA vaccine, expressing HIV-1 env and rev genes, in the 
treatment of HIV-1 infection, demonstrated the generation of specific anti-HIV 
immune responses. Increases in anti-gpl20 antibody levels, increases in cytotoxic T 
lymphocyte activity against gp 160-bearing targets and increases in lymphocyte 
proliferative activity, were observed in some patients (MacGregor et al. 1998). 
However, no consistent changes were observed in CD4 or CD8 lymphocyte counts, 
or in plasma HIV levels. Further trials using expression plasmids encoding a wider 
range of HIV-1 antigens, and in concert with highly active antiretroviral therapy, 
HAART, are now in progress.
A number of reports have shown that DNA vaccines can generate HIV- and SIV- 
specific CTL activity, helper T cells, and antibodies in mice and non-human primates 
(Wang et al. 1993), (Ugen et al. 1997), (Boyer et al. 1997), (Fuller et al. 1997) and 
FIV specific CTL activity in cats (Hosie et al. 1998). Several studies in primates 
have also demonstrated protective immunity following HIV-1 or chimaeric HrV/SIV 
virus challenge (Boyer et al. 1997), (Letvin et al. 1997), although the viruses used 
are largely non-pathogenic, or replicate only at low levels, in the primate species 
described. It is therefore difficult to determine whether DNA vaccination will be as 
successful in inducing protection against retroviral infection in the natural host 
species. However, a recent FIV DNA vaccination trial demonstrated significant 
protection against homologous FIV challenge, in cats vaccinated with defective 
mutant provirus DNA (Hosie et al. 1998). Interestingly, a previous study
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demonstrated immunoenhancement of FIV infection, following immunisation with a 
DNA vaccine expressing a limited range of FIV gene products (Richardson et al.
1997). The former study provides the first evidence that DNA vaccination can protect 
against lentiviral infection, a subfamily of the retroviridae, in its natural host species.
4.1.2 FELINE LEUKAEMIA VIRUS DNA VACCINE CONSTRUCTION
In the light of the success of DNA vaccination to date, and its promising 
development as a prophylactic agent for use against retroviral disease, a novel DNA 
FeLV vaccine was designed and constructed. The single cycle FeLV vector vaccine 
consisted of two separate pUSEl-1 series plasmids, one expressing FeLV gag/pol 
genes, and the other expressing FeLV subgroup A env gene, both under control of the 
CMV-IE promoter. The construction of this vaccine is described in section 4.2.5.1. In 
vitro and in vivo studies have demonstrated the potency of the Thl type cytokines, 
IL-18, IFN-y, and IL-12, in enhancing cellular immunity and altering the magnitude 
and nature of the immune response elicited by DNA vaccination, (Micallef et al. 
1996), (Kohno et al. 1997), (Chow et al. 1998), (Tsuji et al. 1997). It was 
considered that these Th 1 cytokines might augment the immune response elicited by 
the FeLV DNA vaccine, and thus induce better protection against FeLV challenge. 
Therefore, the development of plasmids expressing these feline cytokine genes, to be 
used as vaccine adjuvants, was undertaken, as described in sections 3.2.8., 3.2.9. and 
4.2.6.2.
4.1.3 OBJECTIVES OF THE FELINE LEUKAEMIA VIRUS DNA VACCINE 
TRIAL
There were three main objectives of the trial. Firstly, to determine if the novel FeLV 
DNA vaccine could protect cats against FeLV challenge. Secondly, to establish if 
plasmids encoding feline Thl type cytokines could produce an adjuvant effect, when 
co-inoculated with the vaccine. Thirdly, to establish the presence or absence of DNA 
constructs in blood samples collected 48 hours after each immunisation and at
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specific timepoints after viral challenge. The last objective is considered in detail in 
Chapter 5. Figure 4.1. provides an overview of the vaccine trial schedule.
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4.2 MATERIALS AND METHODS
4.2.1 FELIN E LEUKAEM IA VIRUS DNA VACCINE TRIA L DESIGN
4.2.1.1 Immunisation Groups
Twenty nine SPF kittens, aged 10-12 weeks, were randomly arranged (using a 
random assortment programme), into four groups of six, and one of five, as detailed 
in Table 4.1. One kitten died prior to the start of the trial, explaining why group B 
consisted of only five animals. The kittens were allowed three weeks to adjust to 
their environment and social groups, before beginning the trial. Throughout the trial, 
the animals were housed in two separate rooms and each individual group of six was 
evenly split between the two . rooms. Susceptibility to FeLV persistent infection 
decreases with age (Hoover et al. 1976). Therefore, the immunisation schedule was 
designed so that viral challenge was completed before the unvaccinated control 
kittens were old enough to mount a protective immune response naturally, and thus 
be resistant to infection.
GROUPS CONSTRUCTS NUMBER O F CATS
A Ll-6 CMV-gag-pol + CMV-env A 6
B L7-12 CMV-gag-pol + CMV-env A + IFN-y 5
C L13-18 CMV-gag-pol + CMV-env A + IL-12 6
D L25-30 CMV-gag-pol + CMV-env A + IL-12 + IL-18 6
E LI 9-24 Empty pCI-neo plasmid 6
Table 4.1. Im m unisation groups
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Table 4.1. lists the DNA constructs which each group of cats received. The six cats in 
group A were immunised with the FeLV DNA vaccine, without an adjuvant. The 
construction of the FeLV vaccine antigen plasmids is described and illustrated in 
section 4.2.5.1. The cats in groups B, C and D were inoculated with the FeLV DNA 
vaccine and pCI-neo vector constructs expressing cytokine genes, to act as adjuvants. 
Interferon gamma, interleukin 12 and a combination of interleukin 12 (IL-12) and 
interleukin 18 (IL-18) DNA constructs, respectively, were administered to cats in 
these three groups. The IL-18 DNA construct consisted of the mature form of IL-18, 
fused to a 5’ synthetic signal peptide sequence, as described in section 3.2.9. 
Therefore, following expression of this construct, the biologically active form of the 
IL-18 protein should be transported out of cells. The IL-12 construct consisted of two 
separate plasmids, encoding the p35 and p40 submits. Finally, the cats in Group E, 
the positive control group, were immunised with pCI-neo plasmid only.
4.2.1.2 Immunisation Schedule
Kittens received three consecutive immunisations with high quality endotoxin-free 
DNA, two weeks apart, at the times indicated in Table 4.2. The preparation and 
analysis of this DNA is described in section 4.2.5.3. The cats were inoculated 
intramuscularly in one site, the quadriceps femoris muscle, using the left hindlimb 
for the first and third immunisations and the right hindlimb for the second 
immunisation. They received a total of lOOjug of each DNA construct, as detailed in 
Table 4.1, diluted with endotoxin-free PBS to a volume of 200jil per inoculation. The 
kittens were carefully observed by cattery staff for the twenty-four hours, following 
each treatment. Twenty-four hours after each immunisation the temperature, pulse, 
respiration rate and general demeanour of every kitten was recorded and the 
vaccination site examined. No local or systemic adverse reactions were observed 
after vaccination or viral challenge.
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Immunisation Number Week Age of cats
1 1 13-15 weeks
2 3 15-17 weeks
3 5 17-19 weeks
VIRAL CHALLENGE 8 20-22 weeks
Table 4.2. Immunisation Schedule
4.2.1.3 Viral Challenge
Viral challenge was performed by the intraperitoneal route three weeks after the last 
immunisation when the cats were between 20-22 weeks of age (Table 4.2.)- 2 x 1 0  
ffu (focus forming units), of FeLV-A/Glasgow-1 were administered to each cat, 
diluted with endotoxin-free PBS to a volume of one ml. The results of the assay of 
the virus used for challenge is described in section 4.2.6. As the different groups of 
cats were housed together after viral challenge, the persistently infected cats, 
excreting virus, became a source of infection. This effectively meant that the cats that 
were capable of mounting a protective immune response against the intraperitoneal 
viral challenge were subjected to a second, more prolonged and perhaps more 
rigorous natural viral challenge, more analogous to the situation in the field, 
beginning 3-4 weeks after intraperitoneal challenge.
4.2.1.4 Blood Sampling Schedule
Sampling procedures were constrained by the weight of the kittens. A maximum 
volume of 0.5ml per lOOg of body weight can be obtained at two to three week 
intervals, according to Home Office guidelines. The expected average weight of the 
kittens on Day 1 of the trial was lOOOg, although there was a significant difference 
between individual animals at this stage. The sampling schedule was conveniently 
divided into three parts.
203
4.2.1.4.1 Pre-Immunisation Blood Sample
One pre-immunisation blood sample was taken immediately before the first 
immunisation. This was to ascertain FeLV status of the cats pre-trial and to establish 
normal haematological parameters. The blood was screened for the presence of FeLV 
p27 antigen, infectious virus, and virus neutralising antibodies. These tests are 
described more fully in section 4.2.4. DNA extracted from plasma and PBMCs, 
collected forty-eight hours after each immunisation, was to be screened by PCR for 
the presence of DNA constructs. Therefore, to confirm the absence of the DNA 
constructs pre-trial, this pre-immunisation sample was screened by the same 
technique. Table 4.3. indicates how these samples were analysed.
Blood Sample Volume = 2.0ml Total Analysis
1.5 ml Heparin
a) plasma for VN Ab assay, p27 
ELISA, VI on QN10 cells.
b) Plasma for PCR; to confirm absence 
of DNA constructs pre-trial.
c) Buffy coat (PBMCs) from total 
sample volume for PCR; to confirm 
absence of DNA constructs pre-trial.
0.5ml EDTA Routine Haematology
Table 4.3. Pre-immunisation blood sample analysis
4.2.1.4.2 Immunisation Period blood samples
Blood samples were obtained during the immunisation period, in the seven weeks 
prior to challenge. These samples were taken every two weeks, 48 hours after each 
immunisation, then on the day of challenge (immediately before challenge). Table 
4.4. provides an overview of how sample analysis was conducted. Serum was 
analysed for the presence of FeLV specific non-neutralising antibodies, elicited by 
vaccination, by western blot analysis against complete viral lysate and an anti-gp70
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antibody ELISA. Residual serum was stored in aliquots, for future cytokine analysis. 
Heparinised blood and PBMCs were also isolated and the former was used to 
determine levels of plasma infectious virus, FeLV p27 antigen and FeLV specific 
virus neutralising antibodies. PCR was also performed on DNA extracted from 
plasma and PBMCs in an attempt to detect the presence of DNA constructs, in either 
of these compartments. Lastly EDTA blood was taken on the day of viral challenge 
only, for haematological analysis. The timing of blood sample collection is outlined 
in Table 4.5.
Blood Sample Volume = 2.0ml Analysis
1.5ml Heparin
a) Plasma for VN Ab assay, VI on QNlOs and 
p27 ELISA
b) Plasma for PCR; to isolate DNA constructs.
c) PBMCs from total sample volume; PCR to 
isolate DNA constructs.
0.5ml Plain
a)Serum for detection of non-neutralising 
antibody; gp70 ELISA, western blot analysis of 
viral lysates
b) Remaining serum stored for future cytokine 
analysis.
Table 4.4.. Immunisation Period Blood Sample Analysis
N.B. An extra 0.5ml EDTA sample was taken on day of challenge, for 
haematological analysis; therefore total sample volume = 2.5ml.
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TIMING WEEK
48hrs post first immunisation Week 1
48hrs post second immunisation Week 3
48hrs post third immunisation Week 5
day of challenge Week 8
Table 4.5. Timing of Immunisation Period Blood Samples
4.2.1.4.3 Post-Challenge Period Blood Samples
Sampling began three weeks after viral challenge, and was repeated on three 
occasions, approximately three weeks apart, until week 21 ( weeks 11, 14, 17 and 
21). Virus isolation (VI) on QN10 cells, to determine levels of plasma infectious 
virus, FeLV p27 antigen ELISA and FeLV specific virus neutralising antibody assays 
were performed on plasma from heparinised blood samples. Haematological analysis 
of blood was conducted to establish if the development of FeLV infection produced 
any changes in normal haematological parameters. Lastly, DNA extracted from 
PBMCs and plasma was again screened by the PCR technique, to see if the DNA 
vaccine constructs had persisted in either of these compartments. Table 4.6. 
highlights how sample analysis was conducted and the timing of blood sample 
collection is outlined in Table 4.7.
Blood Sample Volume = 3.0ml Analysis
2.0ml Heparin VN Ab assay, p27 ELISA, VI on QNlOs. 
Store remaining plasma for future 
analysis.
0.5ml EDTA Haematology
0.5ml Plain Store serum for future analysis
Table 4.6. Post challenge Period Blood Sample Analysis
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TIMING WEEK
first post challenge blood sample Week 11
second post challenge blood sample Week 14
third post challenge blood sample Week 17
fourth post challenge blood sample Week 21
Table 4.7. Timing of Post challenge Period Blood Samples
4.2.1.5 Post-trial tissue analysis
All cats, with the exception of L21, L23, L24 and L28, were euthanased at the 
termination of the experiment, at weeks 23 and 24, (between two and three weeks 
after the last post-challenge blood sample, at week 21). Blood samples were collected 
and screened by the virus isolation technique, to determine FeLV status of the cats 
immediately prior to euthanasia. Bone marrow biopsies were obtained from all non- 
viraemic cats and from several viraemic cats, to act as positive controls. These 
biopsies were cultured and then screened for the presence of FeLV, by virus isolation 
and p27 ELISA, to determine if ostensibly immune, non-viraemic cats, harboured 
latent FeLV infection in bone marrow. These collection and culturing techniques are 
described in sections 4.2.2.2. and 4.2.3. Tissues and blood from each cat were also 
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Figure 4.1. Overview of FeLV Vaccine Trial Schedule
The timing of immunisations and challenge are represented by small and large 
arrows, respectively. Haematological analysis, VI, p27 ELISA and PCR to detect 
DNA constructs, and VN antibodies assays were performed at the times indicated by 
the diamond, star and circle symbols, respectively. Gp70 ELISA and western blot 
analysis were performed on day of challenge, as indicated by the large cross symbol. 




Twenty-nine specific pathogen free (SPF) cats were obtained from a commercial 
breeding cattery and housed at Glasgow University. The kittens were between seven 
and nine weeks of age, on arrival, and were fed a commercial diet. After a initial 
settling in period of three weeks, the kittens were randomly arranged into four groups 
of six and one group of five and received their first immunisation at between 13 and 
15 weeks old. All procedures were carried out in accordance with Home Office 
regulations. All cats, with the exception of L21, L23, L24 and L28, were euthanased 
at the termination of the procedure, between weeks 23 and 24, using intracardiac 
injections of pentobarbitone (Euthatal) when anaesthetised.
4.2.3 COLLECTION AND ANALYSIS OF SAMPLES
4.2.3.1 Blood collected for analysis
Animals were restrained manually and blood was collected from either the cephalic 
or the jugular veins. Pre-euthanasia samples (week 23-24) were collected by 
intracardiac puncture, while the animals were under general anaesthesia. A 
combination of ketamine (Ketaset - Willows Francis Veterinary, Crawely, UK) and 
xylazine (Rompun - Bayer pic, Bury St Edmunds, UK), administered by 
intramuscular injection, was used to anaesthetise the cats. Blood for haematology 
was collected into 1.3ml tubes, containing potassium-EDTA (Bibby Sterlin Ltd., 
Stone, UK). Cell counts were obtained using an automated cell counter (ABX Minos 
Vet - Roche Products Limited) and differential counts were performed manually 
using May-Grunwald-Giemsa stained smears.
Blood for detection of plasma infectious virus, p27 viral antigen, virus neutralising 
antibody and DNA constructs, was collected in 2ml heparin coated tubes. Blood for 
serological tests, the detection of non-neutralising antibody, by means of anti-gp70
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ELISA and western blot analysis of viral lysates, was collected into plain two 
millilitre tubes. Plasma and PBMCs obtained from these samples were also screened 
by PCR, to identify DNA vaccine constructs. Plasma, serum and PBMCs were 
separated by centrifugation of heparin and plain blood samples at 2000rpm, for ten 
minutes. Residual plasma and serum were aliquoted and stored at -70°C, for future 
analysis.
4.2.3.2 Bone Marrow collected for culture and viral isolation
Bone marrow biopsies were obtained from all non-viraemic cats and from several 
viraemic cats to act as positive controls. Cats were anaesthetised using 
alphaxelone/alphadolone acetate (Saffan, Pitman-Moore Ltd., Crewe, UK), given by 
intravenous injection. The left gluteal region was clipped and prepared aseptically, 
and aspirates of marrow were then collected from the femur via the inter-trochanteric 
fossa, using sterile disposable 18G Illinois Stemal/Hiac bone marrow aspiration 
needles (Pharmaseal, Allegiance healthcare Corporation, USA.) and 10ml sterile 
disposable syringes. Aspirates were transferred into small sterile universal containers 
containing 3ml of bone marrow collection medium, comprising Alpha Minimal 
Essential Medium (Gibco), supplemented with 10%FCS, 2mM L-glutamine, 400 
units/ml penicillin/streptomycin, 10'6M hydrocortisone succinate (AFC 10) and 
50iu/ml preservative-free heparin (Pularin). Bone marrow aspirates were also 
collected from cats immediately after euthanasia, with the femur being removed and 
opened with bone cutting forceps.
4.2.3.3 Tissues collected for analysis
Samples of liver, lungs, spleen, lymph nodes, (mesenteric, popliteal, prescapular and 
iliac), brain, thymus, kidney, heart, muscle (two samples; one sample from the left 
quadriceps injection site and one control sample from the triceps), ovaries, serum, 
plasma, PBMCs and skin were collected at post-mortem, from each of the euthanased 
cats. Testicles were removed when the male cats were castrated, at five to six months 
old. All tissue samples were snap frozen and stored in liquid nitrogen, for future 
analysis. This will include isolation of DNA and RNA from every tissue sample.
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PCR and RT-PCR techniques will be used to identify the presence of DNA 
constructs and mRNA expression, respectively, in all samples. Plasma and PBMCs 
were collected in an equal volume of Alsever’s solution (20ml of blood), while 
EDTA and heparin samples (2ml of blood) were also obtained for plasma harvest. 
Serum was collected in plain universal containers (50ml of blood) and all of the 
above blood fractions were stored in aliquots at -70°C.
4.2.4 BONE MARROW CULTURE TECHNIQUE AND SCREENING FOR 
FeLV
Single cell suspensions of bone marrow cells were prepared in 10ml of bone marrow 
collection medium (section 4.2.3.2.), by passing the cells through a 21 gauge needle 
and then through a 23 gauge needle. The resulting suspensions were centrifuged at 
2000rpm for ten minutes. The bone marrow supernatants (BMSN) were decanted and 
stored at -70 °C, for future virus isolation on QN10 cells. The cell pellets were 
resuspended in 10ml of 0.83% ammonium chloride and incubated on ice for five 
minutes in order to lyse the red blood cells. Following a second centrifugation at 
2000rpm for ten minutes, the supernatants were discarded and the cell pellets were 
resuspended in 10ml Alpha Minimal Essential Medium supplemented with 20%FCS, 
2mM L-glutamine, 400 units/ml penicillin/streptomycin and 106 M hydrocortisone 
succinate (AFC20). The cells were then counted and were cultured in 10ml AFC20 at 
a concentration of 2 x 106/ml in 25cm2 plastic flasks. Duplicate cultures were 
prepared for each biopsy and were incubated at 37°C in 5 per cent carbon dioxide in 
air.
The bone marrow cells grew as an adherent cell monolayer. After one week in culture 
small colonies of fibroblasts developed, which gradually coalesced, so that by two 
weeks in culture the fibroblasts were confluent. Also, by this time, large granulated 
cells were present and areas of more mature myeloid cells could be identified. After 
two weeks of growth, the bone marrow cells were split 1 to 2, using AFC20 medium, 
and grown for three more days. Cell suspensions were then spun at 2000rpm for ten 
minutes. The bone marrow culture supernatants were decanted and virus isolation,
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using the method described in section 4.2.4., was performed on the culture 
supernatants. After the centrifugation, cell pellets were also obtained. Half of these 
pellets were stored at -70 °C, for future analysis, while the other half of these pellets 
were analysed for the presence of FeLV p27 antigen, using the p27 ELISA assay, 
described in section 4.2.4. At this point, the bone marrow supernatants (BMSN) 
stored at -70 °C, described above, were thawed for virus isolation. Figure 4.2. 
provides an overview of the whole process. These virus isolation and p27 ELISA 
techniques were employed to determine if ostensibly immune, non-viraemic cats, 
harboured latent FeLV infection in bone marrow.
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Figure 4.2. Overview of bone m arrow  culture and FeLV diagnostic tests
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4.2.5 FELINE LEUKAEMIA VIRUS DIAGNOSTIC TESTS
4.2.5.1 Virus isolation protocol
Infectious FeLV in the plasma and bone marrow cultures of cats was detected by the 
virus isolation technique described by Jarrett (Jarrett and Ganiere, 1996). Twelve- 
well cluster plates were used in this technique; each well was 22mm in diameter. On 
day one 5 x 104QN10 cells in 1 ml of growth medium (2.2.1.3.), supplemented with 
4|ig/ml polybrene, were added to each well. The plates were incubated overnight at 
37°C in a humid incubator, with 5% CO2 . On day two, 0.2ml of each sample to be 
screened was added to the individual wells and allowed to absorb for two hours at 
37°C. This was then removed and replaced with 1.5ml fresh growth medium. The 
plates were then incubated as before. Separate pipettes were used for each individual 
sample, to avoid cross-contamination. As a positive virus control a ten-fold dilution 
series of FeLV-A was included in the plates and also a negative control, such as a 
serum sample from a FeLV-free SPF cat. The plates were incubated until between 
day five and day seven, when they were examined for evidence of morphological 
transformation.
Samples were scored positive or negative at this stage. All positive samples were 
defined as definitely positive, while all negative samples were subcultured by 
removing the medium from each well and adding 250|il of trypsin/versene mixture to 
the cells. This was left in place until the cells detached. Cells were then resuspended 
with 1 ml of growth medium and transferred to a 5 cm plate with 4 ml of growth 
medium. The positive and negative controls were also subcultured. These plates were 
then incubated for a further three to four days before they were finally scored positive 
or negative, depending on the presence or absence of transformation. The 
subculturing technique is performed because if a very low titre of FeLV is present in 
the test sample, the week-long initial incubation period may not be long enough to 
allow the virus to reach sufficient levels to cause visible cellular transformation. 
FeLV replicates only in actively dividing cells, so subculturing to five centimetre 
plates allows the QN10 cells to grow and divide at a faster rate, thus speeding up 
viral replication and the appearance of transformation.
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4.2.S.2 Feline leukaemia virus p27 ELISA
FeLV p27 antigen was detected in the plasma of cats using a commercial enzyme- 
linked immunosorbant assay (ELISA) kit (Innochem C. Lutz, Switzerland). All p27 
ELIS As performed were based on the method described by Lutz (Lutz et al. 1983). 
Briefly, the technique employed was a double antibody sandwich ELISA. Test wells 
were pre-coated with a monoclonal antibody, directed against an epitope on the 
species-specific portion of the FeLV p27 molecule. Fifteen microlitres of plasma to 
be screened, 80pl conjugate, and 1 pi of normal mouse serum, to block any anti­
mouse antibody in the sample, were added to each well. Positive and negative 
controls were included and the plates were incubated at room temperature for one 
hour, with shaking.
The conjugate was a second antibody raised to a different epitope on the species- 
specific portion of the FeLV p27 molecule, conjugated to horseradish peroxidase, 
HRP. This labelled antibody should bind to any p27 antigen present in the samples, 
captured by the first antibody. The plates were then removed and washed vigorously 
with PBS/0.05% Tween 20. KPL’s tetramethylbenzidine hydrochloride peroxidase 
substrate was then added to each well, and left for between five and ten minutes at 
room temperature, on a plate shaker, to allow colour development. The enzymatic 
action of HRP on TMP caused a visible blue colour change and the optical density, 
O.D., of each sample was measured on the ELISA reader, at a wavelength of 650nm, 
after stopping the reaction using 0.12% hydrofluoric acid. The O.D. values were 
noted and the ELISA S/P, the sample to positive (S/P) ratio, was calculated for all 
samples, using the formula below:
S/P Ratio =  Sample OD - Negative Control OD
Positive Control OD - Negative Control OD
The positive and negative control OD values were obtained from standard positive
and negative serum samples. These internal controls were tested alongside the
experimental samples and were included in each ELISA. The S/P ratio is a value
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which takes into account both positive and negative control readings, and therefore 
corrects for variations between individual ELISA batches. It is generally accepted 
that a S/P ratio of greater than 0.1 represents a positive ELISA result; i.e., the sample 
contains p27 antigen. However, a sample which possesses an ELISA OD reading 
greater than twice the value of the negative control ELISA OD, may also be defined 
as positive. The latter method of defining a positive is considered more sensitive and 
has been employed when analysing the data obtained during the course of this trial.
4.2.5.3 Feline leukaemia virus neutralising antibodies assay
Virus neutralising antibodies (VNAs) to FeLV-A in the plasma of cats were 
measured in a focus reduction assay, using the basic method described by Jarrett 
(Jarrett and Ganiere, 1996). Briefly, QN10 cells were plated at 4 x 104/well, in 12- 
well plates, in 1 ml of Dulbecco’s MEM, containing HEPES buffer, 10% FCS and 
four microlitres/ml of polybrene. The plates were incubated at 37°C overnight. Four 
wells of cells were used for each plasma sample to be tested. The next day, plasma 
samples were heat inactivated at 56 °C for thirty minutes and were then diluted in 96- 
well plates from 1:4, to 1:256, using 50|il volumes of plasma and Leibovitz medium. 
An equal volume (50|l l 1) of FeLV-A at 4 x 102 FFU/ml was added to each plasma 
sample, and incubated at 37°C for six hours. Twenty-five microlitres of 1:4, 1:8, 1:16 
and 1:32 dilutions were then plated onto the QN10 cells and incubated at 37°C for 
three to four days. The remainder of the dilutions were stored at -70 °C. Positive and 
negative controls were included with each test. On day five, the QN10 cells were 
examined for the presence of foci of transformation, and in this way levels of 
infectious virus were quantified. The titre of antibody present in each plasma sample 
was taken as the reciprocal of the plasma dilution that reduced the focus count of 
FeLV by 75%, compared with a virus control incubated without plasma.
4.2.5.4 Detection of feline leukaemia virus non-neutralising antibodies.
Day of challenge samples of sera were isolated and analysed for the presence of 
FeLV specific non-neutralising antibodies, elicited by vaccination. This was
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performed by western blot analysis against complete viral lysate, and an anti-gp70 
ELISA assay, to detect antibodies raised to this FeLV antigen.
4.2.5.4.1 ELISA fo r  feline antibodies to FeLV gp70
FeLV surface glycoprotein gp70 was captured by an immobilised monoclonal 
antibody coated onto a 96-well plate. Cat serum or plasma were then applied to the 
plate and any anti-gp70 antibody present in the serum or plasma was subsequently 
bound. Capture of the cat antibody was detected by the subsequent binding of goat 
anti-cat IgG conjugated with alkaline phosphatase enzyme, and addition of substrate 
(phosphate substrate). Dilutions of sera were assayed and the titre of antibody was 
calculated as the reciprocal of the highest dilution which gave a pre-determined 
absorbance; an ELISA S/P ratio of greater than 0.1 (as explained in section 4.2.5.2.), 
represented a positive ELISA result. The materials used in this protocol are described 
in section 2.1.11.3.
Purified FeLV was disrupted, before use, in the following manner. The virus was 
thawed rapidly, with gentle shaking, in a 37 °C water bath. Virus was then diluted in 
virus disruption buffer (2.1.11.3.), in an Eppendorf tube, and incubated in a 37°C 
water bath, for 30 minutes. Centrifugation at 6000rpm for five minutes followed this 
incubation, and the supernatant was removed for use. Monoclonal antibody 3-17 was 
diluted 1:1000 in coating buffer and 100pl of this dilution was pipetted into each well 
of a 96 well plate. Working concentrations of virus and antibody were determined 
previously by cross-titrating FeLV and 3-17 antibody in the ELISA, using positive 
cat anti-FeLV control serum, P - l l ,  diluted 1:100. In the ELISA described above, this 
antibody had a titre of 10000. A second positive control serum sample, P-4, of low 
titre (500), and negative control serum from SPF cats were also included in the 
ELISA. The plate was then incubated overnight at 4 °C. Next morning, the plate was 
washed four times with TBT wash buffer. The TBT was then removed, and 200pl of 
blocking buffer was pipetted into each well. The plate was incubated at room 
temperature, 25 °C, for 60 minutes, and after this, washed three times with TBT wash 
buffer. The virus supernatant, as prepared above, was then diluted 1:200 in TBT 
wash buffer, with 20% w/v goat serum. IOOjllI of this mixture was then pipetted into
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each well of the plate and incubated for 60 minutes at room temperature, 25 °C. The 
plate was again washed three times with TBT.
Cat serum to be tested was then diluted in TBT wash buffer, with 20% w/v goat 
serum. A volume of lOOpl of these dilutions were pipetted into the wells and, again, 
the plate was incubated for 60 minutes at room temperature, 25 °C. After four washes 
with TBT wash buffer, lOOpl of diluted conjugate was pipetted into each well of the 
plate and a 60 minute incubation at room temperature followed. The plate was then 
washed six times with TBT wash buffer and 50|il substrate was pipetted into each 
well. The plate was incubated for 20 minutes at room temperature, and the reaction 
was stopped by pipetting 50|il of the stop solution, 0.4M NaOH, into each well. The 
optical density of the solutions in the wells was then read immediately, in a Titertek 
plate reader, at a wavelength of 405nm.
4.2.5.4.2 Western blot analysis o f serum against complete viral lysate
The techniques of SDS - polyacrylamide gel electrophoresis of proteins and detection 
of proteins by immunoblotting, are described in sections 2.2.6.1. and 2.2.6.2., 
respectively. Briefly, complete FeLV lysate, and protein molecular weight standards, 
were run on an SDS-polyacrylamide gel, to separate the viral proteins on the basis of 
molecular size. Fifty microlitres of purified FeLV of a known protein concentration, 
was added to 25|il of 3 x protein sample loading buffer. The p27 concentration of this 
viral lysate had been estimated previously, by comparing the intensity of the 
Coomassie blue stained p27 protein, with the intensity of a Coomassie blue stained 
ovalbumin control, of a known concentration. The p27 concentration of this 
preparation of virus, was estimated to be 1 mg/ml. As p27 protein accounts for 
approximately 30% of the total viral protein, approximately 170|ig of viral protein 
was loaded onto the gel. These proteins were then transferred to a nitrocellulose 
membrane, using electroblotting apparatus. Vertical strips were cut from the blot, 
approximately 1mm thick. In this case, strips were cut for the twenty-nine cats 
involved in the trial and for positive and negative control serum samples. Serum 
samples from individual cats were incubated with the nitrocellulose membrane strips, 
in an attempt to determine if sera contained FeLV-specific antibodies. The detection
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of proteins by immunoblotting exploits the inherent specificity of antigen recognition 
by antibodies (Towbin et al. 1979). The method of detection used to visualise this 
specific interaction of antibody and antigen was the streptavidin peroxidase method, 
which is described below.
Proteins were transferred to the membrane using the electroblotting system, run at 
100V, for one hour, after which time the nitrocellulose membrane was removed and 
rinsed in TBS. Non-specific binding sites were blocked by immersing the membrane 
in a TBS + 2% Marvel solution and placing on the orbital shaker, for 3-4 hours. The 
membrane was then washed with PBS + 0.05% Tween 20, (500ml PBS + 0.25ml 
Tween 20), for two hours. Lastly, the membrane was air dried at room temperature, 
on 3MM paper, inserted into folded parafilm, and stored at -20°C in a sealed freezer 
bag, until required.
Solution A was made by adding 0.8g of Marvel to 20ml TBS and lOOpl Tween 20. 
Nitrocellulose strips were incubated in small individual compartments of large multi- 
compartmented dishes, so that each individual strip was separate from all the others. 
Serum from each of the twenty-nine cats, and positive and negative serum controls, 
was added to each individual nitrocellulose strip, (20jll1 serum per 200jll1 solution A, 
as above, with EDTA; 2jil of 500mM EDTA was added per ml of solution A), and 
incubated for two hours at room temperature, or at 4 °C overnight. Three washes with 
PBS/Tween (0.05% Tween in PBS), were then performed and 200jil of biotinylated 
protein A (Amersham), in solution A (10pl of biotinylated protein A per 2.5ml of 
solution A), was added. The strips were then incubated for one hour at room 
temperature, with gentle rocking. The strips were washed three times as before, with 
PBS/Tween, and 200|ll1 streptavidin peroxidase (Sapu), diluted 1:500 in solution A, 
was added. The strips were again incubated for one hour at room temperature, with 
gentle rocking. After this incubation step, three washes with PBS/Tween were 
performed and 200jil substrate, prepared immediately before use, was added. The 
substrate was prepared as detailed below.
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Ten millilitres of methanol was decanted into a universal container, which was 
capped tightly and submerged into an ice box. An aliquot of H 2 O2 was also 
submerged in ice. 25ml of NT buffer was then measured into a 50ml centrifuge tube, 
and kept on the bench until required. Thirty milligrams of 4-chloro-l-napthol was 
weighed out into an universal container and also kept on ice. After the final 
PBS/Tween wash, the methanol was tipped into the 4-chloro-l-napthol, to give 
reagent A, and 15pl H 2 O2  was added to the NT buffer, to give reagent B. Finally, 5ml 
of reagent A was added to reagent B to give the active developer. As detailed above, 
200|ll1 of this substrate was added to all the strips after the final wash. The reaction 
was then stopped by pouring off the substrate and washing with water. If specific 
binding of FeLV specific antibodies to FeLV antigens has occurred the active 
developer will initiate a colour change on the nitrocellulose strips, which will be 
clearly visible. Thus, this method of detecting proteins by immunoblotting, the 
streptavidin peroxidase method, allows the visualisation of specific antibody and 
antigen interactions.
4.2.6 CONSTRUCTION OF FeLV VACCINE ANTIGEN AND ADJUVANT 
CONSTRUCTS
4.2.6.1 Construction of FeLV antigen DNA constructs
A mammalian expression vector series, comprising pUSE, pUSEl" and pUSE2", 
was constructed by Dr Derek Bain from a commercial plasmid available from 
Promega; pCI-neo. PCR and standard recombinant DNA technology was used to 
construct these bicistronic vectors, incorporating unique restriction sites for the rare 
cutting enzymes, Asc I, Pac I, Pme I and Not I. The use of rare cutting restriction 
enzymes allowed the rapid cloning of promoters, reporter genes, or gag/pol and env, 
without the need to return to an empty plasmid backbone.
The antigen-encoding component of the FeLV DNA vaccine consisted of two 
separate pUSEl" series constructs, one expressing FeLV gag/pol genes, and the 
other expressing FeLV subgroup A env gene, both under control of the CMV-IE
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promoter. The construction of these FeLV antigen DNA constructs is described 
below and illustrated in figure 4.3 and 4.4.
4.2.6.1.1 Construction o f pUSEl~CMVT(gagpol)
The CMV promoter was cloned into the Asc I site in pUSEl" to create 
pUSETCM VT. Gag/pol from the FeLV A/Glasgow-1 molecular clone was then 
subcloned from the vector pCDNA3 into pU SEl“ CMVT. A Not I restriction digest 
and ligation were performed to create pUSEl"CMVT(gag/?c>/).
gag/polhCMVIE AMP'
S p a c e r  Synthetic Poly A
Chimeric intron*
*= 5'- donor site from the first intron o f the human beta-globin gene and the 
branch and 3 '-acceptor o f an immunoglobulin gene heavy chain variable region.
Figure 4.3. pUSEl CMVT(gagpol)
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4.2.6.1.2 Construction of pUSEl CMVT(envA)
Env A from the FeLV A/Glasgow-1 molecular clone was subcloned from pCDNA3 
into pUSEl" CMVT. Env A was first excised from pCDNA3 by Pst VBam HI 
digestion, and then blunt ended. pU SEl- CMVT(g<2 g/?<?/) was then Not I digested, gel 
purified and blunt ended to create pUSEECM VT. Finally, envA was blunt end 
ligated into pUSEECM VT to create pUSEECMVT(ewvA).
*= 5'- donor site from the first intron of the human beta-globin gene and the 
branch and 3 "-acceptor of an immunoglobulin gene heavy chain variable region.
Figure 4.4. pUSEl“CMVT(FwvA)
4.2.6.1.3 Transient co-transfection o f 293 cells to establish that FeLV antigen 
constructs are able to produce virions in vitro
To ascertain that the FeLV constructs described above were capable of producing 
virions, a transient production of recombinant retrovirus containing the reporter gene 
LacZ was performed. Three plasmids were used for this purpose: 
pUSEl" CNFVT(gagpol) and pUSEECM VT(£mA), as described above, and 
p H IT lll. PHIT111 was kindly donated by Dr Alan Kingsman and comprised the 
recombinant MoMLV vector genome, containing the LacZ gene driven by the CMV 
promoter. The Lac Z gene encodes the enzyme p-galactosidase, the enzymatic action 
of which initiates a blue colour change when p-galactosidase assay solution is added 
to cells.
293 cells were split the day before the transfection experiment and transferred to a 
25cm2 flask, so that they would be approximately 30% confluent for the transfection. 




Spacer Synthetic Poly A
Chimeric intron*
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using the calcium phosphate precipitation transfection method. Sixteen hours later 
the media was changed and 5ml of fresh media was added to the cells. Two days 
post-transfection the supernatant was harvested from the cells and filtered through a 
0.45|im syringe filter. Polybrene to a final concentration of 8jig/ml was added to. lml 
of this supernatant which was then added to a flask of FEA cells, a fibroblast cell line 
derived from whole feline embryos, susceptible to infection with FeLV. The 
supernatant was placed on the FEA cells at 37°C for two hours, then fresh medium 
was added to a volume of 5ml. Three days post-infection the cells were labelled for 
LacZ expression, using the p-galactosidase assay method, detailed in section 2.2.2.2. 
Finally, the total number of blue cells in the flask was counted. Approximately 1150 
cells were stained blue indicating that recombinant retrovirus containing the reporter 
gene LacZ (expressing the enzyme P-galactosidase) had been produced. Therefore, it 
was established that the FeLV constructs were able to produce virions in vitro.
4.2.6.2 Construction of feline cytokine DNA constructs
The construction of the plasmids encoding p35 IL-12, p40 IL-12 and IL-18 cDNA is 
described in sections 3.2.8. and 3.2.9 and the expression in vitro of the IL-18 
constructs is described in section 3.2.10. The cloning, characterisation and expression 
of feline interferon gamma, IFN-y, have been described previously (Argyle et al. 
1995), (Argyle et al. 1998). For use as an adjuvant gene in the FeLV DNA vaccine 
trial, the IFN-y cDNA was cut out of the pRC-RSV vector using EcoR I and Not I 
restriction enzymes and subcloned into the pCI-neo vector as a EcoR I-Not I 
fragment.
4.2.6.3 Preparation, quantification, sequencing and endotoxin testing of 
DNA for vaccine trial
4.2.6.3.1 Preparation o f DNA fo r  vaccine trial
The ultrapure, endotoxin-free DNA required for the trial was prepared using 
Qiagen’s Endofree Plasmid Giga kits (Qiagen, UK), following the manufacturer’s
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protocol. All seven DNA constructs, pUSEl CMVT(EnvA), 
pUSEl" CMVT(gagpol), pCI-neo + IFN-y, pCI-neo + IL-12 p35, pCI-neo + IL-12 
p40, pCI-neo + IL-18, (mature form bolted to a 5’ synthetic signal peptide 
sequence), and empty pCI-neo plasmid alone, were prepared using this method. The 
manufacturers claim that yields of up to lOmg of high-copy plasmid DNA, with 
endotoxin levels of less than 0.1EU/pg of DNA may be obtained from a 2.5 litre 
culture volume and that the DNA produced is suitable for gene therapy research and 
genetic vaccination (Qiagen, 1998).
Endotoxin-free plastic pipette tips and tubes were used for elution and all subsequent 
steps. A single bacterial colony, from an ampicillin selective plate was picked and 
inoculated into a starter culture of 5 ml LB medium, supplemented with 50 - 100 
pg/ml ampicillin, in a sterile universal container. The culture was incubated for 8 
hours at 37°C in an orbital incubator with vigorous shaking (250rpm). The starter 
culture was then diluted 1/500 into 2.5 litres of LB medium supplemented with 50 - 
100 pg/ml ampicillin and incubated for 12 - 16 hours at 37°C in an orbital incubator 
with vigorous shaking (250rpm). A 10 litre baffle-bottomed flask was used for this 
purpose. The culture reached a cell density of 1 x 109 cells per ml and the bacterial 
cells were harvested by centrifugation at 4000rpm for 15 minutes at 4°C using a 
Omnigene 2.0RS centrifuge (Heraeus Sepatech, Germany). After centrifugation, the 
supernatant was carefully poured out of the centrifuge bottle without disturbing the 
cell pellet. All traces of supernatant were removed by inverting the open centrifuge 
bottle until all residual medium had been drained.
A QIAfilter Giga cartridge was screwed onto a 45 mm neck glass bottle and 
connected to a vacuum source. The bacterial pellet was completely resuspended, 
leaving no cell clumps, in 125 ml of Buffer PI (resuspension buffer). Rnase A had 
been added to the bottle of Buffer PI previously, to give a final concentration of 
100pg/ml. A volume of 125 ml of Buffer P2 (lysis buffer) was then added and mixed 
gently but thoroughly, to avoid the shearing of genomic DNA, by inverting the bottle 
four - six times. The lysate was then incubated for exactly five minutes, after which 
time it appeared viscous. The next step was the addition of 125 ml of chilled Buffer 
P3 (neutralisation buffer) followed immediately by thorough mixing until a fluffy
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white material had formed and the lysate was no longer viscous. Precipitation was 
enhanced by the use of chilled Buffer P3. The cloudy precipitate contained genomic 
DNA, cell debris, proteins and SDS. Thorough mixing ensured that the QIAfilter 
Giga cartridge would not become clogged. The lysate was then poured into the 
QIAfilter Giga cartridge and incubated at room temperature for 10 minutes. A 
precipitate containing proteins, genomic DNA and detergent floated and formed a 
layer on top of the solution.
By applying a vacuum all of the liquid was pulled through the QIAfilter Giga 
cartridge. The vacuum source was then switched off and 50 ml of Buffer FWB 
(QIAfilter wash buffer), was added to the cartridge and stirred gently with a sterile 
spatula, to enhance the flow of liquid through the filter unit. The vacuum source was 
again switched on until all the liquid had been completely pulled through the unit. 
The glass bottle then contained the filtered lysate containing the plasmid DNA. A 
volume of 30 ml of Buffer ER (endotoxin removal buffer) was then added to the 
filtered lysate, mixed by inverting the bottle approximately 10 times, and incubated 
on ice for 30 minutes. The endotoxin removal buffer, consisting of sodium chloride, 
isopropanol and endotoxin removal agent, bound the endotoxins, cell membrane 
components of Gram-negative bacteria, and formed a fine precipitate which was 
subsequently captured by the QIAGEN-tip 10000. A QLAGEN-tip 10000 was 
equilibrated by applying 75 ml of Buffer QBT (equilibration buffer), and allowing 
the column to empty by gravity flow. The lysate was then applied to the QIAGEN-tip 
and allowed to enter the resin in the tip by gravity flow. The QIAGEN-tip was then 
washed twice with 300 ml of Buffer QC (wash buffer), to remove all contaminants. 
Finally, the DNA was eluted from the QIAGEN-tip using 75 ml of Buffer QN 
(elution buffer).
The eluted DNA was then precipitated by adding 52.5 ml isopropanol (0.7 volumes) 
at room temperature. The solution was mixed and centrifuged immediately at 
4000rpm for 30 minutes at 4°C, using a Omnigene 2.0RS centrifuge. The supernatant 
was carefully decanted and the DNA pellet washed with 10 ml of endotoxin-free 
70% ethanol at room temperature and then centrifuged as before for 10 minutes. The 
supernatant was again carefully decanted without disturbing the DNA pellet. The
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pellet was air dried for approximately 30 minutes to evaporate residual traces of 
ethanol and was then resuspended in 2 ml of endotoxin-free Buffer TE. The DNA 
was incubated overnight in a 37°C water bath to aid resuspension and was mixed on a 
rolling device for two hours to ensure complete dissolution of the DNA pellet. The 
DNA solution was then quantified, sequenced and tested for endotoxin, as described 
below, before inoculation into cats.
4.2.6.3.2 Quantification and sequencing o f DNA fo r  vaccine trial
The concentration and purity of the DNA prepared by the above method was 
determined by spectrophotometry and by estimation of double stranded DNA 
concentration via agarose gel electrophoresis, as described in chapter two, section 
2.2.23. Uncut and restriction enzyme digested DNA samples were run out on 
agarose gels and the DNA concentration was determined. Test digests were 
performed on every DNA sample, to ensure that the correct restriction enzyme sites 
were present and that the original DNA sequence was intact. Finally, the four 
cytokine DNA constructs and the empty pCI-neo DNA prepared by the above method 
were sequenced by the Licor automated sequencing method described in section 
2.2.5.2. Small scale preparations of pUSEl~CMVT(EnvA) and
pU SEl“CMVT(gagpol) DNA had been sequenced by Dr Derek Bain previously.
4.2.6.3.3 Endotoxin testing o f DNA fo r  vaccine trial
Samples of all seven DNA constructs required for the trial were submitted to Q1 
Biotech Ltd. (Glasgow, U.K.) for assessment of the level of endotoxin 
contamination. A sample of 10|ig of DNA in 10|il endotoxin free water was 
submitted for each construct. Endotoxin levels were measured using a chromogenic 
Limulus amoebocyte lysate (LAL) assay. The LAL assay quantifies endotoxin 
through its capacity to initiate clotting of Limulus polyphemus haemolymph.
The simplest LAL endotoxin assay is the gel-clot test which semi-quantitatively 
measures the endotoxin level in a test sample by comparison of the ability of the 
sample to form a solid clot, when mixed with the LAL enzyme and substrate,
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compared to known standards. The chromogenic method replaces the clotting protein 
with a synthetic peptide that forms a substrate for the enzyme. The synthetic peptide 
is covalently attached to a chromophore, para-nitroanilide (p-NA); following pre­
incubation with endotoxin, the activated enzyme cleaves p-NA to form a coloured 
product which can be quantified by spectrophotometry, at 405nm. The colour change 
is proportional to the amount of active enzyme and hence the endotoxin level of the 
test substance (Novitsky, 1983).
4.2.7 VIRUS USED FOR CHALLENGE
The virus used for challenge was derived from a molecular clone of FeLV- 
A/Glasgow-1 (Stewart et al. 1986) and was grown in feline embryo fibroblasts of the 
FEA cell line (Jarrett et al. 1973). The batch used, batch 53, was assayed on QN10 
cells before and after inoculation of cats, as detailed in section 4.2.4.1. The virus was 
kept at -80 °C and thawed immediately before use. Ten-fold dilutions of frozen and 
thawed virus were tested in duplicate, from 10'4 to 10’6 and the number of foci was 
counted for each dilution. The titre of the virus before and after use was calculated to 
be 2.2 x 106 focus forming units (ffu)/ml.
4.2.8 STATISTICAL ANALYSIS
4.2.8.1 Dataset analysed
The data consisted of five treatment groups (A to E) and 29 cats (groups A, C-E: 
n=6, group B: n=5). Measurements were taken at four timepoints after viral 
challenge. Statistical analysis was performed on three separate variables: the ELISA 
S/P ratio, the ELISA result (positive if ELISA optical density exceeds twice that of 
negative control) and the virus isolation result (positive or negative). The small 
number of cats in each treatment group limited the analyses, particularly for the 
binary variables where the tests performed had low power to detect differences
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between treatment groups. Therefore, where no significant results were detected at 
the 5% level of significance, the 10% level of significance was also investigated.
4.2.8.2 Statistical analyses: ELISA S/P ratio
Repeated measures analysis of variance, including factors for treatment, cat 
(treatment), time and treatment-by-time interaction, were performed. The test for a 
treatment-by-time interaction indicates whether the profile of treatment mean S/P 
across time follows a different shape for any treatment group. This may, for example, 
indicate if one group showed a transient elevation not seen in other groups. 
Additionally, one-way analysis of variance was performed individually using the data 
reported for each timepoint. Pairwise comparisons were performed between all pairs 
of treatments using Fisher’s protected LSD test: i.e. if the overall F-test was 
significant, t-tests between treatment means were performed at the same level of 
significance.
4.2.8.3 Statistical analyses: ELISA result and virus isolation result
Fisher’s exact test was performed at each timepoint on the 2 x 5 contingency tables. 
When a significant overall test was detected, pairwise Fisher’s exact tests were 
performed between all pairs of treatments. In addition, for the virus isolation data, 
profiles were summarised as negative, transient or positive. “Negative” was defined 
as those profiles with a negative result at all four timepoints, “transient” as a positive 
result that disappears at later timepoints, and “positive” as a result that becomes and 




4.3.1 THE YIELD, PURITY AND ENDOTOXIN LEVELS OF PLASMID 
DNA USED FOR VACCINE TRIAL
The yields, purity and endotoxin levels of the DNA prepared using Qiagen’s 
Endofree plasmid Giga kits (Qiagen, UK), were determined by the methods outlined 
in sections 2.2.23. and 4.2.5.3. The yields were calculated using spectrophotometry, 
and by estimation of double stranded DNA concentration via agarose gel 
electrophoresis. The results obtained by each method were in good agreement. The 
majority of the DNA yields obtained were greater than the maximum lOmg stated in 
the manufacturer’s protocol.
The purity of all the DNA samples was estimated using the ratio of the OD readings 
at 260nm and 280nm (OD26o/OD28o)- Pure preparations of DNA are known to have 
an OD2 6 0 /OD 2 8 0  of 1.8; a lower value suggests possible protein or phenol 
contamination. The DNA prepared for the trial had OD2 6 0/OD 2 8 0  readings of between 
1.88 and 1.91 indicating that the DNA was of high purity. Endotoxin levels in all 
samples of DNA were almost undetectable; less than 0.5 EU/ml of DNA in 
endotoxin free water, at a concentration of lm g DNA/ml. Therefore, less than 0.5EU 
were present in each milligram of plasmid DNA. No local or systemic reactions were 
observed in any of the kittens, following immunisation with this ultrapure, endotoxin 
free DNA. Table 4.8. illustrates the results.
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OD2 6 0 /OD2 8 0
ENDOTOXIN
LEVELS
pUSE 1 "CM VT (En v A) 11.2mg in 2ml TE 1.9 <0.5 EU/ml
pUSE 1 “CM VT (gagpol) 13.3mg in 2ml TE 1.91 <0.5 EU/ml
pCI-neo + IFN-y 14.8mg in 2ml TE 1.91 <0.5 EU/ml
pCI-neo + DL-12 p35 17.6mg in 2ml TE 1.88 <0.5 EU/ml
pCI-neo + IL-12 p40 19.1 mg in 2ml TE 1.90 <0.5 EU/ml
pCI-neo + IL-18 18.8mg in 2ml TE 1.90 <0.5 EU/ml
Empty pCI-neo 8.5mg in 2ml TE 1.90 <0.5 EU/ml
Table 4.8. Purity, yield and endotoxin levels of the DNA prepared for the 
vaccine trial
4.3.2 INFECTIOUS VIRUS IS NOT PRODUCED AS A RESULT OF 
HOMOLOGOUS RECOMBINATION BETWEEN FeLV VACCINE 
ANTIGENS AND ENDOGENOUS RETROVIRAL SEQUENCES
From the pre-trial, post-vaccination and day of challenge heparinised blood samples, 
plasma and PBMCs were isolated and the former was used to determine levels of 
plasma infectious virus and FeLV p27 antigen. These samples were analysed for the 
presence of virus and p27 antigen during the immunisation period mainly because 
there was a concern that the FeLV antigen component of the vaccine might be able to 
recombine with exogenous non-pathogenic or endogenous feline retroviral 
sequences, enFeLV, described in section 1.1.4 and 1.1.5. In theory, replication 
competent virions could then be produced, and FeLV infection established in the 
cats.
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As detailed in section 4.2.5.2., a positive is defined as an ELISA OD reading greater 
than twice the value of the negative control ELISA OD and none of the pre-challenge 
ELISA OD readings fell into this category. Virus isolation and p27 ELISA results 
were consistently negative for all blood samples collected at all timepoints, pre-viral 
challenge, as illustrated in table 4.9. This indicated that cats were free from FeLV 
infection and suggested that a recombination event, between vaccine antigens and 
exogenous non-pathogenic or endogenous retroviral sequences, generating 
replication competent virus, had not occurred. Moreover, no local or systemic 












2 days post 
3rd vaccination 
09-Jul
Day of viral challenge; three 
weeks after last vaccination 
28-Jul
ELISA O .D V.I VNA ELISA O .D V.I ELISA O .D V.I ELISA O .D V.I ELISA O .D V.I VNA W.B GP70
L 1 0.048 - 0 0.051 - 0.054 - 0.053 - 0.053 - 0 - -
L 2 0.047 - 0 0.052 - 0.057 - 0.049 - 0.050 - 0 - -
L 3 0.048 - 0 0.050 - 0.052 - 0.051 - 0.055 - 0 - -
L 4 0.046 - 0 0.052 - 0.055 - 0.051 - 0.054 - 0 - -
L 5 0.049 - 0 0.056 - 0.053 - 0.052 - 0.052 - 0 - -
L 6 0.055 - 0 0.060 - 0.056 - 0.054 - 0.055 - 0 - -
L 8 0.053 - 0 0.053 - 0.055 - 0.056 - 0.054 - 0 - -
L 9 0.052 - 0 0.062 - 0.053 - 0.053 - 0.064 - 0 - -
L 10 0.054 - 0 0.076 - 0.056 - 0.055 - 0.049 - 0 - -
L 11 0.053 - 0 0.056 - 0.052 - 0.050 - 0.045 - 0 - -
L 12 0.054 - 0 0.061 - 0.055 - 0.051 - 0.047 - 0 - -
L 13 0.056 - 0 0.054 - 0.050 - 0.051 - 0.047 - 0 - -
L 14 0.054 - 0 0.055 - 0.050 - 0.051 - 0.048 - 0 - -
L 15 0.057 - 0 0.063 - 0.049 - 0.055 - 0.049 - 0 - -
L 16 0.047 - 0 0.061 - 0.050 - 0.057 - 0.052 - 0 - -
L 17 0.047 - 0 0.055 - 0.050 - 0.053 - 0.058 - 0 - -
L 18 0.046 - 0 0.052 - 0.048 - 0.052 - 0.052 - 0 - -
L 19 0.048 - 0 0.055 - 0.049 - 0.052 - 0.052 - 0 - -
L 20 0.050 - 0 0.054 - 0.054 - 0.059 - 0.049 - 0 - -
L 21 0.047 - 0 0.057 - 0.050 - 0.056 - 0.051 . 0 - -
L 22 0.050 - 0 0.059 - 0.050 - 0.060 - 0.052 - 0 - -
L 23 0.050 - 0 0.064 - 0.050 - 0.058 - 0.054 - 0 - -
L 24 0.053 - 0 0.054 - 0.048 - 0.053 - 0.054 - 0 - -
L 25 0.050 - 0 0.055 - 0.051 - 0.050 . 0.058 . 0 - -
L 26 0.051 - 0 0.065 - 0.060 - 0.051 - 0.052 - 0 - -
L 27 0.052 - 0 0.053 - 0.052 - 0.051 - 0.051 - 0 - -
L 28 0.053 - 0 0.053 - 0.057 - 0.054 - 0.049 - 0 - -
L 29 0.053 - 0 0.052 - 0.055 - 0.050 - 0.062 . 0 - -
L 30 0.052 - 0 0.058 0.057 - 0.053 - 0.069 - 0 - -
+ 1.514 1.562 1.533 1.775 1.670
- 0.068 0.114 0.079 0.077 0.054
Table 4.9. Table of pre-challenge, (pre-trial and post-immunisation), p27 ELISA 
and VI results, and day of challenge p27 ELISA, VI, anti-gp70 ELISA, VN Ab 
assay and western blot analysis of serum against complete viral lysate results.
ELISA O.D, p27 ELISA OD reading; VI, virus isolation result; VNA, virus 
neutralising antibody titre; GP70, anti-gp70 antibody ELISA result; W.B, western 
blot analysis of serum against complete viral lysate result.
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4.3.3 PRO TECTIO N  AGAINST TRANSIENT, PERSISTENT AND LATENT 
FeLV INFECTION
4.3.3.1 The FeLV DNA vaccine does not provide protection against 
persistent FeLV infection
Sampling began three weeks after viral challenge (week eight), and was repeated on 
three occasions, approximately three weeks apart, until week 21 (weeks 11, 14, 17 
and 21). A final pre-euthanasia sample, at week 23-24, was also collected (cats L21, 
23, 24 and 28 were not euthanased). The main objective was to analyse the blood 
samples for evidence of FeLV infection to determine if vaccination had protected the 
cats from either transient or persistent viraemia. This was done by means of p27 
ELISA and virus isolation (VI) on QN10 cells (section 4.2.4.1. and 4.2.4.2.); positive 
VI and p27 results indicated FeLV infection. Virus neutralising antibody titres were 
also measured at each timepoint as a significant post-challenge VN titre usually 
correlates with protection (Hoover et al. 1976). Table 4.10 lists the DNA constructs 
which each group of cats received. Table 4.11 illustrates the virus isolation, p27 
ELISA and VN Ab assay results of the first and second post-challenge bleeds, for 
each individual cat (three and six weeks post-challenge, respectively), while table 
4.12 illustrates results of the third and fourth post-challenge bleeds, for each 
individual cat (nine and thirteen weeks post-challenge, respectively). Table 4.13. and 
4.14, meanwhile, summarise the virus isolation and p27 ELISA results, respectively, 
for each group of cats at defined timepoints, post-viral challenge.
GROUPS CONSTRUCTS NUMBER OF CATS
A Ll-6 CMV-gag-pol + CMV-env A 6
B L7-12 CMV-gag-pol + CMV-env A + IFN-y 5
C L13-18 CMV-gag-pol + CMV-env A + IL-12 6
D L25-30 CMV-gag-pol + CMV-env A + IL-12 + IL-18 6
E LI 9-24 Empty pCI-neo plasmid 6
Table 4.10. Im m unisation groups
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W eek 11; 3 w eeks P/C W eek 14; 6 w eeks P/C
Cat 18-Aug ELISA 08-Sep ELISA
No G ro u p ELISA O.D ELISA S.P RESULT V.I VNA ELISA O.D ELISA S.P RESULT V.I VNA
L 1 A 0.056 -0.007 - - 8 0.054 -0.013 - - >64
L 2 A 0.587 0.350 + - 0 0.766 0.358 + - 0
L 3 A 0.059 -0.005 - - 0 0.064 -0.008 - - 0
L 4 A 0.206 0.094 + - 0 0.057 -0.011 - - 0
L 5 A 1.538 0..991 + + 0 1.640 0.813 + + 0
L 6 A 0.329 0.177 + + 0 0.074 -0.003 - - 0
L 8 B 0.067 0.000 - - 0 0.067 -0.006 - - 0
L 9 B 1.275 0.814 + + 0 1.063 0.513 + + 0
L 10 B 1.192 0.758 + + 0 1.273 0.622 + + 0
L 11 B 0.205 0.093 + - 0 0.067 -0.006 - - 0
L 12 B 0.069 0.001 - - 0 0.070 -0.005 - - 0
L 13 C 0.217 0.101 + - 0 0.069 -0.005 - - 16
L 14 C 1.556 1.003 + + 0 1.564 0.774 + + 0
L 15 C 0.681 0.414 + + 0 1.527 0.755 + + 0
L 16 C 0.084 0.011 - - 0 0.076 -0.002 - - 8
L 17 C 1.614 1.042 + + 0 1.419 0.698 + + 0
L 18 C 0.940 0.588 + + 0 1.284 0.628 + + 0
L 19 E 0.161 0.063 + - 0 0.094 0.008 - - 0
L 20 E 0.794 0.490 + + 0 0.089 0.005 - - 16
L 21 E 1.291 0.825 + + 0 1.608 0.797 + + 0
L 22 E 1.369 0.877 + + 0 0.863 0.409 + - 0
L 23 E 1.337 0.856 + + 0 1.175 0.571 + + 0
L 24 E 1.317 0.842 + + 0 1.711 0.850 + + 0
L 25 D 0.129 0.042 - - 16 0.065 -0.007 - - 16
L 26 D 0.066 -0.001 - - 0 0.070 -0.005 - - 0
L 27 D 0.099 0.022 - - 0 0.071 -0.004 - - 0
L 28 D 0.104 0.025 - - 0 0.069 -0.005 - - 0
L 29 D 0.087 0.013 - - 0 0.077 -0.001 - - 0
L 30 D 0.280 0.144 + - 0 0.080 0.001 - - 8
+ control 1.551 1.998
- control 0.067 0.079
Table 4.11. Table of VI, p27 ELISA and VN Ab assay results for first and 
second post-challenge bleeds; three and six weeks post-challenge, respectively
ELISA O.D, p27 ELISA OD reading; ELISA S.P, p27 ELISA sample to positive 
ratio; VI, virus isolation result; VNA, virus neutralising antibody titre.
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W eek 17; 9 w eeks P/C W eek 21; 13 w eeks P/C W eek
Cat 02-Oct ELISA 27-Oct ELISA 23-24
No G roup ELISA O.D ELISA S.P RESULT V.I VNA ELISA O.D ELISA S.P RESULT V.I VNA VI
L 1 A 0.053 -0.001 - - >64 0.05 -0.003 - - 1024 -
L 2 A 1.515 0.831 + + 0 1.163 0.728 + + 0 +
L 3 A 0.070 0.009 - - 16 0.05 -0.003 - - 32 -
L 4 A 0.063 0.005 - - 16 0.05 -0.003 - - 128 -
L 5 A 1.455 0.797 + + 0 0.971 0.602 + + 0 +
L 6 A 0.062 0.004 - - 32 0.054 -0.001 - - 128 -
L 8 B 0.055 0.000 - - 0 0.056 0.001 - - 16 -
L 9 B 1.231 0.669 + + 0 0.968 0.600 + + 0 +
L 10 B 1.476 0.809 + + 0 0.942 0.583 + + 0 +
L 11 B 0.062 0.004 - - 0 0.056 0.001 - - 0 -
L 12 B 0.062 0.004 - - 0 0.058 0.002 - - 0 -
L 13 C 0.065 0.006 - - >64 0.058 0.002 - - 512 -
L 14 C 1.567 0.861 + + 0 1.198 0.751 + + 0 +
L 15 C 1.683 0.927 + + 0 1.065 0.664 + + 0 +
L 16 C 0.052 -0.002 - - >64 0.053 -0.001 - - 1024 ■-
L 17 C 0.893 0.477 + - 0 0.597 0.356 + - 0 +
L 18 C 1.384 0.756 + + 0 0.975 0.605 + + 0 +
L 19 E 0.057 0.001 - - 32 0.054 -0.001 - - 128 -
L 20 E 0.074 0.011 - - >64 0.057 0.001 - - 512 -
L 21 E 1.760 0.970 + + 0 1.345 0.848 + + 0 +
L 22 E 0.162 0.061 + - 8 0.104 0.032 - - 128 -
L 23 E 1.475 0.808 + + 0 1.005 0.625 + + 0 +
L 24 E 1.503 0.824 + + 0 1.205 0.756 + + 0 +
L 25 D 0.056 0.001 - - >64 0.056 0.001 - - 1024 -
L 26 D 0.056 0.001 - - 16 0.053 -0.001 - - 64 -
L 27 D 0.058 0.002 - - 32 0.055 0.000 - - 128 -
L 28 D 0.061 0.003 - - 16 0.056 0.001 - - 64 -
L 29 D 0.066 0.006 - - 8 0.058 0.002 - - 32 -
L 30 D 0.086 0.018 - - 32 0.063 0.005 - - 64 -
+ control 1.812 1.576
- control 0.055 0.055
Table 4.12. Table of VI, p27 ELISA and VN Ab assay results for third and 
fourth post-challenge bleeds; nine and thirteen weeks post-challenge, 
respectively.
ELISA O.D, p27 ELISA OD reading; ELISA S.P, p27 ELISA sample to positive 




Number of cats VI positive at week post-challenge
3 6 9 13 15-16
A 6 2/6 1/6 2/6 2/6 2/6
B 5 2/5 2/5 2/5 2/5 2/5
C 6 4/6 4/6 3/6 3/6 4/6
D 6 0/6 0/6 0/6 0/6 0/6
E 6 5/6 3/6 3/6 3/6 3/6
Table 4.13. Virus isolation results for each group of cats at defined timepoints, 





Number of cats p27 antigen positive at week post­
challenge
3 6 9 13
A 6 4/6 2/6 2/6 2/6
B 5 3/5 2/5 2/5 2/5
C 6 5/6 4/6 4/6 4/6
D 6 1/6 0/6 0/6 0/6
E 6 6/6 4/6 4/6 3/6
Table 4.14. p27 ELISA results for each group of cats at defined timepoints, post- 
viral challenge. N.B. viral challenge was performed at week 8.
Firstly, it should be noted that the small numbers of cats in each group and the 
results obtained precluded definitive statistical analyses. Analysing ELISA S/P data,
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the test for a treatment-by-time interaction indicated that group E, the control group, 
had the greatest proportion of transient infections at the first post-challenge bleed (3 
weeks post-challenge) and the sharpest decline between the first and second post­
challenge bleeds (between week three and week six).
Virus isolation (VI) is regarded as the definitive method of diagnosing FeLV 
infection. When comparing the number of cats that were virus isolation positive in 
group A, the FeLV DNA vaccine alone group, with group E, the control group, (table
4.13.), it appeared that, initially, the vaccine was providing some degree of protection 
against FeLV infection. At the first timepoint, three weeks post viral challenge, week 
11, only two cats in group A were VI positive, while five in group E were VI 
positive. There was not, however, a statistically significant difference between these 
two groups, in terms of p27 ELISA and virus isolation results (positive or negative), 
at this or any other timepoint during the trial. By the end of the trial, week 23-24, the 
number of cats that were VI positive in each group was almost identical; two cats in 
group A were VI positive, while three in group E were VI positive. The p27 ELISA 
results (table 4.14), displayed a similar trend. Therefore, it was concluded that the 
FeLV DNA vaccine alone did not provide significant protection against persistent or 
transient FeLV infection.
4.3.3.2 Cytokine DNA constructs act as vaccine adjuvants, enhancing 
protection against persistent FeLV infection
Firstly, an analysis of the mean p27 ELISA S/P profiles indicated that group D had 
consistently the lowest S/P values which were close to zero. Pairwise comparisons 
between mean p27 ELISA S/P values for each group indicated that the mean of group 
D (vaccine + IL-12 + IL-18) was lower than that of group C (vaccine + EL-12) or 
group E (controls); p < 0.1. Statistical analysis of p27 ELISA results (positive or 
negative, table 4.14.), using Fisher’s exact test, and performing pairwise comparisons 
between groups, revealed that group D possessed significantly fewer positives than 
groups C and E at weeks 11, 14 and 17 (3, 6 and 9 weeks post-challenge); p < 0.1. 
Group D also possessed significantly fewer positives than group E, at week 11; 
p<0.05.
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Similarly, analysis of virus isolation results (table 4.13.) revealed that at week 11 
group D possessed significantly fewer positives than groups C and E (p<0.1) and 
significantly fewer positives than group E (p<0.05). In fact, no cat in group D ever 
tested VI positive (table 4.11., 4.12. and 4.13) and only one cat in this group, L30, 
tested weakly p27 ELISA positive at the first timepoint (table 4.11. and 4.14.). 
Therefore the combination of the FeLV DNA vaccine and IL-12 and IL-18 DNA 
constructs protected cats against the development of transient and persistent 
viraemia. Due to the small number of cats in each group, a statistically significant 
difference was not identified between the number of cats virus isolation positive in 
group A, the vaccine alone group, and group D, the vaccine and IL-12 and IL-18 
group. However, at the end of the trial, 2/6 cats in group A were virus isolation 
positive, as opposed to 0/6 virus isolation positive in group D. Therefore, it was 
concluded that the IL-12 and IL-18 combination was acting as a potent adjuvant 
providing protection against the development of both transient and persistent 
viraemia.
The cats in group B were immunised with the FeLV DNA vaccine and the IFN-y 
construct. At all four post-challenge samples and the pre-euthanasia bleed, 2/5 cats in 
this group tested virus isolation and p27 ELISA positive. Statistical analysis as above 
revealed no significant difference between the number of cats p27 ELISA or virus 
isolation positive in this group and the control group E. Similarly, no significant 
difference was detected between the number of cats p27 ELISA and virus isolation 
positive in group B and group A, the FeLV DNA vaccine alone group. Therefore, it 
was concluded that the cats in group B were not protected from the development of 
transient and persistent viraemia and that IFN-y was not an effective vaccine adjuvant 
in this system.
The cats in group C were immunised with the novel FeLV DNA vaccine and the IL- 
12 construct. As detailed above, a statistically significant difference was detected 
between the number of cats p27 ELISA and virus isolation positive in this group and 
group D (vaccine + IL-12 + IL-18), in that group D had significantly fewer positive 
virus isolation results than groups C and E, at week 11 (p<0.1). In fact, throughout
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the trial the number of cats virus isolation and p27 ELISA positive in group C was 
similar to that of group E (the control group) and was consistently, although not 
statistically significantly, higher than that of group A (vaccine alone group), 
especially at the first two post-challenge sampling timepoints. These results indicate 
that IL-12 was not an effective vaccine adjuvant in this system and suggest that the 
inclusion of IL-12 DNA constructs with the novel FeLV DNA vaccine may actually 
reduce vaccine efficacy. Interestingly, the VI status of one of the cats in group C, 
L I7, changed from negative to positive, in the time between the fourth post-challenge 
bleed and the pre-euthanasia bleed, which was between two and three weeks. L I7 
had been VI and p27 ELISA positive at the first and second post-challenge bleeds, 
had been discordant (p27 ELISA positive and VI negative) at the third and fourth 
post-challenge bleeds and had never possessed detectable virus neutralising 
antibodies. The reasons for the changes in p27 ELISA and VI status in this cat are 
considered in the discussion.
4.3.3.3 The FeLV DNA vaccine does not provide protection against the 
development of latent FeLV infection
Bone marrow biopsies were obtained from all non-viraemic cats and from several 
viraemic cats, to act as positive controls. The cells obtained from these biopsies were 
cultured and the resulting cultures were screened for the presence of FeLV by virus 
isolation and p27 ELISA to determine if ostensibly immune, non-viraemic cats, 
harboured latent FeLV infection in bone marrow. Table 4.15. illustrates the number 
of cats in each group which were persistently viraemic or latently infected at the 
termination of the trial (15-16 weeks post viral challenge) while table 4.16. illustrates 
the results of p27 ELISA and VI performed on bone marrow supernatants and 

















Combined total of 
persistent and 
latent infection
A 6 2\6 2\6 2\6 4\6
B 5 2\5 2\5 0\5 2\5
C 6 4\6 4\6 0\6 4\6
D 6 0\6 0\6 1\6 1\6
E 6 3\6 3\6 2\6 5\6
Table 4.15. Number of cats persistently viraemic and latently infected in each 
group at the termination of trial; 15-16 weeks post viral challenge.
Key: VI, virus isolation.
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ELISA test results on BM cell lysates VI on QN10 cells after
Following 1 passage of BM fibroblasts 1 passage of Total
Lutz ELISA BM fibroblasts clinical
ELISA ELISA ELISA BMSN BMSN TCF TCF Clinical score for
Group Date O.D. S/P ratio result VI-1 VI-2 VI-1 VI-2 Score each
Out of 7 group
L 1 A 11/11/98 0.049 <0 - - - - - 0 20
L 2 A 18/11/98 1.21 1.04 + + + + + 7
L 3 A 11/11/98 0.046 <0 - - - - - 0
L 4 A 11/11/98 1.32 1.11 + - - + + 3
L 5 A V I+ N/D N/D N/D N/D N/D N/D N/D 7
L 6 A 18/11/98 1.292 1.11 + - - + + 3
L 8 B 20/11/98 0.049 <0 - - - - - 0 14
L 9 B VI + N/D N/D N/D N/D N/D N/D N/D 7
L 10 B VI + N/D N/D N/D N/D N/D N/D N/D 7
L 11 B 20/11/98 0.05 <0 - - - - - 0
L 12 B 20/11/98 0.054 0.003 - - - - - 0
L 13 C 20/11/98 0.056 0.004 - - - - - 0 28
L 14 C VI + N/D N/D N/D N/D N/D N/D N/D 7
L 15 C VI + N/D N/D N/D N/D N/D N/D N/D 7
L 16 C 20/11/98 0.054 0.003 - - - - - 0
L 17 C 20/11/98 1.233 1.06 + + + + + 7
L 18 C 17/11/98 1.388 1.2 + + + + + 7
L 19 E 11/11/98 0.107 0.05 - - - - - 0 27
L 20 E 11/11/98 0.947 0.78 + - - + + 3
L 21 E 11/11/98 1.062 0.89 + + + + + 7
L 22 E 11/11/98 1.291 1.09 + - - + + 3
L 23 E 11/11/98 1.451 1.23 + + + + + 7
L 24 E 11/11/98 1.248 1.05 + + + + + 7
L 25 D 18/11/98 0.061 0.01 - - - - - 0 1
L 26 D 18/11/98 0.062 0.01 - - - - - 0
L 27 D 18/11/98 0.072 0.02 - - - - - 0
L 28 D 11/11/98 0.084 0.03 - - - - + 1
L 29 D 18/11/98 0.074 0.02 - - - - - 0
L 30 D 18/11/98 0.085 0.03 - - - - - 0
Table 4.16. Results of p27 ELISA and VI performed on bone marrow 
supernatants and cultured bone marrow supernatants and cell lysates.
Key: N/D, not done as confirmed plasma VI positive; BM, bone marrow; BMSN, 
uncultured bone marrow supernatant; TCF, tissue culture fluid (supernatant) of 
cultured bone marrow cells.
VI is performed on uncultured bone marrow supernatants and cultured bone 
marrow supernatants, the latter procedure in an attempt to identify the presence of 
latent FeLV infection. Cultured bone marrow cell lysates are also tested for the 
presence of p27 antigen by Lutz’ commercial ELISA, to further confirm the presence 
of latent infection.
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Cats with latent FeLV infections are by definition non-viraemic but their bone 
marrow cells release infectious virus when cultured for a short period in vitro (Rojko 
et al. 1982). There were insufficient non-viraemic cats in each group to consider 
whether the vaccine alone protected against the development of latent FeLV 
infection. More relevant in determining vaccine efficacy was the combined total of 
cats persistently and latently infected at the end of the trial in group A, the vaccine 
alone group, compared with the group E, the control group. Considering the results in 
table 4.15. and 4.16., it appeared that the vaccine alone did not protect against the 
development of persistent or latent FeLV infection, as the combined total of cats 
persistently and latently infected with FeLV at the end of the trial was almost the 
same in groups A and E; 4\6 cats compared with 5\6 cats, respectively. Two of six 
cats in each of these groups harboured latent FeLV infection in bone marrow.
4.3.3.4 Cytokine DNA constructs act as vaccine adjuvants, enhancing 
protection against latent FeLV infection
Again, there were insufficient non-viraemic cats in each group to consider whether 
the vaccine and cytokine DNA constructs protected against latent FeLV infection 
alone. More relevant in determining how effective the cytokines were in enhancing 
vaccine efficacy, and thus protecting against FeLV challenge, was the combined total 
of cats persistently and latently infected at the end of the trial in groups D (the 
vaccine and IL-12 and IL-18 combination group), B (vaccine and IFN-y group), and 
C (vaccine and IL-12 group), compared with group E, (the control group), and group 
A, (the vaccine alone group).
Considering the results displayed in tables 4.15. and 4.16., it appeared that no cats in 
group C were latently infected, although four out of six were persistently viraemic, at 
the end of the trial. The combined total of cats persistently and latently infected, at 
trial termination, in group C was almost identical to that of group A (vaccine alone) 
and group E (the control group); 4\6, 4\6 and 5\6, respectively. Thus, it appeared that 
the IL-12 DNA constructs were not effective vaccine adjuvants in this system and 
that the IL-12 and FeLV DNA vaccine combination did not protect cats against the 
development of persistent or latent FeLV infection. Similarly the cats receiving
241
vaccine and IFN-y were not protected against the development of persistent or latent 
FeLV infection; at the end of the trial two cats in this group were persistently 
viraemic, while none were latently infected. The combined total of cats persistently 
and latently infected in this group, 2\5, was not statistically significantly different to 
the totals in groups A, C and E, as detailed above. Thus, IFN-y was not an effective 
vaccine adjuvant in this system.
In contrast, analysing the results displayed in tables 4.15. and 4.16., it appeared that 
only one cat in group D was latently infected (L28) and no cats were persistently 
viraemic, at the end of the trial. Moreover, the cultured bone marrow supernatant of 
L28 tested virus isolation positive only after subculture. The combined total of cats 
persistently and latently infected, at trial termination, in group D was much lower 
than either group A (vaccine alone), or group E (control group); 1\6, 4\6 and 5\6 
respectively. Thus, co-inoculated IL-12 and IL-18 DNA constructs were acting as 
potent vaccine adjuvants, and the vaccine, DL-12 and IL-18 combination was 
protecting against the development of transient and persistent viraemia and latent 
FeLV infection.
4.3.3.5 Scoring system to represent the FeLV status of cats at trial 
termination
A scoring system was developed, to rank the groups in terms of overall vaccine 
efficiency. One point was assigned to each of seven individual parameters, to give a 
maximum possible total of seven points per cat. A positive result in any of the seven 
individual parameters counted as one point and plasma and bone marrow samples 
were collected for analysis at 15-16 weeks post-challenge. The seven parameters 
were; p27 ELISA results on cultured bone marrow cell lysates (Lutz’s ELISA), 
primary virus isolation (VI-1) and sub-culture (VI-2) results on plasma, primary 
virus isolation (VI-1) and sub-culture (VI-2) results on uncultured bone marrow 
supernatants and primary virus isolation (VI-1) and sub-culture (VI-2) results on 
cultured bone marrow supernatants. (VI-1 represents the virus isolation result on 
QN10 cells, while VI-2 represents the virus isolation result after subculture, 
following one passage of QN10 cells).
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This system, then, is an indicator of how well each group of cats was protected from 
persistent and latent FeLV infection, at the end of the trial. Two graphs, illustrated in 
figures 4.5. and 4.6., have been created to show, respectively, the mean clinical score 
values and the combined total clinical score values, for each group of cats. The mean 
clinical score value for each group was obtained by adding together the clinical score 
values of all the cats in a group and simply calculating the mean, while the total 
clinical score values were obtained by adding together the clinical score values of all 
the cats in a group, and calculating the total. The graph of mean clinical score values 
for each group of cats has standard deviation bars, to illustrate the degree of variance 
in scores within individual groups. Correlating well with the results described in 
previous sections, mean and total clinical score values for groups C (vaccine and EL- 
12) and E (the control group), were very similar, again suggesting that the inclusion 
of IL-12 DNA constructs with the novel FeLV DNA vaccine may actually reduce 
vaccine efficacy. These graphs clearly show that the cats in group D, receiving the 
FeLV DNA vaccine and IL-12 and IL-18 constructs, had much lower mean and total 
clinical score values, than the other four groups, and were therefore better protected 
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Figure 4.5. Graph of mean clinical score values for each group of cats
Key: A = vaccine alone, B = vaccine + IFN-y, C = vaccine + IL-12,


















Figure 4.6. Graph of total clinical score values for each group of cats
Key: A = vaccine alone, B = vaccine + IFN-y, C = vaccine + IL-12, 
D = vaccine + IL-12 + IL-18 and E = empty pCI-neo plasmid.
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4.3.4 IMMUNISATION WITH DNA DOES NOT ELICIT VIRUS 
NEUTRALISING OR NON-NEUTRALISING ANTIBODIES; 
DEVELOPMENT OF PRECHALLENGE ANTIBODIES DOES NOT 
CORRELATE WITH PROTECTION AGAINST FeLV CHALLENGE
From the day of challenge heparinised blood samples, plasma and PBMCs were 
isolated and the former was used to determine levels of FeLV specific virus 
neutralising antibodies. From a plain tube blood sample, serum was isolated and 
tested for anti-FeLV gp70 antibodies by western blotting against complete viral 
lysate and an anti-gp70 ELISA assay. VN and non-VN antibody titres were measured 
to determine if the vaccine could generate an antibody response that would correlate 
with protection. It was decided to test the day of challenge plasma and serum samples 
first and if detectable levels of antibody were identified, to test the three post­
immunisation samples, retrospectively
Table 4.9. illustrates that neither virus neutralising nor non-neutralising antibodies 
were elicited in any of the cats by FeLV DNA immunisation. All day of challenge 
plasma and serum samples were negative for presence of VN antibodies, anti-gp70 
antibodies and antibodies to other viral proteins. However, obviously some cats were 
protected against viral challenge, so development of pre-challenge antibodies did not 
correlate with protection against persistent FeLV infection. In particular the FeLV 
antigen and IL-12 and IL-18 combination of DNA constructs was able to provide 
protection against FeLV challenge, in the absence of a detectable pre-challenge VN 
or non-VN antibody response. Significant VN antibody titres only developed three to 
six weeks after viral challenge. Protection may therefore have involved the induction 
of cytotoxic T cells and cellular immunity, or alternatively, the vaccine may have 
primed the immune response to produce protective VN antibody titres. However, the 
possibility that, anti-DNA or anti-cytokine antibodies may have overwhelmed the 
FeLV specific humoral immune response, cannot be discounted and will be 
considered in the discussion.
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4.3.5 DEVELOPMENT OF POST-CHALLENGE VN ANTIBODIES
APPEARS TO CORRELATE WITH PROTECTION AGAINST FeLV 
INFECTION
The was a definite correlation between the development of post-challenge virus 
neutralising antibodies and protection against FeLV infection, as expected (Hoover et 
al. 1976). Tables 4.11 and 4.12 clearly illustrate that cats protected from persistent 
viraemia, defined as cats which were virus isolation negative at week 21 (13 weeks 
P/C), possessed a significant virus neutralising antibody titre. Similarly, cats which 
tested virus isolation positive at this time did not possess a detectable virus 
neutralising antibody titre. The only exceptions were cats L8, LI 1 and L I2 (all group 
B, vaccine and IFN-y group), and cat L I7, (group C, vaccine and IL-12 group); 
although these cats tested virus isolation negative at week 21, they possessed either a 
very low (cat L8) or undetectable VN antibody titre (cat LI 1, L12 and L17). The 
latter cat, L I7, was discordant at week 17 and week 21 and became virus isolation 
positive at week 23 (pre-euthanasia bleed). However, cats L8, L l l  and L12 
consistently tested virus isolation negative throughout the trial and at the pre­
euthanasia bleed.
4.3.6 FeLV INFECTION PRODUCES HAEMATOLOGICAL CHANGES
Haematological analysis of blood was conducted, at the timepoints described in 
section 4.1.3., (FeLV DNA vaccine trial design), to establish if the development of 
FeLV infection produced any changes in normal haematological parameters. The 
haematology results are displayed in the appendix.
The main change observed was a profound neutropenia in four persistently infected 
cats, L10 (group B, vaccine and IFN-y), LI 8 (group C, vaccine and IL-12), L2 (group 
A, vaccine alone) and L9 (group B, vaccine and IFN-y), six weeks after viral 
challenge, at the second post-challenge bleed. Additionally, cat L9 also exhibited a 
low total white blood cell and neutrophil count three weeks after viral challenge, at 
the first post-challenge bleed. L9, L10 and LI 8 tested virus isolation positive at the
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first post-challenge bleed, and remained so, while L2 was discordant (p27 ELISA 
positive, but virus isolation negative), at the first and second post-challenge bleeds, 
then became virus isolation positive for the remainder of the trial.
Cat L26 (group D, vaccine and IL-12 and IL18), a vaccinated, protected cat, which 
never tested virus isolation positive, also exhibited a slight neutropenia at the second, 
third and fourth post-challenge bleeds. However, the neutropenia bordered on the low 
range of normal, and it was observed that this cat had possessed a borderline 
neutrophil count even before viral challenge was performed (day of viral challenge 
bleed). By the third post-challenge bleed, nine weeks after viral challenge, neutrophil 
counts had risen in the neutropenic cats and by the fourth blood sample, thirteen 
weeks after viral challenge, they had all returned to within the low end of the normal 
range. The one exception to the above was cat L26, which remained very slightly 
neutropenic. The normal range of neutrophil counts in cats is 2.5-12.5 x 109/L; cat 




p27 ELISA and feline leukaemia virus isolation techniques identify FeLV p27 
antigen and infectious virus, respectively, in plasma or serum. A positive p27 ELISA 
result usually indicates the presence of widespread, disseminated FeLV infection in 
the body, from which viral antigen is being produced (Jarrett et al. 1991). Therefore, 
cats that are p27 ELISA positive are normally also virus isolation positive, as p27 
protein is produced by active FeLV replication. However, this is not always the case. 
In about 10% of blood samples tested at the Glasgow Veterinary School Feline Vims 
Unit, p27 ELISA results were positive, while vims isolation (VI), results were 
negative (Jarrett et al. 1991). As vims isolation is a reliable method of detecting 
active vims in blood, and the p27 ELISA results were consistently positive, using six 
different ELISA kits, it was concluded that these cats were “discordant” cats.
There are several theories as to why this discordant state exists; that is, a cat which is 
p27 ELISA positive and VI negative. The first explanation for the discordant state, is 
that the cat is at the beginning or the end of FeLV infection, when antigen but not 
vims can be detected in the blood (Jarrett et al. 1991). Thus discordancy is only a 
temporary state and a later blood sample would probably yield a consistent result 
between the two tests. Another explanation is that a focus of viral infection exists in 
the body, perhaps sequestered in a tissue such as the bone marrow, so that viral 
infection is not disseminated, but controlled and limited to one or two specific areas. 
This viral focus produces p27 antigen which reaches the blood and can be detected, 
but the low levels of vims produced cannot reach the periphery, and thus the cat is VI 
negative (Jarrett et al. 1991). Cats can remain in this discordant state for up to two 
years, but these cases generally progress to persistent viraemia and clinical FeLV 
infection.
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It is generally regarded that virus isolation is the most definitive method of 
establishing the FeLV status of a cat, as p27 ELISA test kits can be unreliable. 
However, p27 ELISA and VI results should be considered together when assessing 
how well a vaccine protects against viral challenge, for example. On examination of 
the data from the FeLV DNA vaccine trial, it was observed that there were some 
discordant p27 ELISA and VI results. However, these mainly occurred just after viral 
challenge and were not consistent for the remainder of the trial. This related to the 
theory that discordant results may occur at the end or the beginning of FeLV 
infection; either when virus is being cleared and immunity established, (resulting in a 
negative VI and p27 ELISA result, as in the case of cat L I3), or when virus is 
replicating but is not yet at high enough levels to be detected in peripheral blood 
(resulting in a positive VI and p27 ELISA result, as in the case of cat L2).
The one exception to the above was provided by cat L I7. This cat became discordant 
nine weeks post-challenge, and remained so at the fourth post-challenge bleed 
(thirteen weeks post-challenge), being both p27 ELISA and VI positive before this 
time. It was considered that this cat may have developed partial immunity, resisting 
widespread disseminated viral infection, but rather than completely clearing virus 
and developing complete immunity, a focus of sequestered infection developed, 
capable of producing p27 antigenaemia. Interestingly, virus neutralising antibodies 
were never detected in the sera of this cat, illustrating that an incomplete immune 
response was mounted. Moreover, at the subsequent pre-euthanasia bleed, fifteen 
weeks post-challenge, the virus isolation result became positive. This late 
recrudescence may have arisen due to the combination of inadequate immunity and 
increased exposure to high doses of infective virus from persistently infected FeLV 
excreting cats.
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4.4.2 FeLV DNA VACCINE AND ADJUVANTS; POSTULATED 
MECHANISMS OF ACTION
4.4.2.1 Basic antigen component
The single cycle FeLV vector vaccine consisted of two separate pUSETCM VT 
series plasmids, one expressing FeLV gag/pol genes, and the other expressing FeLV 
subgroup A env gene, both under control of the CMV-IE promoter. If a single host 
target cell is transfected with both constructs, structural and non-structural FeLV 
proteins should be expressed in a proportion of transfected cells, allowing the 
assembly of “empty” FeLV virions. These virions may bud from transfected cells, 
initiating an immune response similar to that raised against native FeLV viral 
particles, and will be able to enter adjacent B and T cells, but due to the absence of a 
functional viral genome, will not be capable of replication, proviral integration or 
establishing productive infection.
However, if only one construct transfects a target cell, the protein encoded by the 
DNA may be expressed in that cell, and presented to cytotoxic T lymphocytes in the 
context of the target cell’s endogenous MHC encoded class I molecules. 
Alternatively, the protein produced within the cell may be transported to the cell 
surface and allowed to accumulate there, as in the case of the FeLV-A gp70 protein. 
Antibodies may then be elicited to this foreign protein. The protein may also be 
secreted, engulfed by antigen presenting cells (APC), processed and presented to T 
helper cells in the context of the APC’s MHC class II molecules. The secreted 
antigenic protein may also be recognised by specific, antibody bearing B 
lymphocytes, which, upon antigen recognition and binding, differentiate into 
antibody-forming plasma cells. Thus, both cellular and humoral immune responses 
may be elicited. It was hoped that the FeLV DNA vaccine would elicit FeLV specific 
immune responses, which protect against persistent FeLV infection following viral 
challenge, by one or all of the above mechanisms.
Although the role cell-mediated immunity plays in FeLV infection is undefined and 
the generation of post-challenge virus neutralising antibodies is generally thought to
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correlate with protection (Hoover et al. 1976), the exact mechanism by which FeLV 
vaccines protect cats from infection remains unknown. Indeed, this FeLV DNA 
vaccine and most of the experimental and commercial FeLV vaccines failed to 
induce significant titres of virus neutralising antibodies prior to viral challenge, so 
protection could involve either a priming of the immune system to produce these 
antibodies, or, alternatively, the induction of FeLV specific cytotoxic T cells (Jarrett, 
1996). Interestingly, studies have documented cell mediated responses, (cytotoxic T 
cells and natural killer cells), to FeLV transformed cells, in vitro (Tompkins and 
Tompkins, 1985). Moreover, some cats resistant to infection do not develop VN 
antibodies, and occasionally detectable VN antibodies titres are found in persistently 
viraemic cats (Charreyre and Pedersen, 1991), although the titres are very low. While 
the development of virus-neutralising antibodies in an infected cat may block further 
spread of virus to uninfected cells, elimination of cells already infected may be due to 
other immune mechanisms, such as cell mediated immunity (Charreyre and Pedersen, 
1991). Therefore, cell mediated immunity may be extremely important in the 
generation of an effective immune response to FeLV, especially in protecting against 
the development of latent infection.
The T helper cell type 1, T hl, response, characterised by IFN-y synthesis, controls 
cellular immunity. As mentioned earlier, in section 1.1.3., plasmid DNA itself may 
stimulate the development of cellular immunity, due to the presence of unmethylated 
CpG motifs. CpG motifs, 6-base DNA motifs consisting of an unmethylated CpG 
dinucleotide flanked by two 5' purines and two 3' pyrimidines, are present at high 
frequencies in bacterial plasmid DNA. These CpG motifs have been shown to 
possess T-helper type 1 immunostimulatory activity (Pisetsky, 1996), inducing the 
rapid and coordinated secretion of IL-6, IL-12, and IFN-y in vivo and in vitro 
(Klinman et al. 1996). Moreover, many reports have demonstrated that saline DNA 
inoculations, whether intradermal or intramuscular, as used in this trial, stimulate 
predominantly Thl immune responses (Feltquate et al. 1997). Therefore, the 
endogenous non-specific adjuvant activity possessed by DNA vaccines and the 
delivery method employed, have the potential to enhance the development of the 
cellular immune response elicited in vaccinated cats.
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Initially, p27 ELISA and VI results indicated that the FeLV DNA vaccine alone 
provided some degree of protection against viral challenge. Statistical analysis of the 
ELISA S/P results indicated that group E, the control group, possessed the largest 
transient infection at the first post-challenge bleed (3 weeks post-challenge), while 
virus isolation results revealed that only two cats in group A were VI positive, while 
five cats in group E were VI positive. However, the latter result was not statistically 
significant; p>0.1. Interestingly, the control group E displayed the largest drop in 
transient infection between the first and second post-challenge bleeds (between week 
three and week six). Moreover, two cats which were VI positive in the control group 
E became VI negative between these two timepoints, so only three cats in the control 
group E tested VI positive at the second post-challenge bleed.
Cats in the control group E were immunised with empty pCI-neo plasmid alone, to 
establish whether the presence of CpG motifs could non-specifically enhance the 
immune response raised to challenge virus. Not all cats became persistently viraemic. 
However, the failure to establish persistent viraemia in all of these cats was most 
likely due to the innate, partly age-related resistance to FeLV infection possessed by a 
significant proportion of cats (Hoover and Mullins, 1991), rather than the 
endogenous adjuvant activity of CpG motifs. Obviously it is difficult to assess the 
efficacy of a vaccine if a significant proportion of the control cats develop natural 
immunity to the challenge virus. This is, in fact, a recurrent and consistent problem in 
FeLV vaccine efficacy studies and reflects host resistance factors, such as age at viral 
challenge (Hoover et al. 1976), immune system functional status and known virus 
virulence factors, such as magnitude of exposure and virus genotype. Intraperitoneal 
viral challenge was performed at 20-22 weeks of age in this trial, and this may have 
influenced the proportion of cats in the control group E that became persistently 
viraemic. Although intraperitoneal viral challenge has been performed effectively in 
cats much older than those involved in this trial (Hofmann-Lehmann et al. 1994), an 
experimental challenge study, employing intraperitoneal viral inoculation, has 
documented that persistent viraemia and FeLV-related disease developed in 100% of 
cats inoculated as newborns, in 85% of cats inoculated at 2 weeks to 2 months of age, 
and in 15% of cats inoculated at 4 months or 1 year of age (Hoover et al. 1976).
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Therefore, the age of cats at viral challenge is of crucial importance in determining 
the outcome of infection.
Due in part to the above and the small numbers of cats in each group, a statistically 
significant difference was not detected between these two groups, (A and E), in terms 
of p27 ELISA and virus isolation results (positive or negative), at any timepoint 
during the trial. However, by the end of the trial, at week 23-24, the combined total 
of cats persistently and latently infected with FeLV was almost identical in groups A 
and E; four out of six cats compared with five out of six cats, respectively. Clearly, 
administration of the vaccine to the cats in group A did not confer any resistance to 
infection more potent than that acquired by natural immunity. Therefore, it appeared 
that CpG motifs in bacterial plasmid DNA were not acting as non-specific enhancers 
of the immune response to challenge virus, and it was concluded that the FeLV DNA 
vaccine alone was not effective in preventing the development of transient or 
persistent viraemia or latent FeLV infection.
At the termination of the trial, two cats in each of groups A and E were found to be 
latently infected with FeLV. In group A , cat L4 had tested p27 ELISA positive at the 
first post-challenge bleed only (12-13 weeks earlier) while cat L6 had tested p27 
ELISA and VI positive at the first post-challenge bleed only. In group E, cat L20 had 
tested p27 ELISA and VI positive at the first post-challenge bleed only and cat L22 
had tested p27 ELISA positive at the first, second and third post-challenge bleeds, 
but virus isolation positive at the first post-challenge bleed only. At the fourth post­
challenge bleed, 13 weeks after viral challenge, all four cats possessed a significant 
VN antibody titre. In most exposed cats, immunity is established before or during 
bone marrow infection, so a marrow-associated viraemia does not develop. However, 
in a subset of exposed cats, perhaps exemplified by cats such as L4, L6, L20 and L22, 
immunity does not develop until after bone marrow-origin viraemia is established 
(Sparkes, 1997) so viraemia and/or antigenaemia are observed. Although this 
viraemia and/or antigenaemia are usually short-lived, lasting only days to weeks, they 
indicate that bone marrow infection with FeLV has occurred. Therefore, cats which 
have tested p27 ELISA or VI positive during the trial are more likely to become 
latently infected with FeLV. This may explain why these cats, L4, L6, L20 and L22,
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testing p27 ELISA and VI positive early in the trial, later were found to be latently 
infected with FeLV. Following viral exposure bone marrow infection must have been 
established before a complete and effective immune response was raised. Similarly, 
cats which had not tested p27 ELISA or VI positive at any point during the trial, 
indicating that immunity had been established before bone marrow infection had 
occurred, tended not to develop latent FeLV infection.
4.4.2.2 Adjuvant component
4.4.2.2.1 Overview
In vitro studies have demonstrated that T cells exposed to the cytokines IL-18 and IL- 
12, exhibit a synergistic increase in interferon gamma production (Micallef et al. 
1996), (Kohno et al. 1997). The latter cytokine is known to be integral to the 
development of a functional cellular immune response. Moreover, several in vivo 
studies in mice and cats have shown that the magnitude and nature of an immune 
response elicited by a DNA vaccine, can be engineered by the co-inoculation of 
cytokine, or other immunostimulant, plasmid DNA constructs (Chow et al. 1998), 
(Chow et al. 1998), (Kim et al. 1997), (Tsuji et al. 1997), (Hosie et al. 1998).
Codelivery of E L -12 DNA with vaccine antigens has been shown to significantly 
enhance the development of Thl cell populations and the production of Thl 
cytokines, essential in the generation of a functional cellular immune response (Chow 
et al. 1998). The development of Th2 cells, usually associated with a humoral 
immune response, was markedly inhibited. A dramatic increase in virus-specific CTL 
responses has also been demonstrated, following combined antigen and IL-12 
inoculation (Tsuji et al. 1997), (Kim et al. 1997). As detailed in section 4.4.2.1., cell 
mediated immunity may be extremely important in the generation of an effective 
immune response against FeLV. Therefore, the coadministration of these Thl type 
cytokine genes, IL-12, IL-18 and IFN-y, with FeLV vaccine antigens may have 
steered the immune response further towards the cellular arm, thus enhancing the 
efficacy of the FeLV DNA vaccine.
255
4.4.2.2.2 IFN-y as a vaccine adjuvant
IFN-y is an extremely pleiotropic cytokine that has a major physiological role in 
regulating immune and inflammatory processes. The various roles that interferon 
plays in host defence mechanisms include a role in innate immunity 
(macrophages/neutrophils), lymphocyte migration, antigen recognition by T cells and 
effector T cell development (De Maeyer and De Maeyer-Guignard, 1992). This 
cytokine is known to be the principal agent responsible for macrophage activation, 
and therefore is the primary cytokine responsible for inducing non-specific cell- 
mediated mechanisms of host defence. IFN-y also plays an important role in the 
enhancement of MHC I expression and the induction of MHC II expression on 
antigen presenting cells, and may also induce NK cell proliferation and activation. In 
addition to enhancing non-specific cell-mediated cytocidal activities, IFN-y also 
enhances the ability of macrophages to participate in other immune response effector 
functions. DNA plasmids encoding IFN-y protein have been found to increase the 
efficacy of DNA vaccines (Pasquini et al. 1997). It is thought that IFN-y may 
mediate its adjuvant effects by enhancing MHC II expression on antigen presenting 
cells, and, thus, antigen presentation.
The cats which received vaccine and IFN-y, in group B, were not protected against 
the development of persistent or latent FeLV infection. At the termination of the trial 
the number of cats persistently and latently infected in this group (2/5), was not 
statistically significantly different to that of group A (4/6), the vaccine alone group, 
group C (4/6), the vaccine and IL-12 group, or group E (5/6), the control group, 
although there were obviously fewer infected cats in the vaccine and IFN-y group. 
Thus, IFN-y was not an effective vaccine adjuvant in this system. However, the small 
number of cats in each group made definitive statistical analysis of the results very 
difficult.
Interestingly, a recent report regarding an FTV DNA vaccination trial, immunising 
with a defective mutant pro virus of FTV, FTVDeltaRT, demonstrated that a DNA 
plasmid encoding feline IFN-y could act as an adjuvant (Hosie et al. 1998). In this
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trial, immunisation with FIVDeltaRT in conjunction with IFN-y gave the highest 
proportion of protected cats, with only two of five vaccinates showing evidence of 
infection following challenge. However, direct comparisons cannot be made between 
these trials. Although FTV and FeLV are both retroviruses, they follow very different 
pathogenesis courses and mediate different pathologies in their hosts. Therefore, a 
specific adjuvant may have very different effects in one disease model as opposed to 
another. Moreover, little is known regarding the levels of IFN-y protein expression 
achieved following inoculation with IFN-y expressing DNA plasmids. Perhaps the 
expression achieved was at too low a level, or too localised, to act as an adjuvant, 
stimulating the immune system and potentiating the effect of the vaccine.
4A.2.2.3 IL-12 as a vaccine adjuvant
IL-12 is a potent cytokine, able to enhance proliferation and cytolytic activity of 
activated T lymphocyte and natural killer cells, induce T helper cell type 1 immune 
responses and stimulate the differentiation of CD8+ T lymphocytes (Brunda, 1994). 
The cats which received vaccine and IL-12, in group C, were not protected against 
the development of persistent or latent FeLV infection. The number of cats 
persistently infected in group C was similar throughout the trial to that of group E 
(the control group), was consistently, although not statistically significantly, higher 
than that of group A (the vaccine alone group) and was statistically significantly 
higher than that of group D (the vaccine and IL-12 and IL-18 group). Moreover, the 
late recrudescence of viral infection in cat L17, as detailed in the results section 
4.3.3.2., again suggested that the FeLV DNA vaccine and IL-12 adjuvant 
combination did not provide solid protection against viral challenge. Together, these 
results indicated that IL-12 alone was not an effective vaccine adjuvant in this system 
and that the inclusion of IL-12 DNA constructs with the novel FeLV DNA vaccine 
may actually have reduced vaccine efficacy.
Interestingly, the adjuvant properties of IL-12 have been well documented in other 
DNA vaccination studies, using different disease models (Chow et al. 1998). The 
CTL activity induced by hepatitis B virus (HBV) DNA vaccination was significantly 
enhanced by codelivery of the IL-12 gene, and when challenged with HBV surface
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antigen (HBsAg)-expressing syngeneic tumours, significant reduction of tumour 
growth was observed in mice that were co-inoculated with the IL-12 gene. However, 
HBV and FeLV are very different viruses, interacting with the immune system in 
different ways, and therefore direct comparisons cannot be made between the effects 
IL-12 expressing DNA plasmids mediate in these and other disease models. 
Alternatively, the levels of IL-12 protein expression achieved following inoculation 
with IL-12 expressing DNA plasmids may have been too low or too localised to 
stimulate the immune system.
A criticism of this work might be that in vitro experiments were not performed with 
the IL-12 expressing DNA constructs, to confirm their biological activity in vitro, 
before they were used in vivo in the FeLV DNA vaccination trial. Therefore, a simple 
explanation for the apparent lack of adjuvant activity of the IL-12 constructs, was 
that the protein they expressed was not biologically active and was thus not able to 
mediate the effects of endogenous IL-12. In vitro experiments, such as T lymphocyte 
proliferation assays, should be performed in the future to rule out this possibility. 
However, it is interesting to consider why the coinoculation of IL-12 DNA constructs 
with the FeLV DNA vaccine actually appeared to reduce vaccine efficacy. Indeed, 
the number of cats virus isolation and p27 ELISA positive in group C (vaccine and 
IL-12 group) was consistently, although not statistically significantly, higher than that 
of group A (vaccine alone group), throughout the trial, especially at the first two 
post-challenge sampling timepoints.
An investigation of the role of the human p40 subunit in ligand binding and signal 
transduction, by expressing this subunit alone in COS cells (Ling et al. 1995) 
suggested that the IL-12 p40 subunit contained the essential epitopes for receptor 
binding, although the proper conformation required for high affinity binding was 
achieved only when the p40 subunit was associated with a p35 subunit or another 
p40 subunit. When the p40 subunit was associated with a p35 subunit, the 
heterodimer acted as an agonist, mediating biologic activity. By contrast, when the 
p40 subunit associated with another p40 subunit, the homodimer behaved as a 
receptor antagonist in vitro, inhibiting IL-12-induced T cell proliferation. Similarly, it 
has been reported that recombinant murine p40 is able to form a homodimer, which
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acts as a potent IL-12 antagonist, without biological activity in vitro (Gillessen et al. 
1995). Perhaps the p40 homodimer plays a physiological role in the regulation of the 
biological activity of endogenous IL-12 in immune responses. However, 
administration of exogenous IL-12, as in the case of DNA vaccination, might lead to 
over-expression of the p40 subunit protein, resulting in the blockade of the IL-12 
receptor, such that endogenous EL-12 cannot mediate its effects.
The IL-12 construct utilised in the FeLV DNA vaccination trial consisted of two 
separate plasmids, one expressing the p35 subunit and the other expressing the p40 
subunit, both under the control of the CMV promoter. Although equal amounts of 
each plasmid were administered to each cat, it was impossible to determine if 
expression levels were similar, or even if both constructs transfected the same target 
cells, essential for the generation of the biologically active IL-12 heterodimer. 
Therefore, the p40 subunit may have been over-expressed relative to the p35 subunit, 
resulting in the formation of p40 homodimers, able to act as potent IL-12 receptor 
antagonists. Thus, the immunostimulatory effects of endogenous IL-12 may have 
been inhibited and the cats which were inoculated with the IL-12 and FeLV DNA 
vaccine constructs may have been less able to mount an effective immune response 
to the challenge virus. This may explain why the coinoculation of E L -12 DNA 
constructs with the FeLV DNA vaccine may actually have reduced vaccine efficacy.
A recent paper has described the construction of vectors expressing bioactive 
heterodimeric and single-chain murine interleukin-12 for gene therapy (Ixe et al. 
1998). A vector was constructed that contained two CMV promoters, to drive the 
expression of the p35 and the p40 subunits, respectively, ensuring that a single target 
cell would co-express both subunit proteins. Additionally, a vector was designed with 
a linker which fused the p35 cDNA with the p40 cDNA to produce a bioactive 
single-chain EL-12 protein. This ensured that the p35 and p40 subunits were equally 
expressed, and also that no free p40 subunits interfered with the biological activity of 
IL-12. The use of such vectors should be considered if the adjuvant potential of EL -12 
is to be evaluated in future FeLV DNA vaccination trials.
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4.4.2.2.4 Co-administration of IL-12 and IL-18 as vaccine adjuvants
4.4.2.2.4.1 Proposed mechanisms o f action
The cats which received vaccine, IL-12 and IL-18 DNA constructs, in group D, were 
protected against the development of transient and persistent viraemia and latent 
FeLV infection. No cat in group D ever tested VI positive (tables 4.11., 4.12. and
4.13.) and only one cat, L30, tested weakly p27 ELISA positive at the first timepoint 
(tables 4.11. and 4.14.) At the termination of the trial only one cat, L28, harboured 
latent FeLV infection in her bone marrow and then at a very low level. Moreover, 
when a bone marrow biopsy from this cat was collected and cultured seven weeks 
later, virus isolation results then indicated that the marrow was completely free from 
latent FeLV infection. Late recrudescence of viral infection was not observed in any 
of the cats in group D, indicating that the vaccine, IL-12 and IL-18 combination 
established solid immunity. Statistical analysis of virus isolation results (table 4.13.), 
revealed that group D possessed significantly fewer positives than groups C (vaccine 
and IL-12 group), and E (control group), three weeks post-challenge, at week 11; 
p<0.1 and significantly fewer positives than group E, at week 11; p<0.05. Therefore 
the IL-12 and IL-18 combination acted as a potent vaccine adjuvant. The reason that 
there are only statistically significant differences between the groups D and E at the 
first post-challenge bleed is not because the vaccine, IL-12 and IL-18 combination 
lost its ability to protect cats against FeLV infection as the trial progressed, but that 
some of the infected cats in the control group, E, cleared the virus and became VI 
negative, presumably due to the innate, partly age-related resistance to FeLV 
infection (Hoover and Mullins, 1991).
It is interesting to consider how the IL-12 and IL-18 DNA construct combination 
mediated its potent adjuvant effect in vivo, enhancing protection from FeLV 
infection. IL-12 and IL-18 activate both innate and acquired immunity (Okamura et 
al. 1998). In vitro studies have illustrated that T cells exposed to the cytokines DL-18 
and IL-12, exhibit a synergistic increase in IFN-y production (Micallef et al. 1996) 
and, as explained above, IFN-y is integral to the development of a functional cell- 
mediated immune response. Therefore, IL-12 and IL-18 may have mediated their
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immunostimulatory, adjuvant effect in vivo by means of a synergistic increase in 
IFN-y production. However, the IFN-y expressing DNA plasmid used in this trial was 
not an effective vaccine adjuvant (although IFN-y expressing DNA plasmids have 
been well documented as effective adjuvants in several DNA vaccination studies 
(Pasquini et al. 1997), (Hosie et al. 1998)), which could lead to the assumption that 
IFN-y production was not necessarily the mechanism by which IL-12 and IL-18 
mediated their adjuvant effects.
However, the IFN-y construct may have proved to be an ineffective adjuvant because 
the expression levels of IFN-y protein it produced were too low or too localised to 
stimulate the immune system. In fact, the synergistic effect of IL-12 and IL-18 in 
increasing IFN-y production may have resulted in dramatically enhanced levels of 
IFN-y. Also, as IL-12 and IL-18 are higher up in the cytokine cascade (figure 1.8.), 
their increased expression may have led to an avalanche effect in the amplification of 
IFN-y production. The augmented levels of IFN-y would then be able to stimulate the 
immune system and thus enhance vaccine efficacy. Alternatively, a recent interesting 
report has documented that IFN-y may directly inhibit the expression of genes driven 
by the CMV or SV40 promoters (Harms and Splitter, 1995). As the FeLV antigens 
gag/pol and env A were under the control of the CMV promoter, perhaps the 
simultaneous administration of a DNA plasmid expressing IFN-y decreased the 
expression of the FeLV antigens to such a level that an effective, protective immune 
response was not elicited. In contrast, administration of the IL-12 and IL-18 adjuvant 
combination may have resulted in significantly increased endogenous levels of IFN-y, 
but the delay between the administration of the FeLV antigen constructs and the 
increase in IFN-y production may have been sufficiently long to ensure that the 
developing immune response was not effected. Therefore, increased endogenous 
IFN-y production may indeed have been the mechanism by which the IL-12 and IL- 
18 DNA constructs mediated their adjuvant effects.
Alternatively, the IL-12 and IL-18 expressing plasmids may have functioned directly, 
through a mechanism other than increased IFN-y production. Natural killer cells and 
activated CD8+ T lymphocytes are integral to the cell-mediated immune response.
261
They target and lyse cells which express foreign antigens in the context of their MHC 
class I molecules, such as tumour cells and cells infected with microbial agents. Both 
IL-18 and EL -12 augment natural killer cell and activated T lymphocyte proliferation 
and cytolytic activity (Dao et al. 1998), and IL-18 is able to activate NK cells 
independently of EL -12 (Okamura et al. 1998). Therefore, in this system, the IL-12 
and EL-18 expressing plasmids may mediate their adjuvant effect by directly 
stimulating and expanding the populations of both these cell types, primed by the 
antigenic component of the FeLV DNA vaccine. Consequently, after viral challenge, 
enhanced targeting and lysis of FeLV infected cells should result.
Another option to consider is that the IL-18 expressing DNA plasmid alone was 
responsible for the observed adjuvant effect. Unfortunately, a group of cats co­
inoculated with vaccine and EL-18 alone could not be included for logistical reasons, 
to act as a comparison and to evaluate this hypothesis. IL-12 was considered to 
possess a broader range of actions, and be capable of mediating these actions alone, 
while IL-18 often appeared to require the presence of IL-12 to mediate its effects. For 
example, although E L -18 was found to be essential for the effective induction and 
activation of Thl cells by E L -12, the former cytokine was found to be unable to 
induce the development of Thl cells, by itself (Okamura et al. 1998). For these 
reasons, a vaccine and IL-12 group and vaccine and IL-12 and IL-18 group were 
included in the trial, in preference to a vaccine and IL-18 alone group.
Since the EL-12 expressing DNA plasmid by itself was not an effective vaccine 
adjuvant, and may actually have reduced vaccine efficacy, it is feasible that the IL-18 
component of the IL-12 and IL-18 combination mediated the adjuvant effects. 
Alternatively, although IL-12 by itself was an ineffective adjuvant, perhaps working 
in synergism with IL-18, it became an essential part of the adjuvant combination. 
Future FeLV DNA vaccination trials should include a vaccine and EL-18 alone group, 
to further investigate and dissect the adjuvant effects of EL-12 and IL-18, alone and in 
concert.
An interesting recent report on the efficacy of IL-18 as an adjuvant in DNA 
vaccination studies, has questioned its prototypical Thl type cytokine role (Kim et al.
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1998). When co-inoculated with different plasmids encoding HIV-1 proteins, an IL- 
12 expressing DNA plasmid polarised the resulting immune response strongly 
towards cellular immunity, as expected. In contrast, an IL-18 expressing DNA 
plasmid induced dramatic increases in antibody production, with only modest 
increases in CTL activity. Therefore, in that study, it appeared that the 
immunomodulatory chararcteristics of IL-18 were similar to a Th2 type cytokine, 
rather than a Thl type. The results of this study illustrate an important point; that a 
particular cytokine may mediate different immunomodulatory effects in different 
systems and species of animal. However, if IL-12 and IL-18 mediated similar effects 
to the above in the FeLV DNA vaccination trial, with IL-12 strongly enhancing 
cellular immunity and IL-18 enhancing humoral immunity, this dual enhancement 
may represent another theory to explain how the cytokine combination mediated its 
protective adjuvant effect. Again, future FeLV DNA vaccination trials, including the 
groups detailed previously and fully investigating the cellular and humoral immune 
responses elicited by vaccination, should dissect the mechanisms of protection more 
fully.
Another interesting hypothesis to consider is that the cytokines IL-12 and IL-18 were 
acting as immunotherapeutic agents, rather than vaccine adjuvants, and were, by 
themselves, responsible for the protection against FeLV infection, observed in the 
cats in group D. The antigenic component of the vaccine, therefore, would be 
irrelevant and redundant. Evidence to support this hypothesis is provided by the fact 
that the antigenic component of the FeLV DNA vaccine did not elicit any FeLV 
specific antibodies, before viral challenge. Reasons for this apparent lack of humoral 
immune response are considered in section 4.4.3. Expression of a reporter gene in 
murine skeletal muscle and biological activity of the encoded enzymes for up to 60 
days after inoculation has been reported (Wolff et al. 1990). Consequently, it is 
feasible that the IL-12 and IL-18 expressing DNA plasmids may have been 
expressing the respective cytokine proteins in vivo at a continual low level, over a 
prolonged period of time so that when viral challenge was performed, three weeks 
after the last immunisation, levels of the immunostimulatory IL-12 and IL-18 
proteins may still have been elevated in the animals inoculated with these DNA 
constructs, in group D. The elevated levels of endogenous IL-12 and IL-18 proteins
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may then have acted as immunotherapeutic agents, stimulating the development of 
Thl cell populations and non-specifically yet dramatically enhancing the immune 
response raised against the challenge virus, so that all the cats in group D were 
protected against the development of persistent viraemia. However, although no 
FeLV specific antibody response was elicited in any of the cats, the cellular immune 
response to the FeLV vaccine antigens was not investigated. Therefore, the vaccine 
antigens may have instead generated a protective, FeLV specific cellular immune 
response, to which the cytokines IL-12 and IL-18 added an adjuvant effect. To 
evaluate and investigate this hypothesis further, future FeLV DNA vaccination trials 
should investigate the FeLV specific cellular immune response and include a control 
group of cats, inoculated with only the DNA plasmids expressing IL-12 and IL-18, to 
ascertain whether this combination of cytokines is sufficient to protect cats from 
FeLV challenge. However, the above is an unlikely hypothesis, as the FeLV DNA 
vaccine alone did initially provide some degree of protection against viral challenge.
In conclusion, IL-12 and EL-18 most likely acted as vaccine adjuvants, enhancing the 
efficacy of the novel FeLV DNA vaccine. Considering the well documented 
synergistic effect of IL-12 and IL-18 in increasing IFN-y production (Micallef et al.
1996), elevated endogenous IFN-y levels may indeed have been the mechanism by 
which the IL-12 and IL-18 DNA constructs enhanced vaccine efficacy. Future FeLV 
DNA vaccination trials, including the groups and additional tests suggested above, 
should elucidate the mechanisms of protection more fully.
4.4.2.2.4.2 The role o f viral challenge in establishing protection
The first post-challenge blood sample was collected from all the cats three weeks 
after viral challenge. Although for the remainder of the trial all the cats in group D 
consistently tested negative for p27 antigen and virus, at three weeks after challenge 
one cat in group D tested weakly p27 antigen positive. For an effective cellular 
immune response to be produced in vivo, cells have to be infected with virus. 
Therefore, the vaccine and adjuvants may mediate their protective effects by initially 
allowing the development of low levels of infection after viral challenge, in order to 
stimulate the CTL response.
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Viral challenge may, in fact, act as a booster to the effect of the immunisation course. 
As the CTL response matured, virus infected cells would be targeted and lysed and 
complete immunity would subsequently develop. Therefore, the FeLV DNA vaccine 
may not produce sterilising immunity, but if vaccinated cats are ultimately protected 
from the development of persistent and latent FeLV infection, this may not 
necessarily be important. Perhaps if blood samples had been collected earlier, one or 
two weeks after viral challenge, p27 ELISA and virus isolation results would have 
been positive for more, or even all, of the cats in group D, indicative of low levels of 
FeLV infection. Future trials should thoroughly investigate the role of the cellular 
immune response in establishing immunity to FeLV and include a blood sample 
collected one or two weeks post viral challenge, to investigate the above hypothesis.
4.4.2.2.4.3 Protection against latent infection
Latent infection of bone marrow occurs in a significant proportion (between 30 and 
60%) of ostensibly immune cats, following recent recovery from FeLV infection and 
viraemia (Pedersen et al. 1984). It is usually a temporary state (Pacitti and Jarrett, 
1985), and by six to eight months post-viraemia, most naturally infected cats have 
completely eliminated the virus (Pedersen et al. 1984). Although most latently 
infected animals do not actively excrete virus (Madewell and Jarrett, 1983), 
transmission of FeLV via the milk of a latently infected nonviraemic queen, to her 
kittens, has been demonstrated (Pacitti et al. 1986). This illustrates that in a breeding 
colony, at least, latent FeLV infection may represent a potential source of infective 
virus. Therefore, the production of a vaccine which could completely protect against 
the development of persistent and latent FeLV infection would be extremely 
desirable.
At present, very few commercial or experimental vaccines are able to protect against 
the development of latent FeLV infection. Two inactivated whole viral vaccines are 
available which have been demonstrated to be highly efficacious in protecting cats 
against persistent viraemia and latent FeLV infection: Fel-O-Vax, (Fort Dodge), 
(Hoover et al. 1996), (Legendre et al. 1991) and Fevaxyn FeLV , (Solvay-
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Dulphar/Fort Dodge), (Pedersen, 1993), (Hines et al. 1991). Although Fel-O-Vax is 
extremely efficient in protecting against the development of persistent viraemia, one 
study demonstrated that almost one half of the non-viraemic, protected cats were 
transiently viraemic during the trial (Legendre et al. 1991) and almost half were 
latently infected, 23 weeks after viral exposure. Similarly, a study involving Fevaxyn 
FeLV, found that although this vaccine completely protected all vaccinates (10/10), 
from latent infection (Pedersen, 1993), the strain of FeLV used for challenge did not 
produce a high proportion of latent infections, when compared with other strains 
(Pedersen et al. 1984). Therefore, although Fevaxyn FeLV and Fel-O-Vax 
demonstrate the most consistent protection against FeLV challenge, compared with 
other commercially available vaccines, neither are able to completely prevent the 
development of transient or latent FeLV infection.
In contrast, the FeLV DNA vaccine and IL-12 and IL-18 adjuvant combination 
completely protected all six cats in group D from persistent and transient viraemia; 
that is, the vaccine achieved 100% protection. Section 1.2. reviews the efficacy of 
most of the experimental and commercially available FeLV vaccines and, although 
the size of the protected group D is small (six cats), 100% protection compares 
extremely favourably with the protection achieved by these other vaccines. 
Additionally, only one out of six of the cats in group D was latently infected with 
FeLV, 15 weeks after viral exposure. Moreover, this one cat was retested six weeks 
later, 21 weeks after viral exposure, and was found to be completely clear of virus, 
when virus isolation was performed on cultured bone marrow. Again, this compares 
very favourably with the degree of protection against latency achieved by Fel-O-Vax 
(Legendre et al. 1991); five out of twelve vaccinated cats were found to possess 
latent FeLV infection in their bone marrow, 23 weeks after viral exposure. Therefore, 
the FeLV DNA vaccine and EL-12 and IL-18 adjuvant combination appear to be 
superior to many of the commercially available and experimental FeLV vaccines, in 
terms of protecting against the development of transient and persistent viraemia and 
latent FeLV infection.
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4.4.3 DNA VACCINATION DOES NOT ELICIT VIRUS NEUTRALISING 
OR NON-VIRUS NEUTRALISING ANTIBODIES
Neither virus neutralising nor non-neutralising antibodies were elicited in any of the 
cats, after immunisation with the FeLV DNA vaccine and adjuvants. However, a 
significant number of cats were protected against viral challenge, so development of 
pre-challenge antibodies did not correlate with protection against persistent FeLV 
infection. The absence of an FeLV specific humoral immune response, pre-viral 
challenge, may be due to one or more of the following reasons.
4.4.3.1 Potentiation of the cellular immune response
Firstly, the nature of the DNA used for immunisation and the route of immunisation 
employed may have influenced the type of immune response elicited. Unmethylated 
CpG motifs, present in plasmid DNA, have been shown to possess T-helper type 1 
immunostimulatory activity (Pisetsky, 1996) and stimulate the development of 
cellular immunity, while saline DNA inoculations, intradermal or intramuscular, 
stimulate predominantly Thl type immune responses (Feltquate et al. 1997). 
Therefore, the intramuscular inoculations of naked plasmid DNA, administered to the 
cats in this trial, may have skewed the immune response towards the cellular arm. 
Similarly, all the adjuvants co-inoculated with the vaccine were plasmids expressing 
Thl type cytokine genes, IL-12, IL-18 and IFN-y, potentially able to steer the 
immune response further towards the cellular arm. Moreover, in vitro studies have 
documented the importance of the cell mediated response in host defence against 
FeLV infection (Charreyre and Pedersen, 1991). Perhaps all the above factors 
contributed to the potentiation of the cellular immune response, at the expense of the 
humoral immune response, although the complete absence of FeLV specific humoral 
immunity was an unexpected outcome. Alternatively, immunisation with the FeLV 
DNA vaccine may prime the immune system to produce FeLV specific antibodies, 
subsequent to challenge with live virus. Future FeLV DNA vaccine trials should fully 
investigate the cellular immune response elicited by immunisation, to evaluate the 
above hypothesis.
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4.4.3.2 Cytokine expressing plasmids; vaccine adjuvants or 
immunotherapeutic agents?
Another hypothesis to consider, as discussed in section 4.4.2.2A , is that the cytokine 
expressing plasmids were acting as immunotherapeutic agents and not as vaccine 
adjuvants, non-specifically enhancing the immune response elicited to the challenge 
virus. If the cytokine adjuvants alone were protecting against FeLV infection, and the 
antigenic component of the vaccine was largely irrelevant, an FeLV specific immune 
response, humoral or cellular, would not be elicited in any of the animals. However, 
this is an unlikely hypothesis, as immunisation with the FeLV DNA vaccine alone 
did appear to protect cats from the development of persistent viraemia, at least 
initially. At the first post-challenge bleed only two out of six cats in group A (FeLV 
DNA vaccine alone), tested VI positive, while five out of six of the control cats, in 
group E, tested VI positive. To fully elucidate the mechanisms of protection 
conferred by the FeLV antigen and cytokine DNA constructs, the cellular immune 
response must be investigated in future FeLV vaccination trials.
4.4.3.3 Antigenic competition
Recent studies investigating the humoral immune response elicited in cats following 
DNA vaccination have provided conflicting results. Intramuscular DNA vaccination 
with a defective mutant provirus of feline immunodeficiency virus, FIV, 
(FIVDeltaRT), provided significant protection against FTV infection without inducing 
a detectable pre-challenge antiviral antibody titre. However, pre-challenge cytotoxic 
T-cell (CTL) responses to FIV Gag and Env were elicited (Hosie et al. 1998). 
Meanwhile, immunisation of cats with a DNA vaccine encoding the rabies virus 
glycoprotein G, elicited significant titres of rabies virus neutralising antibody, 
although the intradermal route of inoculation was found to be superior to the 
intramuscular (Osorio et al. 1999). A recent FIV DNA vaccination trial has also 
demonstrated that intramuscular immunisation with DNA plasmids encoding the FIV 
gpl20 protein, induced a humoral immune response (Cuisinier et al. 1997). The 
above may reflect differences in immunogenicity between different antigens and how
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they interact with the feline immune system. Alternatively, the absence of an antigen 
specific humoral immune response in the cats involved in the aforementioned FIV 
trial and this FeLV DNA vaccination trial may be due to antigenic competition. Anti- 
DNA or anti-cytokine antibodies may be elicited as a result of immunisation with 
plasmid DNA or in vivo production of cytokine proteins, respectively, which may 
then overwhelm the FeLV and FIV antigen specific humoral immune response.
4.4.3.3.1 Anti-DNA antibodies
The rapid adoption and implementation of the novel DNA vaccination strategy 
carries with it a number of important safety and efficacy concerns. One of these is 
that DNA vaccination may induce responses against self-antigens, such as the 
induction of anti-DNA antibody production. These anti-DNA antibodies may 
subsequently interfere with the humoral immune response raised against the antigenic 
components of DNA vaccines and trigger the development of autoimmune disease 
(Klinman et al. 1997). In fact, a recent study has documented a three-fold increase in 
the number of B cells secreting immunoglobulin G (IgG) anti-DNA autoantibodies in 
BALB/c mice immunised and boosted with any of three DNA plasmids (Mor et al. 
1997). This correlated with a transient increase in serum anti-DNA autoantibody 
titers but was not associated with the development of glomerulonephritis or 
autoimmune disease. Therefore, the absence of an FeLV specific humoral immune 
response, in the cats involved in this trial, may have been due to the generation of 
such anti-DNA antibodies.
4.4.3.3.2 Anti-cytokine antibodies
Low amounts of high-affinity autoantibodies to various cytokines have been detected 
in serum samples from healthy human donors (van der Meide and Schellekens,
1997). Their levels, although highly variable, were increased in the circulation of 
patients subjected to cytokine therapy or suffering from a variety of immuno- 
inflammatory diseases. It has been suggested that these autoantibodies could play 
various roles, including a regulatory role in the intensity and duration of an immune 
response, and as carrier proteins, preventing the rapid elimination of cytokines from
269
the circulation, thus increasing their bioactivity. However, they may also neutralise 
endogenously produced cytokines with possible pathological consequences. It has 
been hypothesised that immunisation with DNA plasmids encoding cytokine genes, 
as vaccine adjuvants, may elicit such autoantibodies. These, in turn, may interfere 
with the humoral immune response raised against the antigenic components of DNA 
vaccines. Therefore, in theory, the absence of an FeLV specific humoral immune 
response, in the cats involved in the FeLV DNA vaccination trial, may be due to the 
induction of such auto-antibodies.
In conclusion, the inability of the FeLV DNA vaccine to elicit an FeLV specific 
humoral immune response, most likely reflects differences in immunogenicity 
between different antigens and how they interact with the feline immune system, and 
the very nature of the immunising DNA itself. Relatively few DNA vaccination trials 
have been conducted in cats and those that have investigated the humoral immune 
response have provided conflicting results. As more DNA vaccination trials 
involving cats are performed, researchers may develop a greater understanding of the 
humoral and cellular immune responses elicited in the feline immune system, by this 
novel method of vaccination. Of interest and concern is the theory that auto­
antibodies raised against the immunising DNA and expressed cytokine proteins, may 
have overwhelmed the FeLV antigen specific humoral immune response. Serum 
samples obtained from the cats involved in this trial, 48 hours after each 
immunisation, may be examined, retrospectively, for the presence of such anti-DNA 
and anti-cytokine antibodies.
4.4.4 PCI-NEO; AN EFFECTIV E PLASMID FO R DNA-BASED 
VACCINATION
The pCI-neo Mammalian Expression Vector (Promega) was the plasmid into which 
all the cytokine adjuvant genes were cloned and from which the pUSE vector series 
was derived. This plasmid contains the four features considered necessary for an 
effective DNA vaccine plasmid to possess (Davis, 1997). These are, firstly, a 
bacterial origin of replication that allows amplification of large quantities of plasmid
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DNA for purification; the pCI-neo plasmid contains the fl origin of replication. 
Secondly, a prokaryotic selectable marker gene, such as an antibiotic resistance gene; 
the pCI-neo plasmid contains the neomycin phosphotransferase selectable marker 
gene, expression of which confers resistance to the antibiotic G418 (Promega, 1998).
Thirdly, eukaryotic transcription regulatory elements, that are usually strong viral 
promoter/enhancer elements, allowing high levels of gene expression in a wide range 
of different cell types, are desirable; the pCI-neo plasmid contains the CMV 
(cytomegalovirus) immediate-early enhancer/promoter region. Studies have 
demonstrated the promiscuous nature of the CMV enhancer/promoter in transgenic 
mice, where expression of the chloramphenicol acetyltransferase (CAT) gene, under 
the control of the CMV enhancer/promoter, was observed in 24 out of the 48 tissues 
examined (Schmidt et al. 1990). Moreover, several researchers have demonstrated 
that the CMV promoter is significantly stronger in driving gene expression in muscle 
tissue than the RSV (respiratory syncitial virus) promoter, another strong viral 
promoter (Norman et al. 1997), (Davis et al. 1993). Finally, the ideal DNA vaccine 
plasmid should also contain a polyadenylation sequence to ensure appropriate 
termination of the expressed mRNA and enhance RNA stability and translation. The 
pCI-neo plasmid contains the efficient SV40 late polyadenylation signal which has 
been shown to increase the steady-state level of RNA approximately five-fold more 
than the SV40 early polyadenylation signal (Carswell and Alwine, 1989).
Additionally, the pCI-neo plasmid contains a chimaeric intron, downstream of the 
CMV promoter. This is composed of the 5’ donor site of the first intron of the human 
beta-globin gene and the branch and 3’ acceptor site from the intron of an 
immunoglobulin gene heavy chain variable region. The chimaeric intron is situated 
upstream of the inserted gene to prevent the utilisation of possible cryptic 5’ donor 
splice sites within the inserted cDNA sequence. Transfection studies have reported 
that an intron flanking the inserted cDNA frequently increases the level of gene 
expression (Huang and Gorman, 1990). The increase in expression levels due to the 
presence of the chimaeric intron varies according to the particular DNA insert; 
increases in expression levels of between three and twenty fold have been reported, 
with the luciferase gene and the CAT gene, respectively (Brondyk, 1994). Obviously,
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the presence of the chimaeric intron and the CMV promoter/enhancer in the plasmid 
DNA constructs employed in this trial was desirable, to allow maximal enhancement 
of the expression levels of both the FeLV antigen and adjuvant genes.
4.4.5 DEVELOPM ENT OF POST-CHALLENGE VN ANTIBODIES 
APPEARS TO CORRELATE W ITH  PRO TECTIO N  AGAINST FeLV 
IN FECTIO N
The generation of virus neutralising antibodies is generally thought to correlate with 
protection against FeLV infection (Hoover et al. 1976), although very occasionally 
some cats resistant to infection do not develop VN antibodies, and occasionally 
detectable VN antibodies titres are found in persistently viraemic cats (Charreyre and 
Pedersen, 1991). In this vaccine trial, the development of post-challenge virus- 
neutralising antibodies correlated with protection against persistent viraemia, as 
demonstrated in tables 4.11. and 4.12. None of the persistently viraemic cats 
demonstrated a detectable VN antibody titre. Moreover, all cats which tested virus 
isolation negative thirteen weeks post-challenge possessed a significant VN antibody 
titre, with the exception of four cats. However, one of these cats, L I7, in group C 
(vaccine and IL-12), had tested p27 ELISA and VI positive at the first and second 
post-challenge bleeds, had tested p27 ELISA positive and VI negative at the third and 
fourth post-challenge bleeds and then tested virus isolation positive, again, at the 
final pre-euthanasia bleed, fifteen weeks post-viral challenge. Therefore, the absence 
of virus neutralising antibodies at thirteen weeks post-challenge is not surprising, as 
this cat had obviously developed an incomplete immune response, which was 
incapable of completely clearing the virus.
The other three cats that consistently tested virus isolation negative throughout the 
trial, in the absence of a significant VN antibody titre, all belonged to group B 
(vaccine and IFN-y), L8 (VN=16), L l l  (VN=0) and L I2 (VN=0). It is interesting to 
consider why none of these solidly protected cats developed a significant VN 
antibody response. Firstly, the possibility that these three cats were ineffectively 
challenged, rather than protected from infection by the vaccine and adjuvant
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constructs, should be considered. Intraperitoneal inoculation, although not a difficult 
technique, is prone to operator error; vaccines may be inoculated into the bladder or 
gastro-intestinal tract, rather than the peritoneal cavity. However, failure of the 
challenge technique is not a likely possibility, for several reasons. Firstly, it would be 
an unusual coincidence if the three cats which were challenged incorrectly all 
belonged to the same group. Secondly, it does appear that at least one of the cats, 
L l l ,  was exposed to the challenge virus; this cat tested weakly p27 ELISA positive, 
three weeks after viral challenge. Finally, even if intraperitoneal challenge was 
ineffective in these three cats, they would still be exposed to a second FeLV 
challenge later in the trial, when the persistently infected cats they were housed with 
began to excrete productive virus.
The reason why none of these three solidly protected cats, L8, L l l  and L I2, 
receiving the FeLV DNA vaccine and the IFN-y adjuvant constructs, developed a 
significant VN antibody response, remains unknown. One hypothesis is that the IFN- 
y adjuvant potentiated the development of the cellular immune response, at the 
expense of the humoral immune response. IFN-y is known to be central to the 
development of functional cell-mediated immunity. Perhaps this Thl type cytokine 
skewed the immune response towards the cellular arm to such an extent that 
significant post-challenge virus neutralising antibody titres were not elicited in any of 
the animals. Future FeLV DNA vaccination trials should investigate the cellular 
immune response, by examining the CTL (cytotoxic T lymphocyte) response, to 
FeLV infected cells in vitro.
4.4.6 HAEMATOLOGICAL CHANGES ASSOCIATED WITH EARLY FeLV 
INFECTION
Clinically, during the initial stages of persistent FeLV infection, fever, depression 
and generalised lymphadenopathy may be observed. Six to eight weeks after 
exposure, when the virus has invaded the bone marrow and infected precursor cells, 
laboratory evaluation may reveal anaemia, leukopenia, thrombocytopenia, or 
pancytopenia, and death during this stage may be directly related to haematological
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abnormalities (Baldwin and Ledet, 1994). Moreover, during acute viral infection 
neutrophils may migrate into tissues at a rate which exceeds their release from bone 
marrow, also resulting in a clinical neutropenia. However, persistently infected cats 
normally recover from this stage and experience a period of apparent good health, 
before succumbing to FeLV-related conditions associated with stage 2 of disease 
(Baldwin and Ledet, 1994). These conditions are invariably fatal, and are described 
in section 1.1.6.3.
The main change observed in the haematology results collected during the course of 
this trial was a profound neutropenia in four persistently infected cats, L2 (group A, 
vaccine alone), L9 (group B, vaccine and IFN-y), L10 (group B, vaccine and IFN-y) 
and L I8 (group C, vaccine and IL-12), six weeks after viral challenge, at the second 
post-challenge bleed. This neutropenia was, however, transient, as neutrophil 
numbers returned to the low end of the normal range, over the next six weeks. This 
presumably reflected the balance between the rate of marrow precursor cell 
development and differentiation and the rate of viral replication and infection of 
these precursor cells. No significant differences were detected between the four 
neutropenic persistently infected cats and the other persistently infected cats in the 
cohort, either in terms of haematology results, FeLV status (VI, p27 ELISA result 
and VN antibody titres) or which combination of DNA constructs the cats had 
received. The cats which became profoundly neutropenic may simply have elicited a 
less effective initial immune response against the invading virus, thus temporarily 
allowing neutrophil precursor cell development to be almost completely arrested.
Interestingly, although concurrent neutropenia and lymphopenia are well documented 
in FeLV infection (Bush, 1991), the persistently infected cats involved in this trial 
possessed lymphocyte counts within normal ranges, at all times. Aside from one low 
total white cell count in cat L9, at the first post-challenge bleed, the only cell type to 
be affected by FeLV infection was found to be neutrophils. This may reflect the fact 
that the cats were blood sampled at an extremely early stage of FeLV infection. 
Perhaps if the trial had continued over a longer time period haematological changes 
may have been observed in other cell types, such as lymphocytes. Natural field cases 
of FeLV infection are usually only identified when clinical signs become evident and
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therefore disease progression is already fairly advanced. In conclusion, the 
haematological data collected during the trial may be an important source of 
information, documenting the haematological changes in the very earliest stages of 
experimental FeLV infection.
4.4.7 IMPORTANCE OF REMOVAL OF CONTAMINATING ENDOTOXIN 
FROM DNA TO BE USED FOR VACCINATION
Endotoxins are derived from components of the cell wall of gram-negative bacteria 
and consist of lipopolysaccharide and variable amounts of protein and lipid. The 
biological effects of endotoxin are numerous and include activation of complement 
and coagulation pathways and modulation of the activity of platelets, neutrophils, 
monocytes/macrophages and endothelial cells (Morrison and Ulevitch, 1978). 
Bacterial endotoxin may induce pathogenic states in mammals, such as septic shock 
(Lamping et al. 1998). A recent DNA vaccination study demonstrated that the IgG 
response to DNA-encoded antigens, contaminated with high levels of bacterial 
endotoxin, was inhibited in a dose-dependent manner, when the intra-dermal route of 
DNA immunisation was utilised (Boyle et al. 1998). Thus, the presence of 
contaminating endotoxin may actually interfere with the immune response generated 
by DNA vaccine antigens. As the plasmid DNA for this trial was grown in 
Escherichia coli bacteria, and endotoxins are released during the lysis step of plasmid 
purification, it was absolutely imperative that all contaminating bacterial endotoxin 
was removed, prior to the injection of DNA into kittens.
The Qiagen EndoFree plasmid Giga kit used to prepare the DNA for the trial 
included an efficient endotoxin removal step before plasmid purification on a 
Qiagen-tip. This preparation method effectively reduced endotoxin levels, in all 
seven DNA samples, to almost undetectable levels; less than 0.5 EU per millilitre of 
plasmid DNA, as determined by the LAL endotoxin assay, (performed by Q1 
Biotech). As the DNA was supplied to Q1 Biotech at a concentration of one 
milligram per millilitre, 1 mg/ml, this meant that endotoxin levels were less than 
0.5EU per milligram of plasmid DNA. The minimum pyrogenic dose of endotoxin
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for man, administered intravenously, is 4 - 8 EU per kilogram bodyweight and for 
rabbits the figure is 10 - 15 EU/kg (Hochstein, 1987). As the one to two kilogram 
cats were immunised with lOOpg of each construct, receiving a minimum of one and 
a maximum of five constructs and, therefore, only lOOpg - 500|LXg of DNA at any 
timepoint, this meant the endotoxin levels these animals received were almost 
negligible and well below the accepted limits. As expected, no adverse reactions after 
vaccination with this ultrapure, endotoxin free DNA were observed in any of the 
kittens.
4.4.8 PRODUCTIVE VIRUS IS NOT PRODUCED AS A RESULT OF 
HOMOLOGOUS RECOMBINATION BETWEEN VACCINE ANTIGENS 
AND ENDOGENOUS RETROVIRAL SEQUENCES
The FeLV DNA vaccine, consisted of two separate pUSEl"CM VT series plasmids, 
one expressing FeLV gag/pol genes, and the other expressing FeLV subgroup A env 
gene. Although the expressed structural and regulatory FeLV proteins were 
assembled into infective FeLV virions, these “empty” virions lacked a functional 
viral genome, and were therefore not capable of replication, proviral integration or 
establishing infection. However, there was a theoretical concern that the FeLV 
antigen constructs would be able to recombine with exogenous non-pathogenic or 
endogenous feline retroviral sequences, enFeLV, resulting in the production of 
replication competent virions, capable of establishing productive FeLV infection in 
cats. In fact, FeLV B subgroup variants are thought to arise through recombination 
events between exogenous FeLV A subgroup isolates and endogenous feline 
retroviral sequences (Neil et al. 1987), (Stewart et al. 1986).
The consistently negative virus isolation and p27 ELISA results (illustrated in table 
5.9.), obtained after screening the pre-viral challenge blood samples, determined that 
all the cats were free from FeLV infection and productive virus was not produced by 
homologous recombination between FeLV vaccine antigens and exogenous non- 
pathogenic or endogenous feline retroviral sequences. It was obviously very 
important to establish the above, in order to determine that the vaccine was safe to
276
administer and would not, by itself, cause disease or any adverse side-effects, such as 
pyrexia, inappetance, or local reactions at the vaccination site. To this end, the kittens 
were carefully observed by cattery staff for the twenty-four hour period following 
each immunisation. Twenty-four hours after each immunisation the temperature, 
pulse, respiration rate and general demeanour of every kitten was recorded and the 
vaccination site was examined. No local or systemic reactions were observed in any 
of the kittens at any time after immunisation with the FeLV antigen or cytokine 
adjuvant DNA constructs. Therefore, it was concluded that the FeLV DNA vaccine 
and cytokine constructs were safe to administer to cats.
4.4.9 SUMMARY
In conclusion, the FeLV DNA vaccine and cytokine constructs were determined to be 
safe to administer to cats. Although the FeLV DNA vaccine alone did not protect 
cats from the development of FeLV infection, the addition of IL-12 and IL-18 
expressing DNA constructs markedly enhanced vaccine efficacy. IL-12 and IL-18, 
administered together, appeared to act as potent vaccine adjuvants, when co­
inoculated with the novel FeLV DNA vaccine, providing protection against the 
development of transient and persistent viraemia and latent bone marrow infection. 
In contrast, IL-12 alone and IFN-y were not effective vaccine adjuvants in this 
system. Interestingly, FeLV DNA vaccination did not elicit any FeLV specific 
antibodies.
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5. CHAPTER FIVE; DETERMINATION OF 
DISTRIBUTION OF PLASMID DNA CONSTRUCTS IN 
PERIPHERAL BLOOD USING PCR
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5.1 INTRODUCTION
The advent of DNA vaccination technology has generated much excitement 
regarding the potential of these new vaccines to be employed in preventative and 
therapeutic vaccine strategies. As discussed in chapter one, W olff et al demonstrated 
that the injection of pure DNA or RNA directly into mammalian skeletal muscle 
resulted in significant expression of the gene encoded protein within the muscle cells 
(Wolff et al. 1990). Moreover, the expression of the reporter gene in skeletal muscle 
and biological activity of the encoded enzymes were detected for up to 60 days after 
inoculation. Since this initial finding many research groups have continued to explore 
the therapeutic potential of DNA vaccination, achieving effective immunisation 
against viruses by intramuscular injection of DNA plasmids encoding viral proteins 
(Ulmer et al. 1993), (Donnelly et al. 1997a).
However, before DNA vaccines can be considered completely safe for use in human 
clinical trials, preclinical toxicology and pharmokinetics studies must be conducted. 
There are widely held concerns regarding the uptake and long-term persistence of 
plasmid DNA in human tissues, such as the testes and ovaries, with the obvious 
implication that plasmid DNA may integrate into the germline. Integration of plasmid 
DNA into the host genome may lead to insertional mutation, activation of oncogenes 
and, therefore, possible tumourigenesis (Ramsay et al. 1997). Furthermore, aside 
from the safety aspect, information regarding the tissue distribution of the DNA 
vaccine plasmids at specific time points after inoculation may further elucidate the 
mode of action of DNA vaccination.
Performing pharmokinetic studies with nucleic acids, however, presents a challenge. 
The therapeutic potential of a DNA vaccine construct is based on its specific 
nucleotide sequence. Therefore, when determining the distribution of a DNA vaccine 
construct post-inoculation, ascertaining that its specific sequence is present is 
obviously important. The application of traditional radiolabelling techniques in these
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circumstances is extremely limited. Nucleic acids are degraded very rapidly in the 
body, to individual nucleotides, and these nucleotides may then be reincorporated 
into endogenous DNA (Winegar et al. 1996). Hence, the detection of radiolabel in 
tissues or blood may not indicate that an intact DNA sequence is present. Molecular 
biology techniques may overcome these difficulties and allow sequence-specific 
quantification.
The polymerase chain reaction (PCR) allows exponential amplification of specific 
DNA sequences (Mullis and Faloona, 1987). DNA isolated from tissue and body 
fluid samples may be added to a reaction mix containing a pair of sequence specific 
primers, Taq polymerase and deoxyribonucleotides. Following repeated cycles of 
denaturation, annealing and extension, up to 1012 copies of the DNA target sequence 
may be obtained (Winegar et al. 1996). A recent study has described a method 
designed to examine the tissue distribution and level of a DNA plasmid encoding the 
HIV gag/pol genes, following DNA inoculation in rabbits (Winegar et al. 1996). A 
quantitative, competitive PCR technique, which was designed to minimise the 
potential risk of contamination, was employed by this research group. By varying the 
amounts of an internal standard sequence that was competitively co-amplified with 
the target sequence, the copy number of the target sequence could be determined with 
a reasonable degree of accuracy.
Using the above technique, this study examined a variety of tissues and body fluids at 
specific time points after exposure to plasmid DNA. Plasmid DNA was found 
predominantly in the skin and muscle at the injection site and in blood plasma. 
Initially, four hours after dosing with 400|ig of DNA, the plasmid was detected in the 
muscle at higher copy numbers than in the skin. However, plasmid copy number 
declined rapidly in muscle in the first 24 hours after inoculation and was undetectable 
at 7 and 28 days post-inoculation. In contrast, the decline in plasmid copy number 
was slower in skin and, in fact, plasmid was still detectable in this tissue at 28 days 
post-inoculation (Winegar et al. 1996).
In an attempt to establish the presence or absence of DNA constructs in plasma and 
PBMC samples collected at specific time points after immunisation with the FeLV
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DNA vaccine, a PCR technique was developed. The PCR employed primers which 
specifically amplified a 2206bp fragment of the plasmid backbone, present in all the 
cytokine and FeLV antigen vaccine constructs. In order to determine the sensitivity of 
the PCR a number of positive and negative control reactions were set up each time 
PCR amplification was performed. Distilled water and total DNA isolated from 
serum samples were spiked with various copy numbers of the pCI-neo plasmid. 
Additionally, serum samples were spiked with various copy numbers of the pCI-neo 
plasmid before total DNA was isolated from these samples. Therefore, although this 
PCR technique was not quantitative, the inclusion of the three sets of positive 
controls allowed the determination of the lowest copy number of plasmid able to be 
amplified in each separate batch of reactions. Blood samples were collected from the 
kittens 48 hours after each consecutive immunisation and at three week intervals 
post-viral challenge, as described in section 4.2.1. It was hoped that this technique 
would determine whether DNA constructs were detectable in the plasma or cellular 
compartments of the peripheral blood at these times.
5.2 MATERIALS AND METHODS
5.2.1 SAMPLE COLLECTION
Section 4.2.1.4. describes the blood sampling schedule employed in the vaccine trial 
and details when blood samples were collected and subjected to PCR analysis to 
determine the presence or absence of the DNA constructs. To summarise, pre­
immunisation blood samples were collected from all 29 kittens, to confirm the 
absence of the DNA constructs, pre-trial, in the plasma and PBMC fractions. Blood 
samples were then collected forty-eight hours after each immunisation and at three, 
six and nine weeks after the last immunisation, (weeks 8, 11 and 14, respectively, of 
the trial.)
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5.2.2 DNA PURIFICATION FROM PLASMA AND PBMCS
DNA was extracted from plasma and PBMC samples in a tissue culture laminar flow 
hood, in a separate site from where the PCR reactions were set up and from where 
the PCR reaction products were visualised by polyacrylamide gel electrophoresis, in 
order to avoid contamination. Anti-aerosol tips and dedicated micropipettes were 
employed and positive control DNA samples were synthesised at different times from 
the test samples.
5.2.2.1 Test samples
Plasma and PBMC samples had been previously stored at -70°C. DNA was extracted 
from plasma and PBMC samples, using the QIAamp Blood Kit (Qiagen), according 
to the manufacturer’s protocol, with the following modifications. Due to the size of 
the kittens, small volumes of blood were collected. Therefore, DNA was purified 
from lOOjil of plasma diluted with lOOjil of PBS, rather than purifying from a 200|il 
volume of plasma, as recommended by the protocol. Similarly, DNA was purified 
from lOOpl of the PBMC fraction diluted with lOOp.1 of PBS. The yield of DNA for 
the plasma and PBMC samples was predicted to be less than 5|ig. Therefore, elution 
of the DNA was performed using lOOjil of buffer AE, as the protocol recommended 
that for samples containing less than 5(ig of DNA elution in lOOpil rather than 200jll1 
increased the final DNA concentration in the elutate. Finally, the eluted DNA 
samples were stored at -20°C prior to the performance of PCR amplification.
5.2.2.2 Positive and negative controls
To ensure that DNA extraction was being performed correctly, PCR amplification 
was working efficiently and to allow the determination of the lowest copy number of 
plasmid able to be amplified each time the PCR procedure was carried out, two sets 
of positive control DNA samples were synthesised. Firstly, IOOjllI of serum from a 
SPF cat was aliquoted into six 1.5ml tubes. Using the formula;
1 mole of plasmid = length in bp x 660
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1 mole of pCI-neo plasmid was determined to weigh 3.6 x 106g.
Dividing the above by Avagadro’s number, one molecule, or one copy number of 
pCI-neo was calculated to weigh 6 x 10'12|ig. Using this information, the following 
series of dilutions of pCI-neo was then made; 1011 copy numbers/p.1, 109 copy 
numbers/|il, 106 copy numbers/|il, 103 copy numbers/|il, 102copy numbers/p.1 and 10 
copy numbers/ jxl. lp l of these six dilutions of pCI-neo were then added to the six 
tubes containing IOOjllI of SPF cat serum and DNA was extracted from the spiked 
serum samples using the QIAamp Blood Kit (Qiagen), according to the 
manufacturer’s protocol. This set of positive control samples was termed set 1.
A second set of positive control samples, set 2, was created by extracting DNA from 
SPF cat serum using the QIAamp Blood Kit, and then spiking the newly extracted 
DNA with the dilutions of pCI-neo described above. Finally, to ensure that 
contamination was not occurring during the DNA extraction process, DNA was 
extracted from IOOjllI of SPF cat serum, (with no pCI-neo DNA added), each time 
DNA was isolated from test plasma or PBMC samples. This negative control DNA 
sample was subsequently subjected to PCR amplification, to ensure that 
contamination was not occurring during the PCR procedure.
5.2.3 PCR AMPLIFICATION TO DETECT DNA CONSTRUCTS
DNA extracted from plasma and PBMC samples, collected from all 29 kittens forty- 
eight hours after each of three immunisations and at three, six and nine weeks after 
the last immunisation, was subjected to PCR amplification as described below. All 
PCR reactions were performed in duplicate. PCR reactions were set up in a tissue 
culture laminar flow hood, in a different site from where the DNA extraction was 
performed and from where the PCR reaction products were visualised by 
polyacrylamide gel electrophoresis. Anti-aerosol tips and dedicated micropipettes 
were also employed, in order to avoid contamination.
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5.2.3.1 Design of primers
Primers were designed to amplify a 2206 bp fragment from nucleotide 3268 to 5474 
in the backbone of the pCI-neo vector, the plasmid into which all the cytokine 
adjuvant genes were cloned. The pUSEl" vector, into which the FeLV gag/pol and 
env A  antigens genes were cloned, also contained this 2206 bp fragment, as this 
vector series was derived from the pCI-neo plasmid. The following primers were 
employed in the PCR amplification;
5’ primer: 5’-CTGGGTTTAAACATGACCGACCAAGCGAC-3’
3 ’ primer: 5 ’ - ATCTGGCGCGCC ATGTG AGC AAA AG-3 ’
5 .2 3 .2  Reaction conditions
Reactions were performed in 50 |il volumes in 0.5 ml tubes. A master reaction mix 
was prepared by combining 5 jll1 of 10 x PCR buffer, 4 jlx1 of 25mM MgCl2 solution, 
5|il of deoxynucleotide (dNTP) mix (1.25 mM each dNTP), 20|il of dH20 , 20pmoles 
of each primer and 1.25U (0.25pl) of Taq polymerase in 4.75|il dH20  for each 
sample. The use of such a master mix minimises losses and inaccuracies associated 
with pipetting and ensures consistency from tube to tube. 40|il of this mix was then 
pipetted into each reaction tube, which contained 10|il of DNA template (control or 
test template). The reaction mix was then overlaid with mineral oil and the tubes 
were transferred to the thermal cycler. After a 5 minute denaturation incubation at 
94°C, the thermal cycler was programmed to give 30 cycles of denaturation (94°C for 
1 minute), annealing ( 59°C for 1 minute) and extension (72°C for 2 minutes), 
followed by a 10 minute extension step at 72°C and finally by a 4°C ‘soak’. PCR 
reaction products were visualised by polyacrylamide gel electrophoresis as detailed in 
2.2.2.5.2, using 10|il of reaction product per well.
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5.2.3.3 Positive and negative controls
In order to assess the efficiency and sensitivity of the PCR process and to ensure that 
contamination had not occurred, a number of positive and negative controls were set 
up each time PCR amplification was performed.
5.2.3.3.1 Positive controls
Three sets of positive controls were set up each time PCR amplification was 
performed. The synthesis of two of the sets of positive control DNA, sets 1 and 2, is 
described in section 5.2.2.2. As 10|il of DNA template (one tenth of the total elutate 
volume) was added into each PCR reaction, 1010, 108, 105, 102, 10 and 1 copy 
number of the pCI-neo plasmid were amplified. The third positive control set (set 3)
0  f \ ^ 9consisted of 1 0 , 1 0  , 1 0 , 1 0 , 1 0  and 1 copy number of the pCI-neo plasmid simply 
diluted with the appropriate volume of d t^O  and added into the PCR reaction mix.
5.2.3.3.2 Negative controls
Each time a series of PCR reactions was set up two negative controls were also 
included. A reaction mix was prepared containing all PCR components, (primers, 
dNTPs, M gCb solution, PCR buffer and Taq polymerase), except template. This 
control was performed to check that there was no contamination of the PCR reactions 
with extraneous template that might serve as a template for PCR amplification. 
Secondly, lOjal of the negative control DNA sample, the synthesis of which was 
described in section 5.2.2.2., was also subject to PCR amplification. This control was 
performed to determine if contamination had occurred in either the DNA extraction 
process, or in the PCR amplification. The inclusion of both these negative controls 
allowed the source of any potential contamination and the stage at which it occurred 
to be determined more accurately.
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5.3 RESULTS
5.3.1 PCR AMPLIFICATION OF POSITIVE CONTROL DNA SAMPLES
Figure 5.1. shows a polyacrylamide gel loaded with the PCR products obtained after 
amplification with the primers and PCR conditions described in section 5.2.3., and 
using template from all three sets of positive control DNA, described in section 
5.2.3.3.I. Plasmid DNA was able to be amplified from all three sets of positive 
control DNA with a similar degree of sensitivity; from 1010-109 copy numbers of 
plasmid, down to a single copy. In lanes 3, 9 and 15 the presence of a single PCR 
product of the correct size (approximately 2200bp) indicated that a single copy 
number of plasmid was able to be amplified by this PCR technique. However, this 
amplification of a single copy of plasmid was not reliable; perhaps only 1 in 2 or 1 in 
3 PCR amplifications achieved this degree of sensitivity. In contrast, 10 copy 
numbers of plasmid were consistently amplified by this technique, from all three sets 
of positive control DNA, as demonstrated in lanes 4, 10 and 16. Therefore, the limit 
of the sensitivity of this PCR technique was determined to be 10 copy numbers of 
plasmid.
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Lane 1 2 3 4 5 6  7 8 9  10 11 12 13 14 15 16 17 18 19 20
Figure 5.1. 5% polyacrylamide gel showing the reaction products of a typical 
PCR reaction used to amplify the positive and negative control DNA samples.
Lane 1: molecular size markers (<J)X 174 RF DNA/Hae III fragments and X DNA/Hind 
III fragment markers); Lane 2: negative control (DNA extracted from SPF cat 
serum); Lanes 3, 4, 5, 6, 7 and 8: 1, 10, 102, 105, 108 and 10l() copy numbers of the 
pCI-neo plasmid added into the PCR reaction mix, set 1 positive control DNA (pCI- 
neo DNA added to SPF cat serum before QIAamp DNA extraction); Lanes 9, 10, 11, 
12, 13 and 14: 1, 10, 102, 105, 108 and 10lucopy numbers of the pCI-neo plasmid 
added into the PCR reaction mix, set 2 positive control DNA (pCI-neo DNA added 
to SPF cat serum after QIAamp DNA extraction); Lanes 15, 16, 17, 18, 19 and 20: 1, 
10, 102, lO3, 106 and 109 copy numbers of the pCI-neo plasmid diluted with the 
appropriate volume of dFFO and added into the PCR reaction mix, set 3 positive 
control DNA.
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5.3.2 PCR AMPLIFICATION OF NEGATIVE CONTROL DNA SAMPLES
No PCR products were ever detected after PCR amplification of either of the 
negative control reactions, no DNA template and DNA extracted from SPF cat 
serum; the latter is illustrated in figure 5.1., lane 2. Each time DNA was extracted 
from test plasma or PBMC samples an internal negative control DNA extraction 
from SPF cat serum was also performed and each time a batch of PCR reactions was 
set up both negative PCR controls were included. Therefore, it appeared that 
contamination of extracted DNA or PCR reactions with extraneous template was not 
occurring and that positive PCR amplification results obtained were not merely “false 
positives”.
5.3.3 PLASMID DNA CONSTRUCTS WERE NOT DETECTED IN PLASMA 
SAMPLES BY PCR AMPLIFICATION
No PCR products were detected after PCR amplification of DNA extracted from any 
plasma samples, collected either 48 hours after each consecutive immunisation or 
three, six and nine weeks after the last immunisation. In light of the fact that the PCR 
amplification process was determined to be extremely sensitive, consistently 
amplifying as little as 10 copy numbers of plasmid, it appeared that the plasmid DNA 
constructs were not present in the plasma fraction of the peripheral blood at the times 
following immunisation, indicated above.
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5.3.4 PLASMID DNA CONSTRUCTS WERE DETECTED IN PBMC 
SAMPLES BY PCR AMPLIFICATION
5.3.4.1 PBMC samples collected 48 hours after each immunisation
Single PCR products of the correct size were detected after PCR amplification of 
DNA extracted from some of the PBMC samples collected 48 hours after each 
intramuscular plasmid DNA immunisation. Table 5.1. indicates after which 
immunisation and in which kittens the plasmid DNA constructs were identified. The 
kittens were inoculated with lOOpg of each DNA construct, so, in theory the kittens 
in group D, inoculated with lOOpg of five DNA constructs, received five times more 
DNA than the kittens in group E, inoculated with only lOOpg of one DNA construct. 
Therefore, it was predicted that the kittens inoculated with the greatest amount of 
DNA would be more likely to be PCR positive. However, this was not found to be 
the case; the distribution of PCR positive kittens was not related to the group the 
kitten belonged to or the amount of DNA which the animal had received. Indeed, the 
distribution of PCR positive cats was fairly random over the three consecutive post­
immunisation time points. Interestingly, none of the cats in group A and only one cat 
in group B ever tested PCR positive and only two cats, L23 and L28, were 
consistently positive over all three PCR screens, performed on DNA extracted from 
PBMCs collected 48 hours after each of the three consecutive DNA inoculations.
5.3.4.2 PBMC samples collected 3, 6 and 9 weeks after last immunisation
No PCR products were detected after PCR amplification of DNA extracted from the 
PBMC samples collected three, six and nine weeks after the last immunisation. These 
results indicated that although DNA constructs were detected in some of the PBMC 
samples obtained 48 hours after intramuscular immunisation, when longer time 
periods elapsed between immunisation and blood sampling, the PCR technique was 
unable to detect the DNA constructs in PBMCs. The PCR technique described was 
extremely sensitive, amplifying as little as 10 copies of pCI-neo plasmid in positive 
control DNA samples, so it was likely that the DNA constructs had been cleared
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from the cellular fraction of the blood by this time rather than the PCR technique 
failing to amplify the product due to lack of sensitivity.
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48 hours post 48 hours post 48 hours post 
1st immunisation 2nd immunisation 3rd immunisation














L15 C + +
L16 C + +





L22 E + +
L23 E + + +
L24 E +
L25 D + +
L26 D +
L27 D +
L28 D + + +
L29 D + +
L30 D +
Table 5.1. Results of PCR to detect DNA constructs in PBMCs. The results 
indicate in which kittens and after which immunisation the plasmid DNA constructs 
were identified by PCR amplification in DNA extracted from PBMC samples.
Key: A = vaccine alone, B = vaccine + IFN-y, C = vaccine + IL-12,
D = vaccine + IL-12 + IL-18 and E = empty pCI-neo plasmid.
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5.4 DISCUSSION
The PCR technique described in this section is indeed sensitive, amplifying as little 
as 10 copies of pCI-neo plasmid in positive control DNA samples. The PCR 
technique to assess the tissue distribution of a DNA vaccine, described by Winegar et 
al, was also extremely sensitive; quantitative, competitive PCR detected the presence 
of as little as 10 copy numbers of plasmid in rabbit skin, four hours after DNA 
inoculation (Winegar et al. 1996). Using the DNA extraction and PCR techniques 
described in this chapter, plasmid DNA constructs were not detected in any plasma 
samples. Given the extreme sensitivity of the PCR technique, it seemed most likely 
that the plasmid DNA constructs were, in fact, rapidly cleared from the plasma 
fraction of the peripheral blood soon after immunisation. Significantly, Winegar et al 
were only able to detect plasmid DNA in plasma samples collected from two out of 
six rabbits, four hours after they were immunised with 400pg of plasmid DNA. This 
indicated that plasmid DNA entered the bloodstream soon after inoculation. 
However, after this time DNA constructs were not detected in the plasma fraction 
(Winegar et al. 1996) and were assumed to have been cleared from this compartment 
of the peripheral circulation by the next sampling time, 24 hours after DNA 
inoculation. Therefore, in this trial, plasmid DNA constructs may have been detected 
in plasma if blood samples had been collected from the kittens in the first few hours 
following DNA inoculation.
Using the DNA extraction and PCR techniques described in this chapter, DNA 
constructs were detected in some of the PBMC samples collected 48 hours after each 
intramuscular plasmid DNA immunisation, in a random assortment of cats among the 
groups. However, DNA constructs were not detected in PBMC samples collected 
three, six and nine weeks after the last immunisation, indicating that the DNA 
constructs had been cleared from the cellular fraction of the blood by this time. 
Significantly, Winegar et al were only able to detect plasmid DNA in one out of six 
PBMC samples collected four hours after immunisation with 400|ig of plasmid 
DNA. After this time DNA constructs were not detected in the PBMC fraction 
(Winegar et al. 1996) and were assumed to have been cleared from this compartment
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of the peripheral circulation by the next sampling time, 24 hours after DNA 
inoculation. Therefore, the results obtained from this trial indicate that plasmid DNA 
is detectable in PBMCs for a longer time after DNA inoculation, 48 hours at least, 
than had been previously determined (Winegar et al. 1996). Future trials should 
consider collecting PBMCs for PCR amplification at time points between two days 
and three weeks post-immunisation, to determine exactly how long the DNA 
constructs were able to persist in the cellular fraction of the blood.
It is interesting to consider why DNA constructs were detected in PBMC samples 48 
hours after each immunisation and yet were not detected in plasma samples. Recent 
studies have indicated that following intramuscular DNA vaccination, a significant 
proportion of DNA appears to leave the muscle, in blood or lymphatic fluid, and 
travel to the spleen or lymph nodes (Torres et al. 1997). Once there, the DNA may 
transfect resident APCs (Winegar et al. 1996), which then present antigen and 
initiate an immune response. Perhaps plasmid DNA free in plasma is more able to 
enter lymph nodes or the spleen and transfect APCs than plasmid DNA bound to the 
cellular fraction of the blood. Therefore, plasmid DNA bound to PBMCs would be 
more likely to persist in the peripheral circulation. Another important point to 
consider is the random nature of the distribution of PCR positive cats among the 
different groups and over the three consecutive post-immunisation time points, as 
described in section 5.3.4.1. This was perhaps due, at least in part, to the exact 
manner in which inoculations were performed and the site of plasmid DNA 
inoculation. Whether DNA was delivered carefully or with a more destructive, 
aggressive technique into the body of the quadriceps femoris muscle, between layers 
of muscle, or even into a small blood vessel, may have influenced exactly how much 
DNA reached the peripheral circulation and was able to be amplified by the PCR 
technique.
As DNA vaccination is such a recently developed technology, it is too early to 
unequivocally define it as a completely safe method of immunisation. However, to 
date, no experimental evidence for chromosomal integration of injected DNA has 
been produced (Nichols et al. 1995), (Wolff et al. 1992) and several researchers, 
investigating the tissue distribution of DNA plasmids following immunisation, have
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found no evidence to suggest that uptake of recombinant DNA by the testes or 
ovaries occurs (Winegar et al. 1996), (Nabel et al. 1992). At the end of the FeLV 
DNA vaccination trial tissues such as the liver, lungs, spleen, lymph nodes, 
(mesenteric, popliteal, prescapular and iliac), bone marrow, brain, thymus, kidney, 
heart, muscle, (two samples; one from the quadriceps injection site and one from the 
triceps), and ovaries or testes were collected from each cat and stored at -70°C for 
future analysis. Future work will involve the extraction of DNA from these tissues, in 
particular from mesenteric lymph nodes, bone marrow, thymus, spleen and, 
importantly, brain and gonads, and the performance of PCR amplification, in an 
attempt to identify the presence of plasmid DNA constructs. The results obtained will 
determine the tissue distribution of the DNA vaccine constructs; whether plasmid 
DNA is taken up and is able to persist in these important target tissues. Obviously 
this information is crucial when assessing whether this novel mode of vaccination 
will be suitable and safe for widespread use in humans.
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6. CHAPTER SIX; GENERAL DISCUSSION
295
6.1 INTRODUCTION
The primary aims of this project were to clone and sequence the feline homologues 
of the cytokines IL-12 and IL-18, express the IL-18 protein in a mammalian 
expression system and investigate the potential of both IL-12 and IL-18 to act as 
genetic adjuvants in FeLV DNA vaccination studies. These objectives were achieved 
and provide the background for future work investigating the role of these cytokines 
as vaccine adjuvants against feline disease. Furthermore, the production of IL-12 and 
IL-18 recombinant proteins will facilitate the generation of specific polyclonal 
antibodies, through the immunisation of rabbits with the respective cytokine proteins. 
This, in turn, will help to elucidate the role of these cytokines in feline health and 
disease. This chapter briefly considers the advances that have been made in the 
introduction of cytokines to feline medicine and then considers the potential clinical 
applications of IL-12 and IL-18 in cats; as vaccine adjuvants, anti-microbial agents 
and anti-cancer agents.
6.2 THE THERAPEUTIC USE OF CYTOKINES IN FELINE 
MEDICINE
Much interest has been shown in the potential applications of cytokines in domestic 
animals (Dunham, 1999), where the animals are used as models for human disease, 
such as FIV as a model for HIV and AIDS (Willett et al. 1997) and in the therapy 
and prophylaxis of animal diseases, such as the use of IL-12 as an anti-tumour agent 
against an established canine mammary tumour cell line (Okano et al. 1997). Initial 
studies employed human or murine homologues as species specific cytokines were 
either not available, or their supply was extremely limited. This approach, however, 
was restricted by two main factors. In the case of several cytokines there is little or no 
activity in the non-native species. This is especially the case for cytokines which are 
not well conserved between species, such as IL-3. In fact the human and murine IL-3 
proteins share only 29% sequence identity (Yang et al. 1986) and show no cross
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species activity (Gearing et al. 1999). Secondly, even when significant cross-species 
activity does exist, the administration of a heterologous cytokine may result in 
allergic reactions and prolonged administration may lead to the generation of 
neutralising antibodies to the cytokine, in a proportion of animals (Gieger, 1992).
To date, several recombinant human cytokines have been employed in the treatment 
of feline disease, with limited success. Recombinant human erythropoietin, 
granulocyte colony-stimulating factor (G-CSF), interferon alpha and IL-2 have all 
been evaluated in experimental trials. Recombinant human erythropoietin has been 
used in cats to treat the non-regenerative anaemia that accompanies chronic renal 
failure. Administration resulted in increased red blood cell (RBC) counts and clinical 
improvement (Cowgill et al. 1998). However, in a significant number of patients a 
non-regenerative anaemia was observed, more severe than the pre-treatment anaemia, 
attributable to the generation of antibodies to the heterologous recombinant cytokine 
which also cross-react with endogenous feline erythropoietin. Recombinant human 
GCS-F, a lineage specific haemopoietic growth factor, acting principally to increase 
circulating neutrophil counts and upregulate effector functions such as phagocytosis 
and chemotaxis, has been administered to normal cats. Administration has been 
shown to produce a rapid increase in circulating neutrophil numbers (Fulton et al. 
1991). However, prolonged use led to a decrease in neutrophil counts to the normal 
range, again attributable to antibody formation to the heterologous cytokine.
Small scale trials have demonstrated that recombinant human interferon alpha may 
be a useful adjunct to the adoptive transfer of activated lymphocytes to FeLV 
infected cats. With the administration of zidovudine, the above therapy was found to 
reverse viraemia (Zeidner et al. 1995). Interleukin 2 (IL-2), a key cytokine in the 
regulation of T-lymphocyte immune responses, has been widely studied as a potential 
anti-tumour agent, though to invoke anti-tumour immunity, leading to tumour 
regression. The systemic administration of recombinant human EL-2 has been 
successful in the treatment of renal cell carcinomas in human patients (Bukowski et 
al. 1993). However, the systemic administration of IL-2 commonly results in side- 
effects, such as pyrexia, shock and respiratory distress and in more extreme cases, 
comas and death. Local administration of IL-2 is thought to be safer and some
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success has been achieved with this approach in cats. Cats with fibrosarcoma have 
shown less frequent relapses and prolonged survival time when treated with the 
combination of surgery, radiotherapy and the local injection of a human cell line 
expressing the human IL-2 protein, compared to cats receiving surgery and/or 
radiotherapy (Quintin-Colonna et al. 1996).
Although heterologous cytokines may be suitable for short-term use, the cloning of 
species specific cytokines and the subsequent production of recombinant proteins is 
required if the above problems and limitations are to be circumvented. Unfortunately, 
the production of recombinant cytokine proteins in large quantities is extremely 
expensive and, therefore, it is likely that these therapeutic proteins will remain as 
research tools, in the immediate future. However, the use of alternative methods of 
cytokine delivery, such as naked DNA vaccination as described in this thesis, will 
significantly decrease production costs; the cytokine proteins are synthesised 
endogenously using the host cells’ transcriptional machinery. This new technology 
may enable a new array of cytokines to become available for clinical use.
6.3 POTENTIAL CLINICAL USES OF FELINE IL-12 AND IL-18
The clinical applications of IL-12 and IL-18 as anti-microbial and anti-tumour agents 
in human and mouse models have been discussed in sections 3.1.2.6. and 3.1.3.6., 
respectively and their use as vaccine adjuvants has been reviewed in section 1.4.3.2. 
Although almost all of these studies have been conducted in the murine model, the 
encouraging results clearly indicate that both IL-12 and IL-18 have many potential 
uses in the treatment and prevention of feline and ultimately human disease, used as 
single agents or in concert. Indeed, the results obtained from this research and the 
work of other investigators (Osaki et al. 1999), (Zhang et al. 1997), (Qureshi et al. 
1999) indicate that the administration of both cytokines may be the most potent 
combination for use in therapeutic and prophylactic strategies.
Although IL-12 and IL-18 (recombinant proteins or adenoviral vectors expressing 
cytokine proteins) have been administered together, in anti-tumour (Osaki et al.
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1999) and anti-microbial (Qureshi et al. 1999) treatment regimes and both IL-12 (Sin 
et al. 1999) and IL-18 expressing plasmid constructs (Sin et al. 1999) have been 
evaluated separately as DNA vaccine adjuvants, to the author’s knowledge, this is the 
first study to evaluate the combined adjuvant potential of plasmids expressing IL-12 
and IL-18. This is also the first study to attempt to produce a DNA vaccine against 
FeLV. The results obtained clearly demonstrate that the IL-12 and IL-18 combination 
mediated potent adjuvant activity, when coinoculated with the novel FeLV DNA 
vaccine, protecting all immunised cats from FeLV infection. This success leads to the 
idea of investigating the potential of IL-12 and IL-18 to act as adjuvants in FIV 
DNA vaccination, another significant feline retroviral pathogen and an animal model 
for HIV/AIDS (Willett et al. 1997).
To date, limited success has been achieved in the production of an efficacious FTV 
vaccine, with the exception of a whole inactivated virus vaccine (WIV) able to 
protect against homologous challenge with a weakly pathogenic isolate (Petaluma) 
(Hosie et al. 1995) but not against a heterologous FIV isolate (GL-8) which was 
distinct from the Petaluma strain in virus neutralisation. Recently, DNA vaccination 
has been investigated as an alternative approach to FIV vaccine development. In a 
recent DNA vaccination trial immunisation with a defective mutant provirus of FIV, 
FIVDeltaRT, in conjunction with a plasmid expressing feline EFN-y, gave the highest 
proportion of protected cats, with only two of five vaccinates showing evidence of 
infection following challenge (Hosie et al. 1998). As IL-12 and IL-18 are known to 
synergistically increase the production of IFN-y, perhaps the coadministration of both 
these cytokines with the novel FIV DNA vaccine may prove to be a more effective 
adjuvant combination. At present, this work is ongoing in the FIV research group, 
Department of Veterinary Pathology, University of Glasgow. In cats already infected 
with FeLV and FIV IL-12 and EL-18 may also be effective as immunotherapeutic 
agents, acting to non-specifically enhance the cell-mediated immune response against 
these retroviral pathogens.
As discussed in section 3.1. both IL-12 and IL-18 have been shown to be effective 
anti-microbial agents in many murine models of disease (McDyer et al. 1998), 
especially against intracellular bacteria such as Mycobacterium tuberculosis (Cooper
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et al. 1995) and Yersinia enterocolitica (Bohn et al. 1998) and chronic viral 
infections, such as type 2 herpes simplex virus (HSV-2) and murine cytomegalovirus 
(Gately and Mulqueen, 1996). Therefore, these cytokines, administered as DNA 
constructs or recombinant proteins, may be effective therapeutic agents in the 
treatment of chronic infections, such as chlamydia, in cats. Chlamydia, an 
intracellular bacteria, causes reproductive problems and chronic ocular infections, 
which can be extremely problematic to treat. IL-12 and IL-18 may also be useful in 
the treatment of chronic feline herpesvirus type 1 (FHV-1) infections, manifest 
clinically as upper respiratory tract disease. Due to the nature of feline herpesvirus, 
latent infections, able to be reactivated by stress and immunosuppression, are 
common. Interestingly, IL-12 has also been considered as an immunotherapeutic 
agent in the treatment and/or prevention of atopic and allergic disorders (McDyer et 
al. 1998). Therefore, this cytokine may be useful in the therapy of the allergic 
condition, feline asthma.
Due to their multiple immunoregulatory functions, including activation of NK cells, 
CTLs and Thl cells, EL-12 and EL-18, alone or in concert, have been utilised as 
antitumour agents, as discussed in sections 3.1.2.6. and 3.1.3.6. The antimetastatic 
and anti tumour activities of EL-12 have been demonstrated in a number of murine 
models, and the encouraging results have prompted the use of EL-12 as an anti­
tumour agent in the human oncology field. Phase I and II clinical trials in patients 
suffering from renal cell carcinomas and breast carcinomas are ongoing (Lamont and 
Adorini, 1996). To date, EL-18 has been evaluated in murine models as an effective 
anti-tumour agent against malignancies such as fibrosarcoma, melanoma and 
sarcoma (Osaki et al. 1998), (Tan et al. 1998), (Micallef et al. 1997), (Fukumoto et 
al. 1997), (Coughlin et al. 1998), (Osaki et al. 1999), although many of these 
therapeutic strategies have investigated the effects of EL-18 in combination with EL- 
12. The combined administration of feline IL-12 and IL-18 may therefore prove to be 
a useful adjunct to chemotherapy or radiotherapy treatment regimes, either by the 
direct inoculation of recombinant cytokine proteins or DNA plasmids expressing IL- 
12 and EL-18 into tumours, by the systemic administration of recombinant IL-12 and 
EL-18 proteins or by the subcutaneous injection of tumour cells transfected with 
feline EL-12 and/or IL-18 complementary DNA (cDNA). Feline tumours suitable for
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cytokine therapy are melanomas, sarcomas and carcinomas, such as squamous cell 
carcinomas. These cytokines may also be suitable for the treatment of multicentric 
feline lymphosarcoma as murine IL-12 has been demonstrated to inhibit established 
experimental pulmonary or hepatic metastases and reduce spontaneous metastases in 
mice (Brunda et al. 1996).
6.4 FUTURE DIRECTIONS
Clearly, feline IL-12 and IL-18 have a wide therapeutic potential in feline medicine 
and their specific uses and applications have been discussed. Due to the complexity 
of the cytokine network, the administration of one cytokine in vivo may have wide 
ranging and often deleterious effects, altering the levels of other endogenous 
cytokines and disturbing the fine balance that exists between the members of this 
family of glycoproteins. Therefore, the use of cytokines in combination, such as IL- 
12 and IL-18, in experimental animal models may result in the maximisation of their 
potential therapeutic value, while minimising the risk of unwanted side effects.
However, the development of cytokines as therapeutic agents in feline medicine 
depends on a number of other factors, including commercial viability, range of 
potential clinical applications, efficacy, and cost of production. To date the 
commercial application of recombinant DNA technology to clinical veterinary 
medicine has been limited to the development of a recombinant subunit FeLV 
vaccine consisting of the viral glycoprotein gp70, expressed in Escherichia coli 
(Clark et al. 1991). This vaccine, Leucogen (Virbac), is now in widespread use. 
Vaccines obviously have a wide application, as all pet cats may be possible 
recipients, which may compensate for the potentially high research, development and 
production costs. Therefore, the manufacture of the FeLV DNA vaccine and the 
plasmids expressing the cytokines IL-12 and IL-18, to be used as vaccine adjuvants, 
may be a commercially viable venture. Moreover, the wide range of potential clinical 
applications of IL-12 and IL-18, such as anti-tumour and anti-microbial agents, may 
result in the widespread use of these cytokines in clinical veterinary practice.
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Finally, this research may also have wider implications for the field of human 
medicine. As discussed previously, FTV has been described as an animal model for 
HIV and AIDS (Willett et al. 1997). The success of cytokine adjuvant constructs in 
enhancing the efficacy of DNA vaccines against the feline retroviral pathogens FIV 
and FeLV, indicate that this approach should be considered in the development of 
future candidate vaccines against HIV. Moreover, DNA vaccination studies using 
animal models may provide valuable information regarding the safety and efficacy of 
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EMBL European Molecular Biology Laboratory





FBS/FCS foetal bovine serum/foetal calf serum
FeLV feline leukaemia virus
FeSV feline sarcoma virus
FFU focus forming units
FHV feline herpes virus
FTV feline immunodeficiency virus
FOCMA feline oncornavirus-associated cell membrane antigen
g gravity; gram(s)
G gauge; guanine or guanosine; one letter code for glycine
GCG Genetics Computer Group, Wisconsin Package Version 9.1
G-CSF granulocyte colony stimulating factor
GM-CSF granulocyte macrophage colony stimulating factor
gp glycoprotein
GTP guanosine 5’- triphosphate
HA haemagglutinin
HAART highly active antiretroviral therapy
HBS HEPES-buffered saline
HBsAg hepatitis B virus surface antigen
HBV hepatitis B virus
HEPES V-2-hydroxyethylpiperazine-V’-2-ethanesulphonic acid
HIV human immunodeficiency virus
HRP horse radish peroxidase
HSV-2 type 2 herpes simplex virus
HTLV human T-cell leukaemia virus
ICE interleukin 1 p converting enzyme
Id idiotype
i.d. intradermal
IDDM insulin-dependent diabetes mellitus
IFA incomplete Freund’s adjuvant
IFN interferon
Ig immunoglobulin
IGIF interferon gamma inducing factor
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IL interleukin












LAL Limulus amoebocyte lysate
LB Luria Bertani medium
LPS lipopolysaccharide
LTR long terminal repeat
M molar




MHC major histocompatibility complex
mM micromolar
MoMLV Moloney murine leukaemia virus
mRNA messenger ribonucleic acid
NEAA non essential amino acids
NF-kB nuclear factor-KB
NK natural killer cell








ORF open reading frame
PAGE polyacrylamide gel electrophoresis
PB peripheral blood
PBMC peripheral blood mononuclear cell
PBS phosphate buffered saline






RBC red blood cell
RNA ribonucleic acid
RNAse ribonuclease
rpm revolutions per minute
rRNA ribosomal ribonucleic acid
RSV respiratory syncitial virus
RT reverse transcriptase
RT-PCR reverse transcriptase polymerase chain reaction
s.c. subcutaneous
SCF stem cell factor
SCID severe combined immunodeficency
SDS sodium dodecyl sulphate
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis
SIV simian immunodeficiency virus
S/P sample to positive
SPF specific pathogen free
STAT signal transducers and activators of transcription
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T thymine or thymidine; one letter code for threonine
TBE Tris/borate/EDTA
TBS tris buffered saline
TBS-T tris buffered saline-tween solution
TBT tris buffered saline-tween solution
TCF tissue culture fluid (supernatant) of cultured bone marrow cells.
TE Tris-EDTA buffer
TEA Tris/EDT A/acetate
TEMED N ’- tetramethyl-ethylenediamine
Thl T helper cell type 1
Th2 T helper cell type 2
TK thymidine kinase
Tm melting (or midpoint) temperature
TMP tetramethylbenzidine hydrochloride peroxidase
TNF tumour necrosis factor
Tris tris(hy droxymethy l)aminomethane
Tris-HCl Tris hydrochloride
tRNA transfer ribonucleic acid
UV ultraviolet
UWGCG University of Wisconsin Genetics Computer Group
VI virus isolation
VN virus-neutralising
WBC white blood cell






Haematology results from the FeLV DNA vaccination trial
DATE ANIMAL WBC RBC HB HCT MCV MCH MCHC
09/06/98 L1 10.5 5.60 8.7 26.4 47 15.5 32.9
09/06/98 L2 11.2 6.33 9.1 28.6 45 14.3 31.8
09/06/98 L3 9.8 6.24 9.7 29.6 47 15.5 32.7
09/06/98 L4 16.2 7.14 9.1 28.6 40 12.7 31.8
09/06/98 L5 15.8 7.86 11.8 35.9 46 15.0 32.8
09/06/98 L6 8.1 6.48 9.0 28 43 13.8 32.1
09/06/98 L8 17.3 6.48 9.7 31.1 48 14.9 31.1
09/06/98 L9 12.2 6.95 11.1 33.3 48 15.9 33.3
09/06/98 L10 14.1 6.70 10.3 31.8 47 15.3 32.3
09/06/98 L11 14.6 6.42 8.7 27.4 43 13.5 31.7
09/06/98 L12 9.2 5.78 9.2 28.9 50 15.9 31.8
09/06/98 L13 18.9 5.87 8.3 26.4 45 14.1 31.4
09/06/98 L14 13.9 6.36 9.7 29.2 46 15.2 33.2
09/06/98 L15 12.8 6.83 9.4 29.2 43 13.7 32.1
09/06/98 L16 15.6 6.39 9.3 29.2 46 14.5 31.8
09/06/98 L17 7.9 6.46 8.8 27.4 42 13.6 32.1
09/06/98 L18 13.0 6.39 9.0 28 44 14.0 32.1
09/06/98 L19 20.9 6.21 9.7 30.2 49 15.6 32.1
09/06/98 L20 12.0 7.04 10.7 31.5 45 15.1 33.9
09/06/98 L21 24.2 5.75 8.9 27.4 48 15.4 32.4
09/06/98 L22 8.8 5.47 8.0 25.2 46 14.6 31.7
09/06/98 L23 12.3 6.30 9.4 29.6 47 14.9 31.7
09/06/98 L24 9.4 5.84 8.3 26.1 45 14.2 31.8
09/06/98 L25 10.4 6.58 9.7 29.2 44 14.7 33.2
09/06/98 L26 12.4 6.48 9.3 28 43 14.3 33.2
09/06/98 L27 15.6 6.15 9.9 29.2 47 16.0 33.9
09/06/98 L28 12.0 6.58 8.8 27.4 42 13.3 32.1
09/06/98 L29 10.3 6.52 9.3 28.3 43 14.2 32.8
09/06/98 L30 6.8 5.44 7.6 23.9 44 13.9 31.7
Pre-trial haematology results
Abbreviations; WBC, total white blood cell count x 109/L; RBC, total red blood 
cell count x 1012/L; HB, haemoglobin, g/dl; HCT, haematocrit (synonymous with 
PCV, packed cell volume); MCV, mean red cell volume; MCH, mean red cell 
haemoglobin; MCHC, mean red cell haemoglobin concentration; BNEU, band 
(immature) neutrophil count x 109/L; NEU, neutrophil count x 109/L; LYMPH, 
lymphocyte count x 109/L; MONO, monocyte count x 109/L; EOS, eosinophil count 
x 109/L; BASO, basophil count x 109/L
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DATE ANIMAL BNEU NEU LYMPH MONO EOS BASO
09/06/98 L1 0.105 5.775 3.570 0.525 0.525 0.000
09/06/98 L2 0.112 6.496 3.584 0.224 0.560 0.112
09/06/98 L3 0.000 6.370 2.058 0.490 0.784 0.098
09/06/98 L4 0.000 8.424 6.480 0.486 0.810 0.000
09/06/98 L5 0.000 6.478 7.584 0.316 1.422 0.000
09/06/98 L6 0.162 4.455 2.754 0.324 0.405 0.000
09/06/98 L8 0.000 11.072 4.498 1.038 0.692 0.000
09/06/98 L9 0.000 5.856 5.246 0.488 0.488 0.122
09/06/98 L10 0.000 7.614 5.358 0.282 0.846 0.000
09/06/98 L11 0.292 10.804 2.920 0.292 0.292 0.000
09/06/98 L12 0.000 4.416 4.140 0.184 0.368 0.000
09/06/98 L13 0.000 11.151 5.103 0.567 2.079 0.000
09/06/98 L14 0.000 9.313 3.336 0.556 0.417 0.000
09/06/98 L15 0.128 6.400 4.992 0.768 0.512 0.000
09/06/98 L16 0.156 7.488 6.708 0.312 0.780 0.088
09/06/98 L17 0.079 4.424 3.239 0.000 0.158 0.000
09/06/98 L18 0.130 6.890 4.550 0.390 1.040 0.000
09/06/98 L19 0.418 11.913 7.315 0.418 0.836 0.000
09/06/98 L20 0.120 7.560 3.360 0.240 0.360 0.240
09/06/98 L21 0.968 18.876 2.662 0.726 0.726 0.242
09/06/98 L22 0.000 5.016 3.080 0.264 0.352 0.000
09/06/98 L23 0.000 5.289 3.567 0.123 3.198 0.000
09/06/98 L24 0.000 6.204 2.350 0.094 0.752 0.000
09/06/98 L25 0.000 5.408 3.848 0.312 0.624 0.104
09/06/98 L26 0.124 7.564 3.348 0.248 0.992 0.124
09/06/98 L27 0.156 7.644 7.332 0.156 0.312 0.000
09/06/98 L28 0.120 7.440 3.000 0.600 0.720 0.000
09/06/98 L29 0.000 4.223 5.253 0.412 0.412 0.278
09/06/98 L30 0.000 3.400 2.788 0.204 0.340 0.000
Pre-trial haematology results
Normal values; w b c ,  5 .5 - 1 5 . 5  x io 9/L; r b c ,  5 .0 - 1 0 . 0  x io '2/L; h b ,  1 0 .0 -
15.0g/dl; HCT, 0.30-0.45L/L; MCV, 39.0-55.0fl; M CH, 12.5-17.5 pg;
M CHC, 30.0-36.0g/dl; NEU, 2.5-12.5 x 109/L; LYM PH, 1.5-7.0 x 109/L;
MONO, 0.00-0.85 x 109/L; EOS, 0-1.5 x 109/L; BASO, Rare
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DATE ANIMAL WBC RBC HB HCT MCV MCH MCHC
28/07/98 L1 13.3 7.94 13.3 35.3 44 16.7 37.6
28/07/98 L2 12.6 8.00 11.6 32.2 40 14.5 36.0
28/07/98 L3 15.2 7.88 11.9 32.8 42 15.1 36.2
28/07/98 L4 13.2 7.88 9.8 28.4 36 12.4 34.5
28/07/98 L5 17.2 9.39 14.6 38.8 41 15.5 37.6
28/07/98 L6 12.6 7.97 11.5 31.9 40 14.4 36.0
28/07/98 L8 24.2 8.00 11.2 32.5 41 14.0 34.4
28/07/98 L9 11.4 9.46 15.2 41 43 16.0 37.0
28/07/98 L10 15.8 8.28 13.1 34.1 41 15.8 38.4
28/07/98 L11 14.0 7.33 9.9 28.4 39 13.5 34.8
28/07/98 L12 12.6 6.99 11.4 31.2 45 16.3 36.5
28/07/98 L13 17.0 8.37 11.0 31.6 38 13.1 34.8
28/07/98 L14 14.1 7.60 12.1 32.2 42 15.9 37.5
28/07/98 L15 20.1 8.43 11.5 31.2 37 13.6 36.8
28/07/98 L16 19.2 8.28 12.4 33.1 40 14.9 37.4
28/07/98 L17 6.2 8.09 11.4 31.6 39 14.0 36.0
28/07/98 L18 12.2 7.57 11.5 31.6 42 15.1 36.3
28/07/98 L19 23.9 8.09 12.0 34.1 42 14.8 35.1
28/07/98 L20 15.8 7.97 10.9 31.6 40 13.6 34.4
28/07/98 L21 30.7 7.36 11.3 31.2 42 15.3 36.2
28/07/98 L22 12.3 8.00 12.6 33.8 42 15.7 37.2
28/07/98 L23 14.2 7.54 11.9 33.4 44 15.7 35.6
28/07/98 L24 18.0 7.17 10.0 28.7 40 13.9 34.8
28/07/98 L25 13.9 7.30 10.3 28.7 39 14.1 35.8
28/07/98 L26 9.8 7.57 12.2 31.9 42 16.1 38.2
28/07/98 L27 19.1 7.94 13.0 34.7 44 16.3 37.4
28/07/98 L28 14.1 7.24 9.8 28.1 39 13.5 34.8
28/07/98 L29 10.6 8.09 11.6 32.5 40 14.3 35.6
28/07/98 L30 12.3 7.54 11.0 30.6 41 14.5 35.9
Haematology results from day of viral challenge
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DATE ANIMAL BNEU NEU LYMPH MONO EOS BASO
28/07/98 L1 0.133 5.719 5.320 0.931 0.931 0.266
28/07/98 L2 0.000 6.174 5.292 0.126 0.756 0.252
28/07/98 L3 0.000 10.944 2.432 0.456 1.064 0.304
28/07/98 L4 0.000 6.072 5.940 0.264 0.924 0.000
28/07/98 L5 0.000 6.364 8.600 0.688 1.204 0.344
28/07/98 L6 0.252 7.056 3.780 0.630 0.756 0.126
28/07/98 L8 0.000 15.004 5.566 1.210 2.420 0.000
28/07/98 L9 0.000 3.762 6.840 0.114 0.570 0.114
28/07/98 L10 0.000 6.952 6.794 0.474 1.422 0.158
28/07/98 L11 0.000 7.700 5.180 0.280 0.840 0.000
28/07/98 L12 0.000 6.048 5.670 0.126 0.252 0.378
28/07/98 L13 0.170 7.820 6.460 0.510 2.040 0.000
28/07/98 L14 0.000 5.640 7.050 0.141 0.987 0.282
28/07/98 L15 0.000 9.447 9.648 0.402 0.603 0.000
28/07/98 L16 0.000 8.448 7.296 0.960 2.304 0.192
28/07/98 L17 0.062 2.480 3.100 0.248 0.310 0.000
28/07/98 L18 0.000 6.344 4.880 0.244 0.732 0.000
28/07/98 L19 0.239 10.994 10.516 0.239 1.673 0.239
28/07/98 L20 0.000 7.900 6.004 0.316 1.422 0.158
28/07/98 L21 0.614 20.876 6.754 0.921 1.228 0.307
28/07/98 L22 0.000 5.043 6.027 0.246 0.984 0.000
28/07/98 L23 0.000 6.958 4.260 0.568 2.272 0.142
28/07/98 L24 0.000 9.720 5.220 0.720 2.160 0.180
28/07/98 L25 0.139 8.340 4.031 0.278 0.973 0.000
28/07/98 L26 0.000 2.548 5.978 0.196 0.882 0.196
28/07/98 L27 0.000 9.741 8.404 0.191 0.382 0.382
28/07/98 L28 0.141 7.050 4.794 0.141 1.692 0.141
28/07/98 L29 0.000 4.452 5.194 0.318 0.530 0.106
28/07/98 L30 0.123 5.781 4.674 0.246 1.476 0.000
Haematology results from day of viral challenge
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DATE ANIMAL WBC RBC HB HCT MCV MCH MCHC
18/08/98 L1 12.6 8.19 12.9 34 42 15.7 37.9
18/08/98 L2 6.9 7.81 10.8 29.9 38 13.8 36.1
18/08/98 L3 10.8 8.26 11.6 31.5 38 14.0 36.8
18/08/98 L4 17.4 9.41 11.6 31.8 34 12.3 36.4
18/08/98 L5 11.9 9.12 13.6 35.2 39 14.9 38.6
18/08/98 L6 10.4 9.22 12.2 34.3 37 13.2 35.5
18/08/98 L8 17.6 8.07 10.3 30.5 38 12.7 33.7
18/08/98 L9 3.9 8.99 14.5 35.5 39 16.1 40.8
18/08/98 L10 12.4 8.16 12.3 33.3 41 15.0 36.9
18/08/98 L11 14.5 7.56 9.7 27.4 36 12.8 35.4
18/08/98 L12 12.5 7.12 11.2 31.1 44 15.7 36.0
18/08/98 L13 11.2 9.02 11.3 32.1 36 12.5 35.2
18/08/98 L14 8.0 8.16 12.1 31.8 39 14.8 38.0
18/08/98 L15 10.4 7.94 10.0 27.7 35 12.5 36.1
18/08/98 L16 15.5 8.86 12.2 34.6 39 13.7 35.2
18/08/98 L17 6.0 8.51 11.5 31.5 37 13.5 36.5
18/08/98 L18 9.2 8.13 11.6 32.1 39 14.2 36.1
18/08/98 L19 16.4 7.28 10.0 29.2 40 13.7 34.2
18/08/98 L20 9.5 7.66 9.7 28.6 37 12.6 33.9
18/08/98 L21 11.2 6.55 9.0 25.8 39 13.7 34.8
18/08/98 L22 6.2 6.81 9.7 28.3 42 14.2 34.2
18/08/98 L23 11.4 8.22 12.4 34.6 42 15.0 35.8
18/08/98 L24 11.5 6.81 8.6 26.7 39 12.6 32.2
18/08/98 L25 10.7 7.97 10.3 30.2 38 12.9 34.1
18/08/98 L26 11.1 7.09 10.6 28.6 40 14.9 37.0
18/08/98 L27 19.2 7.62 11.6 31.5 41 15.2 36.8
18/08/98 L28 21.0 7.28 9.3 27.7 38 12.7 33.5
18/08/98 L29 13.1 7.81 10.7 30.8 39 13.7 34.7
18/08/98 L30 15.2 7.24 10.0 28.9 40 13.8 34.6
Haematology results from three weeks post-challenge
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DATE ANIMAL BNEU NEU LYMPH MONO EOS BASO
18/08/98 L1 0.000 5.670 5.670 0.252 0.882 0.126
18/08/98 L2 0.000 3.588 2.484 0.207 0.621 0.000
18/08/98 L3 0.000 6.480 3.456 0.216 0.540 0.108
18/08/98 L4 0.174 4.872 11.136 0.696 0.348 0.174
18/08/98 L5 0.000 4.403 6.902 0.119 0.357 0.119
18/08/98 L6 0.104 6.448 2.704 0.208 0.832 0.104
18/08/98 L8 0.352 8.272 5.104 0.880 2.816 0.176
18/08/98 L9 0.000 0.897 2.769 0.000 0.195 0.039
18/08/98 L10 0.000 7.068 4.216 0.248 0.868 0.000
18/08/98 L11 0.145 8.410 5.075 0.290 0.580 0.000
18/08/98 L12 0.000 6.375 5.375 0.250 0.500 0.000
18/08/98 L13 0.000 5.264 4.368 0.448 1.120 0.000
18/08/98 L14 0.000 3.440 3.680 0.080 0.640 0.080
18/08/98 L15 0.000 4.472 5.200 0.104 0.624 0.000
18/08/98 L16 0.000 5.580 8.215 0.465 1.085 0.155
18/08/98 L17 0.000 3.180 2.520 0.120 0.120 0.060
18/08/98 L18 0.000 4.324 4.232 0.184 0.460 0.000
18/08/98 L19 0.164 7.872 7.380 0.328 0.492 0.164
18/08/98 L20 0.000 4.370 4.180 0.095 0.665 0.190
18/08/98 L21 0.000 4.928 5.152 0.336 0.672 0.112
18/08/98 L22 0.000 2.542 2.108 0.310 0.992 0.186
18/08/98 L23 0.000 4.560 4.788 0.228 1.710 0.114
18/08/98 L24 0.000 5.750 4.025 0.690 1.035 0.000
18/08/98 L25 0.000 6.206 2.996 0.214 1.070 0.214
18/08/98 L26 0.000 5.106 5.217 0.222 0.555 0.000
18/08/98 L27 0.000 8.832 9.408 0.000 0.960 0.000
18/08/98 L28 0.210 9.450 7.980 1.050 1.890 0.420
18/08/98 L29 0.000 5.502 6.812 0.000 0.786 0.000
18/08/98 L30 0.000 9.424 4.712 0.456 0.608 0.000
Haematology results from three weeks post-challenge
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DATE ANIMAL WBC RBC HB HCT MCV MCH MCHC
08/09/98 L1 11.9 8.77 14.0 36.5 42 15.9 38.3
08/09/98 L2 8.3 8.80 12.3 33.3 38 13.9 36.9
08/09/98 L3 11.9 8.58 12.4 32.4 38 14.4 38.2
08/09/98 L4 16.6 9.41 11.2 31.5 33 11.9 35.5
08/09/98 L5 13.6 9.22 13.5 36.2 39 14.6 37.2
08/09/98 L6 9.9 9.51 12.8 36.5 38 13.4 35.0
08/09/98 L8 16.8 8.61 11.2 31.5 37 13.0 35.5
08/09/98 L9 6.3 9.89 15.4 38.7 39 15.5 39.7
08/09/98 L10 7.4 9.15 13.8 36.2 40 15.0 38.1
08/09/98 L11 16.0 8.03 10.3 28.3 35 12.8 36.3
08/09/98 L12 12.0 8.32 13.0 33 40 15.6 39.3
08/09/98 L13 15.3 9.83 12.4 34.9 36 12.6 35.5
08/09/98 L14 11.4 8.22 12.7 33.3 41 15.4 38.1
08/09/98 L15 10.8 8.99 11.6 31.5 35 12.9 36.8
08/09/98 L16 15.1 9.35 13.1 36.8 39 14.0 35.5
08/09/98 L17 5.1 7.53 11.0 30.2 40 14.6 36.4
08/09/98 L18 6.6 7.84 10.9 29.9 38 13.9 36.4
08/09/98 L19 22.2 8.77 12.6 34.9 40 14.3 36.1
08/09/98 L20 15.9 8.45 11.0 31.5 37 13.0 34.9
08/09/98 L21 8.2 7.02 9.9 27.7 39 14.1 35.7
08/09/98 L22 10.2 5.65 9.6 27.7 49 16.9 34.6
08/09/98 L23 8.2 8.35 12.4 32.7 39 14.8 37.9
08/09/98 L24 17.8 8.38 10.6 28.9 34 12.6 36.6
08/09/98 L25 10.2 8.10 10.8 30.5 38 13.3 35.4
08/09/98 L26 9.3 8.00 12.3 32.4 40 15.3 37.9
08/09/98 L27 20.1 8.67 13.9 36.5 42 16.0 38.0
08/09/98 L28 15.7 7.37 9.7 27.4 37 13.1 35.4
08/09/98 L29 12.9 8.16 10.9 29.9 37 13.3 36.4
08/09/98 L30 16.1 8.00 10.5 28.9 36 13.1 36.3
Haematology results from six weeks post-challenge
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DATE ANIMAL BNEU NEU LYMPH MONO EOS BASO
08/09/98 L1 0.000 3.570 6.664 0.595 0.714 0.357
08/09/98 L2 0.000 2.241 5.727 0.166 0.083 0.083
08/09/98 L3 0.000 5.950 3.927 0.238 1.785 0.000
08/09/98 L4 0.000 6.142 9.130 0.332 0.830 0.166
08/09/98 L5 0.136 5.440 6.936 0.272 0.816 0.000
08/09/98 L6 0.099 4.851 3.960 0.792 0.198 0.000
08/09/98 L8 0.000 8.568 5.544 0.504 2.016 0.168
08/09/98 L9 0.063 0.819 5.355 0.000 0.000 0.063
08/09/98 L10 0.000 0.444 6.734 0.222 0.000 0.000
08/09/98 L11 0.000 6.400 8.960 0.320 0.320 0.000
08/09/98 L12 0.000 4.440 6.600 0.120 0.840 0.000
08/09/98 L13 0.000 7.497 5.967 0.153 1.530 0.153
08/09/98 L14 0.114 5.016 5.700 0.456 0.114 0.000
08/09/98 L15 0.000 3.240 7.236 0.324 0.000 0.000
08/09/98 L16 0.000 4.983 8.758 0.453 0.906 0.000
08/09/98 L17 0.000 2.652 1.734 0.510 0.102 0.102
08/09/98 L18 0.066 1.518 4.950 0.066 0.000 0.000
08/09/98 L19 0.000 7.992 12.654 0.666 0.666 0.222
08/09/98 L20 0.000 7.791 6.678 0.318 1.113 0.000
08/09/98 L21 0.082 3.198 4.674 0.082 0.082 0.000
08/09/98 L22 0.000 2.652 6.630 0.204 0.408 0.204
08/09/98 L23 0.082 3.772 3.362 0.492 0.410 0.000
08/09/98 L24 0.178 11.036 6.052 0.178 0.356 0.000
08/09/98 L25 0.000 4.182 4.692 0.408 0.918 0.000
08/09/98 L26 0.000 2.139 5.766 0.372 0.930 0.093
08/09/98 L27 0.000 6.030 13.266 0.000 0.603 0.201
08/09/98 L28 0.157 6.908 5.966 0.471 2.198 0.000
08/09/98 L29 0.000 3.870 8.127 0.129 0.774 0.000
08/09/98 L30 0.000 6.118 8.855 0.161 0.966 0.000
Haematology results from six weeks post-challenge
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DATE ANIMAL WBC RBC HB HCT MCV MCH MCHC
02/10/98 L1 18.0 8.45 14.0 38.1 45 16.5 36.7
02/10/98 L2 7.6 8.85 12.3 34.8 39 13.8 35.3
02/10/98 L3 10.1 9.31 13.7 39.1 42 14.7 35.0
02/10/98 L4 16.1 9.90 12.9 35.5 36 13.0 36.3
02/10/98 L5 20.0 9.80 14.7 39.5 40 15.0 37.2
02/10/98 L6 11.4 10.31 13.7 39.8 39 13.2 34.4
02/10/98 L8 21.2 8.72 11.8 34.8 40 13.5 33.9
02/10/98 L9 11.3 9.77 14.9 40.2 41 15.2 37.0
02/10/98 L10 11.0 9.44 14.7 40.5 43 15.5 36.2
02/10/98 L11 18.1 8.29 11.1 30.8 37 13.3 36.0
02/10/98 L12 14.0 7.51 11.8 33.1 44 15.7 35.6
02/10/98 L13 11.0 7.66 11.1 35.8 43 15.5 36.7
02/10/98 L14 13.0 8.06 12.5 33.5 42 15.5 37.3
02/10/98 L15 14.5 9.24 12.6 35.1 38 13.6 35.8
02/10/98 L16 19.5 10.31 14.9 40.2 39 14.4 37.0
02/10/98 L17 7.6 8.75 13.2 35.1 40 15.0 37.6
02/10/98 L18 9.9 8.42 12.4 33.5 40 14.7 37.0
02/10/98 L19 24.0 10.24 14.0 41.2 40 13.6 33.9
02/10/98 L20 19.3 9.90 13.5 38.5 39 13.6 35.0
02/10/98 L21 13.1 7.38 10.7 31.1 42 14.4 34.4
02/10/98 L22 17.8 8.75 14.2 39.8 45 16.2 35.6
02/10/98 L23 14.3 9.28 14.4 40.5 44 15.5 35.5
02/10/98 L24 11.9 7.80 10.1 29.1 37 12.9 34.7
02/10/98 L25 12.2 8.75 11.5 34.1 39 13.1 33.7
02/10/98 L26 11.8 7.97 12.6 34.8 44 15.8 36.2
02/10/98 L27 22.0 9.08 15.2 40.2 44 16.7 37.8
02/10/98 L28 15.2 8.00 11.0 31.8 40 13.7 34.5
02/10/98 L29 10.9 8.39 12.0 34.1 41 14.3 35.1
02/10/98 L30 11.6 8.62 11.7 33.5 39 13.5 34.9
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DATE ANIMAL BNEU NEU LYMPH MONO EOS BASO
02/10/98 L1 0.000 8.820 8.100 0.180 0.720 0.180
02/10/98 L2 0.000 1.596 5.548 0.228 0.228 0.000
02/10/98 L3 0.000 5.050 3.737 0.303 0.909 0.101
02/10/98 L4 0.000 5.635 9.660 0.161 0.644 0.000
02/10/98 L5 0.000 5.800 13.000 0.200 1.000 0.000
02/10/98 L6 0.114 5.472 4.560 0.456 0.684 0.114
02/10/98 L8 0.000 10.176 8.268 0.848 1.908 0.000
02/10/98 L9 0.000 2.373 7.797 0.339 0.791 0.000
02/10/98 L10 0.000 2.860 7.810 0.220 0.110 0.000
02/10/98 L11 0.000 6.516 9.955 0.724 0.905 0.000
02/10/98 L12 0.000 6.440 6.720 0.140 0.560 0.140
02/10/98 L13 0.000 6.712 6.360 0.175 0.567 0.000
02/10/98 L14 0.000 6.890 5.200 0.130 0.780 0.000
02/10/98 L15 0.000 5.510 7.975 0.145 0.725 0.145
02/10/98 L16 0.000 7.215 9.360 0.585 2.145 0.195
02/10/98 L17 0.000 2.508 4.560 0.304 0.228 0.000
02/10/98 L18 0.000 2.673 6.831 0.297 0.099 0.000
02/10/98 L19 0.000 12.480 10.320 0.720 0.240 0.240
02/10/98 L20 0.193 10.615 6.755 0.193 1.351 0.193
02/10/98 L21 0.524 6.681 5.502 0.393 0.000 0.000
02/10/98 L22 0.000 5.518 10.502 0.356 1.246 0.178
02/10/98 L23 0.143 5.577 7.007 0.286 1.287 0.000
02/10/98 L24 0.119 5.236 5.474 0.357 0.714 0.000
02/10/98 L25 0.000 4.758 6.100 0.244 1.098 0.000
02/10/98 L26 0.118 2.478 8.260 0.236 0.472 0.236
02/10/98 L27 0.000 8.140 12.320 0.440 0.660 0.440
02/10/98 L28 0.304 7.600 5.168 0.304 1.824 0.000
02/10/98 L29 0.000 4.251 5.886 0.000 0.763 0.000
02/10/98 L30 0.000 6.032 4.408 0.116 0.928 0.116
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DATE ANIMAL WBC RBC HB HCT MCV MCH MCHC
27/10/98 L1 12.6 8.57 15.0 38.5 45 17.5 38.9
27/10/98 L2 9.8 8.93 12.8 34.5 39 14.3 37.1
27/10/98 L3 10.2 9.12 14.7 39.1 43 16.1 37.5
27/10/98 L4 14.9 9.64 13.1 35.5 37 13.5 36.9
27/10/98 L5 15.0 10.45 15.9 41.8 40 15.2 38.0
27/10/98 L6 12.8 9.70 13.4 36.8 38 13.8 36.4
27/10/98 L8 21.3 9.44 13.7 38.8 41 14.5 35.3
27/10/98 L9 11.6 10.42 16.9 43.8 42 16.2 38.5
27/10/98 L10 10.2 9.96 15.6 42.2 42 15.6 36.9
27/10/98 L11 16.1 8.22 11.8 31.1 38 14.3 37.9
27/10/98 L12 11.2 8.12 13.2 35.5 44 16.2 37.1
27/10/98 L13 17.7 10.06 13.5 38.1 38 13.4 35.4
27/10/98 L14 12.0 8.44 13.7 35.8 42 16.2 38.2
27/10/98 L15 13.4 9.09 13.0 34.5 38 14.3 37.6
27/10/98 L16 15.4 10.52 15.9 43.8 42 15.1 36.3
27/10/98 L17 7.8 9.06 13.4 35.5 39 14.7 37.7
27/10/98 L18 9.2 8.83 13.3 36.1 41 15.0 36.8
27/10/98 L19 19.9 9.47 14.2 38.8 41 14.9 36.5
27/10/98 L20 18.7 8.80 12.8 35.8 41 14.5 35.7
27/10/98 L21 16.5 8.28 12.9 35.1 42 15.5 36.7
27/10/98 L22 12.4 8.83 14.2 39.1 44 16.0 36.3
27/10/98 L23 10.1 9.19 15.5 42.8 47 16.8 36.2
27/10/98 L24 13.0 7.68 10.6 30.1 39 13.8 35.2
27/10/98 L25 10.8 8.93 12.3 34.5 39 13.7 35.6
27/10/98 L26 10.0 8.25 14.0 36.5 44 16.9 38.3
27/10/98 L27 16.0 8.32 14.4 37.8 45 17.3 38.0
27/10/98 L28 17.8 8.15 11.9 33.5 41 14.6 35.5
27/10/98 L29 17.1 9.77 14.4 39.8 41 14.7 36.1
27/10/98 L30 12.2 8.57 12.5 34.8 41 14.5 35.9
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DATE ANIMAL BNEU NEU LYMPH MONO EOS BASO
27/10/98 L1 0.000 3.402 7.812 0.378 0.882 0.126
27/10/98 L2 0.000 4.410 4.998 0.098 0.294 0.000
27/10/98 L3 0.000 4.794 4.386 0.510 0.408 0.102
27/10/98 L4 0.000 5.960 7.897 0.298 0.745 0.000
27/10/98 L5 0.000 3.450 10.500 0.150 0.600 0.300
27/10/98 L6 0.000 6.400 5.248 0.384 0.384 0.384
27/10/98 L8 0.000 9.585 7.029 0.852 3.621 0.213
27/10/98 L9 0.000 2.668 8.468 0.000 0.348 0.116
27/10/98 L10 0.000 2.754 6.630 0.306 0.408 0.000
27/10/98 L11 0.000 6.279 9.177 0.161 0.483 0.000
27/10/98 L12 0.000 4.032 5.936 0.112 1.008 0.112
27/10/98 L13 0.000 9.381 5.133 0.354 2.478 0.354
27/10/98 L14 0.000 4.920 6.000 0.240 0.600 0.240
27/10/98 L15 0.000 4.422 8.576 0.134 0.134 0.134
27/10/98 L16 0.000 4.928 8.162 0.308 1.848 0.154
27/10/98 L17 0.000 3.276 3.978 0.156 0.312 0.078
27/10/98 L18 0.000 3.036 5.612 0.184 0.368 0.000
27/10/98 L19 0.000 10.149 8.756 0.597 0.398 0.000
27/10/98 L20 0.000 8.789 7.667 0.561 1.309 0.374
27/10/98 L21 0.165 10.065 5.115 0.330 0.825 0.000
27/10/98 L22 0.000 3.472 7.316 0.372 1.116 0.124
27/10/98 L23 0.000 4.545 3.838 0.505 1.111 0.101
27/10/98 L24 0.000 5.460 6.370 0.260 0.910 0.000
27/10/98 L25 0.000 5.292 4.536 0.324 0.648 0.000
27/10/98 L26 0.000 2.400 6.800 0.100 0.600 0.100
27/10/98 L27 0.000 5.920 9.280 0.320 0.480 0.000
27/10/98 L28 0.000 7.654 6.764 0.534 2.670 0.178
27/10/98 L29 0.000 5.814 10.089 0.171 1.026 0.000
27/10/98 L30 0.000 5.856 5.612 0.122 0.610 0.000
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